<html class="pb-page" data-request-id="569d4b9c-1f23-4d16-87be-ae92f6744b02" lang="en"><head data-pb-dropzone="head"><script type="text/javascript" src="https://m.addthis.com/live/red_lojson/300lo.json?si=62727c34ed079f2d&amp;bkl=0&amp;bl=1&amp;pdt=544&amp;sid=62727c34ed079f2d&amp;pub=xa-4faab26f2cff13a7&amp;rev=v8.28.8-wp&amp;ln=en&amp;pc=men&amp;cb=0&amp;ab=-&amp;dp=pubs.acs.org&amp;fp=doi%2F10.1021%2Facsomega.0c05589&amp;fr=&amp;of=0&amp;pd=0&amp;irt=1&amp;vcl=1&amp;md=0&amp;ct=1&amp;tct=0&amp;abt=0&amp;cdn=0&amp;pi=1&amp;rb=0&amp;gen=100&amp;chr=UTF-8&amp;colc=1651670068600&amp;jsl=1&amp;uvs=62727bafd7016315038&amp;skipb=1&amp;callback=addthis.cbs.jsonp__37543240508202570"></script><script type="text/javascript" src="https://v1.addthisedge.com/live/boost/xa-4faab26f2cff13a7/_ate.track.config_resp"></script><script type="text/javascript" src="https://z.moatads.com/addthismoatframe568911941483/moatframe.js"></script><meta name="pbContext" content=";journal:journal:acsodf;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acsomega.0c05589;wgroup:string:ACHS website Group;issue:issue:10.1021/acsodf.2021.6.issue-3;website:website:acspubs;requestedJournal:journal:acsodf;pageGroup:string:Publication Pages;subPage:string:Full Text">




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="ACS Omega"><meta name="dc.Title" content="Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth"><meta name="dc.Creator" content="Peter C.  Ray"><meta name="dc.Creator" content="Margaret  Huggett"><meta name="dc.Creator" content="Penelope A.  Turner"><meta name="dc.Creator" content="Malcolm  Taylor"><meta name="dc.Creator" content="Laura A. T.  Cleghorn"><meta name="dc.Creator" content="Julie  Early"><meta name="dc.Creator" content="Anuradha  Kumar"><meta name="dc.Creator" content="Shilah A.  Bonnett"><meta name="dc.Creator" content="Lindsay  Flint"><meta name="dc.Creator" content="Douglas  Joerss"><meta name="dc.Creator" content="James  Johnson"><meta name="dc.Creator" content="Aaron  Korkegian"><meta name="dc.Creator" content="Steven  Mullen"><meta name="dc.Creator" content="Abraham L.  Moure"><meta name="dc.Creator" content="Susan H.  Davis"><meta name="dc.Creator" content="Dinakaran  Murugesan"><meta name="dc.Creator" content="Michael  Mathieson"><meta name="dc.Creator" content="Nicola  Caldwell"><meta name="dc.Creator" content="Curtis A.  Engelhart"><meta name="dc.Creator" content="Dirk  Schnappinger"><meta name="dc.Creator" content="Ola  Epemolu"><meta name="dc.Creator" content="Fabio  Zuccotto"><meta name="dc.Creator" content="Jennifer  Riley"><meta name="dc.Creator" content="Paul  Scullion"><meta name="dc.Creator" content="Laste  Stojanovski"><meta name="dc.Creator" content="Lisa  Massoudi"><meta name="dc.Creator" content="Gregory T.  Robertson"><meta name="dc.Creator" content="Anne J.  Lenaerts"><meta name="dc.Creator" content="Gail  Freiberg"><meta name="dc.Creator" content="Dale J.  Kempf"><meta name="dc.Creator" content="Thierry  Masquelin"><meta name="dc.Creator" content="Philip A.  Hipskind"><meta name="dc.Creator" content="Joshua  Odingo"><meta name="dc.Creator" content="Kevin D.  Read"><meta name="dc.Creator" content="Simon R.  Green"><meta name="dc.Creator" content="Paul G.  Wyatt"><meta name="dc.Creator" content="Tanya  Parish"><meta name="dc.Description" content="With the emergence of multi-drug-resistant strains of Mycobacterium tuberculosis, there is a pressing need for new oral drugs with novel mechanisms of action. A number of scaffolds with potent anti..."><meta name="Description" content="With the emergence of multi-drug-resistant strains of Mycobacterium tuberculosis, there is a pressing need for new oral drugs with novel mechanisms of action. A number of scaffolds with potent anti..."><meta name="dc.Publisher" content="American Chemical Society"><meta name="dc.Date" scheme="WTN8601" content="January 13, 2021"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1021/acsomega.0c05589"><meta name="dc.Language" content="en"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="© 2021 The Authors. Published by American Chemical Society"><meta name="citation_fulltext_world_readable" content="">
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facsomega.0c05589">
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facsomega.0c05589">
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facsomega.0c05589">
        
    
    

<title>Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth | ACS Omega</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive">





    






        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acsomega.0c05589"><meta property="og:title" content="Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth"><meta property="og:image" content="https://pubs.acs.org/cms/10.1021/acsomega.0c05589/asset/images/acsomega.0c05589.social.jpeg_v03"><meta property="og:description" content="With the emergence of multi-drug-resistant strains of Mycobacterium tuberculosis, there is a pressing need for new oral drugs with novel mechanisms of action. A number of scaffolds with potent anti-tubercular in vitro activity have been identified from phenotypic screening that appear to target MmpL3. However, the scaffolds are typically lipophilic, which facilitates partitioning into hydrophobic membranes, and several contain basic amine groups. Highly lipophilic basic amines are typically cytotoxic against mammalian cell lines and have associated off-target risks, such as inhibition of human ether-à-go-go related gene (hERG) and IKr potassium current modulation. The spirocycle compound 3 was reported to target MmpL3 and displayed promising efficacy in a murine model of acute tuberculosis (TB) infection. However, this highly lipophilic monobasic amine was cytotoxic and inhibited the hERG ion channel. Herein, the related spirocycles (1–2) are described, which were identified following phenotypic screening of the Eli Lilly corporate library against M. tuberculosis. The novel N-alkylated pyrazole portion offered improved physicochemical properties, and optimization led to identification of a zwitterion series, exemplified by lead 29, with decreased HepG2 cytotoxicity as well as limited hERG ion channel inhibition. Strains with mutations in MmpL3 were resistant to 29, and under replicating conditions, 29 demonstrated bactericidal activity against M. tuberculosis. Unfortunately, compound 29 had no efficacy in an acute model of TB infection; this was most likely due to the in vivo exposure remaining above the minimal inhibitory concentration for only a limited time."><meta property="og:type" content="Article"><meta property="og:site_name" content="ACS Publications"><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content="@ACSPublications"><meta name="twitter:image" content="https://pubs.acs.org/cms/10.1021/acsomega.0c05589/asset/images/acsomega.0c05589.social.jpeg_v03">
    





    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0">















    

    <meta name="dc.identifier" content="10.1021/acsomega.0c05589">



<meta name="format-detection" content="telephone=no">




<link rel="stylesheet" type="text/css" href="/wro/l6j1~product.css">

<link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-c7d2282eca032afdc856.css"><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css">




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1640088552890.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1648583148410.css">
<script type="text/javascript" async="" src="//img.en25.com/i/elqCfg.min.js"></script><script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script><script async="" src="//www.google-analytics.com/analytics.js"></script><script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer="" src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon="{&quot;rayId&quot;:&quot;5200035e6e4d5180&quot;,&quot;startTime&quot;:1570117212010}"></script>

            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    , 'auto'
                    );
                
                ga('send', 'pageview');
            </script>
            











    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acsomega.0c05589">
            
        







    <!-- loading Javascript for using the persistence Service -->
    <script src="/templates/jsp/pb2/js/plugin/thiss-ds.js"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            alt_context: window.location.origin,
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if (ms == undefined || ms === '') {
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            if (results.length == 0) {
                                persistService.entities(self.alt_context).then((res) => {
                                    return resolve(res.data);
                                }, function (err) {
                                    // failed
                                    reject('failed to retrieve entity from local storage (publisher domain): ' + err);
                                });
                            } else {
                                return resolve(results);
                            }
                        }, function (err) {
                            // failed
                            reject('failed to retrieve entity from local storage: ' + err);
                        });
                    // Set up the timeout
                    setTimeout(function () {
                        reject('Promise timed out ' + ms + ' ms');
                    }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                    persistService.update(self.alt_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage (publisher domain) duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            var results = res.data;
                            if (!results) {
                                persistService.remove(self.alt_context, entityId).then((res) => {
                                    return resolve(res);
                                }, function (err) {
                                    // failed
                                    console.log('failed to remove from local storage (publisher domain) duo to: ' + err);
                                });
                            }
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId, entityTitle) {
                return new Promise(function (resolve, reject) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {
                            doi: doi,
                            entityid: entityId,
                            entityTitle: entityTitle,
                            eventGroupKey: '491ec829-efc4-4954-951e-759a6215ad7c'
                        }

                    }).done(function (status) {
                        return resolve(status);
                    }).fail(function (status) {
                        return reject(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID, ssoInstitution.entity.title)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + ssoInstitution.entity.entityID,err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            }).catch(function (err) {
                                reject(err);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();

                    if ($('.institution-preference-userconsent-checkbox').length > 0) {
                        let institutionPreferenceUserConsentCheckbox = $('.institution-preference-userconsent-checkbox').get(0);
                        if (!$(institutionPreferenceUserConsentCheckbox).is(":checked")) {
                            return;
                        }
                    }

                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err) {
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>







    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY">


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html">

<link rel="shortcut icon" href="/pb-assets/ux3/favicon-1635812676023.ico"><style type="text/css">.at-icon{fill:#fff;border:0}.at-icon-wrapper{display:inline-block;overflow:hidden}a .at-icon-wrapper{cursor:pointer}.at-rounded,.at-rounded-element .at-icon-wrapper{border-radius:12%}.at-circular,.at-circular-element .at-icon-wrapper{border-radius:50%}.addthis_32x32_style .at-icon{width:2pc;height:2pc}.addthis_24x24_style .at-icon{width:24px;height:24px}.addthis_20x20_style .at-icon{width:20px;height:20px}.addthis_16x16_style .at-icon{width:1pc;height:1pc}#at16lb{display:none;position:absolute;top:0;left:0;width:100%;height:100%;z-index:1001;background-color:#000;opacity:.001}#at_complete,#at_error,#at_share,#at_success{position:static!important}.at15dn{display:none}#at15s,#at16p,#at16p form input,#at16p label,#at16p textarea,#at_share .at_item{font-family:arial,helvetica,tahoma,verdana,sans-serif!important;font-size:9pt!important;outline-style:none;outline-width:0;line-height:1em}* html #at15s.mmborder{position:absolute!important}#at15s.mmborder{position:fixed!important;width:250px!important}#at15s{background:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABtJREFUeNpiZGBgaGAgAjAxEAlGFVJHIUCAAQDcngCUgqGMqwAAAABJRU5ErkJggg==);float:none;line-height:1em;margin:0;overflow:visible;padding:5px;text-align:left;position:absolute}#at15s a,#at15s span{outline:0;direction:ltr;text-transform:none}#at15s .at-label{margin-left:5px}#at15s .at-icon-wrapper{width:1pc;height:1pc;vertical-align:middle}#at15s .at-icon{width:1pc;height:1pc}.at4-icon{display:inline-block;background-repeat:no-repeat;background-position:top left;margin:0;overflow:hidden;cursor:pointer}.addthis_16x16_style .at4-icon,.addthis_default_style .at4-icon,.at4-icon,.at-16x16{width:1pc;height:1pc;line-height:1pc;background-size:1pc!important}.addthis_32x32_style .at4-icon,.at-32x32{width:2pc;height:2pc;line-height:2pc;background-size:2pc!important}.addthis_24x24_style .at4-icon,.at-24x24{width:24px;height:24px;line-height:24px;background-size:24px!important}.addthis_20x20_style .at4-icon,.at-20x20{width:20px;height:20px;line-height:20px;background-size:20px!important}.at4-icon.circular,.circular .at4-icon,.circular.aticon{border-radius:50%}.at4-icon.rounded,.rounded .at4-icon{border-radius:4px}.at4-icon-left{float:left}#at15s .at4-icon{text-indent:20px;padding:0;overflow:visible;white-space:nowrap;background-size:1pc;width:1pc;height:1pc;background-position:top left;display:inline-block;line-height:1pc}.addthis_vertical_style .at4-icon,.at4-follow-container .at4-icon{margin-right:5px}html>body #at15s{width:250px!important}#at15s.atm{background:none!important;padding:0!important;width:10pc!important}#at15s_inner{background:#fff;border:1px solid #fff;margin:0}#at15s_head{position:relative;background:#f2f2f2;padding:4px;cursor:default;border-bottom:1px solid #e5e5e5}.at15s_head_success{background:#cafd99!important;border-bottom:1px solid #a9d582!important}.at15s_head_success a,.at15s_head_success span{color:#000!important;text-decoration:none}#at15s_brand,#at15sptx,#at16_brand{position:absolute}#at15s_brand{top:4px;right:4px}.at15s_brandx{right:20px!important}a#at15sptx{top:4px;right:4px;text-decoration:none;color:#4c4c4c;font-weight:700}#at15sptx:hover{text-decoration:underline}#at16_brand{top:5px;right:30px;cursor:default}#at_hover{padding:4px}#at_hover .at_item,#at_share .at_item{background:#fff!important;float:left!important;color:#4c4c4c!important}#at_share .at_item .at-icon-wrapper{margin-right:5px}#at_hover .at_bold{font-weight:700;color:#000!important}#at_hover .at_item{width:7pc!important;padding:2px 3px!important;margin:1px;text-decoration:none!important}#at_hover .at_item.athov,#at_hover .at_item:focus,#at_hover .at_item:hover{margin:0!important}#at_hover .at_item.athov,#at_hover .at_item:focus,#at_hover .at_item:hover,#at_share .at_item.athov,#at_share .at_item:hover{background:#f2f2f2!important;border:1px solid #e5e5e5;color:#000!important;text-decoration:none}.ipad #at_hover .at_item:focus{background:#fff!important;border:1px solid #fff}.at15t{display:block!important;height:1pc!important;line-height:1pc!important;padding-left:20px!important;background-position:0 0;text-align:left}.addthis_button,.at15t{cursor:pointer}.addthis_toolbox a.at300b,.addthis_toolbox a.at300m{width:auto}.addthis_toolbox a{margin-bottom:5px;line-height:initial}.addthis_toolbox.addthis_vertical_style{width:200px}.addthis_button_facebook_like .fb_iframe_widget{line-height:100%}.addthis_button_facebook_like iframe.fb_iframe_widget_lift{max-width:none}.addthis_toolbox a.addthis_button_counter,.addthis_toolbox a.addthis_button_facebook_like,.addthis_toolbox a.addthis_button_facebook_send,.addthis_toolbox a.addthis_button_facebook_share,.addthis_toolbox a.addthis_button_foursquare,.addthis_toolbox a.addthis_button_linkedin_counter,.addthis_toolbox a.addthis_button_pinterest_pinit,.addthis_toolbox a.addthis_button_tweet{display:inline-block}.addthis_toolbox span.addthis_follow_label{display:none}.addthis_toolbox.addthis_vertical_style span.addthis_follow_label{display:block;white-space:nowrap}.addthis_toolbox.addthis_vertical_style a{display:block}.addthis_toolbox.addthis_vertical_style.addthis_32x32_style a{line-height:2pc;height:2pc}.addthis_toolbox.addthis_vertical_style .at300bs{margin-right:4px;float:left}.addthis_toolbox.addthis_20x20_style span{line-height:20px}.addthis_toolbox.addthis_32x32_style span{line-height:2pc}.addthis_toolbox.addthis_pill_combo_style .addthis_button_compact .at15t_compact,.addthis_toolbox.addthis_pill_combo_style a{float:left}.addthis_toolbox.addthis_pill_combo_style a.addthis_button_tweet{margin-top:-2px}.addthis_toolbox.addthis_pill_combo_style .addthis_button_compact .at15t_compact{margin-right:4px}.addthis_default_style .addthis_separator{margin:0 5px;display:inline}div.atclear{clear:both}.addthis_default_style .addthis_separator,.addthis_default_style .at4-icon,.addthis_default_style .at300b,.addthis_default_style .at300bo,.addthis_default_style .at300bs,.addthis_default_style .at300m{float:left}.at300b img,.at300bo img{border:0}a.at300b .at4-icon,a.at300m .at4-icon{display:block}.addthis_default_style .at300b,.addthis_default_style .at300bo,.addthis_default_style .at300m{padding:0 2px}.at300b,.at300bo,.at300bs,.at300m{cursor:pointer}.addthis_button_facebook_like.at300b:hover,.addthis_button_facebook_like.at300bs:hover,.addthis_button_facebook_send.at300b:hover,.addthis_button_facebook_send.at300bs:hover{opacity:1}.addthis_20x20_style .at15t,.addthis_20x20_style .at300bs{overflow:hidden;display:block;height:20px!important;width:20px!important;line-height:20px!important}.addthis_32x32_style .at15t,.addthis_32x32_style .at300bs{overflow:hidden;display:block;height:2pc!important;width:2pc!important;line-height:2pc!important}.at300bs{overflow:hidden;display:block;background-position:0 0;height:1pc;width:1pc;line-height:1pc!important}.addthis_default_style .at15t_compact,.addthis_default_style .at15t_expanded{margin-right:4px}#at_share .at_item{width:123px!important;padding:4px;margin-right:2px;border:1px solid #fff}#at16p{background:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABtJREFUeNpiZGBgaGAgAjAxEAlGFVJHIUCAAQDcngCUgqGMqwAAAABJRU5ErkJggg==);z-index:10000001;position:absolute;top:50%;left:50%;width:300px;padding:10px;margin:0 auto;margin-top:-185px;margin-left:-155px;font-family:arial,helvetica,tahoma,verdana,sans-serif;font-size:9pt;color:#5e5e5e}#at_share{margin:0;padding:0}#at16pt{position:relative;background:#f2f2f2;height:13px;padding:5px 10px}#at16pt a,#at16pt h4{font-weight:700}#at16pt h4{display:inline;margin:0;padding:0;font-size:9pt;color:#4c4c4c;cursor:default}#at16pt a{position:absolute;top:5px;right:10px;color:#4c4c4c;text-decoration:none;padding:2px}#at15sptx:focus,#at16pt a:focus{outline:thin dotted}#at15s #at16pf a{top:1px}#_atssh{width:1px!important;height:1px!important;border:0!important}.atm{width:10pc!important;padding:0;margin:0;line-height:9pt;letter-spacing:normal;font-family:arial,helvetica,tahoma,verdana,sans-serif;font-size:9pt;color:#444;background:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABtJREFUeNpiZGBgaGAgAjAxEAlGFVJHIUCAAQDcngCUgqGMqwAAAABJRU5ErkJggg==);padding:4px}.atm-f{text-align:right;border-top:1px solid #ddd;padding:5px 8px}.atm-i{background:#fff;border:1px solid #d5d6d6;padding:0;margin:0;box-shadow:1px 1px 5px rgba(0,0,0,.15)}.atm-s{margin:0!important;padding:0!important}.atm-s a:focus{border:transparent;outline:0;transition:none}#at_hover.atm-s a,.atm-s a{display:block;text-decoration:none;padding:4px 10px;color:#235dab!important;font-weight:400;font-style:normal;transition:none}#at_hover.atm-s .at_bold{color:#235dab!important}#at_hover.atm-s a:hover,.atm-s a:hover{background:#2095f0;text-decoration:none;color:#fff!important}#at_hover.atm-s .at_bold{font-weight:700}#at_hover.atm-s a:hover .at_bold{color:#fff!important}.atm-s a .at-label{vertical-align:middle;margin-left:5px;direction:ltr}.at_PinItButton{display:block;width:40px;height:20px;padding:0;margin:0;background-image:url(//s7.addthis.com/static/t00/pinit00.png);background-repeat:no-repeat}.at_PinItButton:hover{background-position:0 -20px}.addthis_toolbox .addthis_button_pinterest_pinit{position:relative}.at-share-tbx-element .fb_iframe_widget span{vertical-align:baseline!important}#at16pf{height:auto;text-align:right;padding:4px 8px}.at-privacy-info{position:absolute;left:7px;bottom:7px;cursor:pointer;text-decoration:none;font-family:helvetica,arial,sans-serif;font-size:10px;line-height:9pt;letter-spacing:.2px;color:#666}.at-privacy-info:hover{color:#000}.body .wsb-social-share .wsb-social-share-button-vert{padding-top:0;padding-bottom:0}.body .wsb-social-share.addthis_counter_style .addthis_button_tweet.wsb-social-share-button{padding-top:40px}.body .wsb-social-share.addthis_counter_style .addthis_button_facebook_like.wsb-social-share-button{padding-top:21px}@media print{#at4-follow,#at4-share,#at4-thankyou,#at4-whatsnext,#at4m-mobile,#at15s,.at4,.at4-recommended{display:none!important}}@media screen and (max-width:400px){.at4win{width:100%}}@media screen and (max-height:700px) and (max-width:400px){.at4-thankyou-inner .at4-recommended-container{height:122px;overflow:hidden}.at4-thankyou-inner .at4-recommended .at4-recommended-item:first-child{border-bottom:1px solid #c5c5c5}}</style><style type="text/css">.at-branding-logo{font-family:helvetica,arial,sans-serif;text-decoration:none;font-size:10px;display:inline-block;margin:2px 0;letter-spacing:.2px}.at-branding-logo .at-branding-icon{background-image:url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAMAAAC67D+PAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAAZQTFRF////+GlNUkcc1QAAAB1JREFUeNpiYIQDBjQmAwMmkwEM0JnY1WIxFyDAABGeAFEudiZsAAAAAElFTkSuQmCC")}.at-branding-logo .at-branding-icon,.at-branding-logo .at-privacy-icon{display:inline-block;height:10px;width:10px;margin-left:4px;margin-right:3px;margin-bottom:-1px;background-repeat:no-repeat}.at-branding-logo .at-privacy-icon{background-image:url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAkAAAAKCAMAAABR24SMAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAABhQTFRF8fr9ot/xXcfn2/P5AKva////////AKTWodjhjAAAAAd0Uk5T////////ABpLA0YAAAA6SURBVHjaJMzBDQAwCAJAQaj7b9xifV0kUKJ9ciWxlzWEWI5gMF65KUTv0VKkjVeTerqE/x7+9BVgAEXbAWI8QDcfAAAAAElFTkSuQmCC")}.at-branding-logo span{text-decoration:none}.at-branding-logo .at-branding-addthis,.at-branding-logo .at-branding-powered-by{color:#666}.at-branding-logo .at-branding-addthis:hover{color:#333}.at-cv-with-image .at-branding-addthis,.at-cv-with-image .at-branding-addthis:hover{color:#fff}a.at-branding-logo:visited{color:initial}.at-branding-info{display:inline-block;padding:0 5px;color:#666;border:1px solid #666;border-radius:50%;font-size:10px;line-height:9pt;opacity:.7;transition:all .3s ease;text-decoration:none}.at-branding-info span{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}.at-branding-info:before{content:'i';font-family:Times New Roman}.at-branding-info:hover{color:#0780df;border-color:#0780df}</style><meta http-equiv="origin-trial" content="AxujKG9INjsZ8/gUq8+dTruNvk7RjZQ1oFhhgQbcTJKDnZfbzSTE81wvC2Hzaf3TW4avA76LTZEMdiedF1vIbA4AAABueyJvcmlnaW4iOiJodHRwczovL2ltYXNkay5nb29nbGVhcGlzLmNvbTo0NDMiLCJmZWF0dXJlIjoiVHJ1c3RUb2tlbnMiLCJleHBpcnkiOjE2NTI3NzQ0MDAsImlzVGhpcmRQYXJ0eSI6dHJ1ZX0="><meta http-equiv="origin-trial" content="Azuce85ORtSnWe1MZDTv68qpaW3iHyfL9YbLRy0cwcCZwVnePnOmkUJlG8HGikmOwhZU22dElCcfrfX2HhrBPAkAAAB7eyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiVHJ1c3RUb2tlbnMiLCJleHBpcnkiOjE2NTI3NzQ0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9"><meta http-equiv="origin-trial" content="A16nvcdeoOAqrJcmjLRpl1I6f3McDD8EfofAYTt/P/H4/AWwB99nxiPp6kA0fXoiZav908Z8etuL16laFPUdfQsAAACBeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiVHJ1c3RUb2tlbnMiLCJleHBpcnkiOjE2NTI3NzQ0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9"><meta http-equiv="origin-trial" content="AxBHdr0J44vFBQtZUqX9sjiqf5yWZ/OcHRcRMN3H9TH+t90V/j3ENW6C8+igBZFXMJ7G3Pr8Dd13632aLng42wgAAACBeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiVHJ1c3RUb2tlbnMiLCJleHBpcnkiOjE2NTI3NzQ0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9"><meta http-equiv="origin-trial" content="A88BWHFjcawUfKU3lIejLoryXoyjooBXLgWmGh+hNcqMK44cugvsI5YZbNarYvi3roc1fYbHA1AVbhAtuHZflgEAAAB2eyJvcmlnaW4iOiJodHRwczovL2dvb2dsZS5jb206NDQzIiwiZmVhdHVyZSI6IlRydXN0VG9rZW5zIiwiZXhwaXJ5IjoxNjUyNzc0NDAwLCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv="origin-trial" content="AzoawhTRDevLR66Y6MROu167EDncFPBvcKOaQispTo9ouEt5LvcBjnRFqiAByRT+2cDHG1Yj4dXwpLeIhc98/gIAAACFeyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv="origin-trial" content="A6+nc62kbJgC46ypOwRsNW6RkDn2x7tgRh0wp7jb3DtFF7oEhu1hhm4rdZHZ6zXvnKZLlYcBlQUImC4d3kKihAcAAACLeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><meta http-equiv="origin-trial" content="A/9La288e7MDEU2ifusFnMg1C2Ij6uoa/Z/ylwJIXSsWfK37oESIPbxbt4IU86OGqDEPnNVruUiMjfKo65H/CQwAAACLeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjYxMjk5MTk5LCJpc1N1YmRvbWFpbiI6dHJ1ZSwiaXNUaGlyZFBhcnR5Ijp0cnVlfQ=="><script src="https://securepubads.g.doubleclick.net/gpt/pubads_impl_2022042801.js" async=""></script><script src="https://widgets.figshare.com/static/figshare.js?_=1651670068105"></script><script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.107/CcdcJsmolUtilities.min.js?_=1651670068106"></script><script src="https://common.ccdc.cam.ac.uk/jsmol/14.2.7/JSmol.min.nojq.js?_=1651670068107"></script><link type="text/css" rel="stylesheet" href="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.107/CcdcWidget.min.css"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable="">
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'omega';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/omega/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/omega/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
					console.log("ad display: " + event.creativeId + " " + event.size[0] + "x" + event.size[1]);
				}
				else {
				    console.log("no ad found");
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>

<style>
.articleHeaderDropzone5 .advertisement { display: none; }
.article_header .advertisement {
  margin: -25px auto 25px auto;
}
</style>




        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.107/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&amp;EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Indiana University Libraries - Bloomington</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"><input type="hidden" name="clientID" value="atypon-lives" class="clientID"><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"></a>




        
        <div class="pj-badge"></div><a href="/journal1/acsodf" title="ACS Omega" class="header_article-logo"><img src="/cms/10.1021/acsomega/asset/title.png" alt="ACS Omega"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <!-- Go to www.addthis.com/dashboard to customize your tools --><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook" title="Facebook" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter" title="Twitter" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat" target="_blank" title="WeChat" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin" target="_blank" title="LinkedIn" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit" target="_blank" title="Reddit" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email" target="_blank" title="Email" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li><div class="atclear"></div></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="acsodf" name="SeriesKey" checked="checked" class="all-content"></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"><select name="quickLinkJournal" class="quick-search_journals-select"><option value="acsodf">ACS Omega</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science &amp; Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials &amp; Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio &amp; Med Chem Au</option><option value="abseba">ACS Biomaterials Science &amp; Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health &amp; Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&amp;T Engineering</option><option value="aewcaa">ACS ES&amp;T Water</option><option value="afsthl">ACS Food Science &amp; Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="aoiab5">ACS Organic &amp; Inorganic Au</option><option value="aptsfn">ACS Pharmacology &amp; Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry &amp; Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&amp;EN Global Enterprise</option><option value="cenear">Chemical &amp; Engineering News Archive</option><option value="chlseg">Chemical Health &amp; Safety</option><option value="chlseg0">Chemical Health &amp; Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth &amp; Design</option><option value="enfuem">Energy &amp; Fuels</option><option value="esthag">Environmental Science &amp; Technology</option><option value="estlcu">Environmental Science &amp; Technology Letters</option><option value="iepra6.2">I&amp;EC Product Research and Development</option><option value="iechad">Industrial &amp; Engineering Chemistry</option><option value="iecac0">Industrial &amp; Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series</option><option value="iecfa7">Industrial &amp; Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial &amp; Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial &amp; Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial &amp; Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical &amp; Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health &amp; Safety</option><option value="jchsc20">Journal of Chemical Health &amp; Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial &amp; Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research &amp; Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&amp;D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autocomplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autocomplete="false" placeholder="Page" required="required" class="quick-search_page-input"><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden="”true”"></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><ul><li><a href="/doi/full/10.1021/acsomega.0c04611">Hydroxyaromatic Fluorophores</a></li><li><a href="/doi/full/10.1021/acsomega.0c05518">Optoacoustic/Fluorescent/Acoustic Imaging Probe Based on Air-Filled Bubbles Functionalized with Gold Nanorods and Fluorescein Isothiocyanate</a></li><li><a href="/doi/full/10.1021/acsomega.0c05746">In Situ Spectroelectrochemical Investigations of Electrode-Confined Electron-Transferring Proteins and Redox Enzymes</a></li><li><a href="/doi/full/10.1021/acsomega.0c05510">Influence of the pKa Value of Cinnamic Acid and P-Hydroxycinnamic Acid on the Solubility of a Lurasidone Hydrochloride-Based Coamorphous System</a></li><li><a href="/doi/full/10.1021/acsomega.0c05261">Surface-Enhanced Raman Scattering Sensing of Transition Metal Ions in Waters</a></li></ul></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden="”true”"></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden="”true”"></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden="”true”"></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors &amp; Reviewers');">Authors &amp;
                        Reviewers</a></li>
                <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
				<li><a href="https://pubs.acs.org/page/virtual-collections.html" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Virtual Issues');">Virtual Issues</a></li>
                <li><a href="https://preferences.acs.org/journals" onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS &amp; Mobile');">RSS &amp; Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products &amp; Services');">Products &amp; Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos &amp; Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#" onclick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');" class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/who-we-serve/librarians/" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians &amp; Account Managers');">For
                        Librarians &amp; Account Managers</a></li>
            </ul>
        </li>
        <li class="menu-pair-section hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pb/widgets/affiliateDevice">Pair a device</a></li>
                
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pb/widgets/affiliateDevice">Pair a device</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS &amp; Open Access');">ACS &amp; Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="/events" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><!-- Types--><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><!-- Subjects--><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><!--div.pub-modal_right-cover-gallery.hidden-lg.hidden-md//a(href="/coverGallery") Browse Our Cover Art Gallery
--><!-- Publications list--><!-- 'pub-modal_right--inner' adds styling required for IE--><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><!-- The widget data--><input type="hidden" id="ajaxUrl" name="ajaxUrl" value="/pb/widgets/achs-publication-list?widgetId=cabcb15c-6f7a-494b-a19c-eba4fafaee5c&amp;pbContext=%3Bjournal%3Ajournal%3Aacsodf%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facsomega.0c05589%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Facsodf.2021.6.issue-3%3Bwebsite%3Awebsite%3Aacspubs%3BrequestedJournal%3Ajournal%3Aacsodf%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;key=c7ca46a97ce077568c7371697bcd489c0&amp;ajaxRequest=true"><input type="hidden" name="pubModalData" value=""></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facsomega.0c05589&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facsomega.0c05589&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acsomega.0c05589&amp;href=/doi/10.1021/acsomega.0c05589" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>ACS Omega</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 6</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 2284-2311</span></span></span></div></div></div></div></div><input type="hidden" name="acsodf" id="copyRights" value="/pb-assets/json/journal-info-1641590078917.json"><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/acsodf/6/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acsomega.0c05585" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acsomega.0c05619" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/acsodf" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/cms/10.1021/acsomega/asset/title.png" alt="Journal Logo"></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of <i>Mycobacterium tuberculosis</i> Growth</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Peter C. Ray</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter C. Ray</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+C.++Ray">Peter C. Ray</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Margaret Huggett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Margaret Huggett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Margaret++Huggett">Margaret Huggett</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Penelope A. Turner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Penelope A. Turner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Penelope+A.++Turner">Penelope A. Turner</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Malcolm Taylor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Malcolm Taylor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Malcolm++Taylor">Malcolm Taylor</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Laura A. T. Cleghorn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laura A. T. Cleghorn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laura+A.+T.++Cleghorn">Laura A. T. Cleghorn</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Julie Early</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie Early</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Early">Julie Early</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Anuradha Kumar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anuradha Kumar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anuradha++Kumar">Anuradha Kumar</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Shilah A. Bonnett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shilah A. Bonnett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shilah+A.++Bonnett">Shilah A. Bonnett</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Lindsay Flint</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lindsay Flint</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lindsay++Flint">Lindsay Flint</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Douglas Joerss</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas Joerss</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas++Joerss">Douglas Joerss</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">James Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Johnson">James Johnson</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Aaron Korkegian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aaron Korkegian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aaron++Korkegian">Aaron Korkegian</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Steven Mullen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven Mullen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Mullen">Steven Mullen</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Abraham L. Moure</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Abraham L. Moure</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Abraham+L.++Moure">Abraham L. Moure</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Susan H. Davis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan H. Davis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan+H.++Davis">Susan H. Davis</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Dinakaran Murugesan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dinakaran Murugesan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dinakaran++Murugesan">Dinakaran Murugesan</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Michael Mathieson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Mathieson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Mathieson">Michael Mathieson</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Nicola Caldwell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicola Caldwell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicola++Caldwell">Nicola Caldwell</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Curtis A. Engelhart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Curtis A. Engelhart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Curtis+A.++Engelhart">Curtis A. Engelhart</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Dirk Schnappinger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dirk Schnappinger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dirk++Schnappinger">Dirk Schnappinger</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Ola Epemolu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ola Epemolu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ola++Epemolu">Ola Epemolu</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Fabio Zuccotto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabio Zuccotto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabio++Zuccotto">Fabio Zuccotto</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Jennifer Riley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer Riley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Riley">Jennifer Riley</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Paul Scullion</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Scullion</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Scullion">Paul Scullion</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Laste Stojanovski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laste Stojanovski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laste++Stojanovski">Laste Stojanovski</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Lisa Massoudi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa Massoudi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mycobacteria Research Laboratories, Colorado State University, 200 W. Lake Street, Fort Collins, Colorado 80523-1682, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Massoudi">Lisa Massoudi</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Gregory T. Robertson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory T. Robertson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mycobacteria Research Laboratories, Colorado State University, 200 W. Lake Street, Fort Collins, Colorado 80523-1682, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory+T.++Robertson">Gregory T. Robertson</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Anne J. Lenaerts</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anne J. Lenaerts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Mycobacteria Research Laboratories, Colorado State University, 200 W. Lake Street, Fort Collins, Colorado 80523-1682, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anne+J.++Lenaerts">Anne J. Lenaerts</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Gail Freiberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gail Freiberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gail++Freiberg">Gail Freiberg</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Dale J. Kempf</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dale J. Kempf</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dale+J.++Kempf">Dale J. Kempf</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0002-1408-9099" title="Orcid link">http://orcid.org/0000-0002-1408-9099</a></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Thierry Masquelin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thierry Masquelin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry Research, Eli Lilly and Company, Lilly Corporate Centre, MC/87/02/203, G17, Indianapolis, Indiana 46285, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thierry++Masquelin">Thierry Masquelin</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Philip A. Hipskind</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip A. Hipskind</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lgenia Inc., Fortville, Indiana 46040, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip+A.++Hipskind">Philip A. Hipskind</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Joshua Odingo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joshua Odingo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joshua++Odingo">Joshua Odingo</a></span></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Kevin D. Read</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin D. Read</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+D.++Read">Kevin D. Read</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0002-8536-0130" title="Orcid link">http://orcid.org/0000-0002-8536-0130</a></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Simon R. Green</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon R. Green</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="mailto:s.r.green@dundee.ac.uk">s.r.green@dundee.ac.uk</a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+R.++Green">Simon R. Green</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0001-5054-4792" title="Orcid link">http://orcid.org/0000-0001-5054-4792</a></div></div></span></li><span class="comma-separator">,&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Paul G. Wyatt</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul G. Wyatt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="mailto:P.G.Wyatt@dundee.ac.uk">P.G.Wyatt@dundee.ac.uk</a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+G.++Wyatt">Paul G. Wyatt</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0002-0397-245X" title="Orcid link">http://orcid.org/0000-0002-0397-245X</a></div></div></span></li><span class="comma-separator">,&nbsp;and&nbsp;</span><li><span><span class="hlFld-ContribAuthor">Tanya Parish</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tanya Parish</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">TB Discovery Research, Infectious Disease Research Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="mailto:Tanya.parish@seattlechildrens.org">Tanya.parish@seattlechildrens.org</a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tanya++Parish">Tanya Parish</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0001-7507-0423" title="Orcid link">http://orcid.org/0000-0001-7507-0423</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="acsodf"><input type="hidden" name="journalNameForjhpLink" value="ACS Omega"><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facsomega.0c05589&amp;href=/doi/10.1021%2Facsomega.0c05589" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>ACS Omega</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 6</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 2284–2311</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 13, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 November 2020</li><li><span class="item_label"><b>Accepted</b></span>21 December 2020</li><li><span class="item_label"><b>Published</b> online</span>13 January 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acsomega.0c05589" title="DOI URL">https://doi.org/10.1021/acsomega.0c05589</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS &amp; PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice"><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acsomega.0c05589"><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1436</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <!-- Go to www.addthis.com/dashboard to customize your tools --><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"><input type="hidden" name="clientID" value="atypon-lives" class="clientID"><input type="hidden" class="doi" value="10.1021/acsomega.0c05589"><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;C. Ray&quot;},{&quot;first_name&quot;:&quot;Margaret&quot;,&quot;last_name&quot;:&quot;Huggett&quot;},{&quot;first_name&quot;:&quot;Penelope&quot;,&quot;last_name&quot;:&quot;A. Turner&quot;},{&quot;first_name&quot;:&quot;Malcolm&quot;,&quot;last_name&quot;:&quot;Taylor&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;A. T. Cleghorn&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Early&quot;},{&quot;first_name&quot;:&quot;Anuradha&quot;,&quot;last_name&quot;:&quot;Kumar&quot;},{&quot;first_name&quot;:&quot;Shilah&quot;,&quot;last_name&quot;:&quot;A. Bonnett&quot;},{&quot;first_name&quot;:&quot;Lindsay&quot;,&quot;last_name&quot;:&quot;Flint&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;Joerss&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Aaron&quot;,&quot;last_name&quot;:&quot;Korkegian&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Mullen&quot;},{&quot;first_name&quot;:&quot;Abraham&quot;,&quot;last_name&quot;:&quot;L. Moure&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;H. Davis&quot;},{&quot;first_name&quot;:&quot;Dinakaran&quot;,&quot;last_name&quot;:&quot;Murugesan&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Mathieson&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;Caldwell&quot;},{&quot;first_name&quot;:&quot;Curtis&quot;,&quot;last_name&quot;:&quot;A. Engelhart&quot;},{&quot;first_name&quot;:&quot;Dirk&quot;,&quot;last_name&quot;:&quot;Schnappinger&quot;},{&quot;first_name&quot;:&quot;Ola&quot;,&quot;last_name&quot;:&quot;Epemolu&quot;},{&quot;first_name&quot;:&quot;Fabio&quot;,&quot;last_name&quot;:&quot;Zuccotto&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Riley&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Scullion&quot;},{&quot;first_name&quot;:&quot;Laste&quot;,&quot;last_name&quot;:&quot;Stojanovski&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Massoudi&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;T. Robertson&quot;},{&quot;first_name&quot;:&quot;Anne&quot;,&quot;last_name&quot;:&quot;J. Lenaerts&quot;},{&quot;first_name&quot;:&quot;Gail&quot;,&quot;last_name&quot;:&quot;Freiberg&quot;},{&quot;first_name&quot;:&quot;Dale&quot;,&quot;last_name&quot;:&quot;J. Kempf&quot;},{&quot;first_name&quot;:&quot;Thierry&quot;,&quot;last_name&quot;:&quot;Masquelin&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;A. Hipskind&quot;},{&quot;first_name&quot;:&quot;Joshua&quot;,&quot;last_name&quot;:&quot;Odingo&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;D. Read&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;R. Green&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;G. Wyatt&quot;},{&quot;first_name&quot;:&quot;Tanya&quot;,&quot;last_name&quot;:&quot;Parish&quot;}],&quot;source&quot;:&quot;ACS Omega&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;6&quot;,&quot;pages&quot;:&quot;2284-2311&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acsomega.0c05589&quot;},&quot;abstract&quot;:&quot;With the emergence of multi-drug-resistant strains of Mycobacterium tuberculosis, there is a pressing need for new oral drugs with novel mechanisms of action. A number of scaffolds with potent anti-tubercular in vitro activity have been identified from phenotypic screening that appear to target MmpL3. However, the scaffolds are typically lipophilic, which facilitates partitioning into hydrophobic membranes, and several contain basic amine groups. Highly lipophilic basic amines are typically cytotoxic against mammalian cell lines and have associated off-target risks, such as inhibition of human ether-à-go-go related gene (hERG) and IKr potassium current modulation. The spirocycle compound 3 was reported to target MmpL3 and displayed promising efficacy in a murine model of acute tuberculosis (TB) infection. However, this highly lipophilic monobasic amine was cytotoxic and inhibited the hERG ion channel. Herein, the related spirocycles (1–2) are described, which were identified following phenotypic screening of &quot;}" class="meta-data"><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"><input type="hidden" name="pub-access" value="free" class="pub-access"><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"><input type="hidden" name="selected-share-option" class="selected-share-option"></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facsomega.0c05589&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acsomega.0c05589" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facsomega.0c05589&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acsomega.0c05589" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facsomega.0c05589&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acsomega.0c05589" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facsomega.0c05589&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acsomega.0c05589&amp;href=/doi/10.1021/acsomega.0c05589" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook" title="Facebook" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter" title="Twitter" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat" target="_blank" title="WeChat" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin" target="_blank" title="LinkedIn" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit" target="_blank" title="Reddit" href="#"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><div class="atclear"></div></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acsomega.0c05589"><a href="/doi/pdf/10.1021/acsomega.0c05589" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acsomega.0c05589&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fid%3Ddoi%3A10.1021%252Facsomega.0c05589%26sid%3Dliteratum%253Aachs%26pmid%3D33521468%26genre%3Darticle%26aulast%3DRay%26date%3D2021%26atitle%3DSpirocycle%2BMmpL3%2BInhibitors%2Bwith%2BImproved%2BhERG%2Band%2BCytotoxicity%2BProfiles%2Bas%2BInhibitors%2Bof%2BMycobacterium%2Btuberculosis%2BGrowth%26jtitle%3DACS%2BOmega%26title%3DACS%2BOmega%26volume%3D6%26issue%3D3%26spage%3D2284%26epage%3D2311" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"><input type="hidden" name="is-enabled" value="true" class="is-enabled"><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"><!-- TODO: comment out below line:--><!--input.acs-id(type="hidden" name="acs-id" value="31838729")--><input type="hidden" name="pub-code" value="acsodf" class="pub-code"><input type="hidden" name="linkout-url" value="https://preferences.acs.org/journals" class="linkout-url"><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acs.org/acsodf?ifr=1"></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollduration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a>,</li><li><a href="/action/doSearch?ConceptID=291214" title="Bacteria">Bacteria</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291241" title="Phenyls">Phenyls</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/acsodf/6/3" title="Go to ACS Omega "><img src="/cms/10.1021/acsodf.2021.6.issue-3/asset/acsodf.2021.6.issue-3.largecover.jpg" alt="Go to ACS Omega "></a></div></div>




        
        <!--Article Page E-Alerts-->
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','acsodf');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','acsodf');
	  }
  });
</script>
<!--End Article Script-->




        
        <div class="pj-badge"><input type="hidden" id="partnerJournalInfo" value="/pb-assets/json/journal-info-1641590078917.json"></div>




        
        <div class="aJhp_link"></div>
<input type="hidden" id="aJhpJournalInfo" value="/pb-assets/json/journal-info-1641590078917.json">
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=acsodf" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0012.gif" alt="" id="tgr1"><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">With the emergence of multi-drug-resistant strains of <i>Mycobacterium tuberculosis,</i> there is a pressing need for new oral drugs with novel mechanisms of action. A number of scaffolds with potent anti-tubercular <i>in vitro</i> activity have been identified from phenotypic screening that appear to target MmpL3. However, the scaffolds are typically lipophilic, which facilitates partitioning into hydrophobic membranes, and several contain basic amine groups. Highly lipophilic basic amines are typically cytotoxic against mammalian cell lines and have associated off-target risks, such as inhibition of human ether-à-go-go related gene (hERG) and IKr potassium current modulation. The spirocycle compound <b>3</b> was reported to target MmpL3 and displayed promising efficacy in a murine model of acute tuberculosis (TB) infection. However, this highly lipophilic monobasic amine was cytotoxic and inhibited the hERG ion channel. Herein, the related spirocycles (<b>1–2</b>) are described, which were identified following phenotypic screening of the Eli Lilly corporate library against <i>M. tuberculosis</i>. The novel N-alkylated pyrazole portion offered improved physicochemical properties, and optimization led to identification of a zwitterion series, exemplified by lead <b>29</b>, with decreased HepG2 cytotoxicity as well as limited hERG ion channel inhibition. Strains with mutations in MmpL3 were resistant to <b>29</b>, and under replicating conditions, <b>29</b> demonstrated bactericidal activity against <i>M. tuberculosis</i>. Unfortunately, compound <b>29</b> had no efficacy in an acute model of TB infection; this was most likely due to the <i>in vivo</i> exposure remaining above the minimal inhibitory concentration for only a limited time.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00020" class="dropBlock__holder"></div></div></div></div></div><hr><div class="NLM_p"><i>Mycobacterium tuberculosis</i>, <a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> the causative agent of tuberculosis (TB), can be fatal if not properly treated and disproportionately affects the poor in developing countries. In 2015, TB became the world’s most deadly infectious disease, killing 1.4 million people (1.2 million HIV-negative and 0.3 million HIV-positive) in 2019. <a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The current 6 month treatment results in high default rates, increased transmission, and drug resistance. <a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> In order to reduce treatment length, TB treatments working through novel mechanisms are needed. <a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> However, identifying novel drugs remains a significant challenge, and high-quality leads are still urgently required. <a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a></div><div class="NLM_p">Target-directed TB drug discovery programs have historically been largely unsuccessful in delivering high-quality late-stage leads. <a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> To address this issue, cell-based phenotypic screening became a focus for identifying active starting points. Many of the most potent phenotypic hits target membrane proteins such as DprE1 and MmpL3 that are involved in cell wall biosynthesis. <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> MmpL3 is required for the export of trehalose monomycolates (TMM) to the periplasmic space and outer membrane of <i>M. tuberculosis</i>. A number of structurally diverse putative MmpL3 inhibitor series have been reported. <a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29">(12−29)</a> Several of these series inhibit MmpL3-mediated TMM export but may also have pleiotropic effects targeting the proton motive force. <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">The scaffolds of MmpL3 inhibitors are typically lipophilic, which facilitates partitioning into hydrophobic membranes, and several contain basic amine groups. Highly lipophilic basic amines are typically cytotoxic against mammalian cell lines and have associated off-target risks, such as inhibition of human ether-à-go-go related gene (hERG) and IKr potassium current modulation. One particular spirocyclic series has been reported as a potential MmpL3 inhibitor following a phenotypic screen of the GSK library against <i>Mycobacterium bovis</i>. <a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Although further exploration of this original hit identified compounds with excellent <i>in vivo</i> activity against <i>M. tuberculosis</i> (<b>3</b>), the series was discontinued because of concerns over safety related to the lipophilicity and basic nature of the scaffold. <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Of note, the original authors highlighted that further exploration may be able to design around the series liabilities while retaining the remarkable <i>in vivo</i> potency <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">Herein, we report on a novel pyrazole spirocyclic amine series (<b>1</b> and <b>2</b>) with a putative MmpL3 mechanism of action that is structurally related to <b>3</b> (<a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Table </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a>). The novel pyrazole portion offered improved physicochemical properties, and optimization led to identification of a zwitterionic series, with improved selectivity over both HepG2 cytotoxicity and hERG inhibition. The zwitterionic series retained potent <i>M. tuberculosis</i> whole cell activity, with large shifts against MmpL3 mutant strains. Unfortunately, the series representative with the best overall properties, <b>29</b>, failed to show efficacy in an acute model of TB infection. As such, further work on this series was put on hold. We feel that the approach presented indicates useful insights into mechanisms for reduction of metabolism and hERG liabilities while highlighting the challenge within drug discovery of balancing these properties with potency.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Profile of Early Hits against a Reported MmpL3 Inhibitor</div></div></div><img class="imgWithoutFigViewer " src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0008.gif" alt="" id="GRAPHIC-d7e757-autogenerated"><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left"><col align="left"><col align="left"><col align="left"><col align="left"></colgroup><thead><tr class="colsep0" valign="top"><th class="colsep0 rowsep0" align="center">&nbsp;</th><th class="colsep0 rowsep0" align="center">confirmed hit <b>1</b></th><th class="colsep0 rowsep0" align="center">confirmed hit <b>2</b></th><th class="colsep0 rowsep0" align="center">GSK-SPIRO <b>3</b></th><th class="colsep0 rowsep0" align="center">early lead <b>4</b></th></tr></thead><tbody><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">MIC<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (μM)</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">0.11</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">MIC&nbsp;MmpL3&nbsp;F255L mut.&nbsp;(μM)</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">2.6</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">hERG<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">2.9<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.1<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">3.1<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">3.1<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">HepG2<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a> (μM)</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">38</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">LLE</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">4.3</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">SFI</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="left">5.4</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">kin. solubility (μM)</td><td class="colsep0 rowsep0" align="left">&gt;250</td><td class="colsep0 rowsep0" align="left">&gt;250</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">&gt;250</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">MW</td><td class="colsep0 rowsep0" align="left">379</td><td class="colsep0 rowsep0" align="left">373</td><td class="colsep0 rowsep0" align="left">475</td><td class="colsep0 rowsep0" align="left">373</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">clog&nbsp;<i>D</i><sub>pH7.4</sub></td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">TPSA (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">mouse&nbsp;Cl<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a> (mL/min/g)</td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">human&nbsp;Cl<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a> (mL/min/g)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">4.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">MIC is the minimum concentration required to inhibit the growth of <i>M. tuberculosis</i> (H37Rv) in liquid culture. All MIC values are an average of at least two measurements.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">hERG functional thallium flux inhibitory concentration (IC<sub>50</sub>).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">hERG functional Q-patch inhibitory concentration (IC<sub>50</sub>).</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">HepG2 inhibitory concentration (IC<sub>50</sub>) is the concentration required to inhibit growth of HepG2 cells by 50%.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Intrinsic clearance (Cli) using CD1 mouse liver microsomes.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Intrinsic clearance (Cli) using pooled human liver microsomes. LLE is the lipophilic ligand efficiency; SFI is the solubility forecast index; TPSA is the total polar surface area. Estimations of clog <i>D</i><sub>pH7.4</sub> and TPSA were calculated using StarDrop (<a href="http://www.optibrium.com" class="extLink">http://www.optibrium.com</a>).</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47303" class="dropBlock__holder"></div></div></div></div></div><hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Structure–Activity Relationship</h3><div class="NLM_p">To identify novel anti-tubercular agents, an aerobic whole cell phenotypic screen was undertaken, evaluating the Eli Lilly corporate screening deck against <i>M. tuberculosis</i> strain H37Rv. One of the outcomes of this screen was the identification of a cluster of pyrazole-containing spirocyclic amine analogues; the spirocyclic portion of the molecule showed a clear structural resemblance to <b>3</b>, a previously reported spirocycle series (<a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Table </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a>). <a onclick="showRef(event, 'ref19 ref30'); return false;" href="javascript:void(0);" class="ref ref19 ref30">(19,30)</a> The initial hits had good anti-tubercular activity with a minimum inhibitory concentration (MIC) of 0.22 and 0.14 μM for <b>1</b> and <b>2</b>, respectively (<a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Table </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a>). As the original spirocycle compound was considered to be an MmpL3 inhibitor, we tested the activity of these two compounds against a strain containing a mutation in MmpL3 (F255L) and observed a large shift in the MIC confirming the likely on-target activity (<a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Table </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a>).</div><div class="NLM_p">According to the literature, <b>3</b> had not been developed further because “it suffered from a high clog <i>P</i> value, with the consequent potential liabilities for further development”. <a onclick="showRef(event, 'ref19 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref19 ref30 ref31">(19,30,31)</a> Compounds <b>1</b> and <b>2</b> offered an attractive alternative to <b>3</b> because the central aromatic ring in both was a pyrazole not a phenyl; this modification was predicted to reduce the clog <i>D</i><sub>pH7.4</sub> by around 1 log unit. The reduced lipophilicity translated into a better solubility forecast index and <i>M. tuberculosis</i>-derived LLE, <a onclick="showRef(event, 'ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35">(32−35)</a> providing optimism for improving off-target liabilities, metabolic stability, as well as solubility profile. Unfortunately, as a result of the basic nature of the piperidine group, hERG inhibition remained an issue for <b>1</b> and <b>2</b>; moreover, despite the lower clog <i>D</i><sub>pH7.4</sub>, both showed unexpectedly high mouse microsomal clearance.</div><div class="NLM_p">Initial emphasis for expansion of the confirmed hits <b>1</b> and <b>2</b> was placed on understanding the scope for improving hERG channel inhibition and microsomal stability. The pyrazole of <b>1</b> and the spirocycle of <b>2</b> were combined to afford <b>4</b>, which showed marginally improved selectivity over the hERG channel, although the mouse microsomal clearance remained high (<a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Tables </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-id="tbl2" href="#tbl2">2</a>). In addition, the human microsomal metabolic stability was higher for <b>4</b> than the published molecule <b>3</b>, although both values were lower than the equivalent mouse data. As a first step to attempt to reduce metabolism of <b>4</b>, a mouse microsomal metabolite identification study was carried out to evaluate why the pyrazole series had worse microsomal stability than <b>3</b> despite a lower clog <i>D</i><sub>pH7.4</sub> (<a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Table </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a>). This showed that <b>4</b> was metabolized rapidly to four main metabolites primarily involving hydroxylation. After a 3 min incubation in mouse microsomes, only 29% of the parent ion remained, while 61% of the detectable ions were associated with three metabolites that resulted from hydroxylation associated with regions of the molecule around the spirocycle group (<a href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_001.pdf" class="ext-link">Table S1</a>; <a href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_001.pdf" class="ext-link">Figures S1 and S2</a>). Because phenyl groups are known to be prone to hydroxylation, which can be prevented by fluorination, <a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> the phenyl substituent on the spirocycle was replaced by a series of different fluoro-substituted phenyl groups (<a class="ref showTableEvent internalNav" data-id="tbl2" href="#tbl2">Table </a><a class="ref showTableEvent internalNav" data-id="tbl2" href="#tbl2">2</a>). Unfortunately, compounds that retained good MIC activity remained very unstable in mouse microsomes, while the compounds with improved metabolic stability had significantly decreased potency (<a class="ref showTableEvent internalNav" data-id="tbl2" href="#tbl2">Table </a><a class="ref showTableEvent internalNav" data-id="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Evaluation of Spirocycle Analogues</div></div></div><img class="imgWithoutFigViewer " src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0009.gif" alt="" id="GRAPHIC-d7e1240-autogenerated"><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left"><col align="left"><col align="left"><col char="." align="char"><col align="left"><col char="." align="char"><col align="left"></colgroup><thead><tr class="colsep0" valign="top"><th class="colsep0 rowsep0" align="center">&nbsp;</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">MIC<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> μM</th><th class="colsep0 rowsep0" char="." align="center">clog&nbsp;<i>D</i><sub>pH7.4</sub></th><th class="colsep0 rowsep0" align="center">hERG<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> IC<sub>50</sub> μM</th><th class="colsep0 rowsep0" char="." align="center">HepG2<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> IC<sub>50</sub> μM</th><th class="colsep0 rowsep0" align="center">mouse Cli<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (mL/min/g)</th></tr></thead><tbody><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" char="." align="char">2.5</td><td class="colsep0 rowsep0" align="left">3.1<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" char="." align="char">38</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">no group</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" char="." align="char">1.7</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" char="." align="char">&nbsp;</td><td class="colsep0 rowsep0" align="left">28</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">6-fluorophenyl</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" char="." align="char">2.7</td><td class="colsep0 rowsep0" align="left">3.5<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" char="." align="char">48</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">7-fluorophenyl</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" char="." align="char">2.7</td><td class="colsep0 rowsep0" align="left">4.7<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" char="." align="char">32</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">6,7-difluorophenyl</td><td class="colsep0 rowsep0" align="left">0.69</td><td class="colsep0 rowsep0" char="." align="char">2.8</td><td class="colsep0 rowsep0" align="left">1.8<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" char="." align="char">14</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">6-CF<sub>3</sub>-phenyl</td><td class="colsep0 rowsep0" align="left">&gt;20</td><td class="colsep0 rowsep0" char="." align="char">3.1</td><td class="colsep0 rowsep0" align="left">0.8<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" char="." align="char">7</td><td class="colsep0 rowsep0" align="left">9</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">7,8-difluorophenyl</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" char="." align="char">2.8</td><td class="colsep0 rowsep0" align="left">1.7<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" char="." align="char">16</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">See <a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Table </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a> for explanation.</p></div></div></div><div class="NLM_p">To examine the metabolic stability further, isoform-specific cytochrome P450 studies were carried out on <b>4</b>, evaluating CYP3A4 and CYP2D6 as the two most abundant human CYP450 enzymes. Pyrazole <b>4</b> was more rapidly cleared by CYP2D6 bactosomes (0.34 min<sup>–1</sup>) than CYP3A4 bactosomes (0.07 min<sup>–1</sup>). As the CYP2D6-active site is known to be smaller in comparison to CYP3A4, <a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> it was proposed that increasing the size of substituents on either the 5-methyl pyrazole or the phenyl in <b>4</b> could potentially lead to a decrease in CYP2D6 metabolism and thereby improve the metabolic stability to be more in line with the larger compound <b>3</b>.</div><div class="NLM_p">To test the above hypothesis, the structure–activity relationship (SAR) around the methyl and phenyl substituents was expanded. Initial modifications to the 5-methyl pyrazole had little effect on MIC, hERG channel inhibition, or metabolic stability (<b>11–14</b>), and so further exploration of this substituent was put on hold. For the phenyl substituted compounds <b>15–17</b>, there was a trend toward improved metabolic stability, in particular with the bulky OCF<sub>3</sub> blocking group of <b>17</b> despite it having a high clog <i>D</i><sub>pH7.4</sub> (<a class="ref showTableEvent internalNav" data-id="tbl3" href="#tbl3">Table </a><a class="ref showTableEvent internalNav" data-id="tbl3" href="#tbl3">3</a>). In an attempt to reduce or maintain as low a clog <i>D</i><sub>pH7.4</sub> as possible, the SAR around a 1-pyridyl substituent was explored. For the pyridyl-substituted compounds <b>18–20</b>, again there was a trend toward improved metabolic stability, in particular with bulkier and more lipophilic groups such as the CF<sub>3</sub> in <b>20</b> (<a class="ref showTableEvent internalNav" data-id="tbl3" href="#tbl3">Table </a><a class="ref showTableEvent internalNav" data-id="tbl3" href="#tbl3">3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> Evaluation of Spirocycle Analogues</div></div></div><img class="imgWithoutFigViewer " src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0010.gif" alt="" id="GRAPHIC-d7e1555-autogenerated"><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left"><col align="left"><col align="left"><col align="left"><col char="." align="char"><col align="left"><col align="left"><col align="left"></colgroup><thead><tr class="colsep0" valign="top"><th class="colsep0 rowsep0" align="center">&nbsp;</th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">MIC<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (μM)</th><th class="colsep0 rowsep0" char="." align="center">clog&nbsp;<i>D</i><sub>pH7.4</sub></th><th class="colsep0 rowsep0" align="center">hERG<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">HepG2<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">mouse Cli<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (mL/min/g)</th></tr></thead><tbody><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" char="." align="char">2.5</td><td class="colsep0 rowsep0" align="left">2.1<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">CyPr</td><td class="colsep0 rowsep0" align="left">0.10</td><td class="colsep0 rowsep0" char="." align="char">3.0</td><td class="colsep0 rowsep0" align="left">2.2<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" char="." align="char">3.1</td><td class="colsep0 rowsep0" align="left">3.6<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.09</td><td class="colsep0 rowsep0" char="." align="char">3.1</td><td class="colsep0 rowsep0" align="left">4.7<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">4-(hydroxymethyl)&nbsp;phenyl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" char="." align="char">2.0</td><td class="colsep0 rowsep0" align="left">5.0<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">8.5</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">4-methylphenyl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" char="." align="char">2.6</td><td class="colsep0 rowsep0" align="left">2.5<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">4-(trifluoromethoxy)&nbsp;phenyl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">0.36</td><td class="colsep0 rowsep0" char="." align="char">3.4</td><td class="colsep0 rowsep0" align="left">1.9<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left">7</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">6-methoxy&nbsp;pyridin-3-yl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">0.37</td><td class="colsep0 rowsep0" char="." align="char">2.0</td><td class="colsep0 rowsep0" align="left">3.5<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">44</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">6-(difluoromethoxy)-pyridin-3-yl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">0.21</td><td class="colsep0 rowsep0" char="." align="char">2.5</td><td class="colsep0 rowsep0" align="left">0.52<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">6-(trifluoromethyl)&nbsp;pyridin-3-yl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">0.51</td><td class="colsep0 rowsep0" char="." align="char">2.6</td><td class="colsep0 rowsep0" align="left">2.7<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">2-benzoic acid</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">&gt;20</td><td class="colsep0 rowsep0" char="." align="char">0.6</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">&lt;0.5</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">3-benzoic acid</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" char="." align="char">0.5</td><td class="colsep0 rowsep0" align="left">10.2<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1.6</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" char="." align="char">0.6</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">0.77</td><td class="colsep0 rowsep0" char="." align="char">0.9</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">iPr</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" char="." align="char">1.4</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1.2</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left"><i>t</i>Bu</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" char="." align="char">1.3</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" char="." align="char">1.3</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">0.7</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.65</td><td class="colsep0 rowsep0" char="." align="char">1.5</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">CyPr</td><td class="colsep0 rowsep0" align="left">0.66</td><td class="colsep0 rowsep0" char="." align="char">1.2</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">CyBu</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" char="." align="char">1.5</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1.6</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" char="." align="char">0.6</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left">OEt</td><td class="colsep0 rowsep0" align="left">0.53</td><td class="colsep0 rowsep0" char="." align="char">0.9</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">3.8</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left"><i>N</i>-pyrrolidino-</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" char="." align="char">1.3</td><td class="colsep0 rowsep0" align="left">&nbsp;</td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">4-benzoic acid</td><td class="colsep0 rowsep0" align="left"><i>N</i>-morpholino-</td><td class="colsep0 rowsep0" align="left">&gt;20</td><td class="colsep0 rowsep0" char="." align="char">1.3</td><td class="colsep0 rowsep0" align="left">&nbsp;</td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">&lt;0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">See <a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Table </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a> for explanation.</p></div></div></div><div class="NLM_p last">As an alternative phenyl substitution, the addition of a carboxylic acid group was explored (<a class="ref showTableEvent internalNav" data-id="tbl3" href="#tbl3">Table </a><a class="ref showTableEvent internalNav" data-id="tbl3" href="#tbl3">3</a>). Such a modification adds bulk, introduces polarity, and the presence of a zwitterion has been shown previously to overcome hERG channel inhibition. <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> While the ortho-acid <b>21</b> was not tolerated, the modest <i>M. tuberculosis</i> whole cell activity of <b>22</b> and <b>23</b> was encouraging especially because the para-acid <b>23</b> showed a dramatic improvement in the compound’s liabilities including hERG channel inhibition, mouse metabolic stability, and HepG2 cytotoxicity. Although the overall properties of <b>23</b> were an improvement on <b>4</b>, this came at a significant reduction in antibacterial potency (∼40 fold). To continue optimization of <b>23</b>, we reassessed modifications of the 5-methyl pyrazole as these had been tolerated previously on <b>4</b>. In general, substitutions <b>29–34</b> were well tolerated, apart from cyclic amines <b>33</b> and <b>34</b>, with good profiles in relation to hERG inhibition, mouse metabolic stability, and HepG2 cytotoxicity. Substituted alkyl as well as fluoroalkyl resulted in notable improvements in the whole cell potency for cyclopropyl <b>29</b>, trifluoromethyl <b>28</b>, ethyl <b>24,</b> and ethoxy <b>32</b> (<a class="ref showTableEvent internalNav" data-id="tbl3" href="#tbl3">Table </a><a class="ref showTableEvent internalNav" data-id="tbl3" href="#tbl3">3</a>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Biological Profiling</h3><div class="NLM_p">Compound <b>29</b> was not cytotoxic to HepG2 cells, grown in either glucose or galactose media, nor the THP-1 macrophage-like cell line (data not shown). <b>29</b> had good potency against intracellular bacteria in THP-1 cells [IC<sub>50</sub> = 1.5 ± 1.3]. Compound <b>29</b> was also shown to retain good activity against clinical samples from the four main lineages and strains containing resistance mutations to either isoniazid or rifampicin (<a class="ref showTableEvent internalNav" data-id="tbl4" href="#tbl4">Table </a><a class="ref showTableEvent internalNav" data-id="tbl4" href="#tbl4">4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Activity against <i>M. tuberculosis</i> Clinical Strains of Different Lineage and Resistance<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left"><col align="left"><col align="left"><col align="left"><col align="left"><col align="left"><col align="left"><col align="left"></colgroup><thead><tr class="colsep0" valign="top"><th class="colsep0 rowsep0" align="center">&nbsp;</th><th class="rowsep1 colsep0" colspan="7" align="center">MIC<sub>90</sub> (μM)</th></tr><tr class="colsep0" valign="top"><th class="colsep0 rowsep0" align="center">&nbsp;</th><th class="colsep0 rowsep0" align="center">H37Rv</th><th class="colsep0 rowsep0" align="center">N0157 L1</th><th class="colsep0 rowsep0" align="center">N0052 L2</th><th class="colsep0 rowsep0" align="center">N0004 L3</th><th class="colsep0 rowsep0" align="center">N0136 L4</th><th class="colsep0 rowsep0" align="center">INH-R2</th><th class="colsep0 rowsep0" align="center">RIF-R2</th></tr></thead><tbody><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">9.6</td><td class="colsep0 rowsep0" align="left">8.6</td><td class="colsep0 rowsep0" align="left">13</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">0.37</td><td class="colsep0 rowsep0" align="left">0.76</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">rifampicin</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">isoniazid</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">&gt;200</td><td class="colsep0 rowsep0" align="left">0.58</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">MIC is the minimum concentration required to inhibit the growth of <i>M. tuberculosis</i> (H37Rv) in liquid culture L1 is TB lineage 1 and so forth.</p></div></div></div><div class="NLM_p">Minimum bactericidal concentration (MBC) and kill kinetics were evaluated under both aerobic (replicating) and starvation (nonreplicating) conditions. Under replicating conditions, <b>29</b> showed concentration-dependent kill of <i>M. tuberculosis</i> with an MBC of 3 μM (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure </a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>A). At later stages, outgrowth was observed because of either compound instability over long incubation periods or the appearance of resistant mutants. Under nonreplicating conditions, <b>29</b> showed no bactericidal effect against <i>M. tuberculosis</i> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure </a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>B).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0002.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0002.jpeg" id="gr1" class="inline-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Kill kinetics for <b>29</b> against replicating and nonreplicating <i>M. tuberculosis</i>. Bacterial viability in the presence of compound was determined by cfu over 28 days (A) under replicating conditions and (B) under nonreplicating conditions. The dashed lines represent the upper and lower limits of detection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>29</b> showed a 10-fold decrease in activity against the MmpL3<sub>F255L</sub> strain of <i>M. tuberculosis</i>, indicating that it retained an MmpL3-related mechanism of action. An impact on this pathway was also indicated using a hypomorph strain (P606-5C-mmpL3) that underexpresses MmpL3 when grown in the absence of anhydrotetracycline (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure </a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Initially, it was confirmed that SQ109, a known inhibitor of MmpL3, was more active against the hypomorph strain with a four-fold improvement in MIC<sub>50</sub>, while ethambutol, a cell wall inhibitor targeting a different pathway (arabinosyl transferases), was equally effective against both the wild-type and hypomorph strains. We tested two representatives from the series (<b>4</b> and <b>23</b>); both showed significant shifts in potency, with the MmpL3 hypomorph being at least eight-fold more sensitive. These data support the conclusion that, as shown in the literature for <b>3</b>, the series works through an MmpL3-related mechanism.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0003.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0003.jpeg" id="gr2" class="inline-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Decreased MmpL3 expression results in hypersensitivity to the spirocycle series. Removal of anhydrotetracycline (atc) results in transcriptional repression of <i>mmpL3</i>. Growth in the presence of a negative control ethambutol (A) and a positive control SQ109 (B) as well as representative series compound, <b>4</b> (C) and <b>23</b> (D) are recorded relative to DMSO-treated samples. Data are representative of two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> <i>In Vivo</i> Analysis</h3><div class="NLM_p">Based on the hit to lead SAR, representative compound <b>29</b> was selected for follow-up. A fluorinated derivative, <b>35</b>, was also prepared as such modifications had been shown previously (<a class="ref showTableEvent internalNav" data-id="tbl2" href="#tbl2">Table </a><a class="ref showTableEvent internalNav" data-id="tbl2" href="#tbl2">2</a>) to not have a detrimental effect on MIC activity but could potentially improve metabolic stability and <i>in vivo</i> exposure. As expected, <b>35</b> had a similar MIC activity to <b>29</b> (<a class="ref showTableEvent internalNav" data-id="tbl5" href="#tbl5">Table </a><a class="ref showTableEvent internalNav" data-id="tbl5" href="#tbl5">5</a>). Although there was no significant change in metabolic stability, neither mouse nor human, the fluorination did result in an unexpected increase in activity against the hERG ion channel. The <i>in vivo</i> exposure of both compounds was evaluated in female C57BL/6 mice (<i>n</i> = 3/dose level) (<a class="ref showTableEvent internalNav" data-id="tbl5" href="#tbl5">Table </a><a class="ref showTableEvent internalNav" data-id="tbl5" href="#tbl5">5</a>). Both compounds had moderate <i>in vivo</i> blood clearance, moderate volume of distribution, moderate half-life, and low bioavailability. Although the exposure of <b>35</b> was greater than <b>29</b>, it was not substantially improved enough to make it worthwhile to risk the increase in hERG channel inhibition. Therefore, further work focused on <b>29</b>. As the initial preliminary pharmacokinetic analysis was done on the free-base form of the molecule, a hydrochloride salt form of <b>29</b> was prepared and evaluated at higher doses to determine whether the compound was suitable for an <i>in vivo</i> efficacy assessment. The HCl salt of <b>29</b> was dosed at 200 and 400 mg/kg in 1% carboxymethylcellulose (CMC) generating <i>C</i><sub>max</sub> values of 22,266 and 85,278 ng/mL, respectively. Moreover, at both the 200 and 400 mg/kg doses, the exposure, both total and free (plasma Fu = 0.2), was above the reported MIC (0.66 μM/292 ng/mL) for &gt;6 h.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Biology and ADME/PK Profiles for Selected Best Molecules</div></div></div><img class="imgWithoutFigViewer " src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0011.gif" alt="" id="GRAPHIC-d7e2730-autogenerated"><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left"><col align="left"><col align="left"></colgroup><thead><tr class="colsep0" valign="top"><th class="colsep0 rowsep0" align="center">&nbsp;</th><th class="colsep0 rowsep0" align="center"><b>29</b></th><th class="colsep0 rowsep0" align="center"><b>35</b></th></tr></thead><tbody><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">MIC<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> μM</td><td class="colsep0 rowsep0" align="left">0.66</td><td class="colsep0 rowsep0" align="left">0.79</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">hERG<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> IC<sub>50</sub> μM</td><td class="colsep0 rowsep0" align="left">&gt;30<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">10<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">HepG2<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> μM</td><td class="colsep0 rowsep0" align="left">&gt;50</td><td class="colsep0 rowsep0" align="left">&gt;50</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">clog&nbsp;<i>D</i><sub>pH7.4</sub></td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.4</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">microsomal Cl<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> mL/min/g</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">0.9</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">human micro Cl<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> mL/min/g</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" colspan="3" align="center">C57 mouse PK at 3&nbsp;mg/kg&nbsp;iv&nbsp;and&nbsp;10&nbsp;mg/kg po</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> po (ng/mL)</td><td class="colsep0 rowsep0" align="left">164</td><td class="colsep0 rowsep0" align="left">294</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub>&nbsp;(h)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2.6</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">AUC<sub>0–24</sub> po (ng-min/mL)</td><td class="colsep0 rowsep0" align="left">20,728</td><td class="colsep0 rowsep0" align="left">36,486</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">Cl<sub>b</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">56</td><td class="colsep0 rowsep0" align="left">53</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">Vd<sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr class="colsep0" valign="top"><td class="colsep0 rowsep0" align="left">%&nbsp;<i>F</i></td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">19</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">See <a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">Table </a><a class="ref showTableEvent internalNav" data-id="tbl1" href="#tbl1">1</a> for explanation.</p></div></div></div><div class="NLM_p">Based on the results from the PK studies, <b>29</b> was assessed in an acute mouse model of TB infection using Balb/c mice in a direct comparison with the previously reported compound <b>3</b>. <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> As expected, <b>3</b> was very active in the study promoting a &gt;2.5 log<sub>10</sub> reduction in colony forming units (CFUs), reducing lung burdens in infected mice near to or below the limit of detection (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure </a><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). This was similar to the control drug rifampicin given at a dose of 20 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure </a><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). In contrast, <b>29</b> showed no appreciable reduction in lung CFUs relative to the untreated control in this experiment. Plasma samples for PK from these infected animals were taken during steady state at 1 and 24 h after dosing. Although both compounds showed free plasma concentrations well above MIC at 1 h post-dosing, only <b>3</b> remained above MIC for the full 24 h period. Thus, one potential explanation for the difference in efficacy was inadequate drug exposure above MIC for <b>29</b> compared to <b>3</b>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0004.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0004.jpeg" id="gr3" class="inline-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Efficacy in a mouse model of acute TB infection. BALB/c mice were infected with <i>M. tuberculosis</i> H37Rv <i>via</i> a low-dose aerosol exposure. Treatment was started 7 days post-aerosol and continued for 12 consecutive days. Drugs were administered once daily by oral gavage at 100 mg/kg (<b>3</b>) and 300 mg/kg (<b>29</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24425" class="dropBlock__holder"></div></div></div></div></div><hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthetic Routes</h3><div class="NLM_p">Synthesis of related spirocyclic amines has been previously reported. <a onclick="showRef(event, 'ref19 ref39'); return false;" href="javascript:void(0);" class="ref ref19 ref39">(19,39)</a> The general synthetic routes employed for the synthesis of pyrazole containing spirocyclic amines are shown below (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The appropriately substituted R1 aryls or heteroaryls were reacted with 1-[(4-methoxyphenyl)methyl]piperidin-4-one to form <b>48</b>, which was then deprotected to form amine <b>49</b>. An alternative route involved reacting the appropriately substituted R1 aryls or heteroaryls with the protected piperidin-4-one to form diols <b>40–43</b>. Cyclic dehydration afforded <b>44–47</b>, which were deprotected to afford amines <b>50–53</b>. Substituted pyrazole aldehydes <b>70–77</b> were prepared from the esters <b>63–69</b> (Scheme S1 in <a href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_001.pdf" class="ext-link">Supporting Information</a>) by reduction to the alcohol and then oxidation to the aldehydes. R2- and R3-substituted pyrazole esters <b>63–69</b> were prepared in three main ways: from R3-substituted pyrazole <b>60</b>, using copper-mediated coupling of suitable R2 boronic acids, by cyclo-dehydration of ethyl 4-(R3)-2,4-dioxo-butanoates <b>55–59</b> with R2-substituted hydrazines, and by reaction of dimethyl but-2-ynedioate with R2-substituted hydrazines. In the final step, reductive amination with appropriate R2-and R3-substituted pyrazole aldehydes <b>70–77</b> afforded target compounds <b>1–14</b>, <b>17</b>, <b>18</b>, <b>20</b>, and <b>21</b>. Further Chan–Lam coupling of the NH pyrazole <b>78</b> with appropriate boronic acids afforded target compounds <b>15</b>, <b>16</b>, and <b>19</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0005.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0005.jpeg" id="gr4" class="inline-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Routes for the Synthesis of Compounds <b>1–21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"></p><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) BH<sub>3</sub>.THF, THF, 100 °C, and 1 h; (ii) nBuLi, THF, −78 °C, 1 h, then <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate −78 °C—rt, and 18 h; (iii) MeSO<sub>2</sub>Cl, Et<sub>3</sub>N, DCM, reflux, and 1.5 h; (iv) TFA, DCM, and 18 h; (v) 1-[(4-methoxyphenyl)methyl]piperidin-4-one, MeSO<sub>3</sub>H, PhMe, reflux, Dean–Stark, and 18 h; (vi) 1-chloroethyl carbonochloridate, DCM, 0 °C then MeOH, reflux, and 1 h; (vii) DIPEA, DMSO, rt, and 18 h; (viii) AcOH or EtOH, reflux, and 2 h; (ix) R2B(OH)<sub>2</sub>, Cu(OAc)<sub>2</sub>, pyridine, DCM, and 2 h; (x) Et<sub>2</sub>O, rt, 1 h, then NaOMe, MeOH, rt, 18 h, then H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux, and 48 h; (xi) PPh<sub>3</sub>, DIAD, THF, MeOH, rt, and 18 h; (xii) DIBAL, DCM, −78 °C—rt, then MnO<sub>2</sub>, DCM, rt, and 48 h; (xiii) AcOH, DCM, then NaBH(OAc)<sub>3</sub>, and 18 h; (xiv) R4B(OH)<sub>2</sub>, Cu(OAc)<sub>2</sub>, pyridine, DCM, rt, and 3–18 h.</p><p></p></figure><div class="NLM_p">For compounds containing a carboxylic acid moiety on the phenyl ring attached to the pyrazole core, a different approach was needed. For these compounds, some could be synthesized by carrying the carboxylic acid through the synthesis protected as an oxazoline (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) and some by a late-stage conversion from the bromide (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Carboxylic acid substituted phenyl hydrazines could be reacted with suitable triketo compounds to afford R3-substituted pyrazole esters <b>87</b>, <b>88</b>, and <b>90–92</b>. Because of carrying an ester in these molecules, ester protection of the acid was not a plausible route at this stage, and so to synthetically distinguish the different functional groups, the acids were protected as oxazolines. Amide coupling with ethanolamine followed by chlorination and cyclization easily provided oxazolines <b>93–98</b>, which could then be carried through the synthesis without problem. Reduction to aldehydes <b>99–104</b> as before followed by reductive amination to <b>105–109</b> and simple deprotection with 2 M HCl afforded the target compounds <b>22</b>, <b>23</b>, and <b>26–28</b>. Compound <b>24</b> followed the majority of this route; however, the carboxylate <b>95</b> was synthesized <i>via</i> reaction of 4-aminobenzoic acid with ethyl 2-chloro-3-oxo-butanoate and subsequent cyclization to the pyrazole. Alternatively, when the substituted phenyl hydrazine could be reacted with R3-substituted diethoxy diketo compounds <b>81–83</b>, then only one synthetic step was needed to afford compounds <b>25</b>, <b>29</b>, <b>30</b>, and <b>35</b>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0006.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0006.jpeg" id="gr5" class="inline-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Routes for the Synthesis of Compounds <b>22–30</b> and <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"></p><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EtOH, AcOH, reflux, and 1–18 h; (ii) spiro[isochromane-1,4′-piperidine], AcOH, DCM, then NaBH(OAc)<sub>3</sub>, and 18 h; (iii) EtOH, H<sub>2</sub>O, 35 °C, and 18 h; (iv) SOCl<sub>2</sub>, pyridine, 50 °C, 2 h then ethanolamine, DCM, rt, 3 h, then SOCl<sub>2</sub>, rt, and 18 h; (v) NaH, THF, 0 °C, and 3 h; (vi) DIBAL, DCM, −78 °C—rt, then MnO<sub>2</sub>, DCM, rt, and 48 h; (vii) spiro[isochromane-1,4′-piperidine], AcOH, DCM, then NaBH(OAc)<sub>3</sub>, 18 h; and (viii) 3 M HCl, 100 °C, and 18 h.</p><p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0007.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0007.jpeg" id="gr6" class="inline-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthetic Routes for the Synthesis of Compounds <b>31–34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"></p><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) POCl<sub>3</sub>, DMF, 100 °C, and 2 h; (ii) R3H, K<sub>2</sub>CO<sub>3</sub>, DMF, microwave, 120 °C, and 1 h; (iii) pTsOH, MeOH, microwave, 120 °C, and 1 h; (iv) R3I, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C—rt, and 2 h; (v) DIBAL, DCM, −78 °C—rt, then MnO<sub>2</sub>, DCM, rt, and 48 h; (vi) AcOH, DCM, then NaBH(OAc)<sub>3</sub>, and 18 h; and (vii) <i>N</i>-formylsaccharin, Pd(OAc)<sub>2</sub>, Xantphos, KF, DMF, 80 °C, and 18 h then H<sub>2</sub>O.</p><p></p></figure><div class="NLM_p last">The carboxylic acid compounds could also be realized from the bromides. Reaction of 4-bromophenylhydrazines with dimethyl but-2-ynedioate afforded pyrazole <b>110</b>. Where the desired R group was an alkoxy group, the hydroxyl moiety could be simply alkylated. Where R3 was an amine, this was introduced <i>via</i> a Vilsmeier reaction, followed by S<sub>N</sub>Ar and removal of the aldehyde, to form compounds <b>114–117</b>. As in the previous schemes, reduction to aldehydes <b>118–121</b> followed by reductive amination afforded spirocyclic amino pyrazoles <b>122–125</b>. In order to convert the bromide to carboxylic acid, compounds <b>122–125</b> were carbonylated using <i>N</i>-formylsaccharin as a source of carbon monoxide, which is slowly released <i>in situ</i> as described in the literature. <a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The acyl fluoride formed in the reaction as a result of the caesium fluoride base was quenched with H<sub>2</sub>O to form the final target compounds <b>31–34</b>. For all the compounds discussed in this report, no alerts were found when they were processed through a PAINS filter.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11328" class="dropBlock__holder"></div></div></div></div></div><hr><div class="NLM_p last">Following on from the previous publication of a spirocycle series with potent inhibition of <i>M. tuberculosis</i> but limited by safety concerns, <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> the optimization of a related but novel pyrazole spirocyclic amine is described. This report identified a zwitterionic series, exemplified by lead <b>29</b> that when compared to the original series, <b>3</b> had improved selectivity over HepG2, as well as reduced hERG channel inhibition. As with the original series, <b>29</b> was a putative MmpL3 inhibitor as large shifts against MmpL3 mutant strains were observed. Although <b>29</b> has a better selectivity profile than the earlier molecules, this came at the expense of reduced potency; as such, while <b>3</b> had excellent activity in an acute <i>in</i><i>vivo</i> model of TB infection, <b>29</b> was found not to be efficacious in the same model. The lack of efficacy of <b>29</b> was hypothesized to be as a result of the need for improved <i>in vivo</i> exposure to ensure maximum coverage above the MIC. Thus, despite the original authors highlighting the possibility of eliminating series liabilities while retaining the remarkable <i>in vivo</i> potency, <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> given the complexity of balancing metabolic stability and hERG channel inhibition with MIC activity for this series, no further work was planned to try and improve exposure.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08871" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08871" class="dropBlock__holder"></div></div></div></div></div><hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Determination of MIC</h3><div class="NLM_p last">MICs were determined against <i>M. tuberculosis</i> H37Rv (ATCC 25618) and mutant strains grown in Middlebrook 7H9 medium containing 10% v/v OADC (oleic acid, albumin, dextrose, and catalase) supplement (Becton Dickinson) and 0.05% w/v Tween 80 (7H9-Tw-OADC) under aerobic conditions as previously described. Bacterial growth was measured after 5 days of incubation at 37 °C. <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> MmpL3 Hypomorph</h3><div class="NLM_p last">Wild-type H37Rv and P606-5C (in which the native copy of <i>mmpL3</i> was replaced with <i>kanR</i> and a tetracycline-regulated copy of <i>mmpL3</i> was inserted at the att-L5 site and also contains <i>zeoR</i>) were each cultured in 10 mL of Middlebrook 7H9 [with kanamycin and zeocin at 25 μg/mL and anhydrotetracycline (atc) at 500 ng/mL for the mutant strain] supplemented with 0.2% (v/v) glycerol, 0.05% (v/v) tyloxapol, and ADNaCl (0.5% [w/v] BSA, 0.2% [w/v] dextrose, and 0.85% [w/v] NaCl) in a 25 cm<sup>2</sup> tissue culture flask with a vented cap. After approximately 7 days at 37 °C and 5% CO<sub>2</sub> in a humidified incubator, growing to mid-log to late-log phase, each of the cultures was washed with fresh 7H9 and suspended to an OD<sub>580</sub> of 0.05 in 30 mL of 7H9 (with selection antibiotics for the mutant but without atc to deplete the levels of MmpL3) in a 75 cm<sup>2</sup> tissue culture flask with a vented cap and was incubated for further 14 days with a passage to OD<sub>580</sub> = 0.05 in 30 mL of 7H9 at day 7. Bacteria were then washed once in fresh medium and single-cell suspensions were prepared to a final OD<sub>580</sub> of 0.01 in 7H9. Compounds were solubilized in DMSO and dispensed into 384-well plates using an HP D300e Digital Dispenser as 11-point, 4-fold dilution series in triplicate. DMSO at a final concentration of 1% was used as no-drug control. In all, 50 μL of single-cell suspension was pipetted to each well and cultures were incubated for 7–14 d at 37 °C in the same conditions as mentioned above. Final OD<sub>580</sub> values were normalized to no-drug control.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>M. tuberculosis</i> Kill Kinetics</h3><div class="NLM_p last">For replicating conditions, late-log phase bacteria were exposed to compounds in 5 mL medium under aerobic conditions in standing cultures over 21 days. For starvation conditions, bacteria were resuspended in phosphate-buffered saline plus 0.05% tyloxapol for 14 days before compound addition. Viable bacteria were measured by plating serial dilutions and counting cfus after 4 weeks.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Intracellular Activity</h3><div class="NLM_p last">THP-1 cells were propagated in RPMI-1640 supplemented with 10% FBS, 2 mM glutagro, and 1 mM sodium pyruvate medium in a humidified atmosphere of 37 °C with 5% CO<sub>2</sub>. Cells were differentiated with 80 nM PMA treatment overnight and infected with <i>M. tuberculosis</i> (H37Rv LuxG13) at a multiplicity of infection of 1. Infected cells were harvested with Accutase, 5 mM EDTA, washed twice with PBS, seeded into 96-well plates at 4 × 10<sup>4</sup> cells per well, and incubated for 24 h. Compounds were added as a 10-point three-fold serial dilution (0.5% DMSO final concentration). Bacterial viability was measured after 72 h. Growth inhibition curves were fitted using the Levenberg–Marquardt algorithm. IC<sub>50</sub> and IC<sub>90</sub> were defined as the compound concentrations that inhibited 50 or 90% of the intracellular growth, respectively.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> THP-1 Cytotoxicity</h3><div class="NLM_p last">THP-1 cells were propagated, differentiated into macrophages, and harvested as described above and seeded into 96-well plates at 4 × 10<sup>4</sup> cells per well for 24 h. Compounds were added as a 10-point three-fold serial dilutions (0.5% DMSO final concentration). Viability was measured after 72 h using CellTiter-Glo. Growth inhibition curves were fitted using the Levenberg–Marquardt algorithm. IC<sub>50</sub> was defined as the compound concentration that reduced cell viability by 50%.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> HepG2 Cytotoxicity</h3><div class="NLM_p last">Compound dilution curves were plated directly using a Labcyte Echo 550 acoustic dispenser (125 nL) in 384-well white clear-bottomed plates (Greiner). HepG2 cells (ECACC 85011430) were cultured in minimum essential medium (supplemented with glutamax) with 10% FCS and plated (25 μL) using a WellMate dispenser (1 × 10<sup>5</sup> per well) and incubated for 72 h. Doxorubicin was used as a positive control drug. Resazurin was then added to each well at a final concentration of 45 μM, and fluorescence was measured using PHERAstar LS (BMG Labtech) after 4 h of further incubation (excitation of 528 nm and emission of 590 nm). Raw data were normalized to controls and expressed as % growth. IC<sub>50</sub> was defined as the compound concentration that resulted in 50% inhibition.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Intrinsic Clearance (Cli) Experiments</h3><div class="NLM_p">Test compound (0.5 μM) was incubated with female CD1 mouse liver microsomes (Xenotech LLC) or pooled human liver microsomes (Life Technologies) at a final concentration of 0.5 mg/mL 50 mM potassium phosphate buffer, pH 7.4, and the reaction started with addition of excess NADPH (8 mg/mL 50 mM potassium phosphate buffer, pH 7.4). Immediately, at time zero, then at 3, 6, 9, 15, and 30 min, an aliquot (50 μL) of the incubation mixture was removed and mixed with acetonitrile (100 μL) to stop the reaction. Internal standard was added to all samples, the samples were centrifuged to sediment precipitated protein, and the plates were then sealed prior to ultra-performance liquid chromatography–mass spectrometry (UPLC/MS/MS) analysis using a Quattro Premier XE (Waters Corporation, USA). XLfit (IDBS, UK) was used to calculate the exponential decay and consequently the rate constant (<i>k</i>) from the ratio of peak area of test compound to internal standard at each time point. The rate of intrinsic clearance (CLi) of each test compound was then calculated using the following calculation<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_m001.gif" alt="" id="_i26"></span>where <i>V</i> (mL/mg protein) is the incubation volume/mg protein added and microsomal protein yield is taken as 52.5 mg protein/g liver. Verapamil (0.5 μM) was used as a positive control to confirm acceptable assay performance.</div><div class="NLM_p last">Isoform-specific metabolism studies were performed as mentioned above except that mouse liver microsomes were replaced with incubation mixtures containing EasyCYP bactosomes (50 pmol/mL, 0.5 mg/mL Cypex).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Aqueous Solubility</h3><div class="NLM_p last">The aqueous solubility of the test compounds was measured using laser nephelometry. Compounds were subject to serial dilution from 10 to 0.5 mM in DMSO. An aliquot was then mixed with Milli-Q water to obtain an aqueous dilution plate with a final concentration range of 250–12 μM with a final DMSO concentration of 2.5%. Triplicate aliquots were transferred to a flat-bottomed polystyrene plate, which was immediately read on the NEPHELOstar (BMG Lab Technologies). The amount of laser scatter caused by insoluble particulates (relative nephelometry units, RNU) was plotted against compound concentration using a segmental regression fit, with the point of inflection being quoted as the compound’s aqueous solubility (μM).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Mouse Pharmacokinetics</h3><div class="NLM_p last">The test compound was dosed as a bolus solution intravenously or dosed orally by gavage to female C57 black mice (<i>n</i> = 3/dose level). Blood samples were collected from each mouse tail vein at predetermined time points post-dose, mixed with two volumes of distilled water, and stored frozen until UPLC/MS/MS analysis. Pharmacokinetic parameters were derived from the blood concentration time curve using PK Solutions software v2.0 (Summit Research Services, USA). All regulated procedures, at the University of Dundee, on living animals were carried out under the authority of a project license issued by the Home Office under the Animals (Scientific Procedures) Act 1986, as amended in 2012 (and in compliance with EU Directive EU/2010/63).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> hERG Assays</h3><div class="NLM_p last">These were performed as previously described <a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> in brief: thallium flux high-throughput testing, hERG functional activity was measured in an inducible hERG T-RExTM-CHO Cell line (Thermo Fisher #K1237) using thallium influx as a surrogate indicator of potassium ion channel activity. Thallium enhances the fluorescent signal of BTC-AM dye (Thermo Fisher #B6791). Cells were loaded with the dye for 90 min in a low potassium buffer, dye removed, and compound added to the cells in a high potassium buffer in a 6 pt. dose response. After 30 min of compound incubation, channel activity was recorded upon addition of thallium buffer using a Tetra plate reader. The slope of the kinetic read was used to calculate channel activity. For QPatch testing, HEK-293 cells stably transfected with the hERG channel were tested in either QPatch (Sophion) or PatchXpress (Molecular Devices), automated planar patch-clamp systems. The cells were added to each chamber, negative pressure was applied to obtain intracellular access, and cells were exposed to either three or four ascending concentrations of drug. hERG tail current was measured as the difference in amplitude between a −50 mV pre-pulse and the end of a five-second test pulse to −50 mV, preceded by a depolarizing pulse (+20 mV). The hERG IC<sub>50</sub> value was determined from tail current.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Murine Model of Acute TB Infection</h3><div class="NLM_p last">All infections were performed at Colorado State University in a certified ABSL3 facility in accordance with the guidelines of the Colorado State University Institutional Animal Care and Use Committee. Six to eight week old female specific pathogen-free BALB/c mice were purchased from Charles River Laboratories (Wilmington, MA). The mice were infected with <i>M. tuberculosis</i> H37Rv <i>via</i> a low-dose aerosol exposure in a Glas-Col aerosol generation device (Glas-Col Inc., Terre Haute, IN). <a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Each treatment group consisted of six mice. <b>29</b> was formulated in 1% CMC (Sigma). <b>3</b> was formulated in 1% MC (Sigma). Rifampin was prepared using a mortar and pestle in sterile water. The treatment was started 7 days post-aerosol and continued for 12 consecutive days. Drugs were administered by oral gavage in a 0.2 mL volume at 300, 100, and 20 mg/kg for <b>29</b>, <b>3</b>, and rifampicin, respectively. For endpoint analysis, mice were euthanized 3 days following the end of treatment and lungs were collected. The left lung lobe (1/3rd of the lung by weight) was homogenized for enumeration of cfu by plating dilutions of the organ homogenates on Middlebrook 7H11 medium supplemented with 10% (v/v) OADC, 0.01 mg/mL of cycloheximide, and 0.05 mg/mL of carbenicillin. The data were expressed as mean log 10 cfu ± the standard error of the mean for each group. Statistical analysis was done by one-way analysis of variance with Dunnet’s post-test to control for multiple comparisons (SigmaPlot, San Jose, CA). Values were considered significant at the 95% confidence level.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Chemistry Methods</h3><div class="NLM_p last">Chemicals and solvents were purchased from commercial vendors and used as received unless otherwise stated. Dry solvents were purchased in Sure Seal bottles stored over molecular sieves. Unless otherwise stated herein, reactions have not been optimized. Analytical thin-layer chromatography (TLC) was performed on precoated TLC plates (Kieselgel 60 F254, BDH). Developed plates were air-dried and analyzed under a UV lamp (UV 254/365 nm) and/or KMnO<sub>4</sub> was used for visualization. Flash chromatography was performed using Combiflash Companion Rf (Teledyne ISCO) and prepacked silica gel columns purchased from Grace Davison Discovery Science or SiliCycle. Mass-directed preparative HPLC separations were performed using a Waters HPLC (2545 binary gradient pumps, 515 HPLC make-up pump, and 2767 sample manager) connected to a Waters 2998 photodiode array and a Waters 3100 mass detector. Preparative HPLC separations were performed with a Gilson HPLC (321 pumps, 819 injection module, and 215 liquid handler/injector) connected to a Gilson 155 UV/vis detector. On both instruments, HPLC chromatographic separations were conducted using Waters XBridge C18 columns, 19 mm × 100 mm, 5 μm particle size, using 0.1% ammonia in water (solvent A) and acetonitrile (solvent B) as the mobile phase. <sup>1</sup>H NMR spectra were recorded on a Bruker ADVANCE II 500 or 400 spectrometer operating at 500 and 400 MHz (unless otherwise stated) using CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or CD<sub>3</sub>OD solutions. Chemical shifts (δ) are expressed in ppm recorded using the residual solvent as the internal reference in all cases. Signal splitting patterns are described as singlet (s), doublet (d), triplet (t), multiplet (m), broadened (br), or a combination thereof. Coupling constants (<i>J</i>) are quoted to the nearest 0.1 Hertz (Hz). Low-resolution electrospray mass spectra were recorded on a Bruker Daltonics MicrOTOF mass spectrometer run in the positive mode. High-resolution mass spectroscopy (HRMS) was performed using a Bruker Daltonics MicroTof mass spectrometer. LC–MS analysis and chromatographic separation were conducted with either a Bruker Daltonics MicroTOF mass spectrometer connected to an Agilent diode array detector or a Thermo Dionex Ultimate 3000 RSLC system with a diode array detector, the column used was a Waters XBridge column (50 mm × 2.1 mm, 3.5 μm particle size), and the compounds were eluted with a gradient of 5–95% acetonitrile/water + 0.1% ammonia or with an Advion Expression Mass Spectrometer connected to a Thermo Dionex Ultimate 3000 HPLC with a diode array detector, the column used was a Waters XBridge column (50 mm × 2.1 mm, 3.5 μm particle size), or a Waters X-select column (30 mm × 2.1 mm, 2.5 μm particle size) with a gradient of 5–90% acetonitrile/water + 0.1% formic acid. All final compounds showed chemical purity of ≥95% as determined by the UV chromatogram (190–450 nm) obtained by LC–MS analysis.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Method 1</h3><div class="NLM_p last">Respective spirocyclic amines (1 equiv) and aldehydes (1 equiv) were combined in DCM (0.1–0.2 M), one drop of acetic acid was added, and the mixtures were stirred at rt for 1 h. Sodium triacetoxyborohydride (1.5–2 equiv) was added and the mixtures were stirred at rt for 18 h. The mixtures were washed with NaHCO<sub>3</sub> (saturated solution) and the organics were concentrated <i>in vacuo</i>. The crude materials were purified by preparative HPLC (XBridge column, 0.1% NH<sub>4</sub>OH modifier) and the fractions were concentrated <i>in vacuo</i> to afford the titled compounds.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Method 2</h3><div class="NLM_p last">Respective pyrazoles (1 equiv), boronic acids (2 equiv), and copper acetate (1.5 equiv) were combined in DCM (0.1 M) and pyridine (20 equiv) and stirred at rt for 3–18 h. The solvents were removed <i>in vacuo</i> and the crude products were purified by either flash chromatography (0–100% EtOAc in heptane) or preparative HPLC (XBridge column, 0.1% NH<sub>4</sub>OH modifier), and the fractions were concentrated <i>in vacuo</i> to afford the titled compounds.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> General Method 3a</h3><div class="NLM_p last">Respective hydrazines (1 equiv) and 2,4-dioxo-butanoates (1 equiv) were dissolved in EtOH (0.15 M) and heated to reflux for 1–3 h. The solvent was removed <i>in vacuo</i> and H<sub>2</sub>O was added. The products were extracted with EtOAc and concentrated <i>in vacuo</i>, and the resulting crude products were purified by flash chromatography (5–50% EtOAc in heptane) to afford the titled compounds.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> General Method 3b</h3><div class="NLM_p last">Respective hydrazines or hydrazine hydrochlorides (1 equiv) and 2,4-dioxo-butanoates (1 equiv) were dissolved in AcOH (0.7 M), and the reaction mixtures were heated to reflux for 2 h and then allowed to cool to rt. The solvent was removed <i>in vacuo</i>, and the residue was partitioned between DCM and 1 M NaOH and then passed through a hydrophobic frit. The crude materials were purified by flash chromatography (0–100% EtOAc in heptane) to afford the titled compounds.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Method 4</h3><div class="NLM_p last">Oxazolines (1 equiv) were dissolved in 3 M HCl (30 equiv) and heated to 100 °C for 18 h and then allowed to cool to rt. The reaction mixtures were neutralized with NaHCO<sub>3</sub> (saturated solution) and extracted with DCM. The organics were separated, dried through a hydrophobic frit, and concentrated <i>in vacuo</i> to afford the titled compounds.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> General Method 5</h3><div class="NLM_p last">Bromides (1 equiv), aldehydes (1.2 equiv), Pd(OAc)<sub>2</sub> (3 mol %), Xantphos (4.5 mol %), and KF (2.5 equiv) were combined in DMF (0.12 M) in sealed tubes. The reaction mixtures were heated to 80 °C for 18 h. The reactions were quenched with H<sub>2</sub>O and stirred at rt for 10 min. DCM was added and the mixtures were filtered through Celite and washed with further DCM. The combined organics were concentrated <i>in vacuo</i> and purified by preparative HPLC (XBridge column, 0.1% NH<sub>4</sub>OH modifier), and the fractions were concentrated <i>in vacuo</i> to afford the titled compounds.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> General Method 6a</h3><div class="NLM_p last">Esters (1 equiv) were dissolved in DCM (0.2–0.4 M) and cooled to −78 °C under N<sub>2</sub>. DIBAL (2.5 equiv, 1 M in DCM) was added dropwise over 20 min, and the reactions were stirred for 1 h at −78 °C. The reaction mixtures were quenched carefully with H<sub>2</sub>O and MeOH (1:1, 10 mL) and allowed to warm to rt. DCM was added and the mixtures were passed through hydrophobic frits. The organics were concentrated <i>in vacuo</i>, and the crude products were purified by flash chromatography (0–100% EtOAc in heptane) to afford the titled compounds.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> General Method 6b</h3><div class="NLM_p">Esters (1 equiv) were dissolved in DCM (0.2–0.4 M) and cooled to −78 °C under N<sub>2</sub>. DIBAL (2.5 equiv, 1 M in DCM) was added dropwise over 20 min and the reactions were stirred for 1 h at −78 °C. The reaction mixtures were quenched carefully with H<sub>2</sub>O and MeOH (1:1, 10 mL) and allowed to warm to rt. DCM was added and the mixtures were passed through hydrophobic frits. The organics were concentrated <i>in vacuo</i> to afford the alcohols. The residues were redissolved in DCM and MnO<sub>2</sub> (10 equiv) was added. The reaction mixtures were stirred at rt for 18 h, then filtered through Celite cartridges, and washed well with DCM and MeOH. The solvents were removed <i>in vacuo</i> to afford the titled compounds.</div><div id="sec5_20_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Synthesis of 1-((5-Methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)-4′,5′-dihydrospiro[piperidine-4,7′-thieno[2,3-<i>c</i>]pyran] (<b>1</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 5-Methyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>70</b>)</h5><div class="NLM_p last">Ethyl 5-methyl-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (2.00 g, 8.69 mmol) and DIBAL (1 M in DCM) (21.72 mL, 21.72 mmol) were combined in DCM (20 mL) according to General Method 6a. Work-up and purification afforded the title compound as a pale yellow oil (678 mg, 41%). LCMS (ESI) <i>m</i>/<i>z</i>: 189 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.50–7.42 (m, 4H), 7.42–7.37 (m, 1H), 6.22 (s, 1H), 4.72 (d, <i>J</i> = 5.9 Hz, 2H), 2.34 (s, 3H), 2.10 (br s, 1H).</div></div><div id="sec5_20_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 1-((5-Methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)-4′,5′-dihydrospiro[piperidine-4,7′-thieno[2,3-<i>c</i>]pyran] (<b>1</b>)</h5><div class="NLM_p last">5-Methyl-1-phenyl-pyrazole-3-carbaldehyde (<b>70</b>) (40 mg, 0.21 mmol), spiro[4,5-dihydrothieno[2,3-<i>c</i>]pyran-7,4′-piperidine] (43 mg, 0.20 mmol), and sodium triacetoxyborohydride (91 mg, 0.43 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound (30 mg, 35%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>OS [M + H<sup>+</sup>], 380.1791; found, 380.1794. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.47 (d, <i>J</i> = 4.4 Hz, 4H), 7.39–7.35 (m, 1H), 7.15 (d, <i>J</i> = 5.0 Hz, 1H), 6.78 (d, <i>J</i> = 5.0 Hz, 1H), 6.24 (s, 1H), 3.94 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 3.67 (s, 2H), 2.88 (d, <i>J</i> = 11.6 Hz, 2H), 2.72 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 2.58–2.51 (m, 2H), 2.36 (s, 3H), 2.07–2.03 (m, 4H).</div></div></div><div id="sec5_20_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Synthesis of 1′-((1-Methyl-5-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>2</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (98 mg, 0.48 mmol), 3-(chloromethyl)-1-methyl-5-phenyl-1<i>H</i>-pyrazole (<b>54</b>) (50 mg, 0.24 mmol), and diisopropylethylamine (93 mg, 0.73 mmol) were combined in DMSO (1 mL) and stirred at rt for 18 h. Water (0.3 mL) was added, the mixture was purified by preparative HPLC (XBridge column, 0.1% NH<sub>4</sub>OH modifier), and the fractions were concentrated <i>in vacuo</i> to afford the title compound (40 mg, 42%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O [M + H<sup>+</sup>], 374.2232; found, 374.2180. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.46–7.40 (5H, m), 7.22–7.12 (3H, m), 7.08 (1H, d, <i>J</i> = 7.3 Hz), 6.31 (1H, s), 3.91 (2H, t, <i>J</i> = 5.5 Hz), 3.88 (3H, s), 3.64 (2H, s), 2.90–2.87 (2H, m), 2.83 (2H, t, <i>J</i> = 8.1 Hz), 2.55–2.48 (2H, m), 2.14–2.06 (2H, m), 1.91 (2H, d, <i>J</i> = 11.8 Hz).</div></div><div id="sec5_20_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Synthesis of 1-(4-(4-(Trifluoromethoxy)phenoxy)benzyl)-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-<i>c</i>]pyran] (<b>3</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 1-(4-Methoxybenzyl)-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-<i>c</i>]pyran] (<b>48</b>)</h5><div class="NLM_p last">1-[(4-Methoxyphenyl)methyl]piperidin-4-one (1.71 g, 7.80 mmol) and 2-(thiophen-2-yl)ethan-1-ol (1.00 g, 7.80 mmol) were mixed in toluene (70 mL) and methanesulfonic acid (1 mL, 15.60 mmol) was added. The reaction mixture was heated to 130 °C in Dean–Stark apparatus for 18 h. The reaction mixture was allowed to cool to rt and toluene was removed <i>in vacuo</i>. The residue was dissolved in MeOH and loaded onto a 20 g SCX cartridge, eluting with MeOH and 3 M NH<sub>3</sub>/MeOH. The crude material was purified further by flash chromatography (0–8% MeOH in DCM with NH<sub>3</sub> modifier) to afford the title compound (940 mg, 35%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 6.73 (d, <i>J</i> = 2.7 Hz, 3H), 6.55 (d, <i>J</i> = 1.7 Hz, 1H), 6.35 (dd, <i>J</i> = 10.8, 10.8 Hz, 2H), 6.31–6.28 (m, 1H), 4.77 (d, <i>J</i> = 2.4 Hz, 1H), 3.43–3.38 (m, 2H), 3.29 (d, <i>J</i> = 2.3 Hz, 3H), 2.98 (s, 2H), 2.30 (dd, <i>J</i> = 5.0, 5.0 Hz, 2H), 2.19–2.16 (m, 2H), 1.44 (dd, <i>J</i> = 12.1, 12.1 Hz, 2H), 1.32 (d, <i>J</i> = 12.8 Hz, 2H).</div></div><div id="sec5_20_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 6′,7′-Dihydro-1,2-spiro[piperidine-4,4′-thieno[3,2-<i>c</i>]pyran] (<b>49</b>)</h5><div class="NLM_p last">1′-[(4-Methoxyphenyl)methyl]spiro[6,7-dihydrothieno[3,2-<i>c</i>]pyran-4,4′-piperidine (<b>48</b>) (940 mg, 2.85 mmol) was dissolved in DCM (15 mL) under N<sub>2</sub> and cooled to 0 °C. 1-Chloroethyl carbonochloridate (530 mg, 3.71 mmol) in DCM (3 mL) was then added dropwise, and the reaction mixture was stirred at 0 °C for 30 min and then allowed to warm up to rt. The volatiles were removed <i>in vacuo</i>, and the residue was dissolved in MeOH (15 mL) and heated to reflux for 1 h. After cooling to rt, the reaction mixture was passed through a 20 g SCX cartridge, eluting the amine with 3 M NH<sub>3</sub>/MeOH to afford the title compound as a pale orange gum, which solidified on standing at rt (480 mg, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.10 (d, <i>J</i> = 5.2 Hz, 1H), 6.83 (d, <i>J</i> = 5.2 Hz, 1H), 3.97 (dd, <i>J</i> = 5.4, 5.4 Hz, 2H), 3.11–3.03 (m, 2H), 2.95–2.83 (m, 4H), 1.88–1.83 (m, 4H).</div></div><div id="sec5_20_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 1′-[[4-[4-(Trifluoromethoxy)phenoxy]phenyl]methyl]spiro[6,7-dihydrothieno[3,2-<i>c</i>]pyran-4,4′-piperidine] (<b>3</b>)</h5><div class="NLM_p last">4-(Trifluoromethoxy)phenol (1.0 g, 5.61 mmol) and 4-fluorobenzaldehyde (697 mg, 5.61 mmol) were mixed in DMF (10 mL) and K<sub>2</sub>CO<sub>3</sub> (931 mg, 6.74 mmol) was added. The reaction mixture was heated at 140 °C for 8 h and then allowed to cool to rt. H<sub>2</sub>O was added and the product was extracted with Et<sub>2</sub>O. The combined organics were washed with brine, dried (MgSO<sub>4</sub>), and concentrated <i>in vacuo</i> to afford 4-(4-(trifluoromethoxy)phenoxy)benzaldehyde as a yellow oil (1.40 g, 80%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.98 (s, 1H), 7.90 (d, 2H), 7.30 (m, 2H), 7.11 (m, 4H). 4-[4-(Trifluoromethoxy)phenoxy]benzaldehyde (60 mg, 0.21 mmol), 6′,7′-dihydro-1,2-spiro[piperidine-4,4′-thieno[3,2-<i>c</i>]pyran] (<b>49</b>) (45 mg, 0.21 mmol), and sodium triacetoxyborohydride (90 mg, 0.43 mmol) were combined in DCM (3 mL) according to General Method 1. Work-up and purification afforded the title compound (52 mg, 51%). LCMS (ESI) <i>m</i>/<i>z</i>: 476 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>25</sub>F<sub>3</sub>NO<sub>3</sub>S [M + H<sup>+</sup>], 476.1507; found, 476.1489. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.34 (d, <i>J</i> = 8.6 Hz, 2H), 7.19–7.15 (m, 2H), 7.07 (d, <i>J</i> = 5.2 Hz, 1H), 7.02–6.96 (m, 4H), 6.81 (d, <i>J</i> = 5.2 Hz, 1H), 3.93 (t, <i>J</i> = 5.4 Hz, 2H), 3.54 (s, 1H), 2.83 (t, <i>J</i> = 5.4 Hz, 2H), 2.75–2.70 (m, 2H), 2.40 (td, <i>J</i> = 12.1, 2.6 Hz, 2H), 1.97 (td, <i>J</i> = 13.4, 4.4 Hz, 2H), 1.89–1.83 (m, 2H).</div></div></div><div id="sec5_20_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Synthesis of 1′-((5-Methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>4</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (200 mg, 0.98 mmol), 5-methyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>70</b>) (183 mg, 0.98 mmol), and sodium triacetoxyborohydride (417 mg, 1.97 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound (244 mg, 65%). LCMS (ESI) <i>m</i>/<i>z</i>: 374 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O [M + H<sup>+</sup>], 374.2227; found, 374.2235. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.47–7.43 (m, 4H), 7.38–7.32 (m, 1H), 7.23–7.11 (m, 3H), 7.10–7.06 (m, 1H), 6.22 (s, 1H), 3.90 (t, <i>J</i> = 5.6 Hz, 2H), 3.66 (s, 1H), 2.89–2.80 (m, 4H), 2.52 (t, <i>J</i> = 12.1 Hz, 2H), 2.34 (d, <i>J</i> = 0.7 Hz, 3H), 2.08 (td, <i>J</i> = 13.2, 4.5 Hz, 2H), 1.95–1.87 (m, 2H).</div></div><div id="sec5_20_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Synthesis of 9-((5-Methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)-1-oxa-9-azaspiro[5.5]undecane (<b>5</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">1-Oxa-9-azaspiro[5.5]undecane hydrochloride (50 mg, 0.26 mmol), 5-methyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>70</b>) (51 mg, 0.27 mmol), and sodium triacetoxyborohydride (110 mg, 0.52 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 326 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.45–7.42 (m, 3H), 7.36–7.32 (m, 1H), 6.17 (s, 1H), 3.63 (t, <i>J</i> = 5.2 Hz, 2H), 3.58 (s, 2H), 2.63 (m, 2H), 2.44 (m, 2H), 2.32 (d, <i>J</i> = 0.5 Hz, 3H), 1.89 (d, <i>J</i> = 13.4, 2H), 1.63–1.48 (m, 6H), 1.47–1.41 (m, 2H).</div></div><div id="sec5_20_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Synthesis of 6-Fluoro-1′-((5-methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>6</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 4-(4-Fluoro-2-(2-hydroxyethyl)phenyl)-4-hydroxypiperidine-1-carboxylate (<b>40</b>)</h5><div class="NLM_p last">2-(2-Bromo-5-fluorophenyl)ethan-1-ol (6.48 g, 29.58 mmol) was dissolved in THF (10 mL) and cooled to −78 °C. 2.5 M <i>n</i>-BuLi solution (23.67 mL, 59.17 mmol) was added dropwise and continuously stirred at −78 °C for 1 h. <i>tert</i>-Butyl 4-oxopiperidine-1-carboxylate (5.89 g, 29.58 mmol) was dissolved in THF (10 mL), and the solution was added dropwise to the reaction mixture. The mixture was continuously stirred at −78 °C for 1 h before allowing to warm slowly to rt over 18 h. The reaction was quenched with NH<sub>4</sub>Cl (saturated solution), EtOAc was added, and the organic layer was separated and dried (hydrophobic frit). The crude material was purified by flash chromatography (20–50% EtOAc in heptane) to afford the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 240 (M-CO<sub>2</sub><sup><i>t</i></sup>Bu + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.24 (dd, <i>J</i> = 8.9, 5.9 Hz, 1H), 6.89 (dd, <i>J</i> = 10.0, 2.8 Hz, 1H), 6.84 (ddd, <i>J</i> = 8.9, 7.8, 2.8 Hz, 1H), 3.94 (br s, 2H), 3.89–3.84 (m, 2H), 3.31–3.19 (br m, 4H), 1.94–1.86 (m, 2H), 1.82 (d, <i>J</i> = 12.7 Hz, 2H), 1.80–1.75 (m, 2H), 1.44 (s, 9H).</div></div><div id="sec5_20_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>tert</i>-Butyl 6-Fluorospiro[isochromane-1,4′-piperidine]-1′-carboxylate (<b>44</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-[4-fluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (<b>40</b>) (3.48 g, 10.25 mmol) and triethylamine (2.86 mL, 20.51 mmol) were combined in DCM (15 mL) and cooled to 0 °C. Methanesulfonyl chloride (0.79 mL, 10.25 mmol) was added dropwise and the reaction was allowed to warm to rt and then heated to reflux for 90 min. The reaction was then allowed to cool to rt and washed with H<sub>2</sub>O. The organics were separated and concentrated <i>in vacuo</i>. The crude material was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound (1.96 g, 59%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.03, (dd, <i>J</i> = 8.7, 5.5 Hz, 1H), 6.88 (td, <i>J</i> = 8.5, 2.7 Hz, 1H), 6.79 (dd, <i>J</i> = 9.3, 2.7 Hz, 1H), 3.99 (br s, 2H), 3.89 (t, <i>J</i> = 5.5 Hz, 2H), 3.13 (br s, 2H), 2.81 (t, <i>J</i> = 5.5 Hz, 2H), 1.90–1.76 (m, 4H), 1.49 (s, 9H).</div></div><div id="sec5_20_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 6-Fluorospiro[isochromane-1,4′-piperidine] (<b>50</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 6-fluorospiro[isochromane-1,4′-piperidine]-1′-carboxylate (<b>44</b>) (1.96 g, 6.10 mmol) was dissolved in DCM (5 mL) and trifluoroacetic acid (4.17 mL, 54.50 mmol) was added. The reaction was stirred at rt for 18 h. The reaction mixture was diluted with MeOH and loaded onto an SCX cartridge eluting with MeOH and then 3 M NH<sub>3</sub> in MeOH to elute the product. The solvents were removed <i>in vacuo</i> to afford the title compound (1.21 g, 90%). LCMS (ESI) <i>m</i>/<i>z</i>: 222 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.13 (dd, <i>J</i> = 8.7, 5.7 Hz, 1H), 6.88 (td, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.78 (dd, <i>J</i> = 9.3, 2.7 Hz, 1H), 3.89 (t, <i>J</i> = 5.5 Hz, 2H), 3.11–3.02 (m, 2H), 2.93–2.86 (m, 2H), 2.81 (t, <i>J</i> = 5.5 Hz, 2H), 1.89–1.81 (m, 4H).</div></div><div id="sec5_20_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 6-Fluoro-1′-((5-methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>6</b>)</h5><div class="NLM_p last">6-Fluorospiro[isochromane-1,4′-piperidine] (<b>50</b>) (40 mg, 0.18 mmol), 5-methyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>70</b>) (34 mg, 0.18 mmol), and sodium triacetoxyborohydride (77 mg, 0.36 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 392 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>27</sub>FN<sub>3</sub>O [M + H<sup>+</sup>], 392.2138; found, 392.2080. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.46–7.43 (m, 4H), 7.38–7.32 (m, 1H), 7.15 (dd, <i>J</i><sub>1</sub> = 8.7 Hz, <i>J</i><sub>2</sub> = 5.6 Hz, 1H), 6.87 (td, <i>J</i><sub>1</sub> = 8.6 Hz, <i>J</i><sub>2</sub> = 2.7 Hz, 1H), 6.77 (dd, <i>J</i><sub>1</sub> = 9.3 Hz, <i>J</i><sub>2</sub> = 2.7 Hz, 1H), 6.21 (s, 1H), 3.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.65 (s, 2H), 2.85 (m, 2H), 2.80 (t, <i>J</i> = 5.5 Hz, 2H), 2.51 (t, <i>J</i> = 13.1 Hz, 2H), 2.33 (d, <i>J</i> = 0.6 Hz, 3H), 2.10–2.00 (m, 2H), 1.91–1.84 (m, 2H).</div></div></div><div id="sec5_20_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Synthesis of 7-Fluoro-1′-((5-methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>7</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">7-Fluorospiro[isochromane-1,4′-piperidine] (40 mg, 0.18 mmol), 5-methyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>70</b>) (34 mg, 0.18 mmol), and sodium triacetoxyborohydride (77 mg, 0.36 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 392 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.48–7.42 (m, 4H), 7.38–7.32 (m, 1H), 7.05–7.00 (m, 1H), 6.91 (dd, <i>J</i><sub>1</sub> = 10.3 Hz, <i>J</i><sub>2</sub> = 2.6 Hz, 1H), 6.83 (td, <i>J</i><sub>1</sub> = 8.4 Hz, <i>J</i><sub>2</sub> = 2.6 Hz, 1H), 6.22 (s, 1H), 3.87 (t, <i>J</i> = 5.5 Hz, 2H), 3.64 (s, 2H), 2.85 (m, 2H), 2.77 (t, <i>J</i> = 5.5 Hz, 2H), 2.55–2.46 (m, 2H), 2.43 (d, <i>J</i> = 0.6 Hz, 3H), 2.07–1.97 (m, 2H), 1.93–1.86 (m, 2H).</div></div><div id="sec5_20_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Synthesis of 6,7-Difluoro-1′-((5-methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>8</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 2-(2-Bromo-4,5-difluoro-phenyl)ethanol (<b>38</b>)</h5><div class="NLM_p last">2-(2-Bromo-4,5-difluoro-phenyl)acetic acid (<b>36</b>) (1.04 g, 4.14 mmol) was dissolved in THF (20 mL) and BH<sub>3</sub>.THF (1 M solution, 10.8 mL, 10.8 mmol) was added dropwise. The resultant solution was heated to 100 °C for 1 h. The solution was then allowed to cool to rt and H<sub>2</sub>O (15 mL) was carefully added until effervescence is ceased, followed by K<sub>2</sub>CO<sub>3</sub> portionwise until effervescence is ceased. Et<sub>2</sub>O (20 mL) was then added and the layers were separated. The organic liquors were washed with NaHCO<sub>3</sub> (saturated aqueous solution) and brine, dried (MgSO<sub>4</sub>), separated <i>via</i> a hydrophobic frit and then concentrated <i>in vacuo</i> to afford the crude product. Purification by flash chromatography (10–20% EtOAc in heptane) afforded the title compound. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.38 (dd, <i>J</i><sub>1</sub> = 11.9 Hz, <i>J</i><sub>2</sub> = 9.7 Hz, 1H), 7.14 (dd, <i>J</i><sub>1</sub> = 10.9 Hz, <i>J</i><sub>2</sub> = 8.2 Hz, 1H), 3.89–3.82 (m, 2H), 2.95 (t, <i>J</i> = 6.5 Hz, 2H), 1.62 (t, <i>J</i> = 5.4 Hz, 1H).</div></div><div id="sec5_20_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> <i>tert</i>-Butyl 4-[4,5-Difluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (<b>41</b>)</h5><div class="NLM_p last">2-(2-Bromo-4,5-difluoro-phenyl)ethanol (<b>38</b>) (954 mg, 4.02 mmol) was dissolved in THF (15 mL) and cooled to −78 °C. <i>n</i>-BuLi (2.5 M solution, 3.22 mL, 8.05 mmol) was added dropwise and the mixture was stirred at −78 °C for 1 h. <i>tert</i>-Butyl 4-oxopiperidine-1-carboxylate (0.80 g, 4.02 mmol) was dissolved in THF (10 mL), and the solution was added dropwise to the reaction mixture. The mixture was continuously stirred at −78 °C for 1 h before being allowed to warm slowly to rt over 18 h. The reaction mixture was then quenched with saturated aqueous ammonium chloride (10 mL), EtOAc (20 mL) was added, and then the organic layer was separated <i>via</i> a hydrophobic frit, dried (MgSO<sub>4</sub>), and concentrated <i>in vacuo</i> to afford the crude product. This product was purified by flash chromatography (20–50% EtOAc in heptane) to afford the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 358 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.11 (dd, <i>J</i><sub>1</sub> = 12.6 Hz, <i>J</i><sub>2</sub> = 8.5 Hz, 1H), 7.01 (dd, <i>J</i><sub>1</sub> = 11.2 Hz, <i>J</i><sub>2</sub> = 8.4 Hz, 1H), 4.16–3.89 (m, 4H), 3.48 (d, <i>J</i> = 5.2 Hz, 2H), 3.34–3.18 (m, 4H), 1.94–1.77 (m, 4H), 1.47 (s, 9H).</div></div><div id="sec5_20_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> <i>tert</i>-Butyl 6,7-Difluorospiro[isochromane-1,4′-piperidine]-1′-carboxylate (<b>45</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-[4,5-difluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (<b>41</b>) (185 mg, 0.52 mmol) was dissolved in DCM (6 mL) and Et<sub>3</sub>N (154 μL, 1.11 mmol) was added. The reaction mixture was cooled to 0 °C and then methanesulfonyl chloride (43 μL, 0.55 mmol) was added dropwise. Once the addition was complete, the reaction was allowed to warm to rt for 45 min before heating to reflux for 90 min. The reaction mixture was allowed to cool to rt and washed with H<sub>2</sub>O. The volatiles were removed <i>in vacuo</i> to afford a pale yellow oil. This product was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 6.92–6.82 (m, 2H), 4.17–3.80 (m, 4H), 3.28–2.94 (m, 2H), 2.82–2.68 (m, 2H), 1.93–1.70 (m, 4H), 1.49 (s, 9H).</div></div><div id="sec5_20_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 6,7-Difluorospiro[isochromane-1,4′-piperidine] (<b>51</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 6,7-difluorospiro[isochromane-1,4′-piperidine]-1′-carboxylate (<b>45</b>) (106 mg, 0.31 mmol) was dissolved in DCM (2 mL) and to the solution was added TFA (24 μL, 0.31 mmol) at rt for 18 h and then concentrated <i>in vacuo</i>. The residue was loaded onto a 1 g SCX cartridge using MeOH, eluting with 3 M NH<sub>3</sub> in MeOH. The solvents were removed <i>in vacuo</i> to afford the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 240 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 6.96 (dd, <i>J</i><sub>1</sub> = 11.6 Hz, <i>J</i><sub>2</sub> = 7.9 Hz, 1H), 6.86 (dd, <i>J</i><sub>1</sub> = 10.7 Hz, <i>J</i><sub>2</sub> = 8.0 Hz, 1H), 3.86 (t, <i>J</i> = 5.5 Hz, 2H), 3.10–3.00 (m, 2H), 2.96–2.87 (m, 2H), 2.80–2.60 (m, 3H), 1.91–1.75 (m, 4H).</div></div><div id="sec5_20_8_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 6,7-Difluoro-1′-((5-methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>8</b>)</h5><div class="NLM_p last">6,7-Difluorospiro[isochromane-1,4′-piperidine] (<b>51</b>) (27 mg, 0.11 mmol), 5-methyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>70</b>) (21 mg, 0.11 mmol), and sodium triacetoxyborohydride (48 mg, 0.23 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 410 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.50–7.45 (m, 4H), 7.41–7.35 (m, 1H), 7.06–6.97 (m, 1H), 6.99–6.84 (m, 1H), 6.23 (s, 1H), 3.89 (t, <i>J</i> = 5.6 Hz, 2H), 3.66 (s, 2H), 2.87 (m, 2H), 2.77 (t, <i>J</i> = 5.4 Hz, 2H), 2.51 (td, <i>J</i><sub>1</sub> = 11.9 Hz, <i>J</i><sub>2</sub> = 2.8 Hz, 2H), 2.36 (d, <i>J</i> = 0.5 Hz, 3H), 2.06–1.95 (m, 2H), 1.94–1.86 (m, 2H).</div></div></div><div id="sec5_20_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Synthesis of 1′-((5-Methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)-6-(Trifluoromethyl)spiro[isochromane-1,4′-piperidine] (<b>9</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 2-[2-Bromo-5-(trifluoromethyl)phenyl]ethanol (<b>39</b>)</h5><div class="NLM_p last">2-[2-Bromo-5-(trifluoromethyl)phenyl]acetic acid (<b>37</b>) (850 mg, 3.00 mmol) was dissolved in THF (10 mL) and BH<sub>3</sub>.THF (1 M solution, 3.90 mL, 3.90 mmol) was added dropwise. The resultant solution was heated to 100 °C for 1 h. The solution was then allowed to cool to rt and H<sub>2</sub>O (15 mL) was carefully added until effervescence is ceased, followed by K<sub>2</sub>CO<sub>3</sub> portionwise until effervescence is ceased. Et<sub>2</sub>O (20 mL) was then added and the layers were separated. The organics were washed with NaHCO<sub>3</sub> (saturated aqueous solution) and brine, dried (MgSO<sub>4</sub>), separated <i>via</i> a hydrophobic frit, and then concentrated <i>in vacuo</i> to afford the crude product. This product was purified by flash chromatography (10–20% EtOAc in heptane) to afford the title compound. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.70–7.66 (m, 1H), 7.56–7.52 (m, 1H), 7.37–7.32 (m, 1H), 3.91 (t, <i>J</i> = 6.6 Hz, 2H), 3.08 (t, <i>J</i> = 6.6 Hz, 2H).</div></div><div id="sec5_20_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <i>tert</i>-Butyl 4-Hydroxy-4-[2-(2-hydroxyethyl)-4-(trifluoromethyl)phenyl]piperidine-1-carboxylate (<b>42</b>)</h5><div class="NLM_p last">2-[2-Bromo-5-(trifluoromethyl)phenyl]ethanol (<b>39</b>) (780 mg, 2.90 mmol) was dissolved in THF (15 mL) and cooled to −78 °C. <i>n</i>-BuLi (2.5 M solution, 2.32 mL, 5.80 mmol) was added dropwise and the mixture was stirred at −78 °C for 1 h. <i>tert</i>-Butyl 4-oxopiperidine-1-carboxylate (578 mg, 2.90 mmol) dissolved in THF (10 mL) and the solution was added dropwise to the reaction mixture. The mixture was continuously stirred at −78 °C for 1 h before being allowed to warm slowly to rt over 18 h. The reaction mixture was then quenched with saturated aqueous ammonium chloride (10 mL). EtOAc (20 mL) was added and the organic layer was separated <i>via</i> a hydrophobic frit, dried (MgSO<sub>4</sub>), and concentrated <i>in vacuo</i> to afford the crude product. This product was purified by flash chromatography (20–50% EtOAc in heptane) to afford the title compound. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.46–7.38 (m, 3H), 4.31 (br s, 1H), 4.10–3.88 (m, 3H), 3.52–3.19 (m, 6H), 2.03–1.77 (m, 4H), 1.47 (s, 9H).</div></div><div id="sec5_20_9_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>tert</i>-Butyl 6-(Trifluoromethyl)spiro[isochromane-1,4′-piperidine]-1′-carboxylate (<b>46</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-hydroxy-4-[2-(2-hydroxyethyl)-4-(trifluoromethyl)phenyl]piperidine-1-carboxylate (<b>42</b>) (342 mg, 0.88 mmol) was dissolved in DCM (6 mL) and Et<sub>3</sub>N (245 μL, 1.76 mmol) was added. The reaction mixture was cooled to 0 °C and then methanesulfonyl chloride (68 μL, 0.88 mmol) was added dropwise. Once the addition was complete, the reaction was allowed to warm to rt for 45 min before heating to reflux for 90 min. The reaction mixture was allowed to cool to rt and washed with H<sub>2</sub>O. The organics were concentrated <i>in vacuo</i> to afford a pale yellow oil. This product was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 372 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.43 (d, <i>J</i> = 8.2 Hz, 1H), 7.36 (s, 1H), 7.19 (d, <i>J</i> = 8.2 Hz, 1H), 4.17–3.87 (m, 4H), 3.15 (br s, 2H), 2.93–2.83 (m, 2H), 1.93–1.78 (m, 4H), 1.49 (s, 9H).</div></div><div id="sec5_20_9_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 6-(Trifluoromethyl)spiro[isochromane-1,4′-piperidine] (<b>52</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 6-(trifluoromethyl)spiro[isochromane-1,4′-piperidine]-1′-carboxylate (<b>46</b>) (169 mg, 0.46 mmol) was dissolved in DCM (2 mL) and to the solution was added TFA (0.5 mL, 6.53 mmol) at rt for 18 h and then concentrated <i>in vacuo</i>. The residue was loaded onto a 1 g SCX cartridge using MeOH, eluting with 3 M NH<sub>3</sub> in MeOH. The solvents were removed <i>in vacuo</i> to afford the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 272 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.45–7.24 (m, 3H), 3.91–3.85 (m, 2H), 3.79 (br s, 1H), 3.12–3.02 (m, 2H), 2.99–2.90 (m, 2H), 2.89–2.79 (m, 2H), 2.00–1.78 (m, 4H).</div></div><div id="sec5_20_9_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 1′-((5-Methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)-6-(trifluoromethyl)spiro[isochromane-1,4′-piperidine] (<b>9</b>)</h5><div class="NLM_p last">6-(Trifluoromethyl)spiro[isochromane-1,4′-piperidine] (<b>52</b>) (31 mg, 0.11 mmol), 5-methyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>70</b>) (21 mg, 0.11 mmol), and sodium triacetoxyborohydride (48 mg, 0.23 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 442 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.50–7.42 (m, 5H), 7.40–7.32 (m, 3H), 6.24 (s, 1H), 3.93 (t, <i>J</i> = 5.5 Hz, 2H), 3.68 (s, 2H), 2.94–2.85 (m, 2H), 2.60–2.49 (m, 2H), 2.36 (d, <i>J</i> = 0.7 Hz, 3H), 2.16–2.04 (m, 2H), 1.96–1.88 (m, 2H).</div></div></div><div id="sec5_20_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Synthesis of 7,8-Difluoro-1′-((5-methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>10</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> <i>tert</i>-Butyl 4-[4,5-Difluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (<b>43</b>)</h5><div class="NLM_p last">2-(2-Bromo-4,5-difluoro-phenyl)ethanol (954 mg, 4.02 mmol) was dissolved in THF (15 mL) and cooled to −78 °C. <i>n</i>-BuLi (2.5 M solution, 3.22 mL, 8.05 mmol) was added dropwise and the mixture was stirred at −78 °C for 1 h. <i>tert</i>-Butyl 4-oxopiperidine-1-carboxylate (0.80 g, 4.02 mmol) dissolved in THF (10 mL) and the solution was added dropwise to the reaction mixture. The mixture was continuously stirred at −78 °C for 1 h before being allowed to warm slowly to rt over 18 h. The reaction mixture was then quenched with saturated aqueous ammonium chloride (10 mL). EtOAc (20 mL) was added and the organic layer was separated <i>via</i> a hydrophobic frit, dried (MgSO<sub>4</sub>), and concentrated <i>in vacuo</i> to afford the crude product. This product was purified by flash chromatography (20–50% EtOAc in heptane) to afford the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 358 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.02–6.93 (m, 1H), 6.87–6.80 (m, 1H), 4.00–3.75 (m, 4H), 3.61–3.04 (m, 6H), 2.47–2.31 (m, 2H), 1.68–1.56 (m, 2H), 1.46 (s, 9H).</div></div><div id="sec5_20_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> <i>tert</i>-Butyl 7,8-Difluorospiro[isochromane-1,4′-piperidine]-1′-carboxylate (<b>47</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-[4,5-difluoro-2-(2-hydroxyethyl)phenyl]-4-hydroxy-piperidine-1-carboxylate (<b>43</b>) (198 mg, 0.55 mmol) was dissolved in DCM (6 mL) and Et<sub>3</sub>N (155 μL, 1.11 mmol) was added. The reaction mixture was cooled to 0 °C and then methanesulfonyl chloride (43 μL, 0.55 mmol) was added dropwise. Once the addition was complete, the reaction was allowed to warm to rt for 45 min before heating to reflux for 90 min. The reaction mixture was allowed to cool to room temperature (rt) and washed with water. The organic liquors were concentrated <i>in vacuo</i> to afford a pale yellow oil. This product was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.02–6.95 (m, 1H), 6.88–6.82 (m, 1H), 4.15–3.83 (m, 4H), 3.31–3.01 (m, 2H), 2.84–2.72 (m, 2H), 2.32–2.22 (m, 2H), 1.89–1.67 (m, 2H), 1.49 (s, 9H).</div></div><div id="sec5_20_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 7,8-Difluorospiro[isochromane-1,4′-piperidine] (<b>53</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 7,8-difluorospiro[isochromane-1,4′-piperidine]-1′-carboxylate (<b>47</b>) (81 mg, 0.24 mmol) was dissolved in DCM (2 mL) and to the solution was added TFA (18 μL, 0.24 mmol) at rt for 18 h and then concentrated <i>in vacuo</i>. The residue was loaded onto a 1 g SCX cartridge using MeOH, eluting with 3 M NH<sub>3</sub> in MeOH. The solvents were removed <i>in vacuo</i> to afford the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 240 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.01–6.92 (m, 1H), 6.86–6.79 (m, 1H), 3.86 (t, <i>J</i> = 5.5 Hz, 2H), 3.40 (br s, 1H), 3.17–3.05 (m, 2H), 3.01–2.90 (m, 2H), 2.80–2.71 (m, 2H), 2.35–2.22 (m, 2H), 1.85–1.76 (m, 2H).</div></div><div id="sec5_20_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 7,8-Difluoro-1′-((5-methyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>10</b>)</h5><div class="NLM_p last">7,8-Difluorospiro[isochromane-1,4′-piperidine] (<b>53</b>) (26 mg, 0.11 mmol), 5-methyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (20 mg, 0.11 mmol), and sodium triacetoxyborohydride (46 mg, 0.22 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound. LCMS (ESI) <i>m</i>/<i>z</i>: 410 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.42 (m, 4H), 7.38–7.31 (m, 1H), 7.02–6.92 (m, 1H), 6.85–6.79 (m, 1H), 6.24 (s, 1H), 3.85 (t, <i>J</i> = 5.5 Hz, 2H), 3.65 (s, 2H), 2.86–2.73 (m, 4H), 2.59–2.41 (m, 4H), 2.34 (d, <i>J</i> = 0.7 Hz, 3H), 1.85–1.77 (m, 2H).</div></div></div><div id="sec5_20_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Synthesis of 1′-((5-Methoxy-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>11</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Methyl 5-Hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>62</b>)</h5><div class="NLM_p last">Phenylhydrazine (5.00 g, 46.24 mmol) in Et<sub>2</sub>O (100 mL) was added over 30 min to a mixture of dimethyl but-2-ynedioate (<b>61</b>) (6.57 g, 46.24 mmol) in Et<sub>2</sub>O (50 mL). After stirring for 1 h at rt, the reaction mixture was concentrated <i>in vacuo</i> and redissolved in MeOH (150 mL). This solution was added dropwise over 1 h to NaOMe (25 wt %) (3.99 mg, 184.94 mmol) in MeOH (150 mL) and the mixture was stirred at rt for 18 h. The solvent was removed <i>in vacuo</i> and 5 N HCl (100 mL) was added. The resulting precipitate was collected by filtration, washed with DCM and Et<sub>2</sub>O, and air-dried to afford 5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (8.00 g, 76%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.74 (d, <i>J</i> = 7.5 Hz, 2H), 7.51 (dd, <i>J</i> = 7.9, 7.9 Hz, 2H), 7.36 (dd, <i>J</i> = 7.4, 7.4 Hz, 1H), 5.93 (s, 1H). 5-Oxo-1-phenyl-4<i>H</i>-pyrazole-3-carboxylic acid (8.00 g, 39.18 mmol) was mixed in MeOH (150 mL), and a few drops of concentrated H<sub>2</sub>SO<sub>4</sub> were added. The reaction was heated to reflux for 48 h and then allowed to cool to rt. The volatiles were removed <i>in vacuo</i> and the crude material was purified by flash chromatography (50–100% EtOAc in heptane) to afford the title compound as a pale brown solid (4.00 g, 42%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 12.15 (m, 1H), 7.74 (d, <i>J</i> = 7.6 Hz, 2H), 7.51 (dd, <i>J</i> = 7.9, 7.9 Hz, 2H), 7.38 (dd, <i>J</i> = 7.4, 7.4 Hz, 1H), 5.97 (s, 1H), 3.81 (s, 3H).</div></div><div id="sec5_20_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Methyl 5-Methoxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>63</b>)</h5><div class="NLM_p last">Methyl 5-hydroxy-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>62</b>) (500 mg, 2.29 mmol) was dissolved in THF (10 mL), and PPh<sub>3</sub> (901 mg, 3.44 mmol) and MeOH (0.12 mL, 2.98 mmol) were added. The reaction mixture was cooled to 0 °C and DIAD (0.68 mL, 3.44 mmol) was added dropwise. The reaction mixture was allowed to warm to rt for 18 h. The reaction mixture was partitioned between H<sub>2</sub>O and DCM, passed through a hydrophobic frit, and concentrated <i>in vacuo</i>. The crude material was purified by flash chromatography (0–100% EtOAc in heptane) to afford the title compound as a yellow gum. DIAD side product coeluted but used in the next step with no further purification. <sup>1</sup>H NMR (400 MHz, CDCl3): δ 7.73 (d, <i>J</i> = 8.1 Hz, 2H), 7.46 (dd, <i>J</i> = 7.8, 7.8 Hz, 2H), 7.36 (dd, <i>J</i> = 7.4, 7.4 Hz, 1H), 6.26 (s, 1H), 4.00 (s, 3H)3.96 (s, 3H).</div></div><div id="sec5_20_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 5-Methoxy-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>71</b>)</h5><div class="NLM_p last">Methyl 5-methoxy-1-phenyl-pyrazole-3-carboxylate (<b>63</b>) (600 mg, 2.58 mmol) was mixed with THF (8 mL) and cooled to 0 °C. LiAlH<sub>4</sub> (2.58 mL 2.58 mmol) was added dropwise over 10 min. After 1 h, the reaction was quenched with H<sub>2</sub>O (2 mL) and 2 M NaOH (2 mL). The resulting slurry was filtered through a Celite cartridge and concentrated <i>in vacuo</i>. The crude material was purified by flash chromatography (0–100% EtOAc in heptane) to afford (5-methoxy-1-phenyl-1<i>H</i>-pyrazol-3-yl)methanol as a pale yellow gum (180 mg, 32%). <sup>1</sup>H NMR (400 MHz, CDCl3): δ 7.70 (d, <i>J</i> = 7.6 Hz, 2H), 7.44 (dd, <i>J</i> = 7.9, 7.9 Hz, 2H), 7.29 (m, 1H) 5.74 (s, 1H), 4.69 (d, <i>J</i> = 5.3 Hz, 2H), 3.97 (s, 3H), 2.60 (s, 1H). (5-Methoxy-1-phenyl-pyrazol-3-yl)methanol (300 mg, 1.47 mmol) was dissolved in DCM (10 mL) and MnO<sub>2</sub> (319 mg, 3.67 mmol) was added. The reaction mixture was heated to reflux for 48 h and then allowed to cool to rt. The reaction mixture was filtered through a Celite cartridge and washed with DCM. The filtrate was concentrated <i>in vacuo</i> and purified by flash chromatography (0–100% EtOAc in heptane) to afford the title compound (220 mg, 70%). <sup>1</sup>H NMR (400 MHz, CDCl3): δ 9.92 (s, 1H), 7.76 (d, <i>J</i> = 7.8 Hz, 2H), 7.51 (dd, <i>J</i> = 7.8, 7.8 Hz, 2H), 7.41 (dd, <i>J</i> = 7.4, 7.4 Hz, 1H), 6.22 (s, 1H), 4.02 (s, 3H).</div></div><div id="sec5_20_11_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 1′-((5-Methoxy-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>11</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (40 mg, 0.20 mmol), 5-methoxy-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>71</b>) (40 mg, 0.20 mmol), and sodium triacetoxyborohydride (83 mg, 0.39 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded 1′-((5-methoxy-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] as a colorless gum (40 mg, 50%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub> [M + H<sup>+</sup>], 390.2181; found, 390.2165. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.72 (d, <i>J</i> = 7.6 Hz, 1H), 7.43 (dd, <i>J</i> = 8.0, 8.0 Hz, 1H), 7.27–7.09 (m, 2H), 3.97 (s, 2H), 3.92 (dd, <i>J</i> = 5.5, 5.5 Hz, 1H), 3.63 (s, 1H), 2.89–2.83 (m, 2H), 2.60–2.52 (m, 1H), 2.16–2.03 (m, 1H), 1.94 (d, <i>J</i> = 12.3 Hz, 1H).</div></div></div><div id="sec5_20_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Synthesis of 1′-((5-Cyclopropyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>12</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> Methyl 5-Cyclopropyl-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>64</b>)</h5><div class="NLM_p last">Phenylhydrazine (634 mg, 5.88 mmol) was added to a solution of methyl 4-cyclopropyl-2,4-dioxo-butanoate (<b>55</b>) (1.00 g, 5.88 mmol) in EtOH (40 mL) according to General Method 3a. Work-up and purification afforded the title compound (1.16 g, 81%). LCMS (ESI) <i>m</i>/<i>z</i>: 243 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.63–7.59 (m, 2H), 7.51–7.48 (m, 2H), 7.44–7.40 (m, 1H), 6.50 (s, 1H), 3.92 (s, 3H), 1.81–1.74 (m, 1H), 1.03–0.97 (m, 2H), 0.82–0.76 (m, 2H).</div></div><div id="sec5_20_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 5-Cyclopropyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>72</b>)</h5><div class="NLM_p last">Methyl 5-cyclopropyl-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>64</b>) (1.16 g, 4.79 mmol) and DIBAL (1 M in DCM) (11.97 mL, 11.97 mmol) were combined in DCM (25 mL) according to General Method 6a. Work-up and purification afforded the title compound (719 mg, 67%). LCMS (ESI) <i>m</i>/<i>z</i>: 213 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.97 (s, 1H), 7.66–7.62 (m, 2H), 7.55–7.50 (m, 2H), 7.48–7.44 (m, 1H), 6.48 (s, 1H).</div></div><div id="sec5_20_12_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 1′-((5-Cyclopropyl-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>12</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (48 mg, 0.24 mmol), 5-cyclopropyl-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>72</b>) (50 mg, 0.24 mmol), and sodium triacetoxyborohydride (100 mg, 0.47 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound as a colorless gum (20 mg, 20%). LCMS (ESI) <i>m</i>/<i>z</i>: 400 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>30</sub>N<sub>3</sub>O [M + H<sup>+</sup>], 400.2383; found, 400.2389. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.65–7.61 (m, 2H), 7.48–7.43 (m, 2H), 7.34 (tdd, <i>J</i> = 7.5, 1.5, 1.2 Hz, 1H), 7.21 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.18 (td, <i>J</i> = 7.3, 1.6 Hz, 1H), 7.13 (td, <i>J</i> = 7.3, 1.6 Hz, 1H), 7.08 (d, 7.3 Hz, 1H), 5.99 (s, 1H)3.89 (t, <i>J</i> = 5.6 Hz, 2H), 3.63 (s, 2H), 2.87–2.80 (m, 4H), 2.50 (td, <i>J</i> = 11.9, 2.3 Hz, 2H), 2.08 (td, <i>J</i> = 13.2, 4.6 Hz, 2H), 1.93–1.87 (m, 2H), 1.84–1.77 (m, 1H), 1.00–0.95 (m, 2H), 0.82–0.77 (m, 2H).</div></div></div><div id="sec5_20_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Synthesis of 1′-((5-(Difluoromethyl)-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>13</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> Ethyl 5-(Difluoromethyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>65</b>)</h5><div class="NLM_p last">Ethyl 5,5-difluoro-2,4-dioxo-pentanoate (<b>56</b>) (1.00 g, 5.15 mmol) and phenylhydrazine (557 mg, 5.15 mmol) were dissolved in EtOH (40 mL) according to General Method 3a. Work-up and purification afforded an intermediate compound. This material was then dissolved in THF, 2 M HCl was added, and the mixture was heated to reflux for 18 h. The volatiles were removed <i>in vacuo</i> and the product was extracted with DCM, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford the title compound as a colorless oil (850 mg, 62%). LCMS (ESI) <i>m</i>/<i>z</i>: 267 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.55 (s, 6H), 6.63 (t, <i>J</i> = 53.4 Hz, 1H), 4.47 (q, <i>J</i> = 7.1 Hz, 2H), 1.44 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec5_20_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 5-(Difluoromethyl)-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>73</b>)</h5><div class="NLM_p last">Ethyl 5-(difluoromethyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>65</b>) (187 mg, 0.70 mmol) and DIBAL (1 M in DCM) (1.76 mL, 1.76 mmol) were combined in DCM (10 mL) with MnO<sub>2</sub> (1.22 g, 14.05 mmol) added in the second step according to General Method 6b. Work-up and purification afforded the title compound as a colorless oil (122 mg, 74%).</div></div><div id="sec5_20_13_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> 1′-((5-(Difluoromethyl)-1-phenyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>13</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (62 mg, 0.30 mmol), 5-(difluoromethyl)-1-phenyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>73</b>) (61 mg, 0.27 mmol), and sodium triacetoxyborohydride (116 mg, 0.55 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound as a colorless gum (10 mg, 8%). LCMS (ESI) <i>m</i>/<i>z</i>: 428 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>26</sub>F<sub>2</sub>N<sub>3</sub>O [M + H<sup>+</sup>], 410.2053; found, 410.2054. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.56–7.44 (m, 5H), 7.26–7.19 (m, 2H), 7.17 (td, <i>J</i> = 7.0, 2.0 Hz, 1H), 7.11 (d, <i>J</i> = 7.5 Hz, 1H), 6.80 (s, 1H), 6.65 (t, <i>J</i> = 54 Hz, 3.93 (t, <i>J</i> = 5.5, 2H), 3.74 (s, 2H), 2.89–2.83 (m, 4H), 2.56 (t, <i>J</i> = 12.2 Hz, 2H), 2.11 (td, <i>J</i> = 13.2, 4.2 Hz, 2H), 1.94 (d, <i>J</i> = 13.2 Hz, 2H).</div></div></div><div id="sec5_20_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Synthesis of 1′-((1-Phenyl-5-(Trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>14</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_14_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Ethyl 1-Phenyl-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (<b>66</b>)</h5><div class="NLM_p last">Phenylhydrazine (510 mg, 4.71 mmol) and ethyl 5,5,5-trifluoro-2,4-dioxo-pentanoate (<b>57</b>) (1.00 g, 4.71 mmol) were dissolved in EtOH (40 mL) according to General Method 3a. Work-up and purification afforded an intermediate compound. This material was then dissolved in THF, 2 M HCl was added, and the mixture was heated to reflux for 18 h. The volatiles were removed <i>in vacuo</i>, and the product was extracted with DCM, dried <i>via</i> a hydrophobic frit, and concentrated <i>in vacuo</i>. The crude material was purified by flash chromatography (10–50% EtOAc in heptane) to afford the title compound as a yellow oil (456 mg, 34%). LCMS (ESI) <i>m</i>/<i>z</i>: 285 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.54–7.47 (m, 5H), 7.33 (s, 1H), 4.45 (q, <i>J</i> = 7.2, 2H), 1.41 (t, <i>J</i> = 7.2, 3H).</div></div><div id="sec5_20_14_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 1-Phenyl-5-(Trifluoromethyl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>74</b>)</h5><div class="NLM_p last">Ethyl 1-phenyl-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (<b>66</b>) (417 mg, 1.47 mmol) and DIBAL (1 M in DCM) (3.67 mL, 3.67 mmol) were combined in DCM (10 mL) with MnO<sub>2</sub> (273 mg, 3.14 mmol) added in the second step according to General Method 6b. Work-up afforded the crude product which was used without further purification.</div></div><div id="sec5_20_14_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 1′-((1-Phenyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>14</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (49 mg, 0.24 mmol), 1-phenyl-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>74</b>) (52 mg, 0.22 mmol), and sodium triacetoxyborohydride (92 mg, 0.43 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound as a colorless gum (20 mg, 21%). LCMS (ESI) <i>m</i>/<i>z</i>: 428 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.51–7.43 (m, 5H), 7.23–7.17 (m, 1H), 7.09 (d, <i>J</i> = 7.6 Hz, 1H), 6.84 (s, 1H), 3.90 (t, <i>J</i> = 5.5 Hz, 2H), 3.70 (s, 2H), 2.85–2.80 (m, 4H), 2.53 (td, 12.0, 2.5 Hz, 2H), 2.08 (td, 13.3, 4.4 Hz, 2H), 1.95–1.89 (m, 2H).</div></div></div><div id="sec5_20_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Synthesis of (4-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)phenyl)methanol (<b>15</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_15_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> 1′-((5-Methyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>78</b>)</h5><div class="NLM_p last">To 5-methyl-1<i>H</i>-pyrazole-3-carbaldehyde (1.35 g, 12.30 mmol) in NMP (125 mL) were added spiro[isochromane-1,4′-piperidine] (2.50 g, 12.30 mmol) and a few drops of acetic acid. After 1 h at rt, sodium triacetoxyborohydride (5.21 mg, 24.60 mmol) was added. The reaction mixture was stirred at rt for 18 h. The reaction was quenched with NaHCO<sub>3</sub> (saturated aqueous solution), and the product was extracted with EtOAc, washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated <i>in vacuo</i>. The residue was loaded onto a 20 g SCX cartridge eluting with MeOH and then 20% 2 N NH<sub>3</sub>/MeOH. The volatiles were removed <i>in vacuo</i> to afford the title compound as a pale yellow solid (320 mg, 8%). The initial MeOH washings were concentrated <i>in vacuo</i>, and the resulting material was purified by flash chromatography (0–5% MeOH in DCM) to afford a second batch of title compound as a pale yellow solid (1.60 g, 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.22–7.21 (m, 2H), 7.18–7.14 (m, 1H), 7.10 (d, <i>J</i> = 7.34 Hz), 6.02 (s, 1H), 3.91 (t, <i>J</i> = 5.5 Hz, 2H), 3.61 (s, 2H), 2.84 (t, <i>J</i> = 5.5 Hz, 2H), 2.78–2.75 (m, 2H), 2.49 (t, <i>J</i> = 11.5 Hz, 2H), 2.31 (s, 3H), 2.06 (td, <i>J</i> = 13.5, 3.8 Hz, 2H), 1.93–1.90 (m, 2H). LCMS (ESI) <i>m</i>/<i>z</i>: 298 (M + H)<sup>+</sup>.</div></div><div id="sec5_20_15_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> (4-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)phenyl)methanol (<b>15</b>)</h5><div class="NLM_p last">1′-[(5-methyl-1<i>H</i>-pyrazol-3-yl)methyl]spiro[isochromane-1,4′-piperidine] (<b>78</b>) (100 mg, 0.34 mmol), [4-(hydroxymethyl)phenyl]boronic acid (102 mg, 0.67 mmol), and copper acetate (92 mg, 0.50 mmol) were combined in DCM (3 mL) and pyridine (0.50 mL, 6.20 mmol) according to General Method 2. Work-up and purification afforded the title compound (30 mg, 21%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub> [M + H<sup>+</sup>], 404.2338; found, 404.2365. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.43 (s, 4H), 7.25–7.09 (m, 4H), 6.24 (s, 1H), 4.76 (s, 2H), 3.92 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 3.68 (s, 2H), 2.89–2.82 (m, 4H), 2.59–2.51 (m, 3H), 2.34 (s, 3H), 2.16–2.06 (m, 2H), 1.92 (d, <i>J</i> = 12.2 Hz, 2H).</div></div></div><div id="sec5_20_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Synthesis of 1′-((5-Methyl-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>16</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">1′-[(5-methyl-1<i>H</i>-pyrazol-3-yl)methyl]spiro[isochromane-1,4′-piperidine] (<b>78</b>) (50 mg, 0.17 mmol), <i>p</i>-tolylboronic acid (46 mg, 0.34 mmol), and copper acetate (46 mg, 0.25 mmol) were combined in DCM (1 mL) and pyridine (0.27 mL) according to General Method 2. Work-up and purification afforded the title compound as a yellow gum (15 mg, 22%). LCMS (ESI) <i>m</i>/<i>z</i>: 388 (M + H) <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36–7.32 (m, 2H), 7.28–7.22 (m, 3H), 7.20 (td, <i>J</i> = 6.83, 1.57 Hz, 1H), 7.15 (td, <i>J</i> = 7.32, 1.8 Hz, 1H), 7.11–7.08 (m, 1H), 6.22 (d, <i>J</i> = 0.5 Hz, 1H), 3.9 (t, <i>J</i> = 5.5 Hz, 2H), 6.37 (s, 2H), 2.90–2.83 (m, 4H), 2.53 (td, <i>J</i> = 12.90, 2.44 Hz, 2H), 2.41 (s, 3H), 2.33 (d, <i>J</i> = 0.7 Hz, 3H), 2.10 (td, <i>J</i> = 13.40, 4.47 Hz, 2H), 1.95–1.89 (m, 2H).</div></div><div id="sec5_20_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Synthesis of 1′-((5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>17</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_17_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> Ethyl 5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazole-3-carboxylate (<b>67</b>)</h5><div class="NLM_p last">[4-(Trifluoromethoxy)phenyl]hydrazine hydrochloride (4.34 g, 18.97 mmol) and ethyl 2,4-dioxopentanoate (<b>58</b>) (3.00 g, 18.97 mmol) were dissolved in AcOH (25 mL) according to General Method 3b. Work-up and purification afforded the title compound (3.00 g, 48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.55–7.52 (m, 2H), 7.35 (d, <i>J</i> = 8.3 Hz, 2H), 6.77 (s, 1H), 4.44 (q, <i>J</i> = 7.1 Hz, 2H), 2.37 (s, 3H).</div></div><div id="sec5_20_17_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>75</b>)</h5><div class="NLM_p last">Ethyl 5-methyl-1-[4-(trifluoromethoxy)phenyl]pyrazole-3-carboxylate (<b>67</b>) (2.60 g, 8.27 mmol) and DIBAL (1 M in DCM) (20.68 mL, 20.68 mmol) were combined in DCM (25 mL) according to General Method 6a. Work-up and purification afforded the title compound as a pale yellow oil (2.00 g, 85%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.01 (s, 1H), 7.58–7.55 (m, 2H), 7.41 (d, <i>J</i> = 8.3 Hz, 2H), 6.76 (s, 1H), 2.41 (s, 3H).</div></div><div id="sec5_20_17_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> 1′-((5-Methyl-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>17</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (250 mg, 1.23 mmol), 5-methyl-1-[4-(trifluoromethoxy)phenyl]-1<i>H</i>-pyrazole-3-carbaldehyde (<b>75</b>) (332 mg, 1.23 mmol), and sodium triacetoxyborohydride (521 mg, 2.46 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound (300 mg, 51%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>27</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> [M + H<sup>+</sup>], 458.2055; found, 458.2073. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.52 (d, <i>J</i> = 8.8 Hz, 2H), 7.32 (d, <i>J</i> = 8.8 Hz, 2H), 7.23–7.08 (m, 4H), 6.26 (s, 1H), 3.92 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 3.66 (s, 2H), 2.88–2.83 (m, 4H), 2.54 (dd, <i>J</i> = 11.3, 11.3 Hz, 2H), 2.37 (s, 3H), 2.15–2.05 (m, 2H), 1.94 (d, <i>J</i> = 12.9 Hz, 2H).</div></div></div><div id="sec5_20_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Synthesis of 1′-((1-(6-Methoxypyridin-3-yl)-5-methyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>18</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_18_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> Ethyl 1-(6-Methoxypyridin-3-yl)-5-methyl-1<i>H</i>-pyrazole-3-carboxylate (<b>68</b>)</h5><div class="NLM_p last">Ethyl 5-methyl-1<i>H</i>-pyrazole-3-carboxylate (<b>60</b>) (500 mg, 3.24 mmol), (6-methoxypyridin-3-yl)boronic acid (992 mg, 6.49 mmol), and copper acetate (884 mg, 4.86 mmol) were combined in DCM (10 mL) according to General Method 2. Work-up and purification afforded the title compound (340 mg, 38%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.23 (d, <i>J</i> = 2.7 Hz, 1H), 7.65 (dd, <i>J</i> = 2.7, 8.8 Hz, 1H), 6.85–6.81 (m, 2H), 4.26 (q, <i>J</i> = 7.1 Hz, 2H), 4.00 (s, 3H), 2.38 (s, 3H), 1.29 (dd, <i>J</i> = 7.2, 7.2 Hz, 3H).</div></div><div id="sec5_20_18_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> 1-(6-Methoxypyridin-3-yl)-5-methyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>76</b>)</h5><div class="NLM_p last">Ethyl 1-(6-methoxy-3-pyridyl)-5-methyl-1<i>H</i>-pyrazole-3-carboxylate (<b>68</b>) (380 mg, 1.45 mmol) and DIBAL (1 M in DCM) (3.64 mL, 3.64 mmol) were combined in DCM (10 mL) according to General Method 6a. Work-up and purification afforded the title compound (270 mg, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.00 (s, 1H), 8.31–8.30 (m, 1H), 7.72 (dd, <i>J</i> = 2.8, 8.8 Hz, 1H), 6.92 (d, <i>J</i> = 8.8 Hz, 1H), 6.75 (s, 1H), 4.03 (s, 3H), 2.36 (s, 3H).</div></div><div id="sec5_20_18_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> 1′-((1-(6-Methoxypyridin-3-yl)-5-methyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>18</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (120 mg, 0.59 mmol), 1-(6-methoxy-3-pyridyl)-5-methyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>76</b>) (128 mg, 0.59 mmol), and sodium triacetoxyborohydride (250 mg, 1.18 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound (150 mg, 60%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> [M + H<sup>+</sup>], 405.2288; found, 405.2292. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.25 (d, <i>J</i> = 2.2 Hz, 1H), 7.72 (dd, <i>J</i> = 2.4, 8.8 Hz, 1H), 7.23–7.09 (m, 4H), 6.85 (d, <i>J</i> = 8.8 Hz, 1H), 6.24 (s, 1H), 4.00 (s, 3H), 3.92 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 3.66 (s, 2H), 2.88–2.83 (m, 4H), 2.53 (dd, <i>J</i> = 11.4, 11.4 Hz, 2H), 2.32 (s, 3H), 2.15–2.06 (m, 2H), 1.93 (d, <i>J</i> = 13.1 Hz, 2H).</div></div></div><div id="sec5_20_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Synthesis of 1′-((1-(6-(Difluoromethoxy)pyridin-3-yl)-5-methyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>19</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">1′-[(5-methyl-1<i>H</i>-pyrazol-3-yl)methyl]spiro[isochromane-1,4′-piperidine] (<b>78</b>) (100 mg, 0.34 mmol), 2-(difluoromethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (182 mg, 0.67 mmol), and copper acetate (92 mg, 0.50 mmol) were combined in DCM (3 mL) and pyridine (0.50 mL, 6.20 mmol) according to General Method 2. Work-up and purification afforded the title compound (10 mg, 6%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>27</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H<sup>+</sup>], 441.2102; found, 441.2108. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.32 (d, <i>J</i> = 2.5 Hz, 1H), 7.91 (dd, <i>J</i> = 2.7, 8.7 Hz, 1H), 7.23–7.02 (m, 5H), 6.27 (s, 1H), 3.92 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 3.66 (s, 2H), 2.85 (dd, <i>J</i> = 5.5, 5.5 Hz, 4H), 2.54 (dd, <i>J</i> = 11.0, 11.0 Hz, 2H), 2.36 (s, 3H), 2.14–2.07 (m, 2H), 1.93 (d, <i>J</i> = 12.0 Hz, 2H).</div></div><div id="sec5_20_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Synthesis of 1′-((5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>20</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div id="sec5_20_20_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> Ethyl 5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1<i>H</i>-pyrazole-3-carboxylate (<b>69</b>)</h5><div class="NLM_p last">[6-(Trifluoromethyl)-3-pyridyl]hydrazine (2.46 g, 13.91 mmol) and ethyl 2,4-dioxopentanoate (<b>59</b>) (2.20 g, 13.91 mmol) were dissolved in AcOH (20 mL) according to General Method 3b. Work-up and purification afforded the title compound (2.70 g, 62%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.83 (d, <i>J</i> = 2.4 Hz, 1H), 8.01 (dd, <i>J</i> = 2.1, 8.3 Hz, 1H), 7.80 (d, <i>J</i> = 8.3 Hz, 1H), 6.93 (s, 1H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 2.40 (s, 3H), 1.32 (dd, <i>J</i> = 7.1, 7.1 Hz, 3H).</div></div><div id="sec5_20_20_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> 5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>77</b>)</h5><div class="NLM_p last">Ethyl 5-methyl-1-[6-(trifluoromethyl)-3-pyridyl]-1<i>H</i>-pyrazole-3-carboxylate (<b>69</b>) (1.45 mg, 4.85 mmol) and DIBAL (1 M in DCM) (12.11 mL, 12.11 mmol) were combined in DCM (10 mL) according to General Method 6a. Work-up and purification afforded the title compound (1.00 g, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.04 (s, 1H), 8.98 (d, <i>J</i> = 2.3 Hz, 1H), 8.13 (dd, <i>J</i> = 2.2, 8.3 Hz, 1H), 7.91 (d, <i>J</i> = 8.4 Hz, 1H), 6.82 (s, 1H), 2.51 (s, 3H).</div></div><div id="sec5_20_20_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> 1′-((5-Methyl-1-(6-(trifluoromethyl)pyridin-3-yl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>20</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (40 mg, 0.20 mmol), 5-methyl-1-[6-(trifluoromethyl)-3-pyridyl]-1<i>H</i>-pyrazole-3-carbaldehyde (<b>77</b>) (50 mg, 0.20 mmol), and sodium triacetoxyborohydride (83 mg, 0.39 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded the title compound as a colorless gum (40 mg, 43%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O [M + H<sup>+</sup>], 443.2058; found, 443.2039. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.93 (d, <i>J</i> = 2.2 Hz, 1H), 8.10 (dd, <i>J</i> = 2.2, 8.5 Hz, 1H), 7.82 (d, <i>J</i> = 8.5 Hz, 1H), 7.22–7.09 (m, 4H), 6.33 (s, 1H), 3.92 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 3.67 (s, 2H), 2.86 (dd, <i>J</i> = 5.5, 5.5 Hz, 4H), 2.59–2.51 (m, 2H), 2.48 (s, 3H), 2.15–2.03 (m, 2H), 1.93 (d, <i>J</i> = 12.4 Hz, 2H).</div></div></div><div id="sec5_20_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> Synthesis of 2-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>21</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>)</h4><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (71 mg, 0.35 mmol), <i>tert</i>-butyl 2-(3-formyl-5-methyl-1<i>H</i>-pyrazol-1-yl)benzoate (100 mg, 0.35 mmol), and sodium triacetoxyborohydride (148 mg, 0.70 mmol) were combined in DCM (2 mL) according to General Method 1. Work-up and purification afforded <i>tert</i>-butyl 2-(5-methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoate as a colorless gum (125 mg, 68%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.91 (dd, <i>J</i> = 1.7, 7.6 Hz, 1H), 7.62–7.49 (m, 2H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.25–7.09 (m, 3H), 5.32 (s, 1H), 4.72 (s, 1H), 3.90 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 2.84 (dd, <i>J</i> = 5.4, 5.4 Hz, 2H), 2.57–2.56 (m, 1H), 2.18 (s, 4H), 1.93 (d, <i>J</i> = 13.4 Hz, 2H), 1.38 (d, <i>J</i> = 3.2 Hz, 12H), 1.30–1.25 (m, 1H). <i>tert</i>-Butyl 2-[5-methyl-3-(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl]benzoate (125 mg, 0.26 mmol) was then stirred in TFA (2 mL) at rt for 18 h and then concentrated <i>in vacuo</i>. The residue was loaded onto a 1 g SCX cartridge, eluting with 3 M NH<sub>3</sub>/MeOH. The crude product was purified by preparative HPLC (XBridge column, 0.1% NH<sub>4</sub>OH modifier) to afford the title compound (80 mg, 69%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 418.2125; found, 418.2120. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.97 (dd, <i>J</i> = 1.7, 7.4 Hz, 1H), 7.55–7.45 (m, 2H), 7.36 (dd, <i>J</i> = 1.4, 7.6 Hz, 1H), 7.25–7.05 (m, 4H), 6.37 (s, 1H), 4.01 (s, 2H), 3.81 (dd, <i>J</i> = 5.4, 5.4 Hz, 2H), 3.34 (dd, <i>J</i> = 2.1, 9.1 Hz, 2H), 3.07 (dd, <i>J</i> = 11.6, 11.6 Hz, 2H), 2.79 (dd, <i>J</i> = 5.3, 5.3 Hz, 2H), 2.58–2.49 (m, 2H), 2.31 (s, 3H), 1.92 (d, <i>J</i> = 14 Hz, 2H).</div></div><div id="sec5_20_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Synthesis of 3-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>22</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_22_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> 3-(3-(Ethoxycarbonyl)-5-methyl-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>87</b>)</h5><div class="NLM_p last">Ethyl 2,4-dioxopentanoate (<b>79</b>) (10.29 g, 65.07 mmol) was dissolved in EtOH (100 mL) and 3-hydrazinobenzoic acid (9.90 g, 65.07 mmol) was added. The reaction was heated to reflux for 1 h and then allowed to cool to rt. The solvent was removed <i>in vacuo</i> and H<sub>2</sub>O was added. The product was extracted with EtOAc, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford a mixture of isomers (approximately 1:4 in favor of the desired isomer) (16.48 g, 60 mmol total). No attempt was made to separate the regioisomers at this stage, and the crude material was taken through to the next step without further purification. LCMS (ESI+) <i>m</i>/<i>z</i>: 275 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.20–8.12 (m, 2H), 7.74 (d, <i>J</i> = 8.0, 1H), 7.59 (t, <i>J</i> = 7.8, 1H), 6.76 (s, 1H), 4.41 (q, <i>J</i> = 7.1, 2H), 1.39 (t, <i>J</i> = 7.1, 3H).</div></div><div id="sec5_20_22_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> Ethyl 1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1<i>H</i>-pyrazole-3-carboxylate (<b>93</b>)</h5><div class="NLM_p last">A mixture of 3-(3-ethoxycarbonyl-5-methyl-1<i>H</i>-pyrazol-1-yl)benzoic acid and 3-(5-ethoxycarbonyl-3-methyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (<b>87</b>) (5.00 g, 18.23 mmol in total as a mixture of isomers) was dissolved in thionyl chloride (3.99 mL, 54.69 mmol), and three drops of pyridine were added. The mixture was heated to 50 °C for 1 h and then allowed to cool to rt. The mixture was concentrated <i>in vacuo</i> and the resulting oil was dissolved in DCM (20 mL). Ethanolamine (2.19 mL, 36.46 mmol) was added dropwise and the mixture was stirred for 3 h at rt. Further, thionyl chloride (3.99 mL, 54.69 mmol) was added to convert the OH to Cl. This mixture was stirred at rt for 18 h. The reaction was quenched with the dropwise addition of H<sub>2</sub>O. The aqueous layer was basified with 2 M NaOH and extracted with DCM. The organics were separated, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford a brown oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane). The second compound to elute was the desired isomer. This solid was dissolved in THF, cooled to 0 °C, and sodium hydride (60% in mineral oil) (729 mg, 18.23 mmol) was added. The reaction mixture was allowed to warm to rt and stirred for 2 h. The reaction was quenched carefully with water at 0 °C. The volatiles were removed <i>in vacuo</i> and the product was extracted with EtOAc, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford the title compound (2.1 g, 38%). LCMS (ESI) <i>m</i>/<i>z</i>: 300 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.03–7.98 (m, 2H), 7.60 (d, <i>J</i> = 7.9 Hz, 1H), 7.52 (t, <i>J</i> = 7.9 Hz, 1H), 6.73 (s, 1H), 4.48–4.36 (m, 4H), 4.07 (t, <i>J</i> = 9.5 Hz, 2H), 2.34 (s, 3H), 1.39 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_20_22_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> 1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>99</b>)</h5><div class="NLM_p last">Ethyl 1-[3-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1<i>H</i>-pyrazole-3-carboxylate (<b>93</b>) (2.10 g, 7.02 mmol) and DIBAL (1 M in DCM) (17.54 mL, 17.54 mmol) were combined in DCM (20 mL) with MnO<sub>2</sub> (6.10 g, 70.16 mmol) added in the second step according to General Method 5b. Work-up and purification afforded the title compound, which was used without further purification.</div></div><div id="sec5_20_22_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> 1′-((1-(3-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>105</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (80 mg, 0.39 mmol), 1-[3-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>99</b>) (100 mg, 0.39 mmol), and sodium triacetoxyborohydride (166 mg, 0.78 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (30 mg, 16%). LCMS (ESI) <i>m</i>/<i>z</i>: 442 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.02 (s, 1H), 7.94 (d, <i>J</i> = 7.5 Hz, 1H), 7.61 (d, <i>J</i> = 7.9 Hz, 1H), 7.50 (t, <i>J</i> = 7.9 Hz, 1H), 7.24–7.10 (m, 3H), 7.08 (d, <i>J</i> = 7.5 Hz, 1H), 6.24 (s, 1H), 4.45 (t, <i>J</i> = 9.5 Hz, 2H), 4.08 (t, <i>J</i> = 9.5 Hz, 2H), 3.92–3.87 (m, 2H), 3.66 (s, 2H), 2.89–2.79 (m, 4H), 2.53 (t, <i>J</i> = 11.6 Hz, 2H), 2.36 (s, 3H), 2.09 (t, <i>J</i> = 13.3 Hz, 2H, 1.91 (d, <i>J</i> = 13.3 Hz, 2H).</div></div><div id="sec5_20_22_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> 3-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>22</b>)</h5><div class="NLM_p last">1′-[[1-[3-(4,5-Dihydrooxazol-2-yl)phenyl]-5-methyl-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>105</b>) (30 mg, 0.07 mmol) was dissolved in 3 M HCl according to General Method 3. Work-up and purification afforded the title compound (19 mg, 66%). LCMS (ESI) <i>m</i>/<i>z</i>: 418 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 418.2130; found, 418.2133. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.24–8.16 (m, 2H), 7.53 (d, <i>J</i> = 4.2 Hz, 2H), 7.21–7.02 (m, 4H), 6.44 (s, 1H), 4.17 (s, 2H), 3.88–3.83 (m, 2H), 3.44 (d, <i>J</i> = 10.9 Hz, 2H), 3.13–3.03 (m, 2H), 2.82–2.76 (m, 2H), 2.53 (t, <i>J</i> = 13.3 Hz, 2H), 2.32 (s, 3H), 1.98 (d, <i>J</i> = 14.3 Hz, 2H).</div></div></div><div id="sec5_20_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Synthesis of 4-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>23</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_23_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> 4-(3-(Ethoxycarbonyl)-5-methyl-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>88</b>)</h5><div class="NLM_p last">Ethyl 2,4-dioxopentanoate (10.39 g, 65.73 mmol) was dissolved in EtOH (100 mL) and 4-hydrazinobenzoic acid (<b>80</b>) (10.0 g, 65.73 mmol) was added. The reaction mixture was heated to reflux for 2 h and then allowed to cool to rt. The solvent was removed <i>in vacuo</i>, H<sub>2</sub>O was added, and the product was extracted with EtOAc. The organics were separated, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford a mixture of isomers (approximately 1:4 in favor of the desired isomer) 4-(5-ethoxycarbonyl-3-methyl-1<i>H</i>-pyrazol-1-yl)benzoic acid and 4-(3-ethoxycarbonyl-5-methyl-1<i>H</i>-pyrazol-1-yl)benzoic acid. No attempt was made to separate the regioisomers at this stage and the crude material was taken onto the next step without further purification. LCMS (ESI) <i>m</i>/<i>z</i>: 275 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.24 (d, <i>J</i> = 8.3, 2H), 7.63 (d, <i>J</i> = 8.3, 2H), 6.78 (s, 1H), 4.43 (q, <i>J</i> = 7.1, 2H), 2.41 (s, 3H), 1.41 (t, <i>J</i> = 7.1, 3H) (major isomer reported).</div></div><div id="sec5_20_23_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> Ethyl 1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1<i>H</i>-pyrazole-3-carboxylate (<b>94</b>)</h5><div class="NLM_p last">A mixture of 4-(3-ethoxycarbonyl-5-methyl-1<i>H</i>-pyrazol-1-yl)benzoic acid and 4-(5-ethoxycarbonyl-3-methyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (<b>88</b>) (18.82 g, 68.62 mmol in total as a mixture of isomers) was dissolved in thionyl chloride (20.02 mL, 274.48 mmol), and three drops of pyridine were added. The mixture was heated to 50 °C for 2 h and then allowed to cool to rt. The mixture was concentrated <i>in vacuo</i>, and the resulting oil was dissolved in DCM (20 mL). Ethanolamine (8.26 mL, 137.24 mmol) was added dropwise and the mixture was stirred for 3 h at rt. Further thionyl chloride (20.01 mL, 274.48 mmol) was added to convert the OH to Cl. This mixture was stirred at rt for 18 h. The reaction was quenched with the dropwise addition of H<sub>2</sub>O. The aqueous layer was basified with 2 M NaOH and extracted with EtOAc. The organics were separated, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford a brown oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane). The second compound to elute was the desired isomer, ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-methyl-1<i>H</i>-pyrazole-3-carboxylate (10.62 g, 44%). LCMS (ESI) <i>m</i>/<i>z</i>: 336 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.91 (d, <i>J</i> = 8.1 Hz, 2H), 7.57 (d, <i>J</i> = 8.1 Hz, 2H), 6.75 (s, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 3.86–3.80 (m, 2H), 3.79–3.74 (m, 2H), 2.37 (s, 3H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-methyl-1<i>H</i>-pyrazole-3-carboxylate (10.62 g, 31.63 mmol) was dissolved in THF (50 mL) and cooled to 0 °C. NaH (759 mg, 31.63 mmol) was added portionwise waiting for the effervescence to cease each time. The reaction was allowed to stir at 0 °C for 3 h and then carefully quenched by adding H<sub>2</sub>O dropwise. The mixture was allowed to warm to rt and TBME was added. The organics were separated, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford the title compound, which was used without further purification. LCMS (ESI) <i>m</i>/<i>z</i>: 300 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.06 (d, <i>J</i> = 8.4 Hz, 2H), 7.54 (d, <i>J</i> = 8.4 Hz, 2H), 6.75 (s, 2H), 4.47 (t, <i>J</i> = 9.6 Hz, 2H), 4.42 (q, <i>J</i> = 7.1, 2H), 4.09 (t, <i>J</i> = 9.6 Hz, 2H), 2.37 (s, 3H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_20_23_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> 1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>100</b>)</h5><div class="NLM_p last">Ethyl 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1<i>H</i>-pyrazole-3-carboxylate (<b>94</b>) (9.75 g, 32.57 mmol) and DIBAL (1 M in DCM) (6.51 mL, 6.51 mmol) were combined in DCM (90 mL) with MnO<sub>2</sub> (14.16 g, 162.87 mmol) added in second step according to General Method 5b. Work-up and purification afforded the title compound (5.14 g, 59%). LCMS (ESI) <i>m</i>/<i>z</i>: 256 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 10.00 (s, 1H), 8.11 (d, <i>J</i> = 8.5 Hz, 2H), 7.56 (d, <i>J</i> = 8.5 Hz, 2H), 6.73 (s, 1H), 4.48 (t, <i>J</i> = 9.5 Hz, 2H), 4.10 (t, <i>J</i> = 9.5 Hz, 2H), 2.40 (s, 3H).</div></div><div id="sec5_20_23_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> 1′-((1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-methyl-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>106</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (1.79 g, 8.81 mmol), 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-methyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>100</b>) (2.5 g, 8.81 mmol), and sodium triacetoxyborohydride (3.74 g, 17.63 mmol) were combined in DCM (4 mL) according to General Method 1. The crude material was purified by flash chromatography on a KPNH column (eluting with 10–50% EtOAc in heptane) to afford the title compound (1.99 g, 48%). LCMS (ESI) <i>m</i>/<i>z</i>: 443 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.03 (d, <i>J</i> = 8.5 Hz, 2H), 7.54 (d, <i>J</i> = 8.5 Hz, 2H), 7.22–7.15 (m, 2H), 7.13 (t, <i>J</i> = 7.3 Hz, 1H), 7.08 (d, <i>J</i> = 7.3 Hz, 1H), 6.24 (s, 1H), 4.46 (t, <i>J</i> = 9.5 Hz, 2H), 4.09 (t, <i>J</i> = 9.5 Hz, 2H), 3.92–3.87 (m, 2H), 3.65 (s, 2H), 2.87–2.80 (m, 4H), 2.52 (t, <i>J</i> = 11.8 Hz, 2H), 1.90 (d, <i>J</i> = 13.4 Hz, 2H).</div></div><div id="sec5_20_23_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> 4-(5-Methyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>23</b>)</h5><div class="NLM_p last">1′-[[1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-methyl-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>106</b>) (1.9 g, 4.29 mmol) was dissolved in 3 M HCl according to General Method 4. Work-up and purification afforded the title compound (1 g, 55%). LCMS (ESI) <i>m</i>/<i>z</i>: 418 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 418.2130; found, 418.2159. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.11 (d, <i>J</i> = 8.1 Hz, 2H), 7.52 (d, <i>J</i> = 8.1 Hz, 2H), 7.24–7.11 (m, 4H), 6.48 (s, 1H), 4.30 (s, 1H), 3.94 (t, <i>J</i> = 5.4 Hz, 2H), 3.45 (d, <i>J</i> = 11.4 Hz, 2H), 3.36 (d, <i>J</i> = 12.5 Hz, 2H), 2.87–2.80 (m, 2H), 2.40 (s, 3H), 2.31 (td, <i>J</i> = 13.7, 3.8 Hz, 2H), 2.11 (d, <i>J</i> = 14.6 Hz, 2H).</div></div></div><div id="sec5_20_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Synthesis of 4-(5-Ethyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>24</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_24_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> Lithium 4-(3-(Ethoxycarbonyl)-5-ethyl-1<i>H</i>-pyrazol-1-yl)benzoate (<b>87</b>)</h5><div class="NLM_p last">4-Aminobenzoic acid (2.00 g, 14.58 mmol) was suspended in H<sub>2</sub>O (30 mL) and cooled to 0 °C. Concentrated H<sub>2</sub>SO<sub>4</sub> (15 mL, 14.58 mmol) was added dropwise to this suspension, followed by the dropwise addition of NaNO<sub>2</sub> (5% aqueous solution) (20 mL, 14.58 mmol). The reaction mixture was stirred for 30 min at 0 °C, then NaBF<sub>4</sub> (17% aqueous solution) (12 mL, 14.58 mmol) was added, and the reaction was stirred for further 30 min. A solution of ethyl 2-chloro-3-oxo-butanoate (2.40 g, 14.58 mmol) in MeOH (75 mL) was added to the reaction mixture, which was then allowed to warm to rt and stirred for 3 h. The resulting precipitate was filtered, washed with H<sub>2</sub>O, and air-dried to afford (<i>E</i>)-4-(2-(1-chloro-2-ethoxy-2-oxoethylidene)hydrazinyl)benzoic acid (3.00 g, 72%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 12.65–12.65 (m, 1H), 10.84 (s, 1H), 7.92 (d, <i>J</i> = 8.7 Hz, 2H), 7.43 (d, <i>J</i> = 8.7 Hz, 2H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 1.31 (dd, <i>J</i> = 7.1, 7.1 Hz, 3H). (<i>E</i>)-4-(2-(1-Chloro-2-ethoxy-2-oxoethylidene)hydrazinyl)benzoic acid (1.30 g, 4.80 mmol) and 1-diethoxyphosphorylbutan-2-one (1.00 g, 4.80 mmol) were mixed in diglyme (15 mL) and LiOH (504 mg, 12.01 mmol) was added. The reaction mixture was stirred at rt for 18 h. The reaction mixture was concentrated <i>in vacuo</i> to afford the title compound and was used directly in the next step without further purification.</div></div><div id="sec5_20_24_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> Ethyl 1-(4-(4,5-Dihydrooxazol-2-yl)phenyl-5-ethyl-1<i>H</i>-pyrazole-3-carboxylate) (<b>95</b>)</h5><div class="NLM_p last">Lithium 4-(3-ethoxycarbonyl-5-ethyl-1<i>H</i>-pyrazol-1-yl)benzoate (<b>89</b>) (1.40 g, 4.76 mmol) was mixed in thionyl chloride (3 mL, 18.66 mmol) and heated to reflux for 2 h. The reaction mixture was allowed to cool to rt and then concentrated <i>in vacuo</i>. The resulting orange solid was suspended in DCM (20 mL) and cooled to 0 °C. 2-Chloroethanamine hydrochloride (607 mg, 5.23 mmol) and DIPEA (3.32 mL, 19.03 mmol) were added, and the reaction mixture was allowed to warm up to rt for 18 h. The reaction was quenched with H<sub>2</sub>O, passed through a hydrophobic frit, and concentrated <i>in vacuo</i>. The crude material was purified by flash chromatography (eluting with 0–100% EtOAc in heptane) to afford ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-ethyl-1<i>H</i>-pyrazole-3-carboxylate (1.00 g, 57%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.93 (d, <i>J</i> = 8.6 Hz, 2H), 7.58 (d, <i>J</i> = 8.6 Hz, 2H), 6.82 (s, 1H), 6.67 (d, <i>J</i> = 5.0 Hz, 1H), 4.45 (q, <i>J</i> = 7.1 Hz, 2H), 3.88–3.78 (m, 4H), 2.71 (q, <i>J</i> = 7.5 Hz, 2H), 1.43 (dd, <i>J</i> = 7.1, 7.1 Hz, 3H), 1.30–1.25 (m, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-ethyl-1<i>H</i>-pyrazole-3-carboxylate (1.00 g, 2.86 mmol) was dissolved in THF (30 mL) and cooled to 0 °C. NaH (126 mg, 3.14 mmol) was added, and the reaction mixture was allowed to warm to rt for 18 h and then heated to 50 °C for 1 h. The reaction was allowed to cool to rt and then quenched with H<sub>2</sub>O. The volatiles were removed <i>in vacuo</i>, and the product was extracted with EtOAc. The combined organics were washed with brine, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford the title compound (820 mg, 87%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.09 (d, <i>J</i> = 8.6 Hz, 2H), 7.54 (d, <i>J</i> = 8.7 Hz, 2H), 6.81 (s, 1H), 4.53–4.42 (m, 4H), 4.12 (dd, <i>J</i> = 9.5, 9.5 Hz, 2H), 2.71 (q, <i>J</i> = 7.4 Hz, 2H), 1.43 (dd, <i>J</i> = 7.1, 7.1 Hz, 3H), 1.27 (dd, <i>J</i> = 7.5, 7.5 Hz, 3H).</div></div><div id="sec5_20_24_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> 1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-ethyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>101</b>)</h5><div class="NLM_p last">Ethyl 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-ethyl-1<i>H</i>-pyrazole-3-carboxylate (<b>95</b>) (820 mg, 2.62 mmol) and DIBAL (1 M in DCM) (6.54 mL, 6.54 mmol) were combined in DCM (25 mL) according to General Method 5a. Work-up and purification afforded the title compound (600 mg, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.03 (s, 1H), 8.13 (d, <i>J</i> = 8.6 Hz, 2H), 7.57 (d, <i>J</i> = 8.7 Hz, 2H), 6.80 (s, 1H), 4.51 (dd, <i>J</i> = 9.5, 9.5 Hz, 2H), 4.14 (dd, <i>J</i> = 9.5, 9.5 Hz, 2H), 2.74 (q, <i>J</i> = 7.5 Hz, 2H), 1.28 (dd, <i>J</i> = 7.5, 7.5 Hz, 3H).</div></div><div id="sec5_20_24_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> 4-(5-Ethyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>24</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (175 mg, 0.86 mmol), 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-ethyl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>101</b>) (232 mg, 0.86 mmol), and sodium triacetoxyborohydride (365 mg, 1.72 mmol) were combined in DCM (5 mL) according to General Method 1. The crude oxazoline intermediate was dissolved in 3 M HCl (3 mL) according to General Method 3. Work-up and purification afforded 4-[5-ethyl-3-(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl]benzoic acid (200 mg, 51%). LCMS (ESI) <i>m</i>/<i>z</i>: 432.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.13 (d, <i>J</i> = 8.5 Hz, 2H), 7.37–7.30 (m, 2H), 7.22–7.10 (m, 4H), 6.37 (s, 1H), 4.09 (s, 2H), 3.94 (dd, <i>J</i> = 5.4, 5.4 Hz, 2H), 3.48–3.48 (m, 2H), 3.05 (dd, <i>J</i> = 11.4, 11.4 Hz, 2H), 2.87 (dd, <i>J</i> = 5.2, 5.2 Hz, 2H), 2.73–2.58 (m, 4H), 2.04 (d, <i>J</i> = 13.7 Hz, 2H), 1.19 (dd, <i>J</i> = 7.5, 7.5 Hz, 3H).</div></div></div><div id="sec5_20_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Synthesis of 4-(5-Isopropyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>25</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_25_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> 1,1-Diethoxy-5-methyl-hexane-2,4-dione (<b>81</b>)</h5><div class="NLM_p last">Ethyl 2,2-diethoxyacetate (4.2 mL, 23 mmol) was added portionwise to a solution of 3-methylbutan-2-one (2 g, 23 mmol) in toluene (10 mL) at 0 °C. NaH (60% dispersion, 2.5 mL g, 46 mmol) was added portionwise, and the mixture was stirred at 0 °C for 2 h. H<sub>2</sub>O was added dropwise until the reaction was quenched, followed by 3 M HCl solution, dropwise, until the solution was pH 5. The organics were extracted with DCM, passed through a hydrophobic frit, and concentrated <i>in vacuo</i> to afford the title compound, which was used in the next step with no further purification.</div></div><div id="sec5_20_25_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> 4-(3-Formyl-5-isopropyl-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>84</b>)</h5><div class="NLM_p last">1,1-Diethoxy-5-methyl-hexane-2,4-dione (<b>83</b>) (386 mg, 1.78 mmol) and 4-hydrazinobenzoic acid (<b>80</b>) (272 mg, 1.78 mmol) were dissolved in EtOH (2 mL) and H<sub>2</sub>O (2 mL). The mixture was stirred at 35 °C for 18 h and then allowed to cool to rt and concentrated <i>in vacuo</i> to afford an orange solid. The crude material was triturated with Et<sub>2</sub>O and filtered to afford the title compound (349 mg, 72%). LCMS (ESI) <i>m</i>/<i>z</i>: 259 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 10.01 (s, 1H), 8.30 (d, <i>J</i> = 8.6 Hz, 2H), 7.62 (d, <i>J</i> = 8.6 Hz, 2H), 6.81 (s, 1H), 3.11 (sept, <i>J</i> = 6.8 Hz, 1H), 1.23 (d, <i>J</i> = 6.8 Hz, 6H).</div></div><div id="sec5_20_25_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> 4-(5-Isopropyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>25</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (39 mg, 0.19 mmol), 4-(3-formyl-5-isopropyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (<b>84</b>) (50 mg, 0.19 mmol), and sodium triacetoxyborohydride (82 mg, 0.39 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (20 mg, 23%). LCMS (ESI) <i>m</i>/<i>z</i>: 446 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 446.2443; found, 446.2423. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.08 (d, <i>J</i> = 8.4 Hz, 2H), 7.30–7.26 (m, 3H), 7.18 (td, <i>J</i> = 7.4, 1.4 Hz, 1H), 7.14 (td, <i>J</i> = 7.4, 1.4 Hz, 1H), 7.09 (d, <i>J</i> = 7.4 Hz, 1H), 6.30 (s, 1H), 4.03 (s, 2H), 3.92 (t, <i>J</i> = 5.5 Hz, 2H), 3.48 (d, <i>J</i> = 10.5 Hz, 2H), 3.09–2.98 (m, 3H), 2.85 (t, <i>J</i> = 5.4 Hz, 2H), 2.66–2.57 (m, 2H), 2.03 (d, <i>J</i> = 13.8 Hz, 2H), 1.11 (d, <i>J</i> = 6.8 Hz, 6H).</div></div></div><div id="sec5_20_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Synthesis of 4-(5-(<i>tert</i>-Butyl)-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>26</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> 4-(5-(<i>tert</i>-Butyl)-3-(ethoxycarbonyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>90</b>)</h5><div class="NLM_p last">Ethyl 5,5-dimethyl-2,4-dioxo-hexanoate (2.00 g, 9.99 mmol) was dissolved in EtOH (20 mL) and 4-hydrazinobenzoic acid (<b>80</b>) (1.52 g, 9.99 mmol) was added. The mixture was heated to reflux for 1 h and then allowed to cool to rt, and the solvent was removed <i>in vacuo</i>. H<sub>2</sub>O was added and the product was extracted with EtOAc. The organics were separated, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford the title compound (3.12 g, 99%). LCMS (ESI) <i>m</i>/<i>z</i>: 317 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 8.21 (d, <i>J</i> = 8.4 Hz, 2H), 7.52 (d, <i>J</i> = 8.4 Hz, 2H), 6.79 (s, 1H), 4.41 (q, <i>J</i> = 7.1 Hz, 2H), 1.39 (t, <i>J</i> = 7.1 Hz, 2H), 1.21 (s, 9H).</div></div><div id="sec5_20_26_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> Ethyl 5-(<i>tert</i>-Butyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1<i>H</i>-pyrazole-3-carboxylate (<b>96</b>)</h5><div class="NLM_p last">4-(5-<i>tert</i>-Butyl-3-ethoxycarbonyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (<b>90</b>) (3.12 g, 9.86 mmol) was dissolved in DCM (20 mL), and HOBt (1.60 g, 11.84 mmol), EDC.HCl (2.27 g, 11.84 mmol), DIPEA (6.87 mL, 39.45 mmol), and 2-chloroethanamine hydrochloride (1.37 g, 11.84 mmol) were added. The reaction was stirred at rt for 1 h. The reaction mixture was washed with H<sub>2</sub>O extracting with further DCM. The organics were dried (hydrophobic frit) and the solvent was removed <i>in vacuo</i> to afford an orange oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane) to afford ethyl 5-<i>tert</i>-butyl-1-[4-(2-chloroethylcarbamoyl)phenyl]-1<i>H</i>-pyrazole-3-carboxylate (1.76 g, 47%). LCMS (ESI) <i>m</i>/<i>z</i>: 378 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.88 (d, <i>J</i> = 8.6 Hz, 2H), 7.46 (d, <i>J</i> = 8.6 Hz, 2H), 6.90–6.38 (m, 1H), 6.76 (s, 1H), 4.41 (q, <i>J</i> = 7.1 Hz, 2H), 3.85–3.79 (m, 2H), 3.78–3.73 (m, 2H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H), 1.19 (s, 9H). Ethyl 5-<i>tert</i>-butyl-1-[4-(2-chloroethylcarbamoyl)phenyl]-1<i>H</i>-pyrazole-3-carboxylate (1.76 g, 4.66 mmol) was dissolved in THF (20 mL) and cooled to 0 °C. NaH (186 mg, 4.66 mmol) was then added, and the reaction mixture was stirred at 0 °C for 1 h. H<sub>2</sub>O was added carefully to quench the reaction, and the volatiles were removed <i>in vacuo</i>. The product was extracted with TBME, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford the title compound (1.00 g, 63%). LCMS (ESI) <i>m</i>/<i>z</i>: 342 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.04 (d, <i>J</i> = 8.6 Hz, 2H), 7.45 (d, <i>J</i> = 8.6 Hz, 2H), 6.76 (s, 1H), 4.48 (t, <i>J</i> = 9.5 Hz, 2H), 4.40 (q, <i>J</i> = 7.1 Hz, 2H), 4.10 (t, <i>J</i> = 9.5 Hz, 2H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H), 1.19 (s, 9H).</div></div><div id="sec5_20_26_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> 5-(<i>tert</i>-Butyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>102</b>)</h5><div class="NLM_p last">Ethyl 5-<i>tert</i>-butyl-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1<i>H</i>-pyrazole-3-carboxylate (<b>96</b>) (1.00 g, 2.93 mmol) and DIBAL (1 M in DCM) (6.51 mL, 6.51 mmol) were combined in DCM (5 mL) with MnO<sub>2</sub> (2.55 g, 29.29 mmol) added in the second step according to General Method 5b. Work-up and purification afforded the title compound (624 mg, 68%). LCMS (ESI) <i>m</i>/<i>z</i>: 298 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.95 (s, 1H), 8.10 (d, <i>J</i> = 8.6 Hz, 2H), 7.47 (d, <i>J</i> = 8.6 Hz, 2H), 6.75 (s, 1H), 4.50 (t, <i>J</i> = 9.5 Hz, 2H), 4.12 (t, <i>J</i> = 9.6 Hz, 2H), 1.20 (s, 9H).</div></div><div id="sec5_20_26_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> 1′-((5-(<i>tert</i>-Butyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>107</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (41 mg, 0.20 mmol), 5-<i>tert</i>-butyl-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1<i>H</i>-pyrazole-3-carbaldehyde (<b>102</b>) (60 mg, 0.20 mmol), and sodium triacetoxyborohydride (86 mg, 0.40 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound (41 mg, 40%). LCMS (ESI) <i>m</i>/<i>z</i>: 485 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.02 (d, <i>J</i> = 8.3 Hz, 2H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.22 (d, <i>J</i> = 7.7 Hz, 1H), 7.18 (t, <i>J</i> = 7.7 Hz, 1H), 7.13 (td, <i>J</i> = 7.3 Hz, 1.3, 1H), 7.08 (d, <i>J</i> = 7.3 Hz, 1H), 6.22 (s, 1H), 4.47 (t, <i>J</i> = 9.6 Hz, 2H), 4.10 (t, <i>J</i> = 9.6 Hz, 2H), 3.90 (t, <i>J</i> = 5.5 Hz, 2H), 3.61 (s, 2H), 2.88–2.80 (m, 4H), 2.50 (t, <i>J</i> = 12.1 Hz, 2H), 2.09 (td, <i>J</i> = 13.1, 4.3 Hz, 2H), 1.90 (d, <i>J</i> = 13.1 Hz, 2H), 1.18 (s, 9H).</div></div><div id="sec5_20_26_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> 4-(5-(<i>tert</i>-Butyl)-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>26</b>)</h5><div class="NLM_p last">1′-[[5-<i>tert</i>-butyl-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>107</b>) (41 mg, 0.08 mmol) was dissolved in 3 M HCl according to General Method 4. Work-up and purification afforded the title compound (15 mg, 37%). LCMS (ESI) <i>m</i>/<i>z</i>: 459 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 460.2600; found, 460.2613. <sup>1</sup>H NMR (500 MHz, <i>d</i><sup>6</sup>-DMSO): δ 8.05 (d, <i>J</i> = 8.3 Hz, 2H), 7.52 (d, <i>J</i> = 8.3 Hz, 2H), 7.22 (d, <i>J</i> = 7.4 Hz, 1H), 7.17 (t, <i>J</i> = 7.4 Hz, 1H), 7.13 (t, <i>J</i> = 7.4 Hz, 1H), 7.09 (<i>J</i> = 7.4 Hz, 1H), 6.25 (s, 1H), 3.85–3.80 (m, 2H), 3.53 (br s, 2H), 2.83–2.71 (m, 4H), 2.47–2.39 (m, 2H), 2.01–1.91 (m, 2H), 1.81 (d, <i>J</i> = 13.1 Hz, 2H), 1.14 (s, 9H).</div></div></div><div id="sec5_20_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> Synthesis of 4-(5-(Difluoromethyl)-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>27</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_27_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> 4-(5-(Difluoromethyl)-3-(ethoxycarbonyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>91</b>)</h5><div class="NLM_p last">Ethyl 5,5-difluoro-2,4-dioxo-pentanoate (2.5 g, 12.88 mmol) was dissolved in EtOH (20 mL) and AcOH (5 mL) and 4-hydrazinobenzoic acid (<b>80</b>) (1.96 g, 12.88 mmol) was added. The reaction was heated to reflux for 18 h and then allowed to cool to rt, and the solvent was removed <i>in vacuo</i>. H<sub>2</sub>O was added, and the product was extracted with EtOAc, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford the title compound (4.45 g, 100% in total as a mixture of isomers) and used in the next step without further purification.</div></div><div id="sec5_20_27_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> 5-(Difluoromethyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>97</b>)</h5><div class="NLM_p last">A mixture of 4-[5-(difluoromethyl)-3-ethoxycarbonyl-1<i>H</i>-pyrazol-1-yl]benzoic acid and 4-[3-(difluoromethyl)-5-ethoxycarbonyl-1<i>H</i>-pyrazol-1-yl]benzoic acid (<b>91</b>) (4.45 g, 14.34 mmol in total as a mixture of isomers) was dissolved in DCM (50 mL) and HOBt (2.87 g, 21.23 mmol), EDC.HCl (3.30 g, 17.21 mmol), DIPEA (7.49 mL, 43.03 mmol), and 2-chloroethanamine hydrochloride (2.00 g 17.21 mmol) were added. The reaction was stirred at rt for 18 h. H<sub>2</sub>O was added, extracting with further DCM. The combined organics were dried (hydrophobic frit), and the solvent was removed <i>in vacuo</i> to afford a dark orange oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane). The second compound to elute was the desired isomer, ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(difluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (470 mg, 9%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.94 (d, <i>J</i> = 8.6 Hz, 2H), 7.65 (d, <i>J</i> = 8.6 Hz, 2H), 7.27 (s, 1H), 6.65 (t, <i>J</i> = 53.5 Hz, 1H), 4.45 (q, <i>J</i> = 7.1 Hz, 2H), 3.87–3.81 (m, 2H), 3.79–3.75 (m, 2H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(difluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (470 mg, 1.26 mmol) was dissolved in THF (25 mL), cooled to 0 °C, and NaH (202 mg, 5.06 mmol) was added. The reaction was stirred for 2 h at 0 °C and then quenched by the dropwise addition of H<sub>2</sub>O. The mixture was allowed to warm to rt, and the volatiles were removed <i>in vacuo</i>. The pH was carefully adjusted to pH 6 using 3 M HCl, and the product was extracted with EtOAc, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford a yellow oil. The aqueous phase was also concentrated <i>in vacuo</i> and combined with the material obtained from the EtOAc extraction to afford the title compound, which was used in the next step without further purification.</div></div><div id="sec5_20_27_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> 5-(Difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]pyrazole-3-carbaldehyde (<b>103</b>).</h5><div class="NLM_p last">Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(difluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (<b>97</b>) and DIBAL (1 M in DCM) (2.77 mL, 2.77 mmol) were combined in DCM (30 mL) with MnO<sub>2</sub> (1.20 g, 13.83 mmol) added in the second step according to General Method 5b. Further, DIBAL (1 M in DCM) (2.77 mL, 2.77 mmol) was needed in this case for reaction completion and oxidation with MnO<sub>2</sub> only required 2 h for completion before formation of side products. Work-up and purification afforded the title compound (148 mg, 35%). LCMS (ESI) <i>m</i>/<i>z</i>: 292 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 10.07 (s, 1H), 8.14 (d, <i>J</i> = 8.7 Hz, 2H), 7.62 (d, <i>J</i> = 8.7 Hz, 2H), 6.68 (t, <i>J</i> = 53.5 Hz, 1H), 4.50 (t, <i>J</i> = 9.6 Hz, 2H), 4.12 (t, <i>J</i> = 9.6 Hz, 2H).</div></div><div id="sec5_20_27_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> 1′-((5-(Difluoromethyl)-1-(4-(4,5-dihydrooxazol-2-yl)phenyl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>108</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (52 mg, 0.25 mmol), 5-(difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1<i>H</i>-pyrazole-3-carbaldehyde (<b>103</b>) (74 mg, 0.25 mmol), and sodium triacetoxyborohydride (108 mg, 0.51 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (45 mg, 37%). LCMS (ESI) <i>m</i>/<i>z</i>: 479 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.07 (d, <i>J</i> = 8.7 Hz, 2H), 7.58 (d, <i>J</i> = 8.7 Hz, 2H), 7.22–7.16 (m, 2H), 7.16–7.12 (m, 1H), 7.08 (d, <i>J</i> = 7.5 Hz, 1H), 6.80 (s, 1H), 6.66 (t, <i>J</i> = 53.5 Hz, 1H), 4.47 (t, <i>J</i> = 9.6 Hz, 2H), 4.10 (t, <i>J</i> = 9.6 Hz, 2H), 3.90 (t, <i>J</i> = 5.5 Hz, 2H), 3.71 (s, 2H), 2.85–2.80 (m, 4H), 2.53 (t, <i>J</i> = 12.0 Hz, 2H), 2.08 (td, <i>J</i> = 13.4, 4.3 Hz, 2H), 1.91 (d, <i>J</i> = 13.4 Hz, 2H).</div></div><div id="sec5_20_27_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> 4-(5-(Difluoromethyl)-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>27</b>)</h5><div class="NLM_p last">1′-[[5-(Difluoromethyl)-1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>108</b>) (45 mg, 0.09 mmol) was dissolved in 3 M HCl (3 mL) according to General Method 3. Work-up and purification afforded 4-[5-(difluoromethyl)-3-(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl]benzoic acid (19 mg, 44%). LCMS (ESI) <i>m</i>/<i>z</i>: 454 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>26</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 454.1916; found, 454.1929. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.00 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (d, <i>J</i> = 8.3 Hz, 2H), 7.23 (d, <i>J</i> = 7.7 Hz, 1H), 7.20–7.13 (m, 2H), 7.09 (d, <i>J</i> = 7.3 Hz, 1H), 6.77 (s, 1H), 6.64 (t, <i>J</i> = 53.5 Hz, 1H), 4.02 (s, 2H), 3.96–3.91 (m, 2H), 3.43 (d, <i>J</i> = 10.0 Hz, 2H), 2.98 (t, <i>J</i> = 11.9 Hz, 2H), 2.88–2.82 (m, 2H), 2.52 (t, <i>J</i> = 13.5 Hz, 2H), 2.03 (d, <i>J</i> = 13.5 Hz, 2H).</div></div></div><div id="sec5_20_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> Synthesis of 4-(3-(Spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>28</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_28_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i142" class="anchor-spacer"></div><h5 class="article-section__title" id="_i142"> 4-(3-(Ethoxycarbonyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>92</b>)</h5><div class="NLM_p last">4-Hydrazinobenzoic acid (<b>80</b>) (1.43 g, 9.43 mmol) and ethyl 5,5,5-trifluoro-2,4-dioxo-pentanoate (2.00 g, 9.43 mmol) were dissolved in EtOH (20 mL) and AcOH (5 mL) according to General Method 3a. Work-up and purification afforded the title compound, which was used in the next step with no further purification. LCMS (ESI) <i>m</i>/<i>z</i>: 329 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.95 (d, <i>J</i> = 9.0 Hz, 2H), 7.65 (d, <i>J</i> = 9.0 Hz, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_20_28_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i143" class="anchor-spacer"></div><h5 class="article-section__title" id="_i143"> Ethyl 1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (<b>98</b>)</h5><div class="NLM_p last">4-[3-ethoxycarbonyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl]benzoic acid (<b>92</b>) (3.97 g, 12.10 mmol) was dissolved in DCM (20 mL), and EDC.HCl (2.78 g, 14.51 mmol), DIPEA (6.25 mg, 48.38 mmol), HOBt (1.96 g, 14.51 mmol), and 2-chloroethanamine hydrochloride (1.68 g, 14.51 mmol) were added. The reaction was stirred at rt overnight. H<sub>2</sub>O was then added and the mixture was passed through a hydrophobic frit. The solvent was removed <i>in vacuo</i> to afford a dark orange oil. The crude material was purified by flash chromatography (10–50% EtOAc in heptane). The second fraction to elute afforded the desired isomer, ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (467 mg, 10%). LCMS (ESI) <i>m</i>/<i>z</i>: 390 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.42 (d, <i>J</i> = 9.0 Hz, 2H), 7.35 (d, <i>J</i> = 9.0 Hz, 2H), 4.33 (q, <i>J</i> = 7.1 Hz, 2H), 3.67–3.58 (m, 4H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H). Ethyl 1-[4-(2-chloroethylcarbamoyl)phenyl]-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (467 mg, 1.20 mmol) was dissolved in THF (25 mL) and cooled to 0 °C. Sodium hydride (197 mg, 4.92 mmol) was added, and the reaction was stirred at 0 °C for 1 h, allowed to warm to rt for 2 h, and then heated to reflux for 1 h. The mixture was allowed to cool to rt and was quenched with H<sub>2</sub>O dropwise. The reaction mixture was concentrated <i>in vacuo</i> to afford the title compound, which was used without further purification.</div></div><div id="sec5_20_28_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> 1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>104</b>)</h5><div class="NLM_p last">Ethyl 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylate (<b>98</b>) and DIBAL (1 M in DCM) (3.00 mL, 3.00 mmol) were combined in DCM (50 mL) according to General Method 6b. Further DIBAL (1 M in DCM) (1.20 mL, 1.20 mmol) was added in this case, but the reaction was not pushed to completion. LiAlH<sub>4</sub> (1.20 mL, 1.20 mmol) was therefore added and the reaction was allowed to warm to rt for 18 h before adding further LiAlH<sub>4</sub> (1.20 mL, 1.20 mmol) and stirring at rt for 2 h. MnO<sub>2</sub> (1.04 g, 11.99 mmol) was added in the second step according to General Method 6b. Work-up and purification afforded the title compound as a colorless oil (45 mg, 12%). LCMS (ESI) <i>m</i>/<i>z</i>: 310 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 10.06 (s, 1H), 8.13 (d, <i>J</i> = 8.7 Hz, 2H), 7.59 (d, <i>J</i> = 8.7 Hz, 2H), 5.30 (s, 1H), 4.50 (t, <i>J</i> = 9.6 Hz, 2H), 4.12 (t, <i>J</i> = 9.6 Hz, 2H).</div></div><div id="sec5_20_28_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> 1′-((1-(4-(4,5-Dihydrooxazol-2-yl)phenyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>109</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (30 mg, 0.15 mmol), 1-[4-(4,5-dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>104</b>) (45 mg, 0.15 mmol), and sodium triacetoxyborohydride (62 mg, 0.29 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (32 mg, 44%). LCMS (ESI) <i>m</i>/<i>z</i>: 497 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.08–8.04 (m, 2H), 7.56 (d, <i>J</i> = 8.6 Hz, 2H), 7.22–7.17 (m, 2H), 7.16–7.13 (m, 1H), 7.09 (d, <i>J</i> = 7.5 Hz, 1H), 6.87 (s, 1H), 4.47 (t, <i>J</i> = 9.6 Hz, 2H), 4.10 (t, <i>J</i> = 9.6 Hz, 2H), 3.90 (t, <i>J</i> = 5.5 Hz, 2H), 3.70 (s, 2H), 2.85–2.78 (m, 2H), 2.54 (t, <i>J</i> = 11.7 Hz, 2H), 2.08 (td, <i>J</i> = 13.2, 3.7 Hz, 2H), 1.92 (d, <i>J</i> = 13.7 Hz, 2H).</div></div><div id="sec5_20_28_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i146" class="anchor-spacer"></div><h5 class="article-section__title" id="_i146"> 4-(3-(Spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-5-(trifluoromethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>28</b>)</h5><div class="NLM_p last">1′-[[1-[4-(4,5-Dihydrooxazol-2-yl)phenyl]-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>109</b>) (32 mg, 0.06 mmol) was dissolved in 3 M HCl according to General Method 4. Work-up afforded no product. The aqueous phase was concentrated <i>in vacuo</i> and purified by preparative HPLC (XBridge column, 0.1% NH<sub>4</sub>OH modifier) to afford the title compound (5 mg, 66%). LCMS (ESI) <i>m</i>/<i>z</i>: 472 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>25</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 472.1848; found, 472.1851. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.46 (d, <i>J</i> = 8.5 Hz, 2H), 7.95 (d, <i>J</i> = 8.5 Hz, 2H), 7.74 (t, <i>J</i> = 53.5 Hz, 1H), 7.73 (t, <i>J</i> = 7.2 Hz, 1H), 7.43 (td, <i>J</i> = 8.7, 2.7 Hz, 1H), 7.38 (dd, <i>J</i> = 9.7, 2.7 Hz, 1H), 4.25 (t, <i>J</i> = 5.5 Hz, 2H), 4.03 (s, 2H), 3.19 (t, <i>J</i> = 5.5 Hz, 2H), 3.15 (d, <i>J</i> = 10.5 Hz, 2H), 2.84 (t, <i>J</i> = 11.9 Hz, 2H), 2.41–2.33 (m, 2H), 2.22 (d, <i>J</i> = 13.3 Hz, 2H).</div></div></div><div id="sec5_20_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> Synthesis of 4-(5-Cyclopropyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>29</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_29_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> 1-Cyclopropyl-4,4-diethoxybutane-1,3-dione (<b>82</b>)</h5><div class="NLM_p last">1-Cyclopropylethanone (11.8 mL, 119 mmol) was dissolved in toluene (100 mL) and cooled to 0 °C. NaH (60% dispersion, 9.5 g, 238 mmol) was added portionwise and stirred at 0 °C for 30 min. Ethyl 2,2-diethoxyacetate (21 mL, 119 mmol) was added dropwise, and the reaction was stirred at 0 °C for 2 h, after which the reaction was allowed to warm to rt and left to stir for 1 h. The reaction was cooled to 0 °C and H<sub>2</sub>O was added dropwise until the reaction was quenched, followed by 3 M HCl solution, dropwise, until the solution was pH 2. NH<sub>4</sub>Cl (saturated solution) was added to neutralize, and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i> to afford the title compound, which was used in the next step with no further purification.</div></div><div id="sec5_20_29_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i149" class="anchor-spacer"></div><h5 class="article-section__title" id="_i149"> 4-(5-Cyclopropyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>85</b>)</h5><div class="NLM_p last">1-Cyclopropyl-4,4-diethoxy-butane-1,3-dione (<b>82</b>) (995 mg, 4.64 mmol) was dissolved in EtOH (2 mL) and H<sub>2</sub>O (2 mL), and 4-hydrazinobenzoic acid (642 mg, 4.22 mmol) was added. The reaction mixture was stirred at 35 °C for 18 h and then allowed to cool to rt and concentrated <i>in vacuo</i> to afford an orange solid. The solid was triturated with Et<sub>2</sub>O, and the yellow solid filtered and dried to afford 4-(5-cyclopropyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (443 mg, 39%). LCMS (ESI) <i>m</i>/<i>z</i>: 257 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, <i>d</i><sup>6</sup>-DMSO): δ 13.17 (br s, 1H), 9.92 (s, 1H), 8.16–8.12 (m, 2H), 7.89–7.86 (m, 2H), 6.70 (s, 1H), 1.96–1.89 (m, 1H), 1.04–0.97 (m, 2H), 0.87–0.82 (m, 2H).</div></div><div id="sec5_20_29_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> 4-(5-Cyclopropyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>27</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (10.73 g, 52.80 mmol), 4-(5-cyclopropyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (<b>85</b>) (12.30 g, 48.00 mmol), and sodium triacetoxyborohydride (20.35 g, 95.99 mmol) were combined in DCM (4 mL) according to General Method 1. After work-up, the crude material was passed through a silica plug (washing with 0–30% MeOH in EtOAc) to afford 4-[5-cyclopropyl-3-(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl]benzoic acid (15.00 g, 70%). LCMS (ESI) <i>m</i>/<i>z</i>: 444 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.74 (br s, 1H), 8.09–8.05 (m, 2H), 7.83–7.79 (m, 2H), 7.27–7.06 (m, 4H), 6.17 (s, 1H), 3.82 (t, <i>J</i> = 5.4 Hz, 2H), 3.51 (s, 2H), 2.79–2.65 (m, 4H), 2.40 (t, <i>J</i> = 11.9 Hz, 2H), 1.98–1.89 (m, 4H), 1.78 (d, <i>J</i> = 13.2 Hz, 2H), 1.04–0.99 (m, 2H), 0.80–0.75 (m, 2H).</div></div></div><div id="sec5_20_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> Synthesis of 4-(5-Cyclopropyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>29</b>) Hydrochloride (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div class="NLM_p last">4-[5-Cyclopropyl-3-(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl]benzoic acid (<b>29</b>) (35 g, 79 mmol) was suspended in MeOH (50 mL) and 4 M HCl in dioxane (49 mL, 197 mmol) was added. The suspended solids went into the solution and the reaction was stirred at rt for 2 h. The precipitated solid was filtered and washed with a small amount of cold MeOH and dried. The solid was then recrystallized from 10% H<sub>2</sub>O in EtOH (∼1.70 L) to afford the title compound as the HCl salt (17 g, 44%). LCMS (ESI) <i>m</i>/<i>z</i>: 444 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 444.2287; found, 444.2278. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.21 (br s, 1H), 10.58 (br s, 1H), 8.14–8.11 (m, 2H), 7.87–7.84 (m, 2H), 7.27–7.12 (m, 4H), 6.48 (s, 1H), 4.38 (s, 2H), 3.87 (t, <i>J</i> = 5.3 Hz, 2H), 3.43–3.37 (m, 2H), 3.30–3.20 (m, 2H), 2.78 (t, <i>J</i> = 5.3 Hz, 2H), 2.41–2.33 (m, 2H), 2.06–1.95 (m, 3H), 1.08–1.03 (m, 2H), 0.79–0.75 (m, 2H).</div></div><div id="sec5_20_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> Synthesis of 4-(5-Cyclobutyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>30</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_31_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153"> 1-Cyclobutyl-4,4-diethoxybutane-1,3-dione (<b>85</b>)</h5><div class="NLM_p last">To a solution of 1-cyclobutylethanone (5 g, 51 mmol) in toluene (43 mL) cooled to 0 °C was added NaH (60% dispersion, 4 g, 102 mmol) portionwise. The reaction was stirred at 0 °C for 10 min before the dropwise addition of ethyl 2,2-diethoxyacetate (9.1 mL, 51 mmol). The reaction was stirred at 0 °C for further 10 min before being allowed to warm to rt. After 1 h, the reaction started to exotherm, and the reaction was cooled to 0 °C for an additional 1 h. Water was added dropwise until the reaction was quenched, followed by 3 M HCl until the solution was pH 4. The organics were extracted with DCM, passed through a hydrophobic frit, and concentrated <i>in vacuo</i> to afford the title compound, which was used in the next step with no further purification.</div></div><div id="sec5_20_31_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> 4-(5-Cyclobutyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>86</b>)</h5><div class="NLM_p last">1-Cyclobutyl-4,4-diethoxy-butane-1,3-dione (<b>83</b>) (4.80 g, 21.03 mmol) was dissolved in EtOH (2 mL) and H<sub>2</sub>O (2 mL), and 4-hydrazinobenzoic acid (3.20 g, 21.03 mmol) were added. The mixture was stirred at 35 °C for 18 and then allowed to cool to rt and concentrated <i>in vacuo</i> to afford a mixture of 4-(3-cyclobutyl-5-formyl-pyrazol-1-yl)benzoic acid and 4-(5-cyclobutyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (5.15 g, 86% total). No attempt was made to separate isomers at this stage, and the mixture was used without further purification. LCMS (ESI) <i>m</i>/<i>z</i>: 271 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 11.85 (br s, 1H), 10.04 (s, 1H), 8.29 (d, <i>J</i> = 8.6 Hz, 2H), 7.60 (d, <i>J</i> = 8.6 Hz, 2H), 6.91 (s, 1H), 3.57 (quint, <i>J</i> = 8.6 Hz, 1H), 2.49–1.90 (m, 6H) (desired isomer reported). 4-(5-Cyclobutyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoic acid and 4-(3-cyclobutyl-5-formyl-pyrazol-1-yl)benzoic acid (5.15 g, 19.05 mmol total as a mixture of isomers) were dissolved in <i>tert</i>-butanol (20 mL). DMAP (6.99 g, 57.16 mmol) and EDC.HCl (7.31 g, 38.11 mmol) were added. The mixture was heated to reflux for 2 h and then allowed to cool to rt and poured into H<sub>2</sub>O. The product was extracted with EtOAc, dried (hydrophobic frit), and concentrated <i>in vacuo</i>. The crude material was purified by flash chromatography (0–20% EtOAc in heptane) to afford the transesterified methyl ester, methyl 4-(5-cyclobutyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoate (641 mg, 12%). LCMS (ESI) <i>m</i>/<i>z</i>: 285 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.87 (s, 1H), 8.17 (d, <i>J</i> = 8.6 Hz, 2H), 7.58 (d, <i>J</i> = 8.6 Hz, 2H), 7.02 (s, 1H), 3.66 (quint, <i>J</i> = 8.6 Hz, 1H), 2.45–2.37 (m, 2H), 2.32–2.23 (m, 2H), 2.13–2.02 (m, 1H), 2.01–1.91 (m, 1H). Methyl 4-(5-cyclobutyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoate (641 mg, 2.25 mmol) was dissolved in MeOH, and 2 M NaOH (11.27 mL, 22.55 mmol) was added. The mixture was stirred at rt for 2 h and then neutralized with 3 M HCl and extracted with DCM. The organics were separated, dried (hydrophobic frit), and concentrated <i>in vacuo</i> to afford the title compound (632 mg, 100%). LCMS (ESI) <i>m</i>/<i>z</i>: 271 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 10.02 (s, 1H), 8.27 (d, <i>J</i> = 8.6 Hz, 2H), 7.59 (d, <i>J</i> = 8.6 Hz, 2H), 6.89 (s, 1H), 3.56 (quint, <i>J</i> = 8.4 Hz, 1H), 2.39–2.29 (m, 2H), 2.19 (quint, <i>J</i> = 9.2 Hz, 2H), 2.00 (quint, 9.2 Hz, 1H), 1.98–1.90 (m, 1H).</div></div><div id="sec5_20_31_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i155" class="anchor-spacer"></div><h5 class="article-section__title" id="_i155"> 4-(5-Cyclobutyl-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>30</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (38 mg, 0.19 mmol), 4-(5-cyclobutyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (<b>86</b>) (50 mg, 0.19 mmol), and sodium triacetoxyborohydride (78 mg, 0.37 mmol) were combined in DCM (20 mL) according to General Method 1. Work-up and purification afforded the title compound (16 mg, 18%). LCMS (ESI) <i>m</i>/<i>z</i>: 458 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 458.2433; found, 458.2438. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.03 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (d, <i>J</i> = 7.8 Hz, 1H), 7.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.18 (td, <i>J</i> = 7.3, 1.3 Hz, 1H), 6.40 (s, 1H), 4.01 (s, 2H), 3.93 (t, <i>J</i> = 5.5 Hz, 2H), 3.52–3.44 (m, 3H), 3.00 (t, <i>J</i> = 12.2 Hz, 2H), 2.85 (t, <i>J</i> = 5.4 Hz, 2H), 2.60 (t, <i>J</i> = 13.7 Hz, 2H), 2.28–1.89 (m, 2H), 2.13–1.99 (m, 2H), 1.95–1.86 (m, 1H), 1.86–1.77 (m, 1H).</div></div></div><div id="sec5_20_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> Synthesis of 4-(5-Methoxy-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>31</b>) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>)</h4><div id="sec5_20_32_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157"> Methyl 1-(4-Bromophenyl)-5-hydroxy-1<i>H</i>-pyrazole-3-carboxylate (<b>110</b>)</h5><div class="NLM_p last">Dimethyl but-2-ynedioate (<b>61</b>) (3.29 mL, 26.73 mmol) was dissolved in Et<sub>2</sub>O (50 mL), and a suspension of 4-bromophenylhydrazine (5.00 g, 26.73 mmol) in Et<sub>2</sub>O (50 mL) was added slowly over 30 min. The reaction mixture was stirred at rt for 1 h and then concentrated <i>in vacuo</i>. The residue was redissolved in MeOH (100 mL), NaOMe (25% wt) (23 mL, 106.93 mmol) was added, and the reaction mixture was stirred at rt for 18 h. The mixture was concentrated <i>in vacuo</i>, and then 6 M HCl (10 mL) was added. The resulting precipitate was filtered and washed with DCM and Et<sub>2</sub>O. The solid was redissolved in MeOH, 10 drops of H<sub>2</sub>SO<sub>4</sub> were added, and the mixture was heated to reflux for 4 h and then allowed to cool to rt. The resulting precipitate was filtered and washed with ice-cold MeOH and air-dried to afford the title compound (5.65 g, 64%). LCMS (ESI) <i>m</i>/<i>z</i>: 297/299 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.46 (br s, 1H), 7.76–7.67 (m, 4H), 5.99 (s, 1H), 3.37 (br s, 1H).</div></div><div id="sec5_20_32_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> Methyl 1-(4-Bromophenyl)-5-methoxy-1<i>H</i>-pyrazole-3-carboxylate (<b>114</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-5-hydroxy-1<i>H</i>-pyrazole-3-carboxylate (<b>110</b>) (250 mg, 0.84 mmol) was dissolved in DMF (5 mL) and K<sub>2</sub>CO<sub>3</sub> (174 mg, 1.26 mmol) was added. The reaction mixture was cooled to 0 °C, and iodomethane (0.06 mL, 0.93 mmol) was added dropwise. The reaction was allowed to warm to rt and stirred at this temperature for 2 h. EtOAc and H<sub>2</sub>O were added, and the organics were separated and washed with H<sub>2</sub>0, NaHCO<sub>3</sub> (saturated solution), and brine before concentrating <i>in vacuo</i>. The crude material was purified by flash chromatography (10–20% EtOAc in heptane) to afford the title compound (162 mg, 62%). LCMS (ESI) <i>m</i>/<i>z</i>: 311/313 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.63 (d, <i>J</i> = 8.9 Hz, 2H), 7.56 (d, <i>J</i> = 8.9 Hz, 2H), 6.23 (s, 1H), 3.99 (s, 3H), 3.94 (s, 3H).</div></div><div id="sec5_20_32_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i159" class="anchor-spacer"></div><h5 class="article-section__title" id="_i159"> 1-(4-Bromophenyl)-5-methoxy-1<i>H</i>-pyrazole-3-carbaldehyde (<b>118</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-5-methoxy-1<i>H</i>-pyrazole-3-carboxylate (<b>114</b>) (162 mg, 0.52 mmol) and DIBAL (1 M in DCM) (0.52 mL, 0.52 mmol) were combined in THF (5 mL) according to General Method 5b. Further DIBAL (1 M in DCM) (0.52 mL, 0.52 mmol) was added in this case to push the reaction to completion. MnO<sub>2</sub> (453 mg, 5.21 mmol) was added in the second step according to General Method 5b. Work-up and purification afforded the title compound (146 mg, 100%). LCMS (ESI) <i>m</i>/<i>z</i>: 281/283 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 9.88 (s, 1H), 7.66 (d, <i>J</i> = 9.0 Hz, 2H), 7.60 (d, <i>J</i> = 9.0 Hz, 2H), 6.18 (s, 1H), 4.00 (s, 3H).</div></div><div id="sec5_20_32_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i160" class="anchor-spacer"></div><h5 class="article-section__title" id="_i160"> 1′-((1-(4-Bromophenyl)-5-methoxy-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>122</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (181 mg, 0.89 mmol), 1-(4-bromophenyl)-5-methoxy-1<i>H</i>-pyrazole-3-carbaldehyde (<b>118</b>) (250 mg, 0.89 mmol), and sodium triacetoxyborohydride (377 mg, 1.78 mmol) were combined in DCM (5 mL) according to General Method 1. Work-up and purification afforded the title compound (287 mg, 68%). LCMS (ESI) <i>m</i>/<i>z</i>: 468/470 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.61 (d, <i>J</i> = 8.9 Hz, 2H), 7.52 (d, <i>J</i> = 8.9 Hz, 2H), 7.24–7.18 (m, 2H), 7.17–7.13 (m, 1H), 7.08 (s, <i>J</i> = 7.4 Hz, 1H), 5.85 (s, 1H), 3.96 (s, 3H), 3.88 (t, <i>J</i> = 5.5 Hz, 2H), 3.81–3.70 (m, 2H), 3.08–2.96 (m, 2H), 2.82 (t, <i>J</i> = 5.5 Hz, 2H), 2.77–2.65 (m, 2H), 2.31–2.14 (m, 2H), 1.94 (d, <i>J</i> = 13.8 Hz, 2H).</div></div><div id="sec5_20_32_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i161" class="anchor-spacer"></div><h5 class="article-section__title" id="_i161"> 4-(5-Methoxy-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>31</b>)</h5><div class="NLM_p last">1′-[[1-(4-Bromophenyl)-5-methoxy-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>122</b>) (58 mg, 0.12 mmol), <i>N</i>-formylsaccharin (31 mg, 0.15 mL), Pd(OAc)<sub>2</sub> (0.8 mg, 0.004 mmol), Xantphos (3 mg, 0.006 mmol), and KF (18 mg, 0.31 mmol) were combined in DMF (1 mL) according to General Method 5. Work-up and purification afforded the title compound (11 mg, 21%). LCMS (ESI) <i>m</i>/<i>z</i>: 434 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H<sup>+</sup>], 434.2080; found, 434.2077. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (d, <i>J</i> = 8.6 Hz, 2H), 7.67 (d, <i>J</i> = 8.6 Hz, 2H), 7.23 (d, <i>J</i> = 7.9 Hz, 1H), 7.21–7.11 (m, 2H), 7.08 (d, <i>J</i> = 7.4 Hz, 1H), 5.85 (s, 1H), 3.94–3.88 (m, 7H), 3.35 (d, <i>J</i> = 10.8 Hz, 2H), 2.92 (t, <i>J</i> = 11.9 Hz, 2H), 2.84 (t, <i>J</i> = 5.3 Hz, 2H), 2.46 (t, <i>J</i> = 13.0 Hz, 2H), 2.00 (d, <i>J</i> = 14.0 Hz, 2H.</div></div></div><div id="sec5_20_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> Synthesis of 4-(5-Ethoxy-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>32</b>) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>)</h4><div id="sec5_20_33_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i163" class="anchor-spacer"></div><h5 class="article-section__title" id="_i163"> Methyl 1-(4-Bromophenyl)-5-ethoxy-1<i>H</i>-pyrazole-3-carboxylate (<b>115</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-5-hydroxy-1<i>H</i>-pyrazole-3-carboxylate (<b>110</b>) (500 mg, 1.68 mmol) was dissolved in DMF (5 mL) and K<sub>2</sub>CO<sub>3</sub> (349 mg, 2.52 mmol) was added. The reaction mixture was cooled to 0 °C, and iodoethane (0.13 mL, 1.68 mmol) was added dropwise. The reaction was allowed to warm to rt and stirred for 2 h. EtOAc and H<sub>2</sub>O were added. The organics were separated and washed with H<sub>2</sub>0, NaHCO<sub>3</sub> (saturated aqueous solution), and brine and concentrated <i>in vacuo</i>. The crude material was purified by flash chromatography (10–20% EtOAc in heptane) to afford the title compound (369 mg, 67%). LCMS (ESI) <i>m</i>/<i>z</i>: 369/371 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 8.9 Hz, 2H), 7.56 (d, <i>J</i> = 8.9 Hz, 2H), 6.20 (s, 1H), 4.22 (q, <i>J</i> = 7.1 Hz, 2H), 3.93 (s, 3H), 1.46 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_20_33_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i164" class="anchor-spacer"></div><h5 class="article-section__title" id="_i164"> 1-(4-Bromophenyl)-5-ethoxy-1<i>H</i>-pyrazole-3-carbaldehyde (<b>119</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-5-ethoxy-1<i>H</i>-pyrazole-3-carboxylate (<b>115</b>) (369 mg, 1.13 mmol) and DIBAL (1.36 mL, 1.36 mmol) were combined in THF (5 mL) according to General Method 6b. Further, DIBAL (2.72 mL, 2.72 mmol) was added in this case to push the reaction to completion. MnO<sub>2</sub> (987 mg, 11.45 mmol) was added in the second step according to General Method 6b. Work-up and purification afforded the title compound (164 mg, 47%). LCMS (ESI) <i>m</i>/<i>z</i>: 295/297 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.88 (s, 1H), 7.68 (d, <i>J</i> = 9.0 Hz, 2H), 7.60 (d, <i>J</i> = 9.0 Hz, 2H), 6.15 (s, 1H), 4.23 (q, <i>J</i> = 7.1 Hz, 2H), 1.48 (t, <i>J</i> = 7.1 Hz, 2H).</div></div><div id="sec5_20_33_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i165" class="anchor-spacer"></div><h5 class="article-section__title" id="_i165"> 1′-((1-(4-Bromophenyl)-5-ethoxy-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>123</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (56 mg, 0.28 mmol), 1-(4-bromophenyl)-5-ethoxy-1<i>H</i>-pyrazole-3-carbaldehyde (<b>119</b>) (82 mg, 0.28 mmol), and sodium triacetoxyborohydride (118 mg, 0.56 mmol) were combined in DCM (10 mL) according to General Method 1. Work-up followed by flash chromatography (10–100% EtOAc in heptane) afforded the title compound (96 mg, 72%). LCMS (ESI) <i>m</i>/<i>z</i>: 482/484 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.64 (d, <i>J</i> = 8.9 Hz, 2H), 7.51 (d, <i>J</i> = 8.9 Hz, 2H), 7.23–7.12 (m, 3H), 7.08 (d, <i>J</i> = 7.5 Hz, 1H), 5.76 (s, 1H), 4.18 (q, <i>J</i> = 7.1 Hz, 2H), 3.89 (t, <i>J</i> = 5.5 Hz, 2H), 3.65 (s, 2H), 2.96–2.87 (m, 2H), 2.82 (t, <i>J</i> = 5.5 Hz, 2H), 2.66–2.54 (m, 2H), 2.20–2.07 (m, 2H), 1.91 (d, <i>J</i> = 14.0 Hz, 2H), 1.46 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec5_20_33_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i166" class="anchor-spacer"></div><h5 class="article-section__title" id="_i166"> 4-(5-Ethoxy-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>32</b>)</h5><div class="NLM_p last">1′-[[1-(4-Bromophenyl)-5-ethoxy-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>123</b>) (96 mg, 0.20 mmol), Pd(OAc)<sub>2</sub> (1 mg, 0.01 mmol), Xantphos (5 mg, 0.01 mmol), KF (29 mg, 0.50 mmol), and <i>N</i>-formylsaccharin (50 mg, 0.24 mmol) were combined in DMF (1 mL) according to General Method 5. Work-up and purification afforded the title compound (10 mg, 11%). LCMS (ESI) <i>m</i>/<i>z</i>: 448 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 448.2236; found, 448.2249. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07 (d, <i>J</i> = 8.6 Hz, 2H), 7.70 (d, <i>J</i> = 8.6 Hz, 2H), 7.25–7.21 (m, 1H), 7.20–7.11 (m, 2H), 7.08 (d, <i>J</i> = 7.5 Hz, 1H), 5.84 (s, 1H), 4.11 (q, <i>J</i> = 7.1 Hz, 2H), 3.94–3.88 (m, 2H), 3.33 (d, <i>J</i> = 10.4 Hz, 2H), 2.92 (t, <i>J</i> = 12.1 Hz, 2H), 2.84 (t, <i>J</i> = 5.5 Hz, 2H), 2.45 (t, <i>J</i> = 13.4 Hz, 2H), 2.00 (d, <i>J</i> = 14.0 Hz, 2H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H).</div></div></div><div id="sec5_20_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> Synthesis of 4-[5-Pyrrolidin-1-yl-3-(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)pyrazol-1-yl]benzoic Acid (<b>33</b>) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>)</h4><div id="sec5_20_34_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i168" class="anchor-spacer"></div><h5 class="article-section__title" id="_i168"> Methyl 1-(4-Bromophenyl)-5-chloro-4-formyl-1<i>H</i>-pyrazole-3-carboxylate (<b>111</b>)</h5><div class="NLM_p last">POCl<sub>3</sub> (2 mL, 1.68 mmol) was added cautiously to methyl 1-(4-bromophenyl)-5-hydroxy-pyrazole-3-carboxylate (<b>120</b>) (500 mg, 1.68 mmol), and then DMF (0.16 mL, 2.02 mmol) was added. The reaction mixture was heated to 100 °C for 2 h and then allowed to cool to rt, added to a H<sub>2</sub>O/ice mixture, and stirred for 1 h. The resulting precipitate was filtered, washed with H<sub>2</sub>O and heptane, and air-dried. The solid was dissolved in DCM and passed through a hydrophobic frit. The filtrate was concentrated <i>in vacuo</i> to afford the title compound as a beige solid (450 mg, 70%). <sup>1</sup>H NMR (400 MHz, CDCl3): δ 10.54 (s, 1H), 7.72–7.69 (m, 2H), 7.49–7.46 (m, 2H), 4.05 (s, 3H).</div></div><div id="sec5_20_34_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i169" class="anchor-spacer"></div><h5 class="article-section__title" id="_i169"> Methyl 1-(4-Bromophenyl)-4-formyl-5-(pyrrolidin-1-yl)-1<i>H</i>-pyrazole-3-carboxylate (<b>112</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-5-chloro-4-formyl-pyrazole-3-carboxylate (<b>111</b>) (600 mg, 1.75 mmol) and pyrrolidine (248 mg, 3.49 mmol) were taken up in DMF (3 mL) before the addition of K<sub>2</sub>CO<sub>3</sub> (483 mg, 3.49 mmol). The reaction mixture was heated to 120 °C in the microwave for 1 h and then quenched with water. The product was extracted with DCM, dried (hydrophobic frit), and concentrated <i>in vacuo</i>. The crude material was purified by flash chromatography (0–80% EtOAc in heptane) to afford the title compound (270 mg, 39%). LCMS (ESI) <i>m</i>/<i>z</i>: 378, 380 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.37 (s, 1H), 7.62–7.58 (m, 2H), 7.38–7.45 (m, 2H), 3.97 (s, 3H), 3.26–3.22 (m, 4H), 1.89–1.86 (m, 4H).</div></div><div id="sec5_20_34_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i170" class="anchor-spacer"></div><h5 class="article-section__title" id="_i170"> Methyl 1-(4-Bromophenyl)-5-(pyrrolidin-1-yl)-1<i>H</i>-pyrazole-3-carboxylate (<b>116</b>)</h5><div class="NLM_p last">To a solution of <i>p</i>-TsOH (24 mg, 0.13 mmol) in MeOH (3 mL) was added methyl 1-(4-bromophenyl)-4-formyl-5-pyrrolidin-1-yl-pyrazole-3-carboxylate (<b>112</b>) (220 mg, 0.58 mmol). The reaction mixture was heated to 120 °C in the microwave for 1 h. The reaction was concentrated <i>in vacuo</i> to afford the title compound, which was used in the next step with no further purification (200 mg, 77%). LCMS (ESI) <i>m</i>/<i>z</i>: 350, 352 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.59–7.50 (m, 4H), 6.21 (s, 1H), 3.92 (s, 3H), 3.00 (m, 4H), 1.88–1.85 (m, 4H).</div></div><div id="sec5_20_34_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i171" class="anchor-spacer"></div><h5 class="article-section__title" id="_i171"> 1-(4-Bromophenyl)-5-(pyrrolidin-1-yl)-1<i>H</i>-pyrazole-3-carbaldehyde (<b>120</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-5-pyrrolidin-1-yl-pyrazole-3-carboxylate (<b>116</b>) (200 mg, 0.57 mmol) was dissolved in DCM (10 mL) and cooled to −78 °C under N<sub>2</sub>. DIBAL (1 M in DCM, 1.43 mL, 1.43 mmol) was then added dropwise over 20 min and the reaction was stirred for a further 1 h at −78 °C. The reaction was quenched with 5 mL of 1:1 MeOH/H<sub>2</sub>O, allowed to warm up to rt, and then passed through a hydrophobic frit and concentrated <i>in vacuo</i> to the title compound, which was used in the next step with no further purification (166 mg, 81%). LCMS (ESI) <i>m</i>/<i>z</i>: 320, 322 (M + H)<sup>+</sup>.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.87 (s, 1H), 7.63–7.59 (m, 2H), 7.56–7.53 (m, 2H), 6.15 (s, 1H), 3.00 (m, 4H), 1.89–1.86 (m, 4H).</div></div><div id="sec5_20_34_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i172" class="anchor-spacer"></div><h5 class="article-section__title" id="_i172"> 1′-[[1-(4-Bromophenyl)-5-pyrrolidin-1-yl-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>124</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (50 mg, 0.25 mmol), 1-(4-bromophenyl)-5-pyrrolidin-1-yl-1<i>H</i>-pyrazole-3-carbaldehyde (<b>120</b>) (88 mg, 0.25 mmol), and sodium triacetoxyborohydride (104 mg, 0.49 mmol) were combined in DCM (3 mL) according to General Method 1. Work-up followed by purification afforded the title compound (62 mg, 47%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>32</sub>BrN<sub>4</sub>O [M + H]<sup>+</sup>: 509.1670; found, 509.1756. <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>): δ 7.54–7.53 (m, 4H), 7.24–7.08 (m, 4H), 5.75 (s, 1H), 3.91 (t, <i>J</i> = 5.5 Hz, 2H), 3.58 (s, 2H), 3.00 (t, <i>J</i> = 6.6 Hz, 4H), 2.89–2.81 (m, 4H), 2.56–2.48 (m, 2H), 2.14–2.01 (m, 2H), 1.93–1.84 (m, 6H).</div></div><div id="sec5_20_34_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i173" class="anchor-spacer"></div><h5 class="article-section__title" id="_i173"> 4-[5-Pyrrolidin-1-yl-3-(spiro[isochromane-1,4′-piperidine]-1′-ylmethyl)pyrazol-1-yl]benzoic Acid (<b>33</b>)</h5><div class="NLM_p last">1′-[[1-(4-Bromophenyl)-5-pyrrolidin-1-yl-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>124</b>) (62 mg, 0.12 mmol), <i>N</i>-formylsaccharin (31 mg, 0.15 mmol), Pd(OAc)<sub>2</sub> (0.8 mg, 0.004 mmol), Xantphos (3 mg, 0.006 mmol), and KF (18 mg, 0.31 mmol) were combined in DMF (2 mL) according to General Method 5. Work-up and purification afforded the title compound (4 mg, 6%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>33</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 473.2547; found, 473.2545. <sup>1</sup>H NMR (400 MHz, D6-DMSO): δ 8.02 (d, <i>J</i> = 8.8 Hz, 2H), 7.71 (d, <i>J</i> = 8.7 Hz, 2H), 7.22–7.07 (m, 4H), 5.83 (s, 1H), 3.81 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H), 3.44 (s, 2H), 3.33 (s, 1H), 2.96 (dd, <i>J</i> = 6.4, 6.4 Hz, 4H), 2.73 (dd, <i>J</i> = 5.4, 5.4 Hz, 4H), 2.42–2.33 (m, 2H), 1.97–1.89 (m, 2H), 1.84–1.76 (m, 6H).</div></div></div><div id="sec5_20_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i174" class="anchor-spacer"></div><h4 class="article-section__title" id="_i174"> Synthesis of 4-(5-Morpholino-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>34</b>) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>)</h4><div id="sec5_20_35_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i175" class="anchor-spacer"></div><h5 class="article-section__title" id="_i175"> Methyl 1-(4-Bromophenyl)-4-formyl-5-morpholino-1<i>H</i>-pyrazole-3-carboxylate (<b>113</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-5-chloro-4-formyl-1<i>H</i>-pyrazole-3-carboxylate (<b>111</b>) (100 mg, 0.29 mmol) and K<sub>2</sub>CO<sub>3</sub> (80 mg, 0.58 mmol) were mixed in DMF (1 mL) and morpholine (0.05 mL, 0.58 mmol) was added. The reaction mixture was heated to 120 °C in the microwave for 1 h and then quenched with H<sub>2</sub>O and extracted with DCM. The organics were concentrated <i>in vacuo</i>, and the crude material was purified by flash chromatography (0–80% EtOAc in heptane) to afford the title compound (37 mg, 31%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.44 (s, 1H), 7.66 (d, <i>J</i> = 8.8 Hz, 2H), 7.42 (d, <i>J</i> = 8.7 Hz, 2H), 3.99 (s, 3H), 3.73–3.69 (m, 4H), 3.11 (dd, <i>J</i> = 4.6, 4.6 Hz, 4H).</div></div><div id="sec5_20_35_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i176" class="anchor-spacer"></div><h5 class="article-section__title" id="_i176"> Methyl 1-(4-Bromophenyl)-5-morpholino-1<i>H</i>-pyrazole-3-carboxylate (<b>117</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-4-formyl-5-morpholino-1<i>H</i>-pyrazole-3-carboxylate (<b>113</b>) (250 mg, 0.63 mmol) was mixed in MeOH (5 mL) and <i>p</i>-TsOH (24 mg, 0.13 mmol) was added. The reaction mixture was heated to 120 °C in the microwave for 1 h and then concentrated <i>in vacuo</i> to afford the title compound (200 mg, 78%). <sup>1</sup>H NMR (400 MHz, CDCl3): δ 7.73 (2H, d, <i>J</i> = 8.8 Hz), 7.61 (2H, d, <i>J</i> = 8.9 Hz), 6.47 (1H, s), 3.95 (3H, s), 3.77–3.73 (4H, m), 2.92–2.89 (4H, m).</div></div><div id="sec5_20_35_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i177" class="anchor-spacer"></div><h5 class="article-section__title" id="_i177"> 1-(4-Bromophenyl)-5-morpholino-1<i>H</i>-pyrazole-3-carbaldehyde (<b>121</b>)</h5><div class="NLM_p last">Methyl 1-(4-bromophenyl)-5-morpholino-1<i>H</i>-pyrazole-3-carboxylate (<b>117</b>) (275 mg, 0.75 mmol) and DIBAL (1 M in DCM) (1.88 mL, 1.88 mmol) were combined in DCM (5 mL) according to General Method 6a. Work-up afforded the title compound, which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.93 (1H, s), 7.78–7.56 (4H, m), 6.42 (1H, s), 3.78–3.74 (4H, m), 2.93–2.88 (4H, m). Used crude—contaminated with the benzyl alcohol.</div></div><div id="sec5_20_35_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i178" class="anchor-spacer"></div><h5 class="article-section__title" id="_i178"> 1′-((1-(4-Bromophenyl)-5-morpholino-1<i>H</i>-pyrazol-3-yl)methyl)spiro[isochromane-1,4′-piperidine] (<b>125</b>)</h5><div class="NLM_p last">Spiro[isochromane-1,4′-piperidine] (78 mg, 0.38 mmol), 1-(4-bromophenyl)-5-morpholino-1<i>H</i>-pyrazole-3-carbaldehyde (<b>121</b>) (215 mg, 0.38 mmol), and sodium triacetoxyborohydride (163 mg, 0.77 mmol) were combined in DCM (5 mL) according to General Method 1. Work-up and purification afforded the title compound (200 mg, 95%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 8.8 Hz, 2H), 7.56 (d, <i>J</i> = 8.8 Hz, 2H), 7.24–7.10 (m, 4H), 5.97 (s, 1H), 3.92 (m, 2H), 3.78–3.75 (m, 4H), 3.61 (s, 2H), 2.93–2.83 (m, 8H), 2.57–2.50 (m, 2H), 2.15–2.03 (m, 2H), 1.93 (d, <i>J</i> = 12.5 Hz, 2H).</div></div><div id="sec5_20_35_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i179" class="anchor-spacer"></div><h5 class="article-section__title" id="_i179"> 4-(5-Morpholino-3-(spiro[isochromane-1,4′-piperidin]-1′-ylmethyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>34</b>)</h5><div class="NLM_p last">1′-[[1-(4-Bromophenyl)-5-morpholino-1<i>H</i>-pyrazol-3-yl]methyl]spiro[isochromane-1,4′-piperidine] (<b>125</b>) (150 mg, 0.29 mmol), Pd(OAc)<sub>2</sub> (2 mg, 0.01 mmol), Xantphos (7 mg, 0.01 mmol), KF (42 mg, 0.72 mmol), and <i>N</i>-formylsaccharin (73 mg, 0.34 mmol) were combined in DMF (2 mL) according to General Method 5. Work-up and purification afforded the title compound (8 mg, 5%). HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>33</sub>N<sub>4</sub>O<sub>4</sub> [M + H<sup>+</sup>], 498.2502; found, 489.2498. <sup>1</sup>H NMR (400 MHz, D6-DMSO): δ 8.05–7.95 (m, 4H), 7.23–7.08 (m, 4H), 6.05 (s, 1H), 3.82 (dd, <i>J</i> = 5.4, 5.4 Hz, 2H), 3.70 (dd, <i>J</i> = 4.5, 4.5 Hz, 4H), 3.46 (s, 2H), 2.84 (dd, <i>J</i> = 4.5, 4.5 Hz, 4H), 2.75–2.71 (m, 4H), 2.41–2.33 (m, 2H), 1.97–1.90 (m, 2H), 1.78 (d, <i>J</i> = 12.7 Hz, 2H).</div></div></div><div id="sec5_20_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i180" class="anchor-spacer"></div><h4 class="article-section__title" id="_i180"> Synthesis of 4-(5-Cyclopropyl-3-((6-fluorospiro[isochromane-1,4′-piperidin]-1′-yl)methyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>35</b>) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h4><div id="sec5_20_36_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i181" class="anchor-spacer"></div><h5 class="article-section__title" id="_i181"> 4-(5-Cyclopropyl-3-((6-fluorospiro[isochromane-1,4′-piperidin]-1′-yl)methyl)-1<i>H</i>-pyrazol-1-yl)benzoic Acid (<b>35</b>)</h5><div class="NLM_p last">6-Fluorospiro[isochromane-1,4′-piperidine] (<b>50</b>) (216 mg, 0.98 mmol), 4-(5-cyclopropyl-3-formyl-1<i>H</i>-pyrazol-1-yl)benzoic acid (<b>85</b>) (250 mg, 0.98 mmol), and sodium triacetoxyborohydride (414 mg, 1.95 mmol) were combined in DCM (4 mL) according to General Method 1. Work-up and purification afforded the title compound (261 mg, 57%). LCMS (ESI) <i>m</i>/<i>z</i>: 462 (M + H)<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>27</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>3</sub> [M + H<sup>+</sup>], 462.2193; found, 462.2220. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.07 (d, <i>J</i> = 8.5 Hz, 2H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.25 (dd, <i>J</i> = 8.7, 5.5 Hz, 1H), 6.87 (td, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.78 (dd, <i>J</i> = 9.2, 2.7 Hz, 1H), 6.06 (s, 1H), 3.97 (s, 2H), 3.90 (t, <i>J</i> = 5.5 Hz, 2H), 3.41 (d, <i>J</i> = 10.7 Hz, 2H), 2.94 (t, <i>J</i> = 12.2 Hz, 2H), 2.85–2.79 (m, 2H), 2.54 (td, <i>J</i> = 13.9, 4.0 Hz, 2H), 1.99 (d, <i>J</i> = 13.9 Hz, 2H), 1.86–1.78 (m, 1H), 0.99–0.93 (m, 2H), 0.74–0.69 (m, 2H).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i182">Supporting Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78557" class="dropBlock__holder"></div></div></div></div></div><hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acsomega.0c05589?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acsomega.0c05589</a>.</p><ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Metabolite identification methodologies, chromatograms, proposed metabolite structures, chemistry scheme, PAINS alert analysis and representative compound HPLC UV traces (<a href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular strings (<a href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_002.csv" class="ext-link">CSV</a>)</p></li></ul><p></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_001.pdf">ao0c05589_si_001.pdf (1.45 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_002.csv">ao0c05589_si_002.csv (2.66 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acsomega.0c05589" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms &amp; Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31465" class="dropBlock__holder"></div></div></div></div></div><hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon R. Green</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span>;&nbsp;
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0001-5054-4792" title="Orcid link">http://orcid.org/0000-0001-5054-4792</a>;&nbsp;
    </span><span class="author-email">
                Email: <a href="mailto:s.r.green@dundee.ac.uk">s.r.green@dundee.ac.uk</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul G. Wyatt</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span>;&nbsp;
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0002-0397-245X" title="Orcid link">http://orcid.org/0000-0002-0397-245X</a>;&nbsp;
    </span><span class="author-email">
                Email: <a href="mailto:P.G.Wyatt@dundee.ac.uk">P.G.Wyatt@dundee.ac.uk</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tanya Parish</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span>;&nbsp;
    <span>Present Address:
                        Center for Global Infectious Disease Research, Seattle Children’s Research Institute, 307 Westlake Avenue N, Seattle, WA 98109, USA</span>;&nbsp;
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0001-7507-0423" title="Orcid link">http://orcid.org/0000-0001-7507-0423</a>;&nbsp;
    </span><span class="author-email">
                Email: <a href="mailto:Tanya.parish@seattlechildrens.org">Tanya.parish@seattlechildrens.org</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter C. Ray</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Margaret Huggett</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Penelope A. Turner</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Malcolm Taylor</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura A. T. Cleghorn</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Early</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anuradha Kumar</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shilah A. Bonnett</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lindsay Flint</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas Joerss</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Johnson</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aaron Korkegian</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Mullen</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abraham L. Moure</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan H. Davis</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dinakaran Murugesan</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Mathieson</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola Caldwell</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Curtis A. Engelhart</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Weill Cornell
Medical College, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dirk Schnappinger</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology and Immunology, Weill Cornell
Medical College, New York, New York 10065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ola Epemolu</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabio Zuccotto</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Riley</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Scullion</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laste Stojanovski</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Massoudi</span> - <span class="hlFld-Affiliation affiliation">Mycobacteria
Research Laboratories, Colorado State University, 200 W. Lake Street, Fort Collins, Colorado 80523-1682, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory T. Robertson</span> - <span class="hlFld-Affiliation affiliation">Mycobacteria
Research Laboratories, Colorado State University, 200 W. Lake Street, Fort Collins, Colorado 80523-1682, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne J. Lenaerts</span> - <span class="hlFld-Affiliation affiliation">Mycobacteria
Research Laboratories, Colorado State University, 200 W. Lake Street, Fort Collins, Colorado 80523-1682, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gail Freiberg</span> - <span class="hlFld-Affiliation affiliation">AbbVie, 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dale J. Kempf</span> - <span class="hlFld-Affiliation affiliation">AbbVie, 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span>;&nbsp;
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0002-1408-9099" title="Orcid link">http://orcid.org/0000-0002-1408-9099</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thierry Masquelin</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry Research, Eli Lilly and Company, Lilly Corporate Centre, MC/87/02/203, G17, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip A. Hipskind</span> - <span class="hlFld-Affiliation affiliation">Lgenia
Inc., Fortville, Indiana 46040, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joshua Odingo</span> - <span class="hlFld-Affiliation affiliation">TB
Discovery Research, Infectious Disease Research
Institute, 1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin D. Read</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Division of Biological Chemistry and Drug Discovery,
College of Life Sciences, University of
Dundee, Dundee DD1 5EH, U.K.</span>;&nbsp;
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid"><a href="http://orcid.org/0000-0002-8536-0130" title="Orcid link">http://orcid.org/0000-0002-8536-0130</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i185">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60168" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60168" class="dropBlock__holder"></div></div></div></div></div><hr><p class="last">We thank Lucy Ellis, Fred Simeons, Yoko Shishikura, Liam Ferguson, Lorna Campbell, James Roberts, Susan Lawrie, Alex Cookson, Kirsty Cookson, Emma Gutcher, Desiree Zeller, James Ahn, Torey Alling, Lena Anoshchenko, Bryan Grogan, Megha Gupta, Junitta Guzman, Yulia Ovechkina, David Roberts, Catherine Shelton, Bjorn Sunde, Dean Thompson, and Anisa Tracy for technical assistance. This work was funded in part by an award to P.G.W. from the Bill and Melinda Gates Foundation (OPP1066891) and Wellcome Trust (100195/Z/12/Z); by awards from BMG&amp;F to T.P. (OPP1024038) and A.J.L./G.T.R. (OPP1126594); by Eli Lilly and Company in support of the mission of the Lilly TB Drug Discovery Initiative; and an award to T.P. by NIAID of the National Institutes of Health (R01AI099188). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i186">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38840" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38840" class="dropBlock__holder"></div></div></div></div></div><hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span> <span> </span><span class="NLM_article-title">Microbe Profile: Mycobacterium tuberculosis: Humanity’s deadly microbial foe</span>. <i>Microbiology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">439</span>, <span class="refDoi">&nbsp;DOI: 10.1099/mic.0.000601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1099%2Fmic.0.000601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=29465344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCltbzE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=164&amp;publication_year=2018&amp;pages=437-439&amp;author=S.+V.+Gordonauthor=T.+Parish&amp;title=Microbe+Profile%3A+Mycobacterium+tuberculosis%3A+Humanity%E2%80%99s+deadly+microbial+foe&amp;doi=10.1099%2Fmic.0.000601" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microbe profile: Mycobacterium tuberculosis: Humanity's deadly microbial foe</span></div><div class="casAuthors">Gordon, Stephen V.; Parish, Tanya</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-439</span>CODEN:
                <span class="NLM_cas:coden">MROBEO</span>;
        ISSN:<span class="NLM_cas:issn">1465-2080</span>.
    
            (<span class="NLM_cas:orgname">Microbiology Society</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis is an expert and deadly pathogen, causing the disease tuberculosis (TB) in humans.  It has several notable features: the ability to enter non-replicating states for long periods and cause latent infection; metabolic remodelling during chronic infection; a thick, waxy cell wall; slow growth rate in culture; and intrinsic drug resistance and antibiotic tolerance.  As a pathogen, M. tuberculosis has a complex relationship with its host, is able to replicate inside macrophages, and expresses diverse immunomodulatory mols.  M. tuberculosis currently causes over 1.8 million deaths a year, making it the world's most deadly human pathogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIHaKNZQyUMLVg90H21EOLACvtfcHk0lgq4Rx2OkN4vg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1cXhslCltbzE&amp;md5=78295495d67634bb25957ea52840d899</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1099%2Fmic.0.000601&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fmic.0.000601%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DS.%2BV.%26aulast%3DParish%26aufirst%3DT.%26atitle%3DMicrobe%2520Profile%253A%2520Mycobacterium%2520tuberculosis%253A%2520Humanity%25E2%2580%2599s%2520deadly%2520microbial%2520foe%26jtitle%3DMicrobiology%26date%3D2018%26volume%3D164%26spage%3D437%26epage%3D439%26doi%3D10.1099%2Fmic.0.000601" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">WHO</span>.  <i>Global Tuberculosis Report 2020</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva
(Switzerland)</span>, <span class="NLM_year">2020</span>; ISBN 978-92-4-001313-1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2020&amp;author=WHO&amp;title=Global+Tuberculosis+Report+2020" target="_blank">Google Scholar</a><div class="casRecord empty" id="
                            cas_R
                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DGlobal%2520Tuberculosis%2520Report%25202020%26pub%3DWorld%2520Health%2520Organization%26date%3D2020" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, R. H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, M.</span></span> <span> </span><span class="NLM_article-title">The WHO 2014 Global tuberculosis report-further to go</span>. <i>Lancet Global Health</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">E10</span>– <span class="NLM_lpage">E12</span>, <span class="refDoi">&nbsp;DOI: 10.1016/S2214-109x(14)70361-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2FS2214-109X%2814%2970361-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25539957" title="">PubMed</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=3&amp;publication_year=2015&amp;pages=E10-E12&amp;author=A.+Zumlaauthor=A.+Georgeauthor=V.+Sharmaauthor=R.+H.+N.+Herbertauthor=A.+Oxleyauthor=M.+Oliverauthor=M.+Oliver&amp;title=The+WHO+2014+Global+tuberculosis+report-further+to+go&amp;doi=10.1016%2FS2214-109x%2814%2970361-4" target="_blank">Google Scholar</a><div class="casRecord empty" id="
                            cas_R
                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS2214-109X%2814%2970361-4&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2214-109X%252814%252970361-4%26sid%3Dliteratum%253Aachs%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DGeorge%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DHerbert%26aufirst%3DR.%2BH.%2BN.%26aulast%3DOxley%26aufirst%3DA.%26aulast%3DOliver%26aufirst%3DM.%26aulast%3DOliver%26aufirst%3DM.%26atitle%3DThe%2520WHO%25202014%2520Global%2520tuberculosis%2520report-further%2520to%2520go%26jtitle%3DLancet%2520Global%2520Health%26date%3D2015%26volume%3D3%26spage%3DE10%26epage%3DE12%26doi%3D10.1016%2FS2214-109x%2814%2970361-4" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi">&nbsp;DOI: 10.1016/s0140-6736(15)00151-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2FS0140-6736%2815%2900151-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=26377143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A280%3ADC%252BC283jtVShtg%253D%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=387&amp;publication_year=2016&amp;pages=1211-1226&amp;author=K.+Dhedaauthor=C.+E.+Barryauthor=G.+Maartens&amp;title=Tuberculosis&amp;doi=10.1016%2Fs0140-6736%2815%2900151-8" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis</span></div><div class="casAuthors">Dheda Keertan; Barry Clifton E 3rd; Maartens Gary</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10024</span>),
    <span class="NLM_cas:pages">1211-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although the worldwide incidence of tuberculosis has been slowly decreasing, the global disease burden remains substantial (∼9 million cases and ∼1·5 million deaths in 2013), and tuberculosis incidence and drug resistance are rising in some parts of the world such as Africa.  The modest gains achieved thus far are threatened by high prevalence of HIV, persisting global poverty, and emergence of highly drug-resistant forms of tuberculosis.  Tuberculosis is also a major problem in health-care workers in both low-burden and high-burden settings.  Although the ideal preventive agent, an effective vaccine, is still some time away, several new diagnostic technologies have emerged, and two new tuberculosis drugs have been licensed after almost 50 years of no tuberculosis drugs being registered.  Efforts towards an effective vaccine have been thwarted by poor understanding of what constitutes protective immunity.  Although new interventions and investment in control programmes will enable control, eradication will only be possible through substantial reductions in poverty and overcrowding, political will and stability, and containing co-drivers of tuberculosis, such as HIV, smoking, and diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCv4mFAtl09LP3FVUi_gf8fW6udTcc2eYQiU30HvRsc7ntkvexoksv"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A280%3ADC%252BC283jtVShtg%253D%253D&amp;md5=4da3776db0bff83329a1f2a65805d12f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2900151-8&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252900151-8%26sid%3Dliteratum%253Aachs%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DMaartens%26aufirst%3DG.%26atitle%3DTuberculosis%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26spage%3D1211%26epage%3D1226%26doi%3D10.1016%2Fs0140-6736%2815%2900151-8" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horsburgh, C. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span> <span> </span><span class="NLM_article-title">Treatment of Tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2149</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi">&nbsp;DOI: 10.1056/NEJMra1413919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1056%2FNEJMra1413919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=26605929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVSkt7o%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=373&amp;publication_year=2015&amp;pages=2149-2160&amp;author=C.+R.+Horsburghauthor=C.+E.+Barryauthor=C.+Lange&amp;title=Treatment+of+Tuberculosis&amp;doi=10.1056%2FNEJMra1413919" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of tuberculosis</span></div><div class="casAuthors">Horsburgh, C. Robert, Jr.; Barry, Clifton E., III; Lange, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2149-2160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Tuberculosis, a scourge since prehistoric times, affects more than 9 million people and causes the death of 1.5 million people each year.  Effective treatment has been available for 60 years, but such treatment takes at least 6 mo, and resistance to the drugs, which is increasing throughout the world, threatens the effectiveness of treatment.1 This review summarizes the theor. principles of tuberculosis treatment, current therapeutic approaches, areas of uncertainty, and persistent challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNp74TLwDRXLVg90H21EOLACvtfcHk0lg3LrDrSlh2rA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC28XntVSkt7o%253D&amp;md5=96775985ab332aa82ccc4ab5481e6fe0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1413919&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1413919%26sid%3Dliteratum%253Aachs%26aulast%3DHorsburgh%26aufirst%3DC.%2BR.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DLange%26aufirst%3DC.%26atitle%3DTreatment%2520of%2520Tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2149%26epage%3D2160%26doi%3D10.1056%2FNEJMra1413919" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">The challenge of new drug discovery for tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">490</span>, <span class="refDoi">&nbsp;DOI: 10.1038/nature09657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fnature09657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=21270886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFShsrg%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=469&amp;publication_year=2011&amp;pages=483-490&amp;author=A.+Koulauthor=E.+Arnoultauthor=N.+Lounisauthor=J.+Guillemontauthor=K.+Andries&amp;title=The+challenge+of+new+drug+discovery+for+tuberculosis&amp;doi=10.1038%2Fnature09657" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The challenge of new drug discovery for tuberculosis</span></div><div class="casAuthors">Koul, Anil; Arnoult, Eric; Lounis, Nacer; Guillemont, Jerome; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7331</span>),
    <span class="NLM_cas:pages">483-490</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) is more prevalent in the world today than at any other time in human history.  Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse strategies to survive in a variety of host lesions and to evade immune surveillance.  A key question is how robust are our approaches to discovering new TB drugs, and what measures could be taken to reduce the long and protracted clin. development of new drugs.  The emergence of multi-drug-resistant strains of M. tuberculosis makes the discovery of new mol. scaffolds a priority, and the current situation even necessitates the re-engineering and repositioning of some old drug families to achieve effective control.  Whatever the strategy used, success will depend largely on our proper understanding of the complex interactions between the pathogen and its human host.  In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9J_uIM64vSrVg90H21EOLACvtfcHk0lg3LrDrSlh2rA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3MXhtFShsrg%253D&amp;md5=2c70f07fc0c88727f6b20d35f0c85695</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature09657&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09657%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DThe%2520challenge%2520of%2520new%2520drug%2520discovery%2520for%2520tuberculosis%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D483%26epage%3D490%26doi%3D10.1038%2Fnature09657" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lechartier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybniker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis drug discovery in the post-post-genomic era</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">168</span>, <span class="refDoi">&nbsp;DOI: 10.1002/emmm.201201772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1002%2Femmm.201201772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=24401837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWktb4%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2014&amp;pages=158-168&amp;author=B.+Lechartierauthor=J.+Rybnikerauthor=A.+Zumlaauthor=S.+T.+Cole&amp;title=Tuberculosis+drug+discovery+in+the+post-post-genomic+era&amp;doi=10.1002%2Femmm.201201772" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis drug discovery in the post-post-genomic era</span></div><div class="casAuthors">Lechartier, Benoit; Rybniker, Jan; Zumla, Alimuddin; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-168</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The expectation that genomics would result in new therapeutic interventions for infectious diseases remains unfulfilled.  In the post-genomic era, the decade immediately following the availability of the genome sequence of Mycobacterium tuberculosis, tuberculosis (TB) drug discovery relied heavily on the target-based approach but this proved unsuccessful leading to a return to whole cell screening.  Genomics underpinned screening by providing knowledge and many enabling technologies, most importantly whole genome resequencing to find resistance mutations and targets, and this resulted in a selection of leads and new TB drug candidates that are reviewed here.  Unexpectedly, many new targets were found to be 'promiscuous' as they were inhibited by a variety of different compds.  In the post-post-genomics era, more advanced technologies have been implemented and these include high-content screening, screening for inhibitors of latency, the use of conditional knock-down mutants for validated targets and siRNA screens.  In addn., immunomodulation and pharmacol. manipulation of host functions are being explored in an attempt to widen our therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwFEZdeRp7hLVg90H21EOLACvtfcHk0lg3LrDrSlh2rA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2cXitFWktb4%253D&amp;md5=7db5bd8d9e76b1d69df6966fb75a9712</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Femmm.201201772&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201201772%26sid%3Dliteratum%253Aachs%26aulast%3DLechartier%26aufirst%3DB.%26aulast%3DRybniker%26aufirst%3DJ.%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DTuberculosis%2520drug%2520discovery%2520in%2520the%2520post-post-genomic%2520era%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D158%26epage%3D168%26doi%3D10.1002%2Femmm.201201772" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kana, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakousis, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span> <span> </span><span class="NLM_article-title">Future target-based drug discovery for tuberculosis?</span>. <i>Tuberculosis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">556</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.tube.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.tube.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25458615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWitL%252FE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=94&amp;publication_year=2014&amp;pages=551-556&amp;author=B.+D.+Kanaauthor=P.+C.+Karakousisauthor=T.+Parishauthor=T.+Dick&amp;title=Future+target-based+drug+discovery+for+tuberculosis%3F&amp;doi=10.1016%2Fj.tube.2014.10.003" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Future target-based drug discovery for tuberculosis?</span></div><div class="casAuthors">Kana, Bavesh Davandra; Karakousis, Petros C.; Parish, Tanya; Dick, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">551-556</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New drugs that retain potency against multidrug/extensively drug-resistant strains of Mycobacterium tuberculosis, with the addnl. benefit of a shortened treatment duration and ease of administration, are urgently needed by tuberculosis (TB) control programs.  Efforts to develop this new generation of treatment interventions have been plagued with numerous problems, the most significant being our insufficient understanding of mycobacterial metab. during disease.  This, combined with limited chem. diversity and poor entry of small mols. into the cell, has limited the no. of new bioactive agents that result from drug screening efforts.  The biochem., target-driven approach to drug development has been largely abandoned in the TB field, to be replaced by whole-cell or target-based whole-cell screening approaches.  In this context, the properties of a good drug target are unclear, since these are directly detd. by the ability to find compds., using current screening algorithms, which are able to kill M. tuberculosis.  In this review, we discuss issues related to the identification and validation of drug targets and highlight some key properties for promising targets.  Some of these include essentiality for growth, vulnerability, druggability, reduced propensity to evolve drug resistance and target location to facilitate ready access to drugs during chemotherapy.  We present these in the context of recent drugs that have emerged through various approaches with the aim of consolidating the knowledge gained from these experiences to inform future efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwa9Dp4ihtM7Vg90H21EOLACvtfcHk0liRoqcmBrFbEQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWitL%252FE&amp;md5=c0489ca8150d64b78842ee8edaa94bf1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2014.10.003&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DKana%26aufirst%3DB.%2BD.%26aulast%3DKarakousis%26aufirst%3DP.%2BC.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DDick%26aufirst%3DT.%26atitle%3DFuture%2520target-based%2520drug%2520discovery%2520for%2520tuberculosis%253F%26jtitle%3DTuberculosis%26date%3D2014%26volume%3D94%26spage%3D551%26epage%3D556%26doi%3D10.1016%2Fj.tube.2014.10.003" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5087</span>– <span class="NLM_lpage">5097</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.bmc.2014.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.bmc.2014.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25577708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVamtg%253D%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=23&amp;publication_year=2015&amp;pages=5087-5097&amp;author=U.+H.+Manjunathaauthor=P.+W.+Smith&amp;title=Perspective%3A+Challenges+and+opportunities+in+TB+drug+discovery+from+phenotypic+screening&amp;doi=10.1016%2Fj.bmc.2014.12.031" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening</span></div><div class="casAuthors">Manjunatha, Ujjini H.; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic &amp; Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5087-5097</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tuberculosis poses a major global health problem and multi-drug resistant strains are increasingly prevalent.  Hence there is an urgent need to discover new TB drugs.  Cell based phenotypic screening represents a powerful approach to identify anti-mycobacterial compds. and elucidate novel targets.  Three high throughput phenotypic screens were performed at NITD against mycobacterium.  Hits were identified and chem. series selected for optimization.  This produced compds. with good in vitro anti-mycobacterial activity and pharmacokinetic properties.  Some compds. displayed oral activity in mouse efficacy models of TB.  Herein, the authors review the TB discovery efforts at NITD and share experiences in optimization of phenotypic hits, describing challenges encountered and lessons learned.  The authors also offer perspectives to facilitate future selection and advancement of phenotypic hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGbroyRLtEcrVg90H21EOLACvtfcHk0liRoqcmBrFbEQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2MXltVamtg%253D%253D&amp;md5=8d03c078275a58fa6629eaa9f36a5073</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.031&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DPerspective%253A%2520Challenges%2520and%2520opportunities%2520in%2520TB%2520drug%2520discovery%2520from%2520phenotypic%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D5087%26epage%3D5097%26doi%3D10.1016%2Fj.bmc.2014.12.031" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuniga, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Early, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span> <span> </span><span class="NLM_article-title">The future for early-stage tuberculosis drug discovery</span>. <i>Future Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">229</span>, <span class="refDoi">&nbsp;DOI: 10.2217/fmb.14.125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.2217%2Ffmb.14.125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25689534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGitL0%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=10&amp;publication_year=2015&amp;pages=217-229&amp;author=E.+S.+Zunigaauthor=J.+Earlyauthor=T.+Parish&amp;title=The+future+for+early-stage+tuberculosis+drug+discovery&amp;doi=10.2217%2Ffmb.14.125" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The future for early-stage tuberculosis drug discovery</span></div><div class="casAuthors">Zuniga, Edison S.; Early, Julie; Parish, Tanya</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-229</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  There is an urgent need for new and better drugs to treat tuberculosis due to lengthy and complex treatment regimens and a rising problem of drug resistance.  Drug discovery efforts have increased over the past few years, with a larger focus on modern high-throughput screening technologies.  A combination of target-based approaches, with the traditional empirical means of drug identification, has been complemented by the use of target-based phenotypic screens only recently made possibly with newer genetic tools.  Using these approaches, a no. of promising compd. series have been discovered.  However, significant problems remain in developing these into drugs.  This review highlights recent advances in TB drug discovery, including an overview of screening campaigns, lessons learned and future directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiU6_op9dlNrVg90H21EOLACvtfcHk0liRoqcmBrFbEQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2MXislGitL0%253D&amp;md5=68b5e716e695bf2c3c9c24732da525f5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2217%2Ffmb.14.125&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb.14.125%26sid%3Dliteratum%253Aachs%26aulast%3DZuniga%26aufirst%3DE.%2BS.%26aulast%3DEarly%26aufirst%3DJ.%26aulast%3DParish%26aufirst%3DT.%26atitle%3DThe%2520future%2520for%2520early-stage%2520tuberculosis%2520drug%2520discovery%26jtitle%3DFuture%2520Microbiol.%26date%3D2015%26volume%3D10%26spage%3D217%26epage%3D229%26doi%3D10.2217%2Ffmb.14.125" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, R. C.</span></span> <span> </span><span class="NLM_article-title">Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?</span>. <i>Tuberculosis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">588</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.tube.2013.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.tube.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=24119636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFykurvJ" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=93&amp;publication_year=2013&amp;pages=569-588&amp;author=R.+C.+Goldman&amp;title=Why+are+membrane+targets+discovered+by+phenotypic+screens+and+genome+sequencing+in+Mycobacterium+tuberculosis%3F&amp;doi=10.1016%2Fj.tube.2013.09.003" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?</span></div><div class="casAuthors">Goldman, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">569-588</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  High through put screening (HTS) was extensively used in attempts to discover new TB drugs from libraries of pure small mol. compds. many of which complied with the rule of five.  Coupled with new methods for detg. the target of lead compds. by resistance selection followed by genome sequencing, screening for growth inhibitors led to several recent reports of compds. linked to specific antitubercular targets.  This systematic approach to drug discovery appears at present to select for small, hydrophobic mols. affecting the function of essential membrane proteins, for example DprE, MmpL3, AtpE, QcrB, and Pks13.  All of these mols. possessed bactericidal activity in vitro.  Mutations in GlpK were also selected with hydrophobic compds. identified by screening for growth inhibitors.  The chem. properties of the compds. reported are considered in the context of uptake and possible mechanisms of inhibition of membrane bound targets based on other model systems (e.g. cardiovascular drugs affecting voltage-gated L-type calcium channels, daptomycin, telavancin, gramicidin S, and role of boundary lipids).  The relationship between hydrophobicity, compd. uptake, and mode of action are addressed.  Compared to the av. calcd. logP for approved TB drugs of -1.0, the av. for these hydrophobic compds. is 4.0 representing a major shift in hydrophobicity of 5 orders of magnitude.  Furthermore several hydrophobic compds. in the Prestwick Chem. Library (FDA approved drugs) inhibit growth of M. tuberculosis at 10 μg/mL or less and have an av. calcd. logP of 5.7 signaling caution with respect to specificity.  Key recommendations are made regarding follow-up of the hydrophobic leads recently discovered using phenotypic screening and target elucidation by genome sequencing.  Consideration is also given to the properties of small mol. screening libraries, the types of mols. and targets recently discovered as antitubercular leads and compliance with the rule of 5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-PlhXxyKumbVg90H21EOLACvtfcHk0liRoqcmBrFbEQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXhsFykurvJ&amp;md5=38041438bb2bc16d11bd6a29c81c8a2d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2013.09.003&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DR.%2BC.%26atitle%3DWhy%2520are%2520membrane%2520targets%2520discovered%2520by%2520phenotypic%2520screens%2520and%2520genome%2520sequencing%2520in%2520Mycobacterium%2520tuberculosis%253F%26jtitle%3DTuberculosis%26date%3D2013%26volume%3D93%26spage%3D569%26epage%3D588%26doi%3D10.1016%2Fj.tube.2013.09.003" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A.</span></span> <span> </span><span class="NLM_article-title">The tuberculosis drug discovery and development pipeline and emerging drug targets</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a021154</span>, <span class="refDoi">&nbsp;DOI: 10.1101/cshperspect.a021154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1101%2Fcshperspect.a021154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25635061" title="">PubMed</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=5&amp;publication_year=2015&amp;pages=a021154&amp;author=K.+Mdluliauthor=T.+Kanekoauthor=A.+Upton&amp;title=The+tuberculosis+drug+discovery+and+development+pipeline+and+emerging+drug+targets&amp;doi=10.1101%2Fcshperspect.a021154" target="_blank">Google Scholar</a><div class="casRecord empty" id="
                            cas_R
                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021154&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021154%26sid%3Dliteratum%253Aachs%26aulast%3DMdluli%26aufirst%3DK.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DUpton%26aufirst%3DA.%26atitle%3DThe%2520tuberculosis%2520drug%2520discovery%2520and%2520development%2520pipeline%2520and%2520emerging%2520drug%2520targets%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021154%26doi%3D10.1101%2Fcshperspect.a021154" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontes, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzegorzewicz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crick, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span> <span> </span><span class="NLM_article-title">Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6413</span>– <span class="NLM_lpage">6423</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.03229-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.03229-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25136022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjsrjF" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=58&amp;publication_year=2014&amp;pages=6413-6423&amp;author=W.+Liauthor=A.+Upadhyayauthor=F.+L.+Fontesauthor=E.+J.+Northauthor=Y.+Wangauthor=D.+C.+Cransauthor=A.+E.+Grzegorzewiczauthor=V.+Jonesauthor=S.+G.+Franzblauauthor=R.+E.+Leeauthor=D.+C.+Crickauthor=M.+Jackson&amp;title=Novel+insights+into+the+mechanism+of+inhibition+of+MmpL3%2C+a+target+of+multiple+pharmacophores+in+Mycobacterium+tuberculosis&amp;doi=10.1128%2FAAC.03229-14" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis</span></div><div class="casAuthors">Li, Wei; Upadhyay, Ashutosh; Fontes, Fabio L.; North, E. Jeffrey; Wang, Yuehong; Crans, Debbie C.; Grzegorzewicz, Anna E.; Jones, Victoria; Franzblau, Scott G.; Lee, Richard E.; Crick, Dean C.; Jackson, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6413-6423, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">MmpL3, a resistance-nodulation-division (RND) superfamily transporter, has been implicated in the formation of the outer membrane of Mycobacterium tuberculosis; specifically, MmpL3 is required for the export of mycolic acids in the form of trehalose monomycolates (TMM) to the periplasmic space or outer membrane of M. tuberculosis.  Recently, seven series of inhibitors identified by whole-cell screening against M. tuberculosis, including the antituberculosis drug candidate SQ109, were shown to abolish MmpL3-mediated TMM export.  However, this mode of action was brought into question by the broad-spectrum activities of some of these inhibitors against a variety of bacterial and fungal pathogens that do not synthesize mycolic acids.  This observation, coupled with the ability of three of these classes of inhibitors to kill nonreplicating M. tuberculosis bacilli, led us to investigate alternative mechanisms of action.  Our results indicate that the inhibitory effects of adamantyl ureas, indolecarboxamides, tetrahydropyrazolopyrimidines, and the 1,5-diarylpyrrole BM212 on the transport activity of MmpL3 in actively replicating M. tuberculosis bacilli are, like that of SQ109, most likely due to their ability to dissipate the transmembrane electrochem. proton gradient.  In addn. to providing novel insights into the modes of action of compds. reported to inhibit MmpL3, our results provide the first explanation for the large no. of pharmacophores that apparently target this essential inner membrane transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGsm9zGJpAJ7Vg90H21EOLACvtfcHk0lhKojVp_KmzvA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjsrjF&amp;md5=7bfa39b0ce68ba37d73c56cf160cf6e3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.03229-14&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03229-14%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DUpadhyay%26aufirst%3DA.%26aulast%3DFontes%26aufirst%3DF.%2BL.%26aulast%3DNorth%26aufirst%3DE.%2BJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCrans%26aufirst%3DD.%2BC.%26aulast%3DGrzegorzewicz%26aufirst%3DA.%2BE.%26aulast%3DJones%26aufirst%3DV.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DCrick%26aufirst%3DD.%2BC.%26aulast%3DJackson%26aufirst%3DM.%26atitle%3DNovel%2520insights%2520into%2520the%2520mechanism%2520of%2520inhibition%2520of%2520MmpL3%252C%2520a%2520target%2520of%2520multiple%2520pharmacophores%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D6413%26epage%3D6423%26doi%3D10.1128%2FAAC.03229-14" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consalvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span> <span> </span><span class="NLM_article-title">MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1274</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi">&nbsp;DOI: 10.2174/1389557516666160118105319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.2174%2F1389557516666160118105319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=26776226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Srtr3J" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=16&amp;publication_year=2016&amp;pages=1274-1283&amp;author=G.+Poceauthor=S.+Consalviauthor=M.+Biava&amp;title=MmpL3+Inhibitors%3A+Diverse+Chemical+Scaffolds+Inhibit+the+Same+Target&amp;doi=10.2174%2F1389557516666160118105319" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target</span></div><div class="casAuthors">Poce, Giovanna; Consalvi, Sara; Biava, Mariangela</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1274-1283</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">MmpL3 belongs to the Resistance, Nodulation and Division (RND) superfamily whose role in mycobacteria is the formation of the outer membrane.  Indeed, it has been shown that MmpL3 is assocd. with the export of mycolic acids in the form of trehalose monomycolates (TMM) to the periplasmic space or the outer membrane.  In the last few years several whole cell-based screenings of compd. libraries brought by a no. of diverse chem. scaffolds active against M. tuberculosis (Mtb) that surprisingly share MmpL3 as target.  The diverse identified pharmacophores owe important differences among each other, in fact while some of them display inhibitory activity against pathogens that are devoid of mycolic acids and are active against non-replicating Mtb bacilli, some others specifically target mycobacteria and do not kill non-replicating bacilli.  The scope of this review is to provide the recent advances in MmpL3 inhibitor discovery with a special focus on structure activity relationship (SAR) studies in order to provide information that could help in developing novel membrane-active anti- TB agents.  Moreover, this review will provide the most recent insights into the modes of action of the MmpL3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplq0fvepHl_LVg90H21EOLACvtfcHk0lhKojVp_KmzvA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Srtr3J&amp;md5=32d7eca769eb3dd1390804450a5249f8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1389557516666160118105319&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557516666160118105319%26sid%3Dliteratum%253Aachs%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DConsalvi%26aufirst%3DS.%26aulast%3DBiava%26aufirst%3DM.%26atitle%3DMmpL3%2520Inhibitors%253A%2520Diverse%2520Chemical%2520Scaffolds%2520Inhibit%2520the%2520Same%2520Target%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D1274%26epage%3D1283%26doi%3D10.2174%2F1389557516666160118105319" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sacksteder, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action</span>. <i>Future Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">837</span>, <span class="refDoi">&nbsp;DOI: 10.2217/fmb.12.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.2217%2Ffmb.12.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=22827305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2isLbM" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=7&amp;publication_year=2012&amp;pages=823-837&amp;author=K.+A.+Sackstederauthor=M.+Protopopovaauthor=C.+E.+Barryauthor=K.+Andriesauthor=C.+A.+Nacy&amp;title=Discovery+and+development+of+SQ109%3A+a+new+antitubercular+drug+with+a+novel+mechanism+of+action&amp;doi=10.2217%2Ffmb.12.56" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action</span></div><div class="casAuthors">Sacksteder, Katherine A.; Protopopova, Marina; Barry, Clifton E.; Andries, Koen; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">823-837</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Existing drugs have limited efficacy against the rising threat of drug-resistant TB, have significant side effects, and must be given in combinations of four to six drugs for at least 6 mo for drug-sensitive TB and up to 24 mo for drug-resistant TB.  The long treatment duration has led to increased patient noncompliance with therapy.  This, in turn, drives the development of addnl. drug resistance in a spiral that has resulted in some forms of TB being currently untreatable by existing drugs.  New antitubercular drugs in development, particularly those with mechanisms of action that are different from existing first- and second-line TB drugs, are anticipated to be effective against both drug-sensitive and drug-resistant TB.  SQ109 is a new TB drug candidate with a novel mechanism of action that was safe and well tolerated in Phase I and early Phase II clin. trials.  We describe herein the identification, development and characterization of SQ109 as a promising new antitubercular drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm7rdJnt1LOrVg90H21EOLACvtfcHk0lhKojVp_KmzvA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XhtV2isLbM&amp;md5=c4aaa50d56d54573e6bef6b514c38753</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2217%2Ffmb.12.56&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb.12.56%26sid%3Dliteratum%253Aachs%26aulast%3DSacksteder%26aufirst%3DK.%2BA.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DDiscovery%2520and%2520development%2520of%2520SQ109%253A%2520a%2520new%2520antitubercular%2520drug%2520with%2520a%2520novel%2520mechanism%2520of%2520action%26jtitle%3DFuture%2520Microbiol.%26date%3D2012%26volume%3D7%26spage%3D823%26epage%3D837%26doi%3D10.2217%2Ffmb.12.56" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La
Rosa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canseco, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buroni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretta, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battilocchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javid, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Logu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span> <span> </span><span class="NLM_article-title">MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">331</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.05270-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.05270-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=22024828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Gqtw%253D%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=56&amp;publication_year=2012&amp;pages=324-331&amp;author=V.+La%0ARosaauthor=G.+Poceauthor=J.+O.+Cansecoauthor=S.+Buroniauthor=M.+R.+Pascaauthor=M.+Biavaauthor=R.+M.+Rajuauthor=G.+C.+Porrettaauthor=S.+Alfonsoauthor=C.+Battilocchioauthor=B.+Javidauthor=F.+Sorrentinoauthor=T.+R.+Ioergerauthor=J.+C.+Sacchettiniauthor=F.+Manettiauthor=M.+Bottaauthor=A.+De+Loguauthor=E.+J.+Rubinauthor=E.+De+Rossi&amp;title=MmpL3+is+the+cellular+target+of+the+antitubercular+pyrrole+derivative+BM212&amp;doi=10.1128%2FAAC.05270-11" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212</span></div><div class="casAuthors">La Rosa, Valentina; Poce, Giovanna; Canseco, Julio Ortiz; Buroni, Silvia; Pasca, Maria Rosalia; Biava, Mariangela; Raju, Ravikiran M.; Porretta, Giulio Cesare; Alfonso, Salvatore; Battilocchio, Claudio; Javid, Babak; Sorrentino, Flavia; Ioerger, Thomas R.; Sacchettini, James C.; Manetti, Fabrizio; Botta, Maurizio; De Logu, Alessandro; Rubin, Eric J.; De Rossi, Edda</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">324-331</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The 1,5-diarylpyrrole deriv. BM212 was previously shown to be active against multidrug-resistant clin. isolates and Mycobacterium tuberculosis residing within macrophages as well as against Mycobacterium avium and other atypical mycobacteria.  To det. its mechanism of action, the cellular target was identified.  Spontaneous Mycobacterium smegmatis, Mycobacterium bovis BCG, and M. tuberculosis H37Rv mutants that were resistant to BM212 were isolated.  By the screening of genomic libraries and by whole-genome sequencing, it was found that all the characterized mutants showed mutations in the mmpL3 gene, allowing the conclusion that resistance to BM212 maps to the MmpL3 protein, a member of the MmpL (mycobacterial membrane protein, large) family.  Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonylcyanide m-chlorophenylhydrazone, and verapamil.  Uptake/efflux expts. with [14C]BM212 demonstrated that resistance is not driven by the efflux of BM212.  Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBpqZddgKhTLVg90H21EOLACvtfcHk0lj2XQ-DqFRSkA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Gqtw%253D%253D&amp;md5=f73b43cff2112c31ae27878eeb740d76</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.05270-11&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05270-11%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRosa%26aufirst%3DV.%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DCanseco%26aufirst%3DJ.%2BO.%26aulast%3DBuroni%26aufirst%3DS.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DBiava%26aufirst%3DM.%26aulast%3DRaju%26aufirst%3DR.%2BM.%26aulast%3DPorretta%26aufirst%3DG.%2BC.%26aulast%3DAlfonso%26aufirst%3DS.%26aulast%3DBattilocchio%26aufirst%3DC.%26aulast%3DJavid%26aufirst%3DB.%26aulast%3DSorrentino%26aufirst%3DF.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26aulast%3DDe%2BLogu%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26atitle%3DMmpL3%2520is%2520the%2520cellular%2520target%2520of%2520the%2520antitubercular%2520pyrrole%2520derivative%2520BM212%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D324%26epage%3D331%26doi%3D10.1128%2FAAC.05270-11" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocozza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretta, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Logu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rosa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wae, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span> <span> </span><span class="NLM_article-title">Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e56980</span>, <span class="refDoi">&nbsp;DOI: 10.1371/journal.pone.0056980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1371%2Fjournal.pone.0056980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=23437287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs12ntr0%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2013&amp;pages=e56980&amp;author=G.+Poceauthor=R.+H.+Batesauthor=S.+Alfonsoauthor=M.+Cocozzaauthor=G.+C.+Porrettaauthor=L.+Ballellauthor=J.+Rullasauthor=F.+Ortegaauthor=A.+De+Loguauthor=E.+Agusauthor=V.+La+Rosaauthor=M.+R.+Pascaauthor=E.+De+Rossiauthor=B.+Waeauthor=S.+G.+Franzblauauthor=F.+Manettiauthor=M.+Bottaauthor=M.+Biava&amp;title=Improved+BM212+MmpL3+inhibitor+analogue+shows+efficacy+in+acute+murine+model+of+tuberculosis+infection&amp;doi=10.1371%2Fjournal.pone.0056980" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection</span></div><div class="casAuthors">Poce, Giovanna; Bates, Robert H.; Alfonso, Salvatore; Cocozza, Martina; Porretta, Giulio Cesare; Ballell, Lluis; Rullas, Joaquin; Ortega, Fatima; De Logu, Alessandro; Agus, Emanuela; La Rosa, Valentina; Pasca, Maria Rosalia; De Rossi, Edda; Wae, Baojie; Franzblau, Scott G.; Manetti, Fabrizio; Botta, Maurizio; Biava, Mariangela</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e56980</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">1,5-Di-Ph pyrroles were previously identified as a class of compds. endowed with high in vitro efficacy against M. tuberculosis.  To improve the phys. chem. properties and drug-like parameters of this class of compds., a medicinal chem. effort was undertaken.  By selecting the optimal substitution patterns for the Ph rings at N1 and C5 and by replacing the thiomorpholine moiety with a morpholine one, a new series of compds. was produced.  The replacement of the sulfur with oxygen gave compds. with lower lipophilicity and improved in vitro microsomal stability.  Moreover, since the parent compd. of this family has been shown to target MmpL3, mycobacterial mutants resistant to two compds. have been isolated and characterized by sequencing the mmpL3 gene; all the mutants showed point mutations in this gene.  The best compd. identified to date was progressed to dose-response studies in an acute murine TB infection model.  The resulting ED99 of 49 mg/Kg is within the range of commonly employed tuberculosis drugs, demonstrating the potential of this chem. series.  The in vitro and in vivo target validation evidence presented here adds further wt. to MmpL3 as a druggable target of interest for anti-tubercular drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyyLtc66FRAbVg90H21EOLACvtfcHk0lj2XQ-DqFRSkA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXjs12ntr0%253D&amp;md5=9dd29b729e6bdc9b94409bc1147e28e0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0056980&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0056980%26sid%3Dliteratum%253Aachs%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DBates%26aufirst%3DR.%2BH.%26aulast%3DAlfonso%26aufirst%3DS.%26aulast%3DCocozza%26aufirst%3DM.%26aulast%3DPorretta%26aufirst%3DG.%2BC.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DDe%2BLogu%26aufirst%3DA.%26aulast%3DAgus%26aufirst%3DE.%26aulast%3DLa%2BRosa%26aufirst%3DV.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26aulast%3DWae%26aufirst%3DB.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26aulast%3DBiava%26aufirst%3DM.%26atitle%3DImproved%2520BM212%2520MmpL3%2520inhibitor%2520analogue%2520shows%2520efficacy%2520in%2520acute%2520murine%2520model%2520of%2520tuberculosis%2520infection%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De56980%26doi%3D10.1371%2Fjournal.pone.0056980" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawate, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wivagg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazyanskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquadro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span> <span> </span><span class="NLM_article-title">Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1384</span>, <span class="refDoi">&nbsp;DOI: 10.1021/cb300151m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300151m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvV2guro%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=7&amp;publication_year=2012&amp;pages=1377-1384&amp;author=S.+A.+Stanleyauthor=S.+S.+Grantauthor=T.+Kawateauthor=N.+Iwaseauthor=M.+Shimizuauthor=C.+Wivaggauthor=M.+Silvisauthor=E.+Kazyanskayaauthor=J.+Aquadroauthor=A.+Golasauthor=M.+Fitzgeraldauthor=H.+Daiauthor=L.+Zhangauthor=D.+T.+Hung&amp;title=Identification+of+novel+inhibitors+of+M.+tuberculosis+growth+using+whole+cell+based+high-throughput+screening&amp;doi=10.1021%2Fcb300151m" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening</span></div><div class="casAuthors">Stanley, Sarah A.; Schmidt Grant, Sarah; Kawate, Tomohiko; Iwase, Noriaki; Shimizu, Motohisa; Wivagg, Carl; Silvis, Melanie; Kazyanskaya, Edward; Aquadro, John; Golas, Aaron; Fitzgerald, Michael; Dai, Huanqin; Zhang, Lixin; Hung, Deborah T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1377-1384</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the urgent need for new antitubercular drugs, few are on the horizon.  To combat the problem of emerging drug resistance, structurally unique chem. entities that inhibit new targets will be required.  Here, we describe our investigations using whole cell screening of a diverse collection of small mols. as a methodol. for identifying novel inhibitors that target new pathways for Mycobacterium tuberculosis drug discovery.  We find that conducting primary screens using model mycobacterial species may limit the potential for identifying new inhibitors with efficacy against M. tuberculosis.  In addn., we confirm the importance of developing in vitro assay conditions that are reflective of in vivo biol. for maximizing the proportion of hits from whole cell screening that are likely to have activity in vivo.  Finally, we describe the identification and characterization of two novel inhibitors that target steps in M. tuberculosis cell wall biosynthesis.  The first is a novel benzimidazole, I, that targets mycobacterial membrane protein large 3 (MmpL3), a proposed transporter for cell wall mycolic acids.  The second is a nitro-triazole, II, that inhibits decaprenylphosphoryl-β-d-ribose 2'-epimerase (DprE1), an epimerase required for cell wall biosynthesis.  These proteins are both among the small no. of new targets that have been identified by forward chem. genetics using resistance generation coupled with genome sequencing.  This suggests that methodologies currently employed for screening and target identification may lead to a bias in target discovery and that alternative methods should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPUQqAYK8L3LVg90H21EOLACvtfcHk0lj2XQ-DqFRSkA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XmvV2guro%253D&amp;md5=7293e2cca5001af5bfcf5e1bb4fb1a70</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fcb300151m&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300151m%26sid%3Dliteratum%253Aachs%26aulast%3DStanley%26aufirst%3DS.%2BA.%26aulast%3DGrant%26aufirst%3DS.%2BS.%26aulast%3DKawate%26aufirst%3DT.%26aulast%3DIwase%26aufirst%3DN.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DWivagg%26aufirst%3DC.%26aulast%3DSilvis%26aufirst%3DM.%26aulast%3DKazyanskaya%26aufirst%3DE.%26aulast%3DAquadro%26aufirst%3DJ.%26aulast%3DGolas%26aufirst%3DA.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHung%26aufirst%3DD.%2BT.%26atitle%3DIdentification%2520of%2520novel%2520inhibitors%2520of%2520M.%2520tuberculosis%2520growth%2520using%2520whole%2520cell%2520based%2520high-throughput%2520screening%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1377%26epage%3D1384%26doi%3D10.1021%2Fcb300151m" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remuiñán, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Herrán, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullás, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemparte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Hoyos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Muro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile-Gabaldón, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spivey, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinidou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebollo-López, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza-Losana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammack, N.</span></span> <span> </span><span class="NLM_article-title">Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6’,7’-dihydrospiro[piperidine-4,4’-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e60933</span>, <span class="refDoi">&nbsp;DOI: 10.1371/journal.pone.0060933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1371%2Fjournal.pone.0060933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=23613759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFartro%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2013&amp;pages=e60933&amp;author=M.+J.+Remui%C3%B1%C3%A1nauthor=E.+P%C3%A9rez-Herr%C3%A1nauthor=J.+Rull%C3%A1sauthor=C.+Alemparteauthor=M.+Mart%C3%ADnez-Hoyosauthor=D.+J.+Dowauthor=J.+Afariauthor=N.+Mehtaauthor=J.+Esquiviasauthor=E.+Jim%C3%A9nezauthor=F.+Ortega-Muroauthor=M.+T.+Fraile-Gabald%C3%B3nauthor=V.+L.+Spiveyauthor=N.+J.+Lomanauthor=M.+J.+Pallenauthor=C.+Constantinidouauthor=D.+J.+Minickauthor=M.+Cachoauthor=M.+J.+Rebollo-L%C3%B3pezauthor=C.+Gonz%C3%A1lezauthor=V.+Sousaauthor=I.+Angulo-Barturenauthor=A.+Mendoza-Losanaauthor=D.+Barrosauthor=G.+S.+Besraauthor=L.+Ballellauthor=N.+Cammack&amp;title=Tetrahydropyrazolo%5B1%2C5-a%5Dpyrimidine-3-carboxamide+and+N-benzyl-6%E2%80%99%2C7%E2%80%99-dihydrospiro%5Bpiperidine-4%2C4%E2%80%99-thieno%5B3%2C2-c%5Dpyran%5D+analogues+with+bactericidal+efficacy+against+Mycobacterium+tuberculosis+targeting+MmpL3&amp;doi=10.1371%2Fjournal.pone.0060933" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3</span></div><div class="casAuthors">Remuinan, Modesto J.; Perez-Herran, Esther; Rullas, Joaquin; Alemparte, Carlos; Martinez-Hoyos, Maria; Dow, David J.; Afari, Johnson; Mehta, Nalini; Esquivias, Jorge; Jimenez, Elena; Ortega-Muro, Fatima; Fraile-Gabaldon, Maria Teresa; Spivey, Vickey L.; Loman, Nicholas J.; Pallen, Mark J.; Constantinidou, Chrystala; Minick, Douglas J.; Cacho, Monica; Rebollo-Lopez, Maria Jose; Gonzalez, Carolina; Sousa, Veronica; Angulo-Barturen, Inigo; Mendoza-Losana, Alfonso; Barros, David; Besra, Gurdyal S.; Ballell, Lluis; Cammack, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e60933</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB).  Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug resistant TB.  As part of the authors' efforts towards the discovery of new anti-tubercular leads, a no. of potent tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide (THPP) and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] (Spiro) analogs were recently identified against Mycobacterium tuberculosis and Mycobacterium bovis BCG through a high-throughput whole-cell screening campaign.  Herein, the authors describe the attractive in vitro and in vivo anti-tubercular profiles of both lead series.  The generation of M. tuberculosis spontaneous mutants and subsequent whole genome sequencing of several resistant mutants identified single mutations in the essential mmpL3 gene.  This genetic phenotype was further confirmed by a chem. phenotype, whereby M. bovis BCG treated with both the THPP and Spiro series resulted in the accumulation of trehalose monomycolate.  In vivo efficacy evaluation of two optimized THPP and Spiro leads showed how the compds. were able to reduce &gt;2 logs bacterial cfu counts in the lungs of infected mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCGBbs5TLQArVg90H21EOLACvtfcHk0lhf6XBNVVsJuA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXmvFartro%253D&amp;md5=22123e5b0f762bcd2467bae122c372ca</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060933&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060933%26sid%3Dliteratum%253Aachs%26aulast%3DRemui%25C3%25B1%25C3%25A1n%26aufirst%3DM.%2BJ.%26aulast%3DP%25C3%25A9rez-Herr%25C3%25A1n%26aufirst%3DE.%26aulast%3DRull%25C3%25A1s%26aufirst%3DJ.%26aulast%3DAlemparte%26aufirst%3DC.%26aulast%3DMart%25C3%25ADnez-Hoyos%26aufirst%3DM.%26aulast%3DDow%26aufirst%3DD.%2BJ.%26aulast%3DAfari%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DN.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DE.%26aulast%3DOrtega-Muro%26aufirst%3DF.%26aulast%3DFraile-Gabald%25C3%25B3n%26aufirst%3DM.%2BT.%26aulast%3DSpivey%26aufirst%3DV.%2BL.%26aulast%3DLoman%26aufirst%3DN.%2BJ.%26aulast%3DPallen%26aufirst%3DM.%2BJ.%26aulast%3DConstantinidou%26aufirst%3DC.%26aulast%3DMinick%26aufirst%3DD.%2BJ.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DRebollo-L%25C3%25B3pez%26aufirst%3DM.%2BJ.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DC.%26aulast%3DSousa%26aufirst%3DV.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMendoza-Losana%26aufirst%3DA.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DCammack%26aufirst%3DN.%26atitle%3DTetrahydropyrazolo%255B1%252C5-a%255Dpyrimidine-3-carboxamide%2520and%2520N-benzyl-6%25E2%2580%2599%252C7%25E2%2580%2599-dihydrospiro%255Bpiperidine-4%252C4%25E2%2580%2599-thieno%255B3%252C2-c%255Dpyran%255D%2520analogues%2520with%2520bactericidal%2520efficacy%2520against%2520Mycobacterium%2520tuberculosis%2520targeting%2520MmpL3%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De60933%26doi%3D10.1371%2Fjournal.pone.0060933" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondreddi, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8849</span>– <span class="NLM_lpage">8859</span>, <span class="refDoi">&nbsp;DOI: 10.1021/jm4012774</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012774" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOisLjL" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=56&amp;publication_year=2013&amp;pages=8849-8859&amp;author=R.+R.+Kondreddiauthor=J.+Jiricekauthor=S.+P.+S.+Raoauthor=S.+B.+Lakshminarayanaauthor=L.+R.+Camachoauthor=R.+Raoauthor=M.+Herveauthor=P.+Bifaniauthor=N.+L.+Maauthor=K.+Kuhenauthor=A.+Gohauthor=A.+K.+Chatterjeeauthor=T.+Dickauthor=T.+T.+Diaganaauthor=U.+H.+Manjunathaauthor=P.+W.+Smith&amp;title=Design%2C+synthesis%2C+and+biological+evaluation+of+indole-2-carboxamides%3A+a+promising+class+of+antituberculosis+agents&amp;doi=10.1021%2Fjm4012774" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides: A Promising Class of Antituberculosis Agents</span></div><div class="casAuthors">Kondreddi, Ravinder Reddy; Jiricek, Jan; Rao, Srinivasa P. S.; Lakshminarayana, Suresh B.; Camacho, Luis R.; Rao, Ranga; Herve, Maxime; Bifani, Pablo; Ma, Ngai Ling; Kuhen, Kelli; Goh, Anne; Chatterjee, Arnab K.; Dick, Thomas; Diagana, Thierry T.; Manjunatha, Ujjini H.; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8849-8859</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indole-2-carboxamides have been identified as a promising class of antituberculosis agents from phenotypic screening against mycobacteria.  One of the hits, indole-2-carboxamide analog (I), had low micromolar potency against Mycobacterium tuberculosis (Mtb), high mouse liver microsomal clearance, and low aq. soly.  Structure-activity relationship studies revealed that attaching alkyl groups to the cyclohexyl ring significantly improved Mtb activity but reduced soly.  Furthermore, chloro, fluoro, or cyano substitutions on the 4- and 6-positions of the indole ring as well as Me substitution on the cyclohexyl ring significantly improved metabolic stability.  II and III, the lead candidates, displayed improved in vitro activity compared to most of the current std. TB drugs.  The low aq. soly. could not be mitigated because of the pos. correlation of lipophilicity with Mtb potency.  However, both compds. displayed favorable oral pharmacokinetic properties in rodents and demonstrated in vivo efficacy.  Thus, indole-2-carboxamides represent a promising new class of antituberculosis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4KW8om-6fZ7Vg90H21EOLACvtfcHk0lhf6XBNVVsJuA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOisLjL&amp;md5=ab732bc84632b1f9f364e45610bcbc1b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm4012774&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012774%26sid%3Dliteratum%253Aachs%26aulast%3DKondreddi%26aufirst%3DR.%2BR.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DCamacho%26aufirst%3DL.%2BR.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DHerve%26aufirst%3DM.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DN.%2BL.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520indole-2-carboxamides%253A%2520a%2520promising%2520class%2520of%2520antituberculosis%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8849%26epage%3D8859%26doi%3D10.1021%2Fjm4012774" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onajole, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipparaju, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammerman, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span> <span> </span><span class="NLM_article-title">Indoleamides are active against drug-resistant Mycobacterium tuberculosis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2907</span>, <span class="refDoi">&nbsp;DOI: 10.1038/ncomms3907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fncomms3907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=24352433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A280%3ADC%252BC2c3oslKgtw%253D%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=4&amp;publication_year=2013&amp;pages=2907&amp;author=S.+Lunauthor=H.+Guoauthor=O.+K.+Onajoleauthor=M.+Pieroniauthor=H.+Gunosewoyoauthor=G.+Chenauthor=S.+K.+Tipparajuauthor=N.+C.+Ammermanauthor=A.+P.+Kozikowskiauthor=W.+R.+Bishai&amp;title=Indoleamides+are+active+against+drug-resistant+Mycobacterium+tuberculosis&amp;doi=10.1038%2Fncomms3907" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamides are active against drug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Lun Shichun; Guo Haidan; Onajole Oluseye K; Gunosewoyo Hendra; Chen Gang; Kozikowski Alan P; Pieroni Marco; Tipparaju Suresh K; Ammerman Nicole C; Bishai William R</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2907</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Responsible for nearly two million deaths each year, the infectious disease tuberculosis remains a serious global health challenge.  The emergence of multidrug- and extensively drug-resistant strains of Mycobacterium tuberculosis confounds control efforts, and new drugs with novel molecular targets are desperately needed.  Here we describe lead compounds, the indoleamides, with potent activity against both drug-susceptible and drug-resistant strains of M. tuberculosis by targeting the mycolic acid transporter MmpL3.  We identify a single mutation in mmpL3, which confers high resistance to the indoleamide class while remaining susceptible to currently used first- and second-line tuberculosis drugs, indicating a lack of cross-resistance.  Importantly, an indoleamide derivative exhibits dose-dependent antimycobacterial activity when orally administered to M. tuberculosis-infected mice.  The bioavailability of the indoleamides, combined with their ability to kill tubercle bacilli, indicates great potential for translational developments of this structure class for the treatment of drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4ame_FVdejL7NkxioyDXTfW6udTcc2eZwNavULkZujLntkvexoksv"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A280%3ADC%252BC2c3oslKgtw%253D%253D&amp;md5=29323f5b10dff540b38973491545d1c5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fncomms3907&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms3907%26sid%3Dliteratum%253Aachs%26aulast%3DLun%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DPieroni%26aufirst%3DM.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DTipparaju%26aufirst%3DS.%2BK.%26aulast%3DAmmerman%26aufirst%3DN.%2BC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26atitle%3DIndoleamides%2520are%2520active%2520against%2520drug-resistant%2520Mycobacterium%2520tuberculosis%26jtitle%3DNat.%2520Commun.%26date%3D2013%26volume%3D4%26spage%3D2907%26doi%3D10.1038%2Fncomms3907" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grzegorzewicz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundi, V. A. K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruppo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Born, S. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korduláková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavadi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">341</span>, <span class="refDoi">&nbsp;DOI: 10.1038/nchembio.794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fnchembio.794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=22344175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKktrg%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2012&amp;pages=334-341&amp;author=A.+E.+Grzegorzewiczauthor=H.+Phamauthor=V.+A.+K.+B.+Gundiauthor=M.+S.+Schermanauthor=E.+J.+Northauthor=T.+Hessauthor=V.+Jonesauthor=V.+Gruppoauthor=S.+E.+M.+Bornauthor=J.+Kordul%C3%A1kov%C3%A1author=S.+S.+Chavadiauthor=C.+Morisseauauthor=A.+J.+Lenaertsauthor=R.+E.+Leeauthor=M.+R.+McNeilauthor=M.+Jackson&amp;title=Inhibition+of+mycolic+acid+transport+across+the+Mycobacterium+tuberculosis+plasma+membrane&amp;doi=10.1038%2Fnchembio.794" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane</span></div><div class="casAuthors">Grzegorzewicz, Anna E.; Pham, Ha; Gundi, Vijay A. K. B.; Scherman, Michael S.; North, Elton J.; Hess, Tamara; Jones, Victoria; Gruppo, Veronica; Born, Sarah E. M.; Kordulakova, Jana; Chavadi, Sivagami Sundaram; Morisseau, Christophe; Lenaerts, Anne J.; Lee, Richard E.; McNeil, Michael R.; Jackson, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-341</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New chemotherapeutics active against multidrug-resistant Mycobacterium tuberculosis are urgently needed.  We report on the identification of an adamantyl urea compd. that shows potent bactericidal activity against M. tuberculosis and a unique mode of action, namely the abolition of the translocation of mycolic acids from the cytoplasm, where they are synthesized to the periplasmic side of the plasma membrane and are in turn transferred onto cell wall arabinogalactan or used in the formation of virulence-assocd., outer membrane, trehalose-contg. glycolipids.  Whole-genome sequencing of spontaneous-resistant mutants of M. tuberculosis selected in vitro followed by genetic validation expts. revealed that our prototype inhibitor targets the inner membrane transporter MmpL3.  Conditional gene expression of mmpL3 in mycobacteria and anal. of inhibitor-treated cells validate MmpL3 as essential for mycobacterial growth and support the involvement of this transporter in the translocation of trehalose monomycolate across the plasma membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow3tM24PWRw7Vg90H21EOLACvtfcHk0lgP1pVKK9ITSg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XisVKktrg%253D&amp;md5=0068aca13a9d9f342705035d0cb2c677</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.794&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.794%26sid%3Dliteratum%253Aachs%26aulast%3DGrzegorzewicz%26aufirst%3DA.%2BE.%26aulast%3DPham%26aufirst%3DH.%26aulast%3DGundi%26aufirst%3DV.%2BA.%2BK.%2BB.%26aulast%3DScherman%26aufirst%3DM.%2BS.%26aulast%3DNorth%26aufirst%3DE.%2BJ.%26aulast%3DHess%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DV.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DBorn%26aufirst%3DS.%2BE.%2BM.%26aulast%3DKordul%25C3%25A1kov%25C3%25A1%26aufirst%3DJ.%26aulast%3DChavadi%26aufirst%3DS.%2BS.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DMcNeil%26aufirst%3DM.%2BR.%26aulast%3DJackson%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520mycolic%2520acid%2520transport%2520across%2520the%2520Mycobacterium%2520tuberculosis%2520plasma%2520membrane%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D334%26epage%3D341%26doi%3D10.1038%2Fnchembio.794" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haiderer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramovitch, R. B.</span></span> <span> </span><span class="NLM_article-title">HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e02459</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.02459-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.02459-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=29661875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOlur3M" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=62&amp;publication_year=2018&amp;pages=e02459&amp;author=H.+Zhengauthor=J.+T.+Williamsauthor=G.+B.+Coulsonauthor=E.+R.+Haidererauthor=R.+B.+Abramovitch&amp;title=HC2091+Kills+Mycobacterium+tuberculosis+by+Targeting+the+MmpL3+Mycolic+Acid+Transporter&amp;doi=10.1128%2FAAC.02459-17" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter</span></div><div class="casAuthors">Zheng, Huiqing; Williams, John T.; Coulson, Garry B.; Haiderer, Elizabeth R.; Abramovitch, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e02459-17/1-e02459-17/12</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tuberculosis, caused by the intracellular pathogen Mycobacterium tuberculosis, is a deadly disease that requires a long course of treatment.  The emergence of drug-resistant strains has driven efforts to discover new small mols. that can kill the bacterium.  Here, we report characterizations of the compd. HC2091, which kills M. tuberculosis in a time- and dose-dependent manner in vitro and inhibits M. tuberculosis growth in macrophages.  Whole-genome sequencing of spontaneous HC2091-resistant mutants identified single-nucleotide variants in the mmpL3 mycolic acid transporter gene.  HC2091-resistant mutants do not exhibit cross-resistance with the well-characterized Mycobacterium membrane protein large 3 (MmpL3) inhibitor SQ109, suggesting a distinct mechanism of interaction with MmpL3.  Addnl., HC2091 does not modulate bacterial membrane potential or kill nonreplicating M. tuberculosis, thus acting differently from other known MmpL3 inhibitors.  RNA sequencing (RNA-seq) transcriptional profiling and lipid profiling of M. tuberculosis treated with HC2091 or SQ109 show that the two compds. target a similar pathway.  HC2091 has a chem. structure dissimilar to those of previously described MmpL3 inhibitors, supporting the notion that HC2091 is a new class of MmpL3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiL0V3v68er7Vg90H21EOLACvtfcHk0lgP1pVKK9ITSg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOlur3M&amp;md5=19dd032282c9598fdd65f0d9039ce9ef</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1128%2FAAC.02459-17&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02459-17%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DCoulson%26aufirst%3DG.%2BB.%26aulast%3DHaiderer%26aufirst%3DE.%2BR.%26aulast%3DAbramovitch%26aufirst%3DR.%2BB.%26atitle%3DHC2091%2520Kills%2520Mycobacterium%2520tuberculosis%2520by%2520Targeting%2520the%2520MmpL3%2520Mycolic%2520Acid%2520Transporter%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De02459%26doi%3D10.1128%2FAAC.02459-17" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roquet-Banères, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onajole, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">337</span>, <span class="refDoi">&nbsp;DOI: 10.1021/acsinfecdis.9b00389</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.9b00389" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGhtbfN" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2020&amp;pages=324-337&amp;author=C.+Raynaudauthor=W.+Daherauthor=M.+D.+Johansenauthor=F.+Roquet-Ban%C3%A8resauthor=M.+Blaiseauthor=O.+K.+Onajoleauthor=A.+P.+Kozikowskiauthor=J.-L.+Herrmannauthor=J.+Dziadekauthor=K.+Gobisauthor=L.+Kremer&amp;title=Active+Benzimidazole+Derivatives+Targeting+the+MmpL3+Transporter+in+Mycobacterium+abscessus&amp;doi=10.1021%2Facsinfecdis.9b00389" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus</span></div><div class="casAuthors">Raynaud, Clement; Daher, Wassim; Johansen, Matt D.; Roquet-Baneres, Francoise; Blaise, Mickael; Onajole, Oluseye K.; Kozikowski, Alan P.; Herrmann, Jean-Louis; Dziadek, Jaroslaw; Gobis, Katarzyna; Kremer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-337</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The prevalence of pulmonary infections due to nontuberculous mycobacteria such as Mycobacterium abscessus has been increasing and surpassing tuberculosis (TB) in some industrialized countries.  Because of intrinsic resistance to most antibiotics that drastically limits conventional chemotherapeutic treatment options, new anti-M. abscessus therapeutics are urgently needed against this emerging pathogen.  Extensive screening of a library of benzimidazole derivs. that were previously shown to be active against Mycobacterium tuberculosis led to the identification of a lead compd. exhibiting very potent in vitro activity against a wide panel of M. abscessus clin. strains.  Designated EJMCh-6, this compd., a 2-(2-cyclohexylethyl)-5,6-dimethyl-1H-benzo[d]imidazole, also exerted very strong activity against intramacrophage-residing M. abscessus.  Moreover, the treatment of infected zebrafish embryos with EJMCh-6 was correlated with significantly increased embryo survival and a decrease in the bacterial burden as compared to those for untreated fish.  Insights into the mechanism of action were inferred from the generation of spontaneous benzimidazole-resistant strains and the identification of a large set of missense mutations in MmpL3, the mycolic acid transporter in mycobacteria.  Overexpression of the mutated mmpL3 alleles in a susceptible M. abscessus strain was assocd. with high resistance levels to EJMCh-6 and to other known MmpL3 inhibitors.  Mapping the mutations conferring resistance on an MmpL3 three-dimensional homol. model defined a potential EJMCh-6-binding cavity.  These data emphasize a yet unexploited chem. structure class against M. abscessus with promising translational development for the treatment of M. abscessus lung diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWKP6HQM9btrVg90H21EOLACvtfcHk0lgP1pVKK9ITSg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXisVGhtbfN&amp;md5=3d5af8b3b2dab83f408912d04e666bb5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.9b00389&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.9b00389%26sid%3Dliteratum%253Aachs%26aulast%3DRaynaud%26aufirst%3DC.%26aulast%3DDaher%26aufirst%3DW.%26aulast%3DJohansen%26aufirst%3DM.%2BD.%26aulast%3DRoquet-Ban%25C3%25A8res%26aufirst%3DF.%26aulast%3DBlaise%26aufirst%3DM.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DHerrmann%26aufirst%3DJ.-L.%26aulast%3DDziadek%26aufirst%3DJ.%26aulast%3DGobis%26aufirst%3DK.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DActive%2520Benzimidazole%2520Derivatives%2520Targeting%2520the%2520MmpL3%2520Transporter%2520in%2520Mycobacterium%2520abscessus%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2020%26volume%3D6%26spage%3D324%26epage%3D337%26doi%3D10.1021%2Facsinfecdis.9b00389" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dal
Molin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selchow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschumi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laage-Witt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, P.</span></span> <span> </span><span class="NLM_article-title">Identification of novel scaffolds targeting Mycobacterium tuberculosis</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1601</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi">&nbsp;DOI: 10.1007/s00109-019-01840-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1007%2Fs00109-019-01840-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=31728550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12ks73M" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=97&amp;publication_year=2019&amp;pages=1601-1613&amp;author=M.+Dal%0AMolinauthor=P.+Selchowauthor=D.+Sch%C3%A4fleauthor=A.+Tschumiauthor=T.+Ryckmansauthor=S.+Laage-Wittauthor=P.+Sander&amp;title=Identification+of+novel+scaffolds+targeting+Mycobacterium+tuberculosis&amp;doi=10.1007%2Fs00109-019-01840-7" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel scaffolds targeting Mycobacterium tuberculosis</span></div><div class="casAuthors">Dal Molin, Michael; Selchow, Petra; Schafle, Daniel; Tschumi, Andreas; Ryckmans, Thomas; Laage-Witt, Stephan; Sander, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1601-1613</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Drug resistance in Mycobacterium tuberculosis is relentlessly progressing while only a handful of novel drug candidates are developed.  Here we describe a GFP-based high-throughput screening of 386,496 diverse compds. to identify putative tuberculosis drug candidates.  In an exploratory anal. of the model organism M. bovis BCG and M. smegmatis and the subsequent screening of the main library, we identified 6354 compds. with anti-mycobacterial activity.  These hit compds. were predominantly selective for mycobacteria while dozens had activity in the low μM range.  We tested toxicity against the human monocyte/macrophage cell line THP-1 and elaborated activity against M. tuberculosis growing in liq. broth, under unique conditions such as non-replicating persistence or inhibition of M. tuberculosis residing in macrophages.  Finally, spontaneous compd.-resistant M. tuberculosis mutants were selected and subsequently analyzed by whole genome sequencing.  In addn. to compds. targeting the well-described proteins Pks13 and MmpL3, we identified two novel scaffolds targeting the bifunctional guanosine pentaphosphate synthetase/ polyribonucleotide nucleotidyltransferase GpsI, or interacting with the aminopeptidase PepB, a probable pro-drug activator.  A newly identified scaffold targets the bifunctional enzyme GpsI.  The aminopeptidase PepB is interacting with a second novel scaffold.  Phenotypic screenings regularly identify novel compds. targeting Pks13 and MmpL3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpka14rxYjQgLVg90H21EOLACvtfcHk0lhM9nLS6hWveg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXit12ks73M&amp;md5=91c786e6a7ea154583dc4943146b156b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00109-019-01840-7&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-019-01840-7%26sid%3Dliteratum%253Aachs%26aulast%3DDal%2BMolin%26aufirst%3DM.%26aulast%3DSelchow%26aufirst%3DP.%26aulast%3DSch%25C3%25A4fle%26aufirst%3DD.%26aulast%3DTschumi%26aufirst%3DA.%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DLaage-Witt%26aufirst%3DS.%26aulast%3DSander%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520scaffolds%2520targeting%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2019%26volume%3D97%26spage%3D1601%26epage%3D1613%26doi%3D10.1007%2Fs00109-019-01840-7" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consalvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venditti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desideri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Menendez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros Aguirre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Logu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span> <span> </span><span class="NLM_article-title">Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi">&nbsp;DOI: 10.1021/acsmedchemlett.9b00204</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00204" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rM" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=10&amp;publication_year=2019&amp;pages=1423-1429&amp;author=G.+Poceauthor=S.+Consalviauthor=G.+Vendittiauthor=S.+Alfonsoauthor=N.+Desideriauthor=R.+Fernandez-Menendezauthor=R.+H.+Batesauthor=L.+Ballellauthor=D.+Barros+Aguirreauthor=J.+Rullasauthor=A.+De+Loguauthor=M.+Gardnerauthor=T.+R.+Ioergerauthor=E.+J.+Rubinauthor=M.+Biava&amp;title=Novel+Pyrazole-Containing+Compounds+Active+against+Mycobacterium+tuberculosis&amp;doi=10.1021%2Facsmedchemlett.9b00204" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis</span></div><div class="casAuthors">Poce, Giovanna; Consalvi, Sara; Venditti, Giulia; Alfonso, Salvatore; Desideri, Nicoletta; Fernandez-Menendez, Raquel; Bates, Robert H.; Ballell, Lluis; Barros Aguirre, David; Rullas, Joaquin; De Logu, Alessandro; Gardner, Michelle; Ioerger, Thomas R.; Rubin, Eric J.; Biava, Mariangela</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1423-1429</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 49 five-membered heterocyclic compds. contg. either a pyridine- or a pyrrole-type nitrogen were synthesized and tested against Mycobacterium tuberculosis.  Among them, only the 1,3,5-trisubstituted pyrazoles exhibited min. inhibitory concn. values in the low micromolar range, and some also exhibited an improved physicochem. profile without cytotoxic effects.  Three pyrazoles were subjected to an animal tuberculosis efficacy model, and 1-((1-(4-Fluorophenyl)-5-(4-isopropylphenyl)-1H-pyrazol-3-yl)methyl)-4-methoxypiperidine induced a statistically significant difference in lung bacterial counts compared with untreated mice.  Moreover, to det. the target of this series, resistors were generated, and whole genome sequencing revealed mutations in the mmpL3 gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQbGTdOFbohLVg90H21EOLACvtfcHk0lhM9nLS6hWveg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rM&amp;md5=cd921aadaba2214fae338c358cea363b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00204&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00204%26sid%3Dliteratum%253Aachs%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DConsalvi%26aufirst%3DS.%26aulast%3DVenditti%26aufirst%3DG.%26aulast%3DAlfonso%26aufirst%3DS.%26aulast%3DDesideri%26aufirst%3DN.%26aulast%3DFernandez-Menendez%26aufirst%3DR.%26aulast%3DBates%26aufirst%3DR.%2BH.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBarros%2BAguirre%26aufirst%3DD.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DDe%2BLogu%26aufirst%3DA.%26aulast%3DGardner%26aufirst%3DM.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26aulast%3DBiava%26aufirst%3DM.%26atitle%3DNovel%2520Pyrazole-Containing%2520Compounds%2520Active%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1423%26epage%3D1429%26doi%3D10.1021%2Facsmedchemlett.9b00204" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roquet-Banères, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guérardel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">17512</span>– <span class="NLM_lpage">17523</span>, <span class="refDoi">&nbsp;DOI: 10.1074/jbc.RA119.010135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1074%2Fjbc.RA119.010135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=31562241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKlurfN" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=294&amp;publication_year=2019&amp;pages=17512-17523&amp;author=C.+Dupontauthor=Y.+Chenauthor=Z.+Xuauthor=F.+Roquet-Ban%C3%A8resauthor=M.+Blaiseauthor=A.-K.+Wittauthor=F.+Dubarauthor=C.+Biotauthor=Y.+Gu%C3%A9rardelauthor=F.+P.+Maurerauthor=S.-S.+Chngauthor=L.+Kremer&amp;title=A+piperidinol-containing+molecule+is+active+against+Mycobacterium+tuberculosis+by+inhibiting+the+mycolic+acid+flippase+activity+of+MmpL3&amp;doi=10.1074%2Fjbc.RA119.010135" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3</span></div><div class="casAuthors">Dupont, Christian; Chen, Yushu; Xu, Zhujun; Roquet-Baneres, Francoise; Blaise, Mickael; Witt, Anne-Kathrin; Dubar, Faustine; Biot, Christophe; Guerardel, Yann; Maurer, Florian P.; Chng, Shu-Sin; Kremer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">17512-17524</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, the causative agent of tuberculosis, remains a major human pathogen, and current treatment options to combat this disease are under threat because of the emergence of multidrug-resistant and extensively drug-resistant tuberculosis.  High-throughput whole-cell screening of an extensive compd. library has recently identified a piperidinol-contg. mol., PIPD1, as a potent lead compd. against M. tuberculosis.  Herein, we show that PIPD1 and related analogs exert in vitro bactericidal activity against the M. tuberculosis strain mc26230 and also against a panel of multidrug-resistant and extensively drug-resistant clin. isolates of M. tuberculosis, suggesting that PIPD1's mode of action differs from those of most first- and second-line anti-tubercular drugs.  Selection and DNA sequencing of PIPD1-resistant mycobacterial mutants revealed the presence of single-nucleotide polymorphisms in mmpL3, encoding an inner membrane-assocd. mycolic acid flippase in M. tuberculosis.  Results from functional assays with spheroplasts derived from a M. smegmatis strain lacking the endogenous mmpL3 gene but harboring the M. tuberculosis mmpL3 homolog indicated that PIPD1 inhibits the MmpL3-driven translocation of trehalose monomycolate across the inner membrane without altering the proton motive force.  Using a predictive structural model of MmpL3 from M. tuberculosis, docking studies revealed a PIPD1-binding cavity recently found to accommodate different inhibitors in M. smegmatis MmpL3.  In conclusion, our findings have uncovered bactericidal activity of a new chem. scaffold.  Its anti-tubercular activity is mediated by direct inhibition of the flippase activity of MmpL3 rather than by inhibition of the inner membrane proton motive force, significantly advancing our understanding of MmpL3-targeted inhibition in mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcjxDOj6T9KbVg90H21EOLACvtfcHk0lhM9nLS6hWveg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXitlKlurfN&amp;md5=3a099709e2505c05a6397742cfa9360d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.010135&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.010135%26sid%3Dliteratum%253Aachs%26aulast%3DDupont%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DRoquet-Ban%25C3%25A8res%26aufirst%3DF.%26aulast%3DBlaise%26aufirst%3DM.%26aulast%3DWitt%26aufirst%3DA.-K.%26aulast%3DDubar%26aufirst%3DF.%26aulast%3DBiot%26aufirst%3DC.%26aulast%3DGu%25C3%25A9rardel%26aufirst%3DY.%26aulast%3DMaurer%26aufirst%3DF.%2BP.%26aulast%3DChng%26aufirst%3DS.-S.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DA%2520piperidinol-containing%2520molecule%2520is%2520active%2520against%2520Mycobacterium%2520tuberculosis%2520by%2520inhibiting%2520the%2520mycolic%2520acid%2520flippase%2520activity%2520of%2520MmpL3%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D17512%26epage%3D17523%26doi%3D10.1074%2Fjbc.RA119.010135" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haiderer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Cabrera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramovitch, R. B.</span></span> <span> </span><span class="NLM_article-title">Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e00547</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.00547-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.00547-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=31405862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1eisbvE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=63&amp;publication_year=2019&amp;pages=e00547&amp;author=J.+T.+Williamsauthor=E.+R.+Haidererauthor=G.+B.+Coulsonauthor=K.+N.+Connerauthor=E.+Ellsworthauthor=C.+Chenauthor=N.+Alvarez-Cabreraauthor=W.+Liauthor=M.+Jacksonauthor=T.+Dickauthor=R.+B.+Abramovitch&amp;title=Identification+of+New+MmpL3+Inhibitors+by+Untargeted+and+Targeted+Mutant+Screens+Defines+MmpL3+Domains+with+Differential+Resistance&amp;doi=10.1128%2FAAC.00547-19" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new MmpL3 inhibitors by untargeted and targeted mutant screens defines MmpL3 domains with differential resistance</span></div><div class="casAuthors">Williams, John T.; Haiderer, Elizabeth R.; Coulson, Garry B.; Conner, Kayla N.; Ellsworth, Edmund; Chen, Chao; Alvarez-Cabrera, Nadine; Li, Wei; Jackson, Mary; Dick, Thomas; Abramovitch, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e00547-19</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Mycobacterium tuberculosis mycolate flippase MmpL3 has been the proposed target for multiple inhibitors with diverse chem. scaffolds.  This diversity in chem. scaffolds has made it difficult to predict compds. that inhibit MmpL3 without whole-genome sequencing of isolated resistant mutants.  Here, we describe the identification of four new inhibitors that select for resistance mutations in mmpL3.  Using these resistant mutants, we conducted a targeted whole-cell phenotypic screen of 163 novel M. tuberculosis growth inhibitors for differential growth inhibition of wild-type M. tuberculosis compared to the growth of a pool of 24 unique mmpL3 mutants.  The screen successfully identified six addnl. putative MmpL3 inhibitors.  The compds. were bactericidal both in vitro and against intracellular M. tuberculosis.  M. tuberculosis cells treated with these compds. were shown to accumulate trehalose monomycolates, have reduced levels of trehalose dimycolate, and displace an MmpL3-specific probe, supporting MmpL3 as the target.  The inhibitors were mycobacterium specific, with several also showing activity against the nontuberculous mycobacterial species M. abscessus.  Cluster anal. of cross-resistance profiles generated by dose-response expts. for each combination of 13 MmpL3 inhibitors against each of the 24 mmpL3 mutants defined two clades of inhibitors and two clades of mmpL3 mutants.  Pairwise combination studies of the inhibitors revealed interactions that were specific to the clades identified in the cross-resistance profiling.  Addnl., modeling of resistance-conferring substitutions to the MmpL3 crystal structure revealed clade-specific localization of the residues to specific domains of MmpL3, with the clades showing differential resistance.  Several compds. exhibited high soly. and stability in microsomes and low cytotoxicity in macrophages, supporting their further development.  The combined study of multiple mutants and novel compds. provides new insights into structure-function interactions of MmpL3 and small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVVOs0AmlkSrVg90H21EOLACvtfcHk0ljPpC0qajEhBw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXit1eisbvE&amp;md5=d8ff582f4e360ed404e7d9e49c5838fe</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1128%2FAAC.00547-19&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00547-19%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DHaiderer%26aufirst%3DE.%2BR.%26aulast%3DCoulson%26aufirst%3DG.%2BB.%26aulast%3DConner%26aufirst%3DK.%2BN.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DAlvarez-Cabrera%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DAbramovitch%26aufirst%3DR.%2BB.%26atitle%3DIdentification%2520of%2520New%2520MmpL3%2520Inhibitors%2520by%2520Untargeted%2520and%2520Targeted%2520Mutant%2520Screens%2520Defines%2520MmpL3%2520Domains%2520with%2520Differential%2520Resistance%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De00547%26doi%3D10.1128%2FAAC.00547-19" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korycka-Machala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viljoen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawelczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzostek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strapagiel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadek, J.</span></span> <span> </span><span class="NLM_article-title">1H-Benzo[d]Imidazole Derivatives Affect MmpL3 in Mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e00441</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.00441-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.00441-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=31332069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1eisbvO" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=63&amp;publication_year=2019&amp;pages=e00441&amp;author=M.+Korycka-Machalaauthor=A.+Viljoenauthor=J.+Pawelczykauthor=P.+Borowkaauthor=B.+Dziadekauthor=K.+Gobisauthor=A.+Brzostekauthor=M.+Kawkaauthor=M.+Blaiseauthor=D.+Strapagielauthor=L.+Kremerauthor=J.+Dziadek&amp;title=1H-Benzo%5Bd%5DImidazole+Derivatives+Affect+MmpL3+in+Mycobacterium+tuberculosis&amp;doi=10.1128%2FAAC.00441-19" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">1H-Benzo[d]imidazole derivatives affect mmpL3 in Mycobacterium tuberculosis</span></div><div class="casAuthors">Korycka-Machala, Malgorzata; Viljoen, Albertus; Pawelczyk, Jakub; Borowka, Paulina; Dziadek, Bozena; Gobis, Katarzyna; Brzostek, Anna; Kawka, Malwina; Blaise, Mickael; Strapagiel, Dominik; Kremer, Laurent; Dziadek, Jaroslaw</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e00441-19</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">1H-benzo[d]imidazole derivs. exhibit antitubercular activity in vitro at a nanomolar range of concns. and are not toxic to human cells, but their mode of action remains unknown.  Here, we showed that these compds. are active against intracellular Mycobacterium tuberculosis.  To identify their target, we selected drug-resistant M. tuberculosis mutants and then used whole-genome sequencing to unravel mutations in the essential mmpL3 gene, which encodes the integral membrane protein that catalyzes the export of trehalose monomycolate, a precursor of the mycobacterial outer membrane component trehalose dimycolate (TDM), as well as mycolic acids bound to arabinogalactan.  The drug-resistant phenotype was also obsd. in the parental strain overexpressing the mmpL3 alleles carrying the mutations identified in the resistors.  However, no cross-resistance was obsd. between 1H-benzo[d]imidazole derivs. and SQ109, another MmpL3 inhibitor, or other first-line antitubercular drugs.  Metabolic labeling and quant. thin-layer chromatog. (TLC) anal. of radiolabeled lipids from M. tuberculosis cultures treated with the benzoimidazoles indicated an inhibition of trehalose dimycolate (TDM) synthesis, as well as reduced levels of mycolylated arabinogalactan, in agreement with the inhibition of MmpL3 activity.  Overall, this study emphasizes the pronounced activity of 1H-benzo[d]imidazole derivs. in interfering with mycolic acid metab. and their potential for therapeutic application in the fight against tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7u07oTQeSoLVg90H21EOLACvtfcHk0ljPpC0qajEhBw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXit1eisbvO&amp;md5=3c668ccbe1706f02f280dd6fb52e1275</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.00441-19&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00441-19%26sid%3Dliteratum%253Aachs%26aulast%3DKorycka-Machala%26aufirst%3DM.%26aulast%3DViljoen%26aufirst%3DA.%26aulast%3DPawelczyk%26aufirst%3DJ.%26aulast%3DBorowka%26aufirst%3DP.%26aulast%3DDziadek%26aufirst%3DB.%26aulast%3DGobis%26aufirst%3DK.%26aulast%3DBrzostek%26aufirst%3DA.%26aulast%3DKawka%26aufirst%3DM.%26aulast%3DBlaise%26aufirst%3DM.%26aulast%3DStrapagiel%26aufirst%3DD.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DDziadek%26aufirst%3DJ.%26atitle%3D1H-Benzo%255Bd%255DImidazole%2520Derivatives%2520Affect%2520MmpL3%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De00441%26doi%3D10.1128%2FAAC.00441-19" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiget, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Guerra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nxumalo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanye, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Herrán, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile-Gabaldón, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encinas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Siles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osende, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiola, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remuiñán, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemparte, C.</span></span> <span> </span><span class="NLM_article-title">Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11327</span>– <span class="NLM_lpage">11340</span>, <span class="refDoi">&nbsp;DOI: 10.1021/acs.jmedchem.8b01533</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1OqsLjJ" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=61&amp;publication_year=2018&amp;pages=11327-11340&amp;author=A.+Guardiaauthor=J.+Baigetauthor=M.+Cachoauthor=A.+P%C3%A9rezauthor=M.+Ortega-Guerraauthor=W.+Nxumaloauthor=S.+D.+Khanyeauthor=J.+Rullasauthor=F.+Ortegaauthor=E.+Jim%C3%A9nezauthor=E.+P%C3%A9rez-Herr%C3%A1nauthor=M.+T.+Fraile-Gabald%C3%B3nauthor=J.+Esquiviasauthor=R.+Fernandezauthor=E.+Fern%C3%A1ndezauthor=L.+Encinasauthor=M.+Alonsoauthor=I.+Giordanoauthor=C.+Riveroauthor=J.+Miguel-Silesauthor=J.+G.+Osendeauthor=K.+A.+Badiolaauthor=P.+J.+Rutledgeauthor=M.+H.+Toddauthor=M.+Remui%C3%B1%C3%A1nauthor=C.+Alemparte&amp;title=Easy-To-Synthesize+Spirocyclic+Compounds+Possess+Remarkable+in+Vivo+Activity+against+Mycobacterium+tuberculosis&amp;doi=10.1021%2Facs.jmedchem.8b01533" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis</span></div><div class="casAuthors">Guardia, Ana; Baiget, Jessica; Cacho, Monica; Perez, Arancha; Ortega-Guerra, Montserrat; Nxumalo, Winston; Khanye, Setshaba D.; Rullas, Joaquin; Ortega, Fatima; Jimenez, Elena; Perez-Herran, Esther; Fraile-Gabaldon, Maria Teresa; Esquivias, Jorge; Fernandez, Raquel; Porras-De Francisco, Esther; Encinas, Lourdes; Alonso, Marta; Giordano, Ilaria; Rivero, Cristina; Miguel-Siles, Juan; Osende, Javier G.; Badiola, Katrina A.; Rutledge, Peter J.; Todd, Matthew H.; Remuinan, Modesto; Alemparte, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11327-11340</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Society urgently needs new, effective medicines for the treatment of tuberculosis.  To kick-start the required hit-to-lead campaigns, the libraries of pharmaceutical companies have recently been evaluated for starting points.  The GlaxoSmithKline (GSK) library yielded many high-quality hits, and the assocd. data were placed in the public domain to stimulate engagement by the wider community.  One such series, the spiro compds., are described here.  The compds. were explored by a combination of traditional inhouse research and open source methods.  The series benefits from a particularly simple structure and a short assocd. synthetic chem. route.  Many members of the series displayed striking potency and low toxicity, and highly promising in vivo activity in a mouse model was confirmed with one of the analogs.  Ultimately the series was discontinued due to concerns over safety, but the assocd. data remain public domain, empowering others to resume the series if the perceived deficiencies can be overcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmizcPsa-ok7Vg90H21EOLACvtfcHk0ljPpC0qajEhBw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1cXit1OqsLjJ&amp;md5=ca3395ecd8dc725c5162f0965eee84db</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01533&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01533%26sid%3Dliteratum%253Aachs%26aulast%3DGuardia%26aufirst%3DA.%26aulast%3DBaiget%26aufirst%3DJ.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez%26aufirst%3DA.%26aulast%3DOrtega-Guerra%26aufirst%3DM.%26aulast%3DNxumalo%26aufirst%3DW.%26aulast%3DKhanye%26aufirst%3DS.%2BD.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DE.%26aulast%3DP%25C3%25A9rez-Herr%25C3%25A1n%26aufirst%3DE.%26aulast%3DFraile-Gabald%25C3%25B3n%26aufirst%3DM.%2BT.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DE.%26aulast%3DEncinas%26aufirst%3DL.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DI.%26aulast%3DRivero%26aufirst%3DC.%26aulast%3DMiguel-Siles%26aufirst%3DJ.%26aulast%3DOsende%26aufirst%3DJ.%2BG.%26aulast%3DBadiola%26aufirst%3DK.%2BA.%26aulast%3DRutledge%26aufirst%3DP.%2BJ.%26aulast%3DTodd%26aufirst%3DM.%2BH.%26aulast%3DRemui%25C3%25B1%25C3%25A1n%26aufirst%3DM.%26aulast%3DAlemparte%26aufirst%3DC.%26atitle%3DEasy-To-Synthesize%2520Spirocyclic%2520Compounds%2520Possess%2520Remarkable%2520in%2520Vivo%2520Activity%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11327%26epage%3D11340%26doi%3D10.1021%2Facs.jmedchem.8b01533" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">655</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.drudis.2010.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.drudis.2010.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=20570751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=15&amp;publication_year=2010&amp;pages=648-655&amp;author=A.+P.+Hillauthor=R.+J.+Young&amp;title=Getting+physical+in+drug+discovery%3A+a+contemporary+perspective+on+solubility+and+hydrophobicity&amp;doi=10.1016%2Fj.drudis.2010.05.016" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span></div><div class="casAuthors">Hill, Alan P.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15/16</span>),
    <span class="NLM_cas:pages">648-655</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Suboptimal phys. properties have been identified as a particular shortcoming of compds. in contemporary drug discovery, contributing to high attrition levels.  An anal. of the relationship between hydrophobicity (calcd. and measured) and ∼100 k measured kinetic soly. values has been undertaken.  In line with the General Soly. Equation, ests. of hydrophobicity, particularly ACD c log D pH7.4, give a useful indication of the likely soly. classification of particular mols.  Taking ACD c log D pH7.4 values together with the no. of arom. rings in a given mol. provides enhanced prediction.  The Soly. Forecast Index' (SFI = c log D pH7.4 + #Ar) is proposed as a simple, yet effective, guide to predicting soly.  Moreover, anal. of measured distribution/partition coeff. values highlighted statistically significant shortcomings in the applicability of octanol/water as a model system for hydrophobicity detn. with poorly sol. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtQyfNjbFUrVg90H21EOLACvtfcHk0liEre0Nuh_S4w"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P&amp;md5=7b201081c5586a6ea4b7af00d507d462</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.05.016&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%253A%2520a%2520contemporary%2520perspective%2520on%2520solubility%2520and%2520hydrophobicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D648%26epage%3D655%26doi%3D10.1016%2Fj.drudis.2010.05.016" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palovich, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. J.</span></span> <span> </span><span class="NLM_article-title">Quality guidelines for oral drug candidates: dose, solubility and lipophilicity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.drudis.2016.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.drudis.2016.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=27423371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aisb%252FK" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=21&amp;publication_year=2016&amp;pages=1719-1727&amp;author=M.+K.+Baylissauthor=J.+Butlerauthor=P.+L.+Feldmanauthor=D.+V.+S.+Greenauthor=P.+D.+Leesonauthor=M.+R.+Palovichauthor=A.+J.+Taylor&amp;title=Quality+guidelines+for+oral+drug+candidates%3A+dose%2C+solubility+and+lipophilicity&amp;doi=10.1016%2Fj.drudis.2016.07.007" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Quality guidelines for oral drug candidates: dose, solubility and lipophilicity</span></div><div class="casAuthors">Bayliss, Martin K.; Butler, James; Feldman, Paul L.; Green, Darren V. S.; Leeson, Paul D.; Palovich, Michael R.; Taylor, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1719-1727</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In an attempt to seek increased understanding of compd. attributes that influence successful drug pipeline progression, GlaxoSmithKline's portfolio of oral candidates was compared with ref. sets of marketed oral drugs.  The approach differs from other attrition studies by explicitly focusing on choosing 'the right compd.' by applying relevant, exptl. derived properties.  The anal. led to four proposed compd. quality categories, created by combining specific criteria for three measures: dose, soly. and the property forecast index, a composite measure of lipophilicity using chromatog. detd. Log D and aromaticity.  The 'three properties' provide benchmarked guidelines for project teams to use when seeking and selecting clin. candidates, because they reflect the property distribution of marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRMpjV3EZ_4rVg90H21EOLACvtfcHk0liEre0Nuh_S4w"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC28Xht1aisb%252FK&amp;md5=d9d145b1ee399b6ad54cdc55fff43c48</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.07.007&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DBayliss%26aufirst%3DM.%2BK.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DFeldman%26aufirst%3DP.%2BL.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DTaylor%26aufirst%3DA.%2BJ.%26atitle%3DQuality%2520guidelines%2520for%2520oral%2520drug%2520candidates%253A%2520dose%252C%2520solubility%2520and%2520lipophilicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1719%26epage%3D1727%26doi%3D10.1016%2Fj.drudis.2016.07.007" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi">&nbsp;DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2007&amp;pages=881-890&amp;author=P.+D.+Leesonauthor=B.+Springthorpe&amp;title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&amp;doi=10.1038%2Fnrd2445" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0liEre0Nuh_S4w"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&amp;md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Molecular Property Design: Does Everyone Get It?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">725</span>, <span class="refDoi">&nbsp;DOI: 10.1021/acsmedchemlett.5b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2015&amp;pages=722-725&amp;author=P.+D.+Leesonauthor=R.+J.+Young&amp;title=Molecular+Property+Design%3A+Does+Everyone+Get+It%3F&amp;doi=10.1021%2Facsmedchemlett.5b00157" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Property Design: Does Everyone Get It?</span></div><div class="casAuthors">Leeson, Paul D.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-725</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The principles of mol. property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space.  Lead optimization trajectories aimed at reducing physicochem. risk, assisted by ligand efficiency metrics, could help to reduce clin. attrition rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_t8gIn79arVg90H21EOLACvtfcHk0liEre0Nuh_S4w"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D&amp;md5=5a807a8d049ce8cf4adc186891a9234d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00157&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00157%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520Property%2520Design%253A%2520Does%2520Everyone%2520Get%2520It%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D722%26epage%3D725%26doi%3D10.1021%2Facsmedchemlett.5b00157" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=16&amp;publication_year=2011&amp;pages=822-830&amp;author=R.+J.+Youngauthor=D.+V.+S.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&amp;title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity&amp;doi=10.1016%2Fj.drudis.2011.06.001" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0lhXGB_QzMDGHA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&amp;md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirschl, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harikrishnan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seethala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael Lawrence, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, M. E.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6503</span>– <span class="NLM_lpage">6508</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.bmcl.2012.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.bmcl.2012.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=22995620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlymtLbF" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=22&amp;publication_year=2012&amp;pages=6503-6508&amp;author=M.+M.+Millerauthor=Y.+Liuauthor=J.+Jiangauthor=J.+A.+Johnsonauthor=M.+Kamauauthor=D.+S.+Nirschlauthor=Y.+Wangauthor=L.+Harikrishnanauthor=D.+S.+Taylorauthor=A.+Y.+A.+Chenauthor=X.+Yinauthor=R.+Seethalaauthor=T.+L.+Petersonauthor=T.+Zvyagaauthor=J.+Zhangauthor=C.+S.+Huangauthor=R.+R.+Wexlerauthor=M.+A.+Possauthor=R.+Michael+Lawrenceauthor=L.+P.+Adamauthor=M.+E.+Salvati&amp;title=Identification+of+a+potent+and+metabolically+stable+series+of+fluorinated+diphenylpyridylethanamine-based+cholesteryl+ester+transfer+protein+inhibitors&amp;doi=10.1016%2Fj.bmcl.2012.08.011" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors</span></div><div class="casAuthors">Miller, Michael M.; Liu, Yalei; Jiang, Ji; Johnson, James A.; Kamau, Muthoni; Nirschl, David S.; Wang, Yufeng; Harikrishnan, Lalgudi; Taylor, David S.; Chen, Alice Ye A.; Yin, Xiaohong; Seethala, Ramakrishna; Peterson, Tara L.; Zvyaga, Tatyana; Zhang, Jun; Huang, Christine S.; Wexler, Ruth R.; Poss, Michael A.; Michael Lawrence, R.; Adam, Leonard P.; Salvati, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic &amp; Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6503-6508</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of diphenylpyridylethanamine-based inhibitors of cholesteryl ester transfer protein, e.g. I, is described.  Optimization of the urea moiety, particularly by incorporation of fluorine, is explored to balance in vitro metabolic stability with CETP potency in the whole plasma assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLpqF9RExgLVg90H21EOLACvtfcHk0lhXGB_QzMDGHA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XhtlymtLbF&amp;md5=6473c4b4e6dbac03d5532e57932aa04c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.011&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DKamau%26aufirst%3DM.%26aulast%3DNirschl%26aufirst%3DD.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHarikrishnan%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DA.%2BY.%2BA.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSeethala%26aufirst%3DR.%26aulast%3DPeterson%26aufirst%3DT.%2BL.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DMichael%2BLawrence%26aufirst%3DR.%26aulast%3DAdam%26aufirst%3DL.%2BP.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26atitle%3DIdentification%2520of%2520a%2520potent%2520and%2520metabolically%2520stable%2520series%2520of%2520fluorinated%2520diphenylpyridylethanamine-based%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6503%26epage%3D6508%26doi%3D10.1016%2Fj.bmcl.2012.08.011" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masimirembwa, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">199</span>, <span class="refDoi">&nbsp;DOI: 10.1124/dmd.109.028670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1124%2Fdmd.109.028670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=19797609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aqsr%252FE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=38&amp;publication_year=2010&amp;pages=187-199&amp;author=B.+Bonnauthor=C.+M.+Masimirembwaauthor=N.+Castagnoli&amp;title=Exploration+of+catalytic+properties+of+CYP2D6+and+CYP3A4+through+metabolic+studies+of+levorphanol+and+levallorphan&amp;doi=10.1124%2Fdmd.109.028670" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan</span></div><div class="casAuthors">Bonn, Britta; Masimirembwa, Collen M.; Castagnoli, Neal, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-199</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CYP2D6 and CYP3A4, two members of the cytochrome P 450 superfamily of monooxygenases, mediate the biotransformation of a variety of xenobiotics.  The two enzymes differ in substrate specificity and size and characteristics of the active site cavity.  The aim of this study was to det. whether the catalytic properties of these isoforms, reflected by the differences obsd. from crystal structures and homol. models, could be confirmed with exptl. data.  Detailed metabolite identification, reversible inhibition, and time-dependent inhibition were examd. for levorphanol and levallorphan with CYP2D6 and CYP3A4.  The studies were designed to provide a comparison of the orientations of substrates, the catalytic sites of the two enzymes, and the subsequent outcomes on metab. and inhibition.  The metabolite identification revealed that CYP3A4 catalyzed the formation of a variety of metabolites as a result of presenting different parts of the substrates to the heme.  CYP2D6 was a poorer catalyst that led to a more limited no. of metabolites that were interpreted in terms to two orientations of the substrates.  The inhibition studies showed evidence for strong reversible inhibition of CYP2D6 but not for CYP3A4.  Levallorphan acted as a time-dependent inhibitor on CYP3A4, indicating a productive binding mode with this enzyme not obsd. with CYP2D6 that presumably resulted from close interactions of the N-allyl moiety oriented toward the heme.  All the results are in agreement with the large and flexible active site of CYP3A4 and the more restricted active site of CYP2D6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGHPt2fpx8g7Vg90H21EOLACvtfcHk0lhXGB_QzMDGHA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aqsr%252FE&amp;md5=cfe782b062b1bbac3c4e1f3c2d6a9618</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028670&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028670%26sid%3Dliteratum%253Aachs%26aulast%3DBonn%26aufirst%3DB.%26aulast%3DMasimirembwa%26aufirst%3DC.%2BM.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DExploration%2520of%2520catalytic%2520properties%2520of%2520CYP2D6%2520and%2520CYP3A4%2520through%2520metabolic%2520studies%2520of%2520levorphanol%2520and%2520levallorphan%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D187%26epage%3D199%26doi%3D10.1124%2Fdmd.109.028670" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi">&nbsp;DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=49&amp;publication_year=2006&amp;pages=5029-5046&amp;author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&amp;title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups&amp;doi=10.1021%2Fjm060379l" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lgamKl2dnTsAA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&amp;md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badiola, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triccas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. H.</span></span> <span> </span><span class="NLM_article-title">Efficient Synthesis and Anti-Tubercular Activity of a Series of Spirocycles: An Exercise in Open Science</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e111782</span>, <span class="refDoi">&nbsp;DOI: 10.1371/journal.pone.0111782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1371%2Fjournal.pone.0111782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25493550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFyjs7nE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=9&amp;publication_year=2014&amp;pages=e111782&amp;author=K.+A.+Badiolaauthor=D.+H.+Quanauthor=J.+A.+Triccasauthor=M.+H.+Todd&amp;title=Efficient+Synthesis+and+Anti-Tubercular+Activity+of+a+Series+of+Spirocycles%3A+An+Exercise+in+Open+Science&amp;doi=10.1371%2Fjournal.pone.0111782" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient synthesis and anti-tubercular activity of a series of spirocycles: an exercise in open science</span></div><div class="casAuthors">Badiola, Katrina A.; Quan, Diana H.; Triccas, James A.; Todd, Matthew H.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e111782/1-e111782/20, 20 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">An efficient synthesis of a series of spirocyclic pyrans I [R = benzodioxan-6-yl, benzodioxol-5-yl, 4-hydroxy-3-methoxyphenyl, etc.] and II [R1 = C6H5, 4-BrC6H4, 2-BrC6H4] via oxa-Pictet-Spengler reaction is developed.  The oxa-Pictet-Spengler reaction of 4-benzylpiperidone and 2-thiopheneethanol gives N-benzylated intermediate III, which on further debenzylation produces secondary amine IV.  Secondary amine IV upon reductive amination with aldehydes/ketones yielded spirocyclic pyrans I and upon acylation with acyl chlorides yielded spirocyclic pyrans II in moderate to good yields.  The synthesized spirocyclic pyrans I and II were tested against the virulent M. tuberculosis strain (H37Rv), of which compds. I [R = benzodioxan-6-yl, benzodioxol-5-yl, 4-chlorophenyl, 1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl] and III showd excellent anti-tubercular activity.  The toxicity of spirocyclic pyrans I displaying anti-H37Rv activity was assessed using the human monocytic cell line THP1, results showed that spirocyclic pyrans I [R = benzodioxan-6-yl, benzodioxol-5-yl, 4-chlorophenyl] and III displayed THP1 toxicty at relatively high concns.(&gt;50 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7oCV08HTMArVg90H21EOLACvtfcHk0lgamKl2dnTsAA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2cXitFyjs7nE&amp;md5=ffff8fe33d16469205ea56402be70da2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0111782&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0111782%26sid%3Dliteratum%253Aachs%26aulast%3DBadiola%26aufirst%3DK.%2BA.%26aulast%3DQuan%26aufirst%3DD.%2BH.%26aulast%3DTriccas%26aufirst%3DJ.%2BA.%26aulast%3DTodd%26aufirst%3DM.%2BH.%26atitle%3DEfficient%2520Synthesis%2520and%2520Anti-Tubercular%2520Activity%2520of%2520a%2520Series%2520of%2520Spirocycles%253A%2520An%2520Exercise%2520in%2520Open%2520Science%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De111782%26doi%3D10.1371%2Fjournal.pone.0111782" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manabe, K.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5370</span>– <span class="NLM_lpage">5373</span>, <span class="refDoi">&nbsp;DOI: 10.1021/ol4026815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol4026815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKks77O" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=15&amp;publication_year=2013&amp;pages=5370-5373&amp;author=T.+Uedaauthor=H.+Konishiauthor=K.+Manabe&amp;title=Palladium-Catalyzed+Fluorocarbonylation+Using+N-Formylsaccharin+as+CO+Source%3A+General+Access+to+Carboxylic+Acid+Derivatives&amp;doi=10.1021%2Fol4026815" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives</span></div><div class="casAuthors">Ueda, Tsuyoshi; Konishi, Hideyuki; Manabe, Kei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5370-5373</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Formylsaccharin, an easily accessible cryst. compd., has been employed as an efficient CO source in Pd-catalyzed fluorocarbonylation of aryl halides to afford the corresponding acyl fluorides in high yields.  The reactions use a near-stoichiometric amt. of the CO source (1.2 equiv) and tolerate diverse functional groups.  The acyl fluorides obtained could be readily transformed into various carboxylic acid derivs. such as carboxylic acid, esters, thioesters, and amides in a one-pot procedure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqTUEhxhGH57Vg90H21EOLACvtfcHk0lgamKl2dnTsAA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKks77O&amp;md5=c3c3e96e8e986e2b8b496bb8846bea07</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fol4026815&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol4026815%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DH.%26aulast%3DManabe%26aufirst%3DK.%26atitle%3DPalladium-Catalyzed%2520Fluorocarbonylation%2520Using%2520N-Formylsaccharin%2520as%2520CO%2520Source%253A%2520General%2520Access%2520to%2520Carboxylic%2520Acid%2520Derivatives%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D5370%26epage%3D5373%26doi%3D10.1021%2Fol4026815" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ollinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraski, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alling, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span> <span> </span><span class="NLM_article-title">A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e60531</span>, <span class="refDoi">&nbsp;DOI: 10.1371/journal.pone.0060531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1371%2Fjournal.pone.0060531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=23593234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1Gls74%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2013&amp;pages=e60531&amp;author=J.+Ollingerauthor=M.+A.+Baileyauthor=G.+C.+Moraskiauthor=A.+Caseyauthor=S.+Florioauthor=T.+Allingauthor=M.+J.+Millerauthor=T.+Parish&amp;title=A+dual+read-out+assay+to+evaluate+the+potency+of+compounds+active+against+Mycobacterium+tuberculosis&amp;doi=10.1371%2Fjournal.pone.0060531" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ollinger, Juliane; Bailey, Mai Ann; Moraski, Garrett C.; Casey, Allen; Florio, Stephanie; Alling, Torey; Miller, Marvin J.; Parish, Tanya</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e60531</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tuberculosis is a serious global health problem caused by the bacterium Mycobacterium tuberculosis.  There is an urgent need for discovery and development of new treatments, but this can only be accomplished through rapid and reproducible M. tuberculosis assays designed to identify potent inhibitors.  We developed an automated 96-well assay utilizing a recombinant strain of M. tuberculosis expressing a far-red fluorescent reporter to det. the activity of novel compds.; this allowed us to measure growth by monitoring both optical d. and fluorescence.  We detd. that optical d. and fluorescence were correlated with cell no. during logarithmic phase growth.  Fluorescence was stably maintained without antibiotic selection over 5 days, during which time cells remained actively growing.  We optimized parameters for the assay, with the final format being 5 days' growth in 96-well plates in the presence of 2% w/v DMSO.  We confirmed reproducibility using rifampicin and other antibiotics.  The dual detection method allows for a reproducible calcn. of the min. inhibitory concn. (MIC), at the same time detecting artifacts such as fluorescence quenching or compd. pptn.  We used our assay to confirm anti-tubercular activity and establish the structure activity relationship (SAR) around the imidazo[1,2-a]pyridine-3-carboxamides, a promising series of M. tuberculosis inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzifhn6ZGfK7Vg90H21EOLACvtfcHk0lgamKl2dnTsAA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXmt1Gls74%253D&amp;md5=f8e7dcf8aa8dfe4b71c7a8885ad44bf1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060531&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060531%26sid%3Dliteratum%253Aachs%26aulast%3DOllinger%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DM.%2BA.%26aulast%3DMoraski%26aufirst%3DG.%2BC.%26aulast%3DCasey%26aufirst%3DA.%26aulast%3DFlorio%26aufirst%3DS.%26aulast%3DAlling%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26aulast%3DParish%26aufirst%3DT.%26atitle%3DA%2520dual%2520read-out%2520assay%2520to%2520evaluate%2520the%2520potency%2520of%2520compounds%2520active%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De60531%26doi%3D10.1371%2Fjournal.pone.0060531" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridal, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margulis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorota, S.</span></span> <span> </span><span class="NLM_article-title">Comparison of human Ether-a-go-go related gene screening assays based on IonWorks Quattro and thallium flux</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">765</span>, <span class="refDoi">&nbsp;DOI: 10.1089/adt.2010.0267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1089%2Fadt.2010.0267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=20658944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOjsLvL" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2010&amp;pages=755-765&amp;author=T.+R.+Bridalauthor=M.+Margulisauthor=X.+Wangauthor=M.+Donioauthor=S.+Sorota&amp;title=Comparison+of+human+Ether-a-go-go+related+gene+screening+assays+based+on+IonWorks+Quattro+and+thallium+flux&amp;doi=10.1089%2Fadt.2010.0267" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of Human Ether-a-go-go Related Gene Screening Assays Based on IonWorks Quattro and Thallium Flux</span></div><div class="casAuthors">Bridal, Terry R.; Margulis, Michael; Wang, Xin; Donio, Michael; Sorota, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-765</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">In vitro screens using cellular prepns. expressing human Ether-a-go-go related gene (hERG) potassium channels have become an intrinsic tool for evaluating cardiac liability of compds. during early preclin. stage development.  Although hERG channel blocking effects are most reliably evaluated using the low-throughput, manual patch clamp technique, methods and technologies that yield hERG activity data in multiwell format are required to address increased throughput requirements.  In most cases, multiwell approaches to measuring hERG activity involve achieving a reasonable balance between throughput and data fidelity.  Here we compared two functional multiwell hERG assays: A fluorescence-based fluorometric imaging plate reader (FLIPR) screen measuring thallium (Tl+) influx through hERG channels and an automated patch clamp assay using an IonWorks Quattro.  Mean Z' values for FLIPR-Tl+ and IonWorks Quattro assays were similar, 0.57 ± 0.09 (±SD; n = 10) vs. 0.63 ± 0.11 (n = 12), resp.  IC50 detns. for a set of 17 ref. compds. were used to evaluate potency shifts relative to conventional voltage clamp data.  The ref. compd. set included members that are known to exert severe potency shifts in multiwell assays.  Mean potency shift values for FLIPR-Tl+ and IonWorks Quattro assays were 117- and 8-fold, resp.  On the basis of reduced potency shifts and low data variability, we conclude that the IonWorks Quattro screen was a better predictor of hERG activity in conventional whole-cell patch clamp than the Tl+ influx assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiyFqk1FTpqrVg90H21EOLACvtfcHk0lhB1nma5knBiA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOjsLvL&amp;md5=50ffad1fc10ad4a7a944956b71a2fae1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1089%2Fadt.2010.0267&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2010.0267%26sid%3Dliteratum%253Aachs%26aulast%3DBridal%26aufirst%3DT.%2BR.%26aulast%3DMargulis%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDonio%26aufirst%3DM.%26aulast%3DSorota%26aufirst%3DS.%26atitle%3DComparison%2520of%2520human%2520Ether-a-go-go%2520related%2520gene%2520screening%2520assays%2520based%2520on%2520IonWorks%2520Quattro%2520and%2520thallium%2520flux%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2010%26volume%3D8%26spage%3D755%26epage%3D765%26doi%3D10.1089%2Fadt.2010.0267" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi">&nbsp;DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=11&amp;publication_year=2012&amp;pages=909-922&amp;author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&amp;title=Reducing+safety-related+drug+attrition%3A+the+use+of+in+vitro+pharmacological+profiling&amp;doi=10.1038%2Fnrd3845" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0lhB1nma5knBiA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&amp;md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520safety-related%2520drug%2520attrition%253A%2520the%2520use%2520of%2520in%2520vitro%2520pharmacological%2520profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruppo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marietta, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, I. M.</span></span> <span> </span><span class="NLM_article-title">Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2294</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.49.6.2294-2301.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.49.6.2294-2301.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=15917524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrw%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=49&amp;publication_year=2005&amp;pages=2294-2301&amp;author=A.+J.+Lenaertsauthor=V.+Gruppoauthor=K.+S.+Mariettaauthor=C.+M.+Johnsonauthor=D.+K.+Driscollauthor=N.+M.+Tompkinsauthor=J.+D.+Roseauthor=R.+C.+Reynoldsauthor=I.+M.+Orme&amp;title=Preclinical+testing+of+the+nitroimidazopyran+PA-824+for+activity+against+Mycobacterium+tuberculosis+in+a+series+of+in+vitro+and+in+vivo+models&amp;doi=10.1128%2FAAC.49.6.2294-2301.2005" target="_blank">Google Scholar</a><div class="casRecord" id="
                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models</span></div><div class="casAuthors">Lenaerts, Anne J.; Gruppo, Veronica; Marietta, Karen S.; Johnson, Christine M.; Driscoll, Diane K.; Tompkins, Nicholas M.; Rose, Jerry D.; Reynolds, Robert C.; Orme, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2294-2301</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study extends earlier reports regarding the in vitro and in vivo efficacies of the nitroimidazopyran PA-824 against M. tuberculosis.  PA-824 was tested in vitro against a broad panel of multidrug-resistant clin. isolates and was found to be highly active against all isolates (MIC &lt;1 μg/mL).  The activity of PA-824 against M. tuberculosis was also assessed grown under conditions of O2 depletion.  PA-824 showed significant activity at 2, 10, and 50 μg/mL, similar to that of metronidazole, in a dose-dependent manner.  In a short-course mouse infection model, the efficacy of PA-824 at 50, 100, and 300 mg/kg of body wt. formulated in methylcellulose or cyclodextrin/lecithin after 9 oral treatments was compared with those of isoniazid, rifampin, and moxifloxacin.  PA-824 at 100 mg/kg in cyclodextrin/lecithin was as active as moxifloxacin at 100 mg/kg and isoniazid at 25 mg/kg and was slightly more active than rifampin at 20 mg/kg.  Long-term treatment with PA-824 at 100 mg/kg in cyclodextrin/lecithin reduced the bacterial load below 500 CFU in the lungs and spleen.  No significant differences in activity between PA-824 and the other single drug treatments tested (isoniazid at 25 mg/kg, rifampin at 10 mg/kg, gatifloxacin at 100 mg/kg, and moxifloxacin at 100 mg/kg) could be obsd.  In summary, its good activity in in vivo models, as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes PA-824 an attractive drug candidate for the therapy of tuberculosis.  These data indicate that there is significant potential for effective oral delivery of PA-824 for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm0IFHIxA0KrVg90H21EOLACvtfcHk0lhB1nma5knBiA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrw%253D&amp;md5=69ac4231bc1270bee6203ee69e955e26</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.6.2294-2301.2005&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.6.2294-2301.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DMarietta%26aufirst%3DK.%2BS.%26aulast%3DJohnson%26aufirst%3DC.%2BM.%26aulast%3DDriscoll%26aufirst%3DD.%2BK.%26aulast%3DTompkins%26aufirst%3DN.%2BM.%26aulast%3DRose%26aufirst%3DJ.%2BD.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DOrme%26aufirst%3DI.%2BM.%26atitle%3DPreclinical%2520testing%2520of%2520the%2520nitroimidazopyran%2520PA-824%2520for%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520in%2520a%2520series%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520models%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D2294%26epage%3D2301%26doi%3D10.1128%2FAAC.49.6.2294-2301.2005" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li></ol></div><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lutete Peguy Khonde, Rudolf Müller, Grant A. Boyle, Virsinha Reddy, Aloysius T. Nchinda, Charles J. Eyermann, Stephen Fienberg, Vinayak Singh, Alissa Myrick, Efrem Abay, Mathew Njoroge, Nina Lawrence, Qin Su, Timothy G. Myers, Helena I. M. Boshoff, Clifton E. Barry,  , Frederick A. Sirgel, Paul D. van Helden, Lisa M. Massoudi, Gregory T. Robertson, Anne J. Lenaerts, Gregory S. Basarab, Sandeep R. Ghorpade, <span class="NLM_string-name hlFld-ContribAuthor">Kelly Chibale</span>. </span><span class="cited-content_cbyCitation_article-title">1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (17)
                                     , 12790-12807. <a href="https://doi.org/10.1021/acs.jmedchem.1c00837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00837&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1%25252C3-Diarylpyrazolyl-acylsulfonamides%252Bas%252BPotent%252BAnti-tuberculosis%252BAgents%252BTargeting%252BCell%252BWall%252BBiosynthesis%252Bin%252BMycobacterium%252Btuberculosis%26aulast%3DKhonde%26aufirst%3DLutete%2BPeguy%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08052021%26date%3D20082021%26volume%3D64%26issue%3D17%26spage%3D12790%26epage%3D12807" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joanna C. Evans, Dinakaran Murugesan, John M. Post, Vitor Mendes, Zhe Wang, Navid Nahiyaan, Sasha L. Lynch, Stephen Thompson, Simon R. Green, Peter C. Ray, Jeannine Hess, Christina Spry, Anthony G. Coyne, Chris Abell, Helena I. M. Boshoff, Paul G. Wyatt, Kyu Y. Rhee, Tom L. Blundell, Clifton E. Barry,  , <span class="NLM_string-name hlFld-ContribAuthor">Valerie Mizrahi</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4′-Phosphopantothenoyl-l-cysteine Synthetase (CoaB) Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (6)
                                     , 1666-1679. <a href="https://doi.org/10.1021/acsinfecdis.0c00904" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00904&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00904%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DTargeting%252BMycobacterium%252Btuberculosis%252BCoaBC%252Bthrough%252BChemical%252BInhibition%252Bof%252B4%2525E2%252580%2525B2-Phosphopantothenoyl-l-cysteine%252BSynthetase%252B%252528CoaB%252529%252BActivity%26aulast%3DEvans%26aufirst%3DJoanna%2BC.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23122020%26date%3D03052021%26volume%3D7%26issue%3D6%26spage%3D1666%26epage%3D1679" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William  Addison</span>, <span class="hlFld-ContribAuthor ">Martyn  Frederickson</span>, <span class="hlFld-ContribAuthor ">Anthony G.  Coyne</span>, <span class="hlFld-ContribAuthor ">Chris  Abell</span>. </span><span class="cited-content_cbyCitation_article-title">Potential therapeutic targets from
              Mycobacterium abscessus
              (
              Mab
              ): recently reported efforts towards the discovery of novel antibacterial agents to treat
              Mab
              infections. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2022,</strong> <em>13 </em>
                                    (4)
                                     , 392-404. <a href="https://doi.org/10.1039/D1MD00359C" title="DOI URL">https://doi.org/10.1039/D1MD00359C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00359C&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00359C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPotential%252Btherapeutic%252Btargets%252Bfrom%252BMycobacterium%252Babscessus%252B%252528%252BMab%252B%252529%25253A%252Brecently%252Breported%252Befforts%252Btowards%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Bantibacterial%252Bagents%252Bto%252Btreat%252BMab%252Binfections%26aulast%3DAddison%26aufirst%3DWilliam%26date%3D2022%26date%3D2022%26volume%3D13%26issue%3D4%26spage%3D392%26epage%3D404" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory S.  Basarab</span>, <span class="hlFld-ContribAuthor ">Sandeep  Ghorpade</span>, <span class="hlFld-ContribAuthor ">Liezl  Gibhard</span>, <span class="hlFld-ContribAuthor ">Rudolf  Mueller</span>, <span class="hlFld-ContribAuthor ">Mathew  Njoroge</span>, <span class="hlFld-ContribAuthor ">Nashied  Peton</span>, <span class="hlFld-ContribAuthor ">Preshendren  Govender</span>, <span class="hlFld-ContribAuthor ">Lisa M.  Massoudi</span>, <span class="hlFld-ContribAuthor ">Gregory Thomas  Robertson</span>, <span class="hlFld-ContribAuthor ">Anne J.  Lenaerts</span>, <span class="hlFld-ContribAuthor ">Helena Ingrid  Boshoff</span>, <span class="hlFld-ContribAuthor ">Douglas  Joerss</span>, <span class="hlFld-ContribAuthor ">Tanya  Parish</span>, <span class="hlFld-ContribAuthor ">Thomas F.  Durand-Reville</span>, <span class="hlFld-ContribAuthor ">Manos  Perros</span>, <span class="hlFld-ContribAuthor ">Vinayak  Singh</span>, <span class="hlFld-ContribAuthor ">Kelly  Chibale</span>. </span><span class="cited-content_cbyCitation_article-title">Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones. </span><span class="cited-content_cbyCitation_journal-name">Antimicrobial Agents and Chemotherapy</span><span> <strong>2022,</strong> <em>66 </em>
                                    (4)
                                     <a href="https://doi.org/10.1128/aac.02192-21" title="DOI URL">https://doi.org/10.1128/aac.02192-21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/aac.02192-21&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2Faac.02192-21%26sid%3Dliteratum%253Aachs%26jtitle%3DAntimicrobial%2520Agents%2520and%2520Chemotherapy%26atitle%3DSpiropyrimidinetriones%25253A%252Ba%252BClass%252Bof%252BDNA%252BGyrase%252BInhibitors%252Bwith%252BActivity%252Bagainst%252BMycobacterium%252Btuberculosis%252Band%252Bwithout%252BCross-Resistance%252Bto%252BFluoroquinolones%26aulast%3DBasarab%26aufirst%3DGregory%2BS.%26date%3D2022%26volume%3D66%26issue%3D4" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenbin  Kuang</span>, <span class="hlFld-ContribAuthor ">Haolin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2022,</strong> <em>393 </em><a href="https://doi.org/10.1016/j.apsb.2022.04.014" title="DOI URL">https://doi.org/10.1016/j.apsb.2022.04.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2022.04.014&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2022.04.014%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DOvercoming%252BMycobacterium%252Btuberculosis%252Bthrough%252Bsmall%252Bmolecule%252Binhibitors%252Bto%252Bbreak%252Bdown%252Bcell%252Bwall%252Bsynthesis%26aulast%3DKuang%26aufirst%3DWenbin%26date%3D2022%26volume%3D393" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bree B.  Aldridge</span>, <span class="hlFld-ContribAuthor ">David  Barros-Aguirre</span>, <span class="hlFld-ContribAuthor ">Clifton E.  Barry</span>, <span class="hlFld-ContribAuthor ">Robert H.  Bates</span>, <span class="hlFld-ContribAuthor ">Steven J.  Berthel</span>, <span class="hlFld-ContribAuthor ">Helena I.  Boshoff</span>, <span class="hlFld-ContribAuthor ">Kelly  Chibale</span>, <span class="hlFld-ContribAuthor ">Xin-Jie  Chu</span>, <span class="hlFld-ContribAuthor ">Christopher B.  Cooper</span>, <span class="hlFld-ContribAuthor ">Véronique  Dartois</span>, <span class="hlFld-ContribAuthor ">Ken  Duncan</span>, <span class="hlFld-ContribAuthor ">Nader  Fotouhi</span>, <span class="hlFld-ContribAuthor ">Fabian  Gusovsky</span>, <span class="hlFld-ContribAuthor ">Philip A.  Hipskind</span>, <span class="hlFld-ContribAuthor ">Dale J.  Kempf</span>, <span class="hlFld-ContribAuthor ">Joël  Lelièvre</span>, <span class="hlFld-ContribAuthor ">Anne J.  Lenaerts</span>, <span class="hlFld-ContribAuthor ">Case W.  McNamara</span>, <span class="hlFld-ContribAuthor ">Valerie  Mizrahi</span>, <span class="hlFld-ContribAuthor ">Carl  Nathan</span>, <span class="hlFld-ContribAuthor ">David B.  Olsen</span>, <span class="hlFld-ContribAuthor ">Tanya  Parish</span>, <span class="hlFld-ContribAuthor ">H. Michael  Petrassi</span>, <span class="hlFld-ContribAuthor ">Alexander  Pym</span>, <span class="hlFld-ContribAuthor ">Kyu Y.  Rhee</span>, <span class="hlFld-ContribAuthor ">Gregory T.  Robertson</span>, <span class="hlFld-ContribAuthor ">Jeremy Michael  Rock</span>, <span class="hlFld-ContribAuthor ">Eric J.  Rubin</span>, <span class="hlFld-ContribAuthor ">Betsy  Russell</span>, <span class="hlFld-ContribAuthor ">David G.  Russell</span>, <span class="hlFld-ContribAuthor ">James C.  Sacchettini</span>, <span class="hlFld-ContribAuthor ">Dirk  Schnappinger</span>, <span class="hlFld-ContribAuthor ">Michael  Schrimpf</span>, <span class="hlFld-ContribAuthor ">Anna M.  Upton</span>, <span class="hlFld-ContribAuthor ">Peter  Warner</span>, <span class="hlFld-ContribAuthor ">Paul Graham  Wyatt</span>, <span class="hlFld-ContribAuthor ">Ying  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">The Tuberculosis Drug Accelerator at year 10: what have we learned?. </span><span class="cited-content_cbyCitation_journal-name">Nature Medicine</span><span> <strong>2021,</strong> <em>27 </em>
                                    (8)
                                     , 1333-1337. <a href="https://doi.org/10.1038/s41591-021-01442-2" title="DOI URL">https://doi.org/10.1038/s41591-021-01442-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41591-021-01442-2&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41591-021-01442-2%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Medicine%26atitle%3DThe%252BTuberculosis%252BDrug%252BAccelerator%252Bat%252Byear%252B10%25253A%252Bwhat%252Bhave%252Bwe%252Blearned%25253F%26aulast%3DAldridge%26aufirst%3DBree%2BB.%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D8%26spage%3D1333%26epage%3D1337" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0012.gif" alt="" id="tgr1"><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0002.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Kill kinetics for <b>29</b> against replicating and nonreplicating <i>M. tuberculosis</i>. Bacterial viability in the presence of compound was determined by cfu over 28 days (A) under replicating conditions and (B) under nonreplicating conditions. The dashed lines represent the upper and lower limits of detection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0003.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Decreased MmpL3 expression results in hypersensitivity to the spirocycle series. Removal of anhydrotetracycline (atc) results in transcriptional repression of <i>mmpL3</i>. Growth in the presence of a negative control ethambutol (A) and a positive control SQ109 (B) as well as representative series compound, <b>4</b> (C) and <b>23</b> (D) are recorded relative to DMSO-treated samples. Data are representative of two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0004.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Efficacy in a mouse model of acute TB infection. BALB/c mice were infected with <i>M. tuberculosis</i> H37Rv <i>via</i> a low-dose aerosol exposure. Treatment was started 7 days post-aerosol and continued for 12 consecutive days. Drugs were administered once daily by oral gavage at 100 mg/kg (<b>3</b>) and 300 mg/kg (<b>29</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0005.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Routes for the Synthesis of Compounds <b>1–21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"></p><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) BH<sub>3</sub>.THF, THF, 100 °C, and 1 h; (ii) nBuLi, THF, −78 °C, 1 h, then <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate −78 °C—rt, and 18 h; (iii) MeSO<sub>2</sub>Cl, Et<sub>3</sub>N, DCM, reflux, and 1.5 h; (iv) TFA, DCM, and 18 h; (v) 1-[(4-methoxyphenyl)methyl]piperidin-4-one, MeSO<sub>3</sub>H, PhMe, reflux, Dean–Stark, and 18 h; (vi) 1-chloroethyl carbonochloridate, DCM, 0 °C then MeOH, reflux, and 1 h; (vii) DIPEA, DMSO, rt, and 18 h; (viii) AcOH or EtOH, reflux, and 2 h; (ix) R2B(OH)<sub>2</sub>, Cu(OAc)<sub>2</sub>, pyridine, DCM, and 2 h; (x) Et<sub>2</sub>O, rt, 1 h, then NaOMe, MeOH, rt, 18 h, then H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux, and 48 h; (xi) PPh<sub>3</sub>, DIAD, THF, MeOH, rt, and 18 h; (xii) DIBAL, DCM, −78 °C—rt, then MnO<sub>2</sub>, DCM, rt, and 48 h; (xiii) AcOH, DCM, then NaBH(OAc)<sub>3</sub>, and 18 h; (xiv) R4B(OH)<sub>2</sub>, Cu(OAc)<sub>2</sub>, pyridine, DCM, rt, and 3–18 h.</p><p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0006.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Routes for the Synthesis of Compounds <b>22–30</b> and <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"></p><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EtOH, AcOH, reflux, and 1–18 h; (ii) spiro[isochromane-1,4′-piperidine], AcOH, DCM, then NaBH(OAc)<sub>3</sub>, and 18 h; (iii) EtOH, H<sub>2</sub>O, 35 °C, and 18 h; (iv) SOCl<sub>2</sub>, pyridine, 50 °C, 2 h then ethanolamine, DCM, rt, 3 h, then SOCl<sub>2</sub>, rt, and 18 h; (v) NaH, THF, 0 °C, and 3 h; (vi) DIBAL, DCM, −78 °C—rt, then MnO<sub>2</sub>, DCM, rt, and 48 h; (vii) spiro[isochromane-1,4′-piperidine], AcOH, DCM, then NaBH(OAc)<sub>3</sub>, 18 h; and (viii) 3 M HCl, 100 °C, and 18 h.</p><p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/cms/10.1021/acsomega.0c05589/asset/images/medium/ao0c05589_0007.gif" alt="" data-lg-src="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav"><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthetic Routes for the Synthesis of Compounds <b>31–34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/cms/10.1021/acsomega.0c05589/asset/images/large/ao0c05589_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acsomega.0c05589&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"></p><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) POCl<sub>3</sub>, DMF, 100 °C, and 2 h; (ii) R3H, K<sub>2</sub>CO<sub>3</sub>, DMF, microwave, 120 °C, and 1 h; (iii) pTsOH, MeOH, microwave, 120 °C, and 1 h; (iv) R3I, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C—rt, and 2 h; (v) DIBAL, DCM, −78 °C—rt, then MnO<sub>2</sub>, DCM, rt, and 48 h; (vi) AcOH, DCM, then NaBH(OAc)<sub>3</sub>, and 18 h; and (vii) <i>N</i>-formylsaccharin, Pd(OAc)<sub>2</sub>, Xantphos, KF, DMF, 80 °C, and 18 h then H<sub>2</sub>O.</p><p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i186">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22127" class="dropBlock__holder"></div></div></div></div></div><hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span> <span> </span><span class="NLM_article-title">Microbe Profile: Mycobacterium tuberculosis: Humanity’s deadly microbial foe</span>. <i>Microbiology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">439</span>, <span class="refDoi">&nbsp;DOI: 10.1099/mic.0.000601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1099%2Fmic.0.000601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=29465344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCltbzE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=164&amp;publication_year=2018&amp;pages=437-439&amp;author=S.+V.+Gordonauthor=T.+Parish&amp;title=Microbe+Profile%3A+Mycobacterium+tuberculosis%3A+Humanity%E2%80%99s+deadly+microbial+foe&amp;doi=10.1099%2Fmic.0.000601" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microbe profile: Mycobacterium tuberculosis: Humanity's deadly microbial foe</span></div><div class="casAuthors">Gordon, Stephen V.; Parish, Tanya</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-439</span>CODEN:
                <span class="NLM_cas:coden">MROBEO</span>;
        ISSN:<span class="NLM_cas:issn">1465-2080</span>.
    
            (<span class="NLM_cas:orgname">Microbiology Society</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis is an expert and deadly pathogen, causing the disease tuberculosis (TB) in humans.  It has several notable features: the ability to enter non-replicating states for long periods and cause latent infection; metabolic remodelling during chronic infection; a thick, waxy cell wall; slow growth rate in culture; and intrinsic drug resistance and antibiotic tolerance.  As a pathogen, M. tuberculosis has a complex relationship with its host, is able to replicate inside macrophages, and expresses diverse immunomodulatory mols.  M. tuberculosis currently causes over 1.8 million deaths a year, making it the world's most deadly human pathogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIHaKNZQyUMLVg90H21EOLACvtfcHk0ljs-shCgSAoFA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1cXhslCltbzE&amp;md5=78295495d67634bb25957ea52840d899</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1099%2Fmic.0.000601&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fmic.0.000601%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DS.%2BV.%26aulast%3DParish%26aufirst%3DT.%26atitle%3DMicrobe%2520Profile%253A%2520Mycobacterium%2520tuberculosis%253A%2520Humanity%25E2%2580%2599s%2520deadly%2520microbial%2520foe%26jtitle%3DMicrobiology%26date%3D2018%26volume%3D164%26spage%3D437%26epage%3D439%26doi%3D10.1099%2Fmic.0.000601" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">WHO</span>.  <i>Global Tuberculosis Report 2020</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva
(Switzerland)</span>, <span class="NLM_year">2020</span>; ISBN 978-92-4-001313-1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;publication_year=2020&amp;author=WHO&amp;title=Global+Tuberculosis+Report+2020" target="_blank">Google Scholar</a><div class="casRecord empty" id="
                            rightTab-cas_R
                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DGlobal%2520Tuberculosis%2520Report%25202020%26pub%3DWorld%2520Health%2520Organization%26date%3D2020" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, R. H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, M.</span></span> <span> </span><span class="NLM_article-title">The WHO 2014 Global tuberculosis report-further to go</span>. <i>Lancet Global Health</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">E10</span>– <span class="NLM_lpage">E12</span>, <span class="refDoi">&nbsp;DOI: 10.1016/S2214-109x(14)70361-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2FS2214-109X%2814%2970361-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25539957" title="">PubMed</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=3&amp;publication_year=2015&amp;pages=E10-E12&amp;author=A.+Zumlaauthor=A.+Georgeauthor=V.+Sharmaauthor=R.+H.+N.+Herbertauthor=A.+Oxleyauthor=M.+Oliverauthor=M.+Oliver&amp;title=The+WHO+2014+Global+tuberculosis+report-further+to+go&amp;doi=10.1016%2FS2214-109x%2814%2970361-4" target="_blank">Google Scholar</a><div class="casRecord empty" id="
                            rightTab-cas_R
                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS2214-109X%2814%2970361-4&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2214-109X%252814%252970361-4%26sid%3Dliteratum%253Aachs%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DGeorge%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DHerbert%26aufirst%3DR.%2BH.%2BN.%26aulast%3DOxley%26aufirst%3DA.%26aulast%3DOliver%26aufirst%3DM.%26aulast%3DOliver%26aufirst%3DM.%26atitle%3DThe%2520WHO%25202014%2520Global%2520tuberculosis%2520report-further%2520to%2520go%26jtitle%3DLancet%2520Global%2520Health%26date%3D2015%26volume%3D3%26spage%3DE10%26epage%3DE12%26doi%3D10.1016%2FS2214-109x%2814%2970361-4" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi">&nbsp;DOI: 10.1016/s0140-6736(15)00151-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2FS0140-6736%2815%2900151-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=26377143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A280%3ADC%252BC283jtVShtg%253D%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=387&amp;publication_year=2016&amp;pages=1211-1226&amp;author=K.+Dhedaauthor=C.+E.+Barryauthor=G.+Maartens&amp;title=Tuberculosis&amp;doi=10.1016%2Fs0140-6736%2815%2900151-8" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis</span></div><div class="casAuthors">Dheda Keertan; Barry Clifton E 3rd; Maartens Gary</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10024</span>),
    <span class="NLM_cas:pages">1211-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although the worldwide incidence of tuberculosis has been slowly decreasing, the global disease burden remains substantial (∼9 million cases and ∼1·5 million deaths in 2013), and tuberculosis incidence and drug resistance are rising in some parts of the world such as Africa.  The modest gains achieved thus far are threatened by high prevalence of HIV, persisting global poverty, and emergence of highly drug-resistant forms of tuberculosis.  Tuberculosis is also a major problem in health-care workers in both low-burden and high-burden settings.  Although the ideal preventive agent, an effective vaccine, is still some time away, several new diagnostic technologies have emerged, and two new tuberculosis drugs have been licensed after almost 50 years of no tuberculosis drugs being registered.  Efforts towards an effective vaccine have been thwarted by poor understanding of what constitutes protective immunity.  Although new interventions and investment in control programmes will enable control, eradication will only be possible through substantial reductions in poverty and overcrowding, political will and stability, and containing co-drivers of tuberculosis, such as HIV, smoking, and diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCv4mFAtl09LP3FVUi_gf8fW6udTcc2eaFWNegAxUO7rntkvexoksv"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A280%3ADC%252BC283jtVShtg%253D%253D&amp;md5=4da3776db0bff83329a1f2a65805d12f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2900151-8&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252900151-8%26sid%3Dliteratum%253Aachs%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DMaartens%26aufirst%3DG.%26atitle%3DTuberculosis%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26spage%3D1211%26epage%3D1226%26doi%3D10.1016%2Fs0140-6736%2815%2900151-8" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horsburgh, C. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span> <span> </span><span class="NLM_article-title">Treatment of Tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2149</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi">&nbsp;DOI: 10.1056/NEJMra1413919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1056%2FNEJMra1413919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=26605929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVSkt7o%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=373&amp;publication_year=2015&amp;pages=2149-2160&amp;author=C.+R.+Horsburghauthor=C.+E.+Barryauthor=C.+Lange&amp;title=Treatment+of+Tuberculosis&amp;doi=10.1056%2FNEJMra1413919" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of tuberculosis</span></div><div class="casAuthors">Horsburgh, C. Robert, Jr.; Barry, Clifton E., III; Lange, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2149-2160</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Tuberculosis, a scourge since prehistoric times, affects more than 9 million people and causes the death of 1.5 million people each year.  Effective treatment has been available for 60 years, but such treatment takes at least 6 mo, and resistance to the drugs, which is increasing throughout the world, threatens the effectiveness of treatment.1 This review summarizes the theor. principles of tuberculosis treatment, current therapeutic approaches, areas of uncertainty, and persistent challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNp74TLwDRXLVg90H21EOLACvtfcHk0lhy7g_SycBXBw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC28XntVSkt7o%253D&amp;md5=96775985ab332aa82ccc4ab5481e6fe0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1413919&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1413919%26sid%3Dliteratum%253Aachs%26aulast%3DHorsburgh%26aufirst%3DC.%2BR.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DLange%26aufirst%3DC.%26atitle%3DTreatment%2520of%2520Tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2149%26epage%3D2160%26doi%3D10.1056%2FNEJMra1413919" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">The challenge of new drug discovery for tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">490</span>, <span class="refDoi">&nbsp;DOI: 10.1038/nature09657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fnature09657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=21270886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFShsrg%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=469&amp;publication_year=2011&amp;pages=483-490&amp;author=A.+Koulauthor=E.+Arnoultauthor=N.+Lounisauthor=J.+Guillemontauthor=K.+Andries&amp;title=The+challenge+of+new+drug+discovery+for+tuberculosis&amp;doi=10.1038%2Fnature09657" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The challenge of new drug discovery for tuberculosis</span></div><div class="casAuthors">Koul, Anil; Arnoult, Eric; Lounis, Nacer; Guillemont, Jerome; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7331</span>),
    <span class="NLM_cas:pages">483-490</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) is more prevalent in the world today than at any other time in human history.  Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse strategies to survive in a variety of host lesions and to evade immune surveillance.  A key question is how robust are our approaches to discovering new TB drugs, and what measures could be taken to reduce the long and protracted clin. development of new drugs.  The emergence of multi-drug-resistant strains of M. tuberculosis makes the discovery of new mol. scaffolds a priority, and the current situation even necessitates the re-engineering and repositioning of some old drug families to achieve effective control.  Whatever the strategy used, success will depend largely on our proper understanding of the complex interactions between the pathogen and its human host.  In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9J_uIM64vSrVg90H21EOLACvtfcHk0lhBKG6VYwDhew"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3MXhtFShsrg%253D&amp;md5=2c70f07fc0c88727f6b20d35f0c85695</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature09657&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09657%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DThe%2520challenge%2520of%2520new%2520drug%2520discovery%2520for%2520tuberculosis%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D483%26epage%3D490%26doi%3D10.1038%2Fnature09657" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lechartier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybniker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zumla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis drug discovery in the post-post-genomic era</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">168</span>, <span class="refDoi">&nbsp;DOI: 10.1002/emmm.201201772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1002%2Femmm.201201772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=24401837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWktb4%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2014&amp;pages=158-168&amp;author=B.+Lechartierauthor=J.+Rybnikerauthor=A.+Zumlaauthor=S.+T.+Cole&amp;title=Tuberculosis+drug+discovery+in+the+post-post-genomic+era&amp;doi=10.1002%2Femmm.201201772" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis drug discovery in the post-post-genomic era</span></div><div class="casAuthors">Lechartier, Benoit; Rybniker, Jan; Zumla, Alimuddin; Cole, Stewart T.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-168</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The expectation that genomics would result in new therapeutic interventions for infectious diseases remains unfulfilled.  In the post-genomic era, the decade immediately following the availability of the genome sequence of Mycobacterium tuberculosis, tuberculosis (TB) drug discovery relied heavily on the target-based approach but this proved unsuccessful leading to a return to whole cell screening.  Genomics underpinned screening by providing knowledge and many enabling technologies, most importantly whole genome resequencing to find resistance mutations and targets, and this resulted in a selection of leads and new TB drug candidates that are reviewed here.  Unexpectedly, many new targets were found to be 'promiscuous' as they were inhibited by a variety of different compds.  In the post-post-genomics era, more advanced technologies have been implemented and these include high-content screening, screening for inhibitors of latency, the use of conditional knock-down mutants for validated targets and siRNA screens.  In addn., immunomodulation and pharmacol. manipulation of host functions are being explored in an attempt to widen our therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwFEZdeRp7hLVg90H21EOLACvtfcHk0lhBKG6VYwDhew"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2cXitFWktb4%253D&amp;md5=7db5bd8d9e76b1d69df6966fb75a9712</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Femmm.201201772&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201201772%26sid%3Dliteratum%253Aachs%26aulast%3DLechartier%26aufirst%3DB.%26aulast%3DRybniker%26aufirst%3DJ.%26aulast%3DZumla%26aufirst%3DA.%26aulast%3DCole%26aufirst%3DS.%2BT.%26atitle%3DTuberculosis%2520drug%2520discovery%2520in%2520the%2520post-post-genomic%2520era%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D158%26epage%3D168%26doi%3D10.1002%2Femmm.201201772" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kana, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakousis, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span> <span> </span><span class="NLM_article-title">Future target-based drug discovery for tuberculosis?</span>. <i>Tuberculosis</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">556</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.tube.2014.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.tube.2014.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25458615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWitL%252FE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=94&amp;publication_year=2014&amp;pages=551-556&amp;author=B.+D.+Kanaauthor=P.+C.+Karakousisauthor=T.+Parishauthor=T.+Dick&amp;title=Future+target-based+drug+discovery+for+tuberculosis%3F&amp;doi=10.1016%2Fj.tube.2014.10.003" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Future target-based drug discovery for tuberculosis?</span></div><div class="casAuthors">Kana, Bavesh Davandra; Karakousis, Petros C.; Parish, Tanya; Dick, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">551-556</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New drugs that retain potency against multidrug/extensively drug-resistant strains of Mycobacterium tuberculosis, with the addnl. benefit of a shortened treatment duration and ease of administration, are urgently needed by tuberculosis (TB) control programs.  Efforts to develop this new generation of treatment interventions have been plagued with numerous problems, the most significant being our insufficient understanding of mycobacterial metab. during disease.  This, combined with limited chem. diversity and poor entry of small mols. into the cell, has limited the no. of new bioactive agents that result from drug screening efforts.  The biochem., target-driven approach to drug development has been largely abandoned in the TB field, to be replaced by whole-cell or target-based whole-cell screening approaches.  In this context, the properties of a good drug target are unclear, since these are directly detd. by the ability to find compds., using current screening algorithms, which are able to kill M. tuberculosis.  In this review, we discuss issues related to the identification and validation of drug targets and highlight some key properties for promising targets.  Some of these include essentiality for growth, vulnerability, druggability, reduced propensity to evolve drug resistance and target location to facilitate ready access to drugs during chemotherapy.  We present these in the context of recent drugs that have emerged through various approaches with the aim of consolidating the knowledge gained from these experiences to inform future efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwa9Dp4ihtM7Vg90H21EOLACvtfcHk0lgwroxOYc-Tgw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWitL%252FE&amp;md5=c0489ca8150d64b78842ee8edaa94bf1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2014.10.003&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2014.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DKana%26aufirst%3DB.%2BD.%26aulast%3DKarakousis%26aufirst%3DP.%2BC.%26aulast%3DParish%26aufirst%3DT.%26aulast%3DDick%26aufirst%3DT.%26atitle%3DFuture%2520target-based%2520drug%2520discovery%2520for%2520tuberculosis%253F%26jtitle%3DTuberculosis%26date%3D2014%26volume%3D94%26spage%3D551%26epage%3D556%26doi%3D10.1016%2Fj.tube.2014.10.003" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5087</span>– <span class="NLM_lpage">5097</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.bmc.2014.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.bmc.2014.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25577708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVamtg%253D%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=23&amp;publication_year=2015&amp;pages=5087-5097&amp;author=U.+H.+Manjunathaauthor=P.+W.+Smith&amp;title=Perspective%3A+Challenges+and+opportunities+in+TB+drug+discovery+from+phenotypic+screening&amp;doi=10.1016%2Fj.bmc.2014.12.031" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening</span></div><div class="casAuthors">Manjunatha, Ujjini H.; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic &amp; Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5087-5097</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tuberculosis poses a major global health problem and multi-drug resistant strains are increasingly prevalent.  Hence there is an urgent need to discover new TB drugs.  Cell based phenotypic screening represents a powerful approach to identify anti-mycobacterial compds. and elucidate novel targets.  Three high throughput phenotypic screens were performed at NITD against mycobacterium.  Hits were identified and chem. series selected for optimization.  This produced compds. with good in vitro anti-mycobacterial activity and pharmacokinetic properties.  Some compds. displayed oral activity in mouse efficacy models of TB.  Herein, the authors review the TB discovery efforts at NITD and share experiences in optimization of phenotypic hits, describing challenges encountered and lessons learned.  The authors also offer perspectives to facilitate future selection and advancement of phenotypic hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGbroyRLtEcrVg90H21EOLACvtfcHk0lgwroxOYc-Tgw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2MXltVamtg%253D%253D&amp;md5=8d03c078275a58fa6629eaa9f36a5073</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.031&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DPerspective%253A%2520Challenges%2520and%2520opportunities%2520in%2520TB%2520drug%2520discovery%2520from%2520phenotypic%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D5087%26epage%3D5097%26doi%3D10.1016%2Fj.bmc.2014.12.031" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuniga, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Early, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span> <span> </span><span class="NLM_article-title">The future for early-stage tuberculosis drug discovery</span>. <i>Future Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">229</span>, <span class="refDoi">&nbsp;DOI: 10.2217/fmb.14.125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.2217%2Ffmb.14.125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25689534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGitL0%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=10&amp;publication_year=2015&amp;pages=217-229&amp;author=E.+S.+Zunigaauthor=J.+Earlyauthor=T.+Parish&amp;title=The+future+for+early-stage+tuberculosis+drug+discovery&amp;doi=10.2217%2Ffmb.14.125" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The future for early-stage tuberculosis drug discovery</span></div><div class="casAuthors">Zuniga, Edison S.; Early, Julie; Parish, Tanya</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-229</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  There is an urgent need for new and better drugs to treat tuberculosis due to lengthy and complex treatment regimens and a rising problem of drug resistance.  Drug discovery efforts have increased over the past few years, with a larger focus on modern high-throughput screening technologies.  A combination of target-based approaches, with the traditional empirical means of drug identification, has been complemented by the use of target-based phenotypic screens only recently made possibly with newer genetic tools.  Using these approaches, a no. of promising compd. series have been discovered.  However, significant problems remain in developing these into drugs.  This review highlights recent advances in TB drug discovery, including an overview of screening campaigns, lessons learned and future directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiU6_op9dlNrVg90H21EOLACvtfcHk0ljT0ssHlfCmEw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2MXislGitL0%253D&amp;md5=68b5e716e695bf2c3c9c24732da525f5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2217%2Ffmb.14.125&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb.14.125%26sid%3Dliteratum%253Aachs%26aulast%3DZuniga%26aufirst%3DE.%2BS.%26aulast%3DEarly%26aufirst%3DJ.%26aulast%3DParish%26aufirst%3DT.%26atitle%3DThe%2520future%2520for%2520early-stage%2520tuberculosis%2520drug%2520discovery%26jtitle%3DFuture%2520Microbiol.%26date%3D2015%26volume%3D10%26spage%3D217%26epage%3D229%26doi%3D10.2217%2Ffmb.14.125" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, R. C.</span></span> <span> </span><span class="NLM_article-title">Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?</span>. <i>Tuberculosis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">588</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.tube.2013.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.tube.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=24119636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFykurvJ" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=93&amp;publication_year=2013&amp;pages=569-588&amp;author=R.+C.+Goldman&amp;title=Why+are+membrane+targets+discovered+by+phenotypic+screens+and+genome+sequencing+in+Mycobacterium+tuberculosis%3F&amp;doi=10.1016%2Fj.tube.2013.09.003" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?</span></div><div class="casAuthors">Goldman, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Tuberculosis (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">569-588</span>CODEN:
                <span class="NLM_cas:coden">TUBECU</span>;
        ISSN:<span class="NLM_cas:issn">1472-9792</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  High through put screening (HTS) was extensively used in attempts to discover new TB drugs from libraries of pure small mol. compds. many of which complied with the rule of five.  Coupled with new methods for detg. the target of lead compds. by resistance selection followed by genome sequencing, screening for growth inhibitors led to several recent reports of compds. linked to specific antitubercular targets.  This systematic approach to drug discovery appears at present to select for small, hydrophobic mols. affecting the function of essential membrane proteins, for example DprE, MmpL3, AtpE, QcrB, and Pks13.  All of these mols. possessed bactericidal activity in vitro.  Mutations in GlpK were also selected with hydrophobic compds. identified by screening for growth inhibitors.  The chem. properties of the compds. reported are considered in the context of uptake and possible mechanisms of inhibition of membrane bound targets based on other model systems (e.g. cardiovascular drugs affecting voltage-gated L-type calcium channels, daptomycin, telavancin, gramicidin S, and role of boundary lipids).  The relationship between hydrophobicity, compd. uptake, and mode of action are addressed.  Compared to the av. calcd. logP for approved TB drugs of -1.0, the av. for these hydrophobic compds. is 4.0 representing a major shift in hydrophobicity of 5 orders of magnitude.  Furthermore several hydrophobic compds. in the Prestwick Chem. Library (FDA approved drugs) inhibit growth of M. tuberculosis at 10 μg/mL or less and have an av. calcd. logP of 5.7 signaling caution with respect to specificity.  Key recommendations are made regarding follow-up of the hydrophobic leads recently discovered using phenotypic screening and target elucidation by genome sequencing.  Consideration is also given to the properties of small mol. screening libraries, the types of mols. and targets recently discovered as antitubercular leads and compliance with the rule of 5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-PlhXxyKumbVg90H21EOLACvtfcHk0ljT0ssHlfCmEw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXhsFykurvJ&amp;md5=38041438bb2bc16d11bd6a29c81c8a2d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.tube.2013.09.003&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tube.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DR.%2BC.%26atitle%3DWhy%2520are%2520membrane%2520targets%2520discovered%2520by%2520phenotypic%2520screens%2520and%2520genome%2520sequencing%2520in%2520Mycobacterium%2520tuberculosis%253F%26jtitle%3DTuberculosis%26date%3D2013%26volume%3D93%26spage%3D569%26epage%3D588%26doi%3D10.1016%2Fj.tube.2013.09.003" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A.</span></span> <span> </span><span class="NLM_article-title">The tuberculosis drug discovery and development pipeline and emerging drug targets</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">a021154</span>, <span class="refDoi">&nbsp;DOI: 10.1101/cshperspect.a021154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1101%2Fcshperspect.a021154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25635061" title="">PubMed</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=5&amp;publication_year=2015&amp;pages=a021154&amp;author=K.+Mdluliauthor=T.+Kanekoauthor=A.+Upton&amp;title=The+tuberculosis+drug+discovery+and+development+pipeline+and+emerging+drug+targets&amp;doi=10.1101%2Fcshperspect.a021154" target="_blank">Google Scholar</a><div class="casRecord empty" id="
                            rightTab-cas_R
                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021154&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021154%26sid%3Dliteratum%253Aachs%26aulast%3DMdluli%26aufirst%3DK.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DUpton%26aufirst%3DA.%26atitle%3DThe%2520tuberculosis%2520drug%2520discovery%2520and%2520development%2520pipeline%2520and%2520emerging%2520drug%2520targets%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021154%26doi%3D10.1101%2Fcshperspect.a021154" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upadhyay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontes, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzegorzewicz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crick, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span> <span> </span><span class="NLM_article-title">Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6413</span>– <span class="NLM_lpage">6423</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.03229-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.03229-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25136022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjsrjF" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=58&amp;publication_year=2014&amp;pages=6413-6423&amp;author=W.+Liauthor=A.+Upadhyayauthor=F.+L.+Fontesauthor=E.+J.+Northauthor=Y.+Wangauthor=D.+C.+Cransauthor=A.+E.+Grzegorzewiczauthor=V.+Jonesauthor=S.+G.+Franzblauauthor=R.+E.+Leeauthor=D.+C.+Crickauthor=M.+Jackson&amp;title=Novel+insights+into+the+mechanism+of+inhibition+of+MmpL3%2C+a+target+of+multiple+pharmacophores+in+Mycobacterium+tuberculosis&amp;doi=10.1128%2FAAC.03229-14" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis</span></div><div class="casAuthors">Li, Wei; Upadhyay, Ashutosh; Fontes, Fabio L.; North, E. Jeffrey; Wang, Yuehong; Crans, Debbie C.; Grzegorzewicz, Anna E.; Jones, Victoria; Franzblau, Scott G.; Lee, Richard E.; Crick, Dean C.; Jackson, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6413-6423, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">MmpL3, a resistance-nodulation-division (RND) superfamily transporter, has been implicated in the formation of the outer membrane of Mycobacterium tuberculosis; specifically, MmpL3 is required for the export of mycolic acids in the form of trehalose monomycolates (TMM) to the periplasmic space or outer membrane of M. tuberculosis.  Recently, seven series of inhibitors identified by whole-cell screening against M. tuberculosis, including the antituberculosis drug candidate SQ109, were shown to abolish MmpL3-mediated TMM export.  However, this mode of action was brought into question by the broad-spectrum activities of some of these inhibitors against a variety of bacterial and fungal pathogens that do not synthesize mycolic acids.  This observation, coupled with the ability of three of these classes of inhibitors to kill nonreplicating M. tuberculosis bacilli, led us to investigate alternative mechanisms of action.  Our results indicate that the inhibitory effects of adamantyl ureas, indolecarboxamides, tetrahydropyrazolopyrimidines, and the 1,5-diarylpyrrole BM212 on the transport activity of MmpL3 in actively replicating M. tuberculosis bacilli are, like that of SQ109, most likely due to their ability to dissipate the transmembrane electrochem. proton gradient.  In addn. to providing novel insights into the modes of action of compds. reported to inhibit MmpL3, our results provide the first explanation for the large no. of pharmacophores that apparently target this essential inner membrane transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGsm9zGJpAJ7Vg90H21EOLACvtfcHk0lhzMns6YvolYg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjsrjF&amp;md5=7bfa39b0ce68ba37d73c56cf160cf6e3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.03229-14&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03229-14%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DUpadhyay%26aufirst%3DA.%26aulast%3DFontes%26aufirst%3DF.%2BL.%26aulast%3DNorth%26aufirst%3DE.%2BJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCrans%26aufirst%3DD.%2BC.%26aulast%3DGrzegorzewicz%26aufirst%3DA.%2BE.%26aulast%3DJones%26aufirst%3DV.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DCrick%26aufirst%3DD.%2BC.%26aulast%3DJackson%26aufirst%3DM.%26atitle%3DNovel%2520insights%2520into%2520the%2520mechanism%2520of%2520inhibition%2520of%2520MmpL3%252C%2520a%2520target%2520of%2520multiple%2520pharmacophores%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D6413%26epage%3D6423%26doi%3D10.1128%2FAAC.03229-14" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consalvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span> <span> </span><span class="NLM_article-title">MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1274</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi">&nbsp;DOI: 10.2174/1389557516666160118105319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.2174%2F1389557516666160118105319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=26776226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Srtr3J" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=16&amp;publication_year=2016&amp;pages=1274-1283&amp;author=G.+Poceauthor=S.+Consalviauthor=M.+Biava&amp;title=MmpL3+Inhibitors%3A+Diverse+Chemical+Scaffolds+Inhibit+the+Same+Target&amp;doi=10.2174%2F1389557516666160118105319" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target</span></div><div class="casAuthors">Poce, Giovanna; Consalvi, Sara; Biava, Mariangela</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1274-1283</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">MmpL3 belongs to the Resistance, Nodulation and Division (RND) superfamily whose role in mycobacteria is the formation of the outer membrane.  Indeed, it has been shown that MmpL3 is assocd. with the export of mycolic acids in the form of trehalose monomycolates (TMM) to the periplasmic space or the outer membrane.  In the last few years several whole cell-based screenings of compd. libraries brought by a no. of diverse chem. scaffolds active against M. tuberculosis (Mtb) that surprisingly share MmpL3 as target.  The diverse identified pharmacophores owe important differences among each other, in fact while some of them display inhibitory activity against pathogens that are devoid of mycolic acids and are active against non-replicating Mtb bacilli, some others specifically target mycobacteria and do not kill non-replicating bacilli.  The scope of this review is to provide the recent advances in MmpL3 inhibitor discovery with a special focus on structure activity relationship (SAR) studies in order to provide information that could help in developing novel membrane-active anti- TB agents.  Moreover, this review will provide the most recent insights into the modes of action of the MmpL3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplq0fvepHl_LVg90H21EOLACvtfcHk0lhzMns6YvolYg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Srtr3J&amp;md5=32d7eca769eb3dd1390804450a5249f8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1389557516666160118105319&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557516666160118105319%26sid%3Dliteratum%253Aachs%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DConsalvi%26aufirst%3DS.%26aulast%3DBiava%26aufirst%3DM.%26atitle%3DMmpL3%2520Inhibitors%253A%2520Diverse%2520Chemical%2520Scaffolds%2520Inhibit%2520the%2520Same%2520Target%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D1274%26epage%3D1283%26doi%3D10.2174%2F1389557516666160118105319" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sacksteder, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protopopova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacy, C. A.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action</span>. <i>Future Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">837</span>, <span class="refDoi">&nbsp;DOI: 10.2217/fmb.12.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.2217%2Ffmb.12.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=22827305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2isLbM" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=7&amp;publication_year=2012&amp;pages=823-837&amp;author=K.+A.+Sackstederauthor=M.+Protopopovaauthor=C.+E.+Barryauthor=K.+Andriesauthor=C.+A.+Nacy&amp;title=Discovery+and+development+of+SQ109%3A+a+new+antitubercular+drug+with+a+novel+mechanism+of+action&amp;doi=10.2217%2Ffmb.12.56" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action</span></div><div class="casAuthors">Sacksteder, Katherine A.; Protopopova, Marina; Barry, Clifton E.; Andries, Koen; Nacy, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">823-837</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Existing drugs have limited efficacy against the rising threat of drug-resistant TB, have significant side effects, and must be given in combinations of four to six drugs for at least 6 mo for drug-sensitive TB and up to 24 mo for drug-resistant TB.  The long treatment duration has led to increased patient noncompliance with therapy.  This, in turn, drives the development of addnl. drug resistance in a spiral that has resulted in some forms of TB being currently untreatable by existing drugs.  New antitubercular drugs in development, particularly those with mechanisms of action that are different from existing first- and second-line TB drugs, are anticipated to be effective against both drug-sensitive and drug-resistant TB.  SQ109 is a new TB drug candidate with a novel mechanism of action that was safe and well tolerated in Phase I and early Phase II clin. trials.  We describe herein the identification, development and characterization of SQ109 as a promising new antitubercular drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm7rdJnt1LOrVg90H21EOLACvtfcHk0ljCBYMd4LMIuQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XhtV2isLbM&amp;md5=c4aaa50d56d54573e6bef6b514c38753</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2217%2Ffmb.12.56&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb.12.56%26sid%3Dliteratum%253Aachs%26aulast%3DSacksteder%26aufirst%3DK.%2BA.%26aulast%3DProtopopova%26aufirst%3DM.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DNacy%26aufirst%3DC.%2BA.%26atitle%3DDiscovery%2520and%2520development%2520of%2520SQ109%253A%2520a%2520new%2520antitubercular%2520drug%2520with%2520a%2520novel%2520mechanism%2520of%2520action%26jtitle%3DFuture%2520Microbiol.%26date%3D2012%26volume%3D7%26spage%3D823%26epage%3D837%26doi%3D10.2217%2Ffmb.12.56" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La
Rosa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canseco, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buroni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretta, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battilocchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javid, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Logu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span> <span> </span><span class="NLM_article-title">MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">331</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.05270-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.05270-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=22024828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Gqtw%253D%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=56&amp;publication_year=2012&amp;pages=324-331&amp;author=V.+La%0ARosaauthor=G.+Poceauthor=J.+O.+Cansecoauthor=S.+Buroniauthor=M.+R.+Pascaauthor=M.+Biavaauthor=R.+M.+Rajuauthor=G.+C.+Porrettaauthor=S.+Alfonsoauthor=C.+Battilocchioauthor=B.+Javidauthor=F.+Sorrentinoauthor=T.+R.+Ioergerauthor=J.+C.+Sacchettiniauthor=F.+Manettiauthor=M.+Bottaauthor=A.+De+Loguauthor=E.+J.+Rubinauthor=E.+De+Rossi&amp;title=MmpL3+is+the+cellular+target+of+the+antitubercular+pyrrole+derivative+BM212&amp;doi=10.1128%2FAAC.05270-11" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212</span></div><div class="casAuthors">La Rosa, Valentina; Poce, Giovanna; Canseco, Julio Ortiz; Buroni, Silvia; Pasca, Maria Rosalia; Biava, Mariangela; Raju, Ravikiran M.; Porretta, Giulio Cesare; Alfonso, Salvatore; Battilocchio, Claudio; Javid, Babak; Sorrentino, Flavia; Ioerger, Thomas R.; Sacchettini, James C.; Manetti, Fabrizio; Botta, Maurizio; De Logu, Alessandro; Rubin, Eric J.; De Rossi, Edda</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">324-331</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The 1,5-diarylpyrrole deriv. BM212 was previously shown to be active against multidrug-resistant clin. isolates and Mycobacterium tuberculosis residing within macrophages as well as against Mycobacterium avium and other atypical mycobacteria.  To det. its mechanism of action, the cellular target was identified.  Spontaneous Mycobacterium smegmatis, Mycobacterium bovis BCG, and M. tuberculosis H37Rv mutants that were resistant to BM212 were isolated.  By the screening of genomic libraries and by whole-genome sequencing, it was found that all the characterized mutants showed mutations in the mmpL3 gene, allowing the conclusion that resistance to BM212 maps to the MmpL3 protein, a member of the MmpL (mycobacterial membrane protein, large) family.  Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonylcyanide m-chlorophenylhydrazone, and verapamil.  Uptake/efflux expts. with [14C]BM212 demonstrated that resistance is not driven by the efflux of BM212.  Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBpqZddgKhTLVg90H21EOLACvtfcHk0ljCBYMd4LMIuQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Gqtw%253D%253D&amp;md5=f73b43cff2112c31ae27878eeb740d76</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.05270-11&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05270-11%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRosa%26aufirst%3DV.%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DCanseco%26aufirst%3DJ.%2BO.%26aulast%3DBuroni%26aufirst%3DS.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DBiava%26aufirst%3DM.%26aulast%3DRaju%26aufirst%3DR.%2BM.%26aulast%3DPorretta%26aufirst%3DG.%2BC.%26aulast%3DAlfonso%26aufirst%3DS.%26aulast%3DBattilocchio%26aufirst%3DC.%26aulast%3DJavid%26aufirst%3DB.%26aulast%3DSorrentino%26aufirst%3DF.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26aulast%3DDe%2BLogu%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26atitle%3DMmpL3%2520is%2520the%2520cellular%2520target%2520of%2520the%2520antitubercular%2520pyrrole%2520derivative%2520BM212%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D324%26epage%3D331%26doi%3D10.1128%2FAAC.05270-11" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocozza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretta, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Logu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rosa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasca, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wae, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span> <span> </span><span class="NLM_article-title">Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e56980</span>, <span class="refDoi">&nbsp;DOI: 10.1371/journal.pone.0056980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1371%2Fjournal.pone.0056980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=23437287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjs12ntr0%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2013&amp;pages=e56980&amp;author=G.+Poceauthor=R.+H.+Batesauthor=S.+Alfonsoauthor=M.+Cocozzaauthor=G.+C.+Porrettaauthor=L.+Ballellauthor=J.+Rullasauthor=F.+Ortegaauthor=A.+De+Loguauthor=E.+Agusauthor=V.+La+Rosaauthor=M.+R.+Pascaauthor=E.+De+Rossiauthor=B.+Waeauthor=S.+G.+Franzblauauthor=F.+Manettiauthor=M.+Bottaauthor=M.+Biava&amp;title=Improved+BM212+MmpL3+inhibitor+analogue+shows+efficacy+in+acute+murine+model+of+tuberculosis+infection&amp;doi=10.1371%2Fjournal.pone.0056980" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection</span></div><div class="casAuthors">Poce, Giovanna; Bates, Robert H.; Alfonso, Salvatore; Cocozza, Martina; Porretta, Giulio Cesare; Ballell, Lluis; Rullas, Joaquin; Ortega, Fatima; De Logu, Alessandro; Agus, Emanuela; La Rosa, Valentina; Pasca, Maria Rosalia; De Rossi, Edda; Wae, Baojie; Franzblau, Scott G.; Manetti, Fabrizio; Botta, Maurizio; Biava, Mariangela</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e56980</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">1,5-Di-Ph pyrroles were previously identified as a class of compds. endowed with high in vitro efficacy against M. tuberculosis.  To improve the phys. chem. properties and drug-like parameters of this class of compds., a medicinal chem. effort was undertaken.  By selecting the optimal substitution patterns for the Ph rings at N1 and C5 and by replacing the thiomorpholine moiety with a morpholine one, a new series of compds. was produced.  The replacement of the sulfur with oxygen gave compds. with lower lipophilicity and improved in vitro microsomal stability.  Moreover, since the parent compd. of this family has been shown to target MmpL3, mycobacterial mutants resistant to two compds. have been isolated and characterized by sequencing the mmpL3 gene; all the mutants showed point mutations in this gene.  The best compd. identified to date was progressed to dose-response studies in an acute murine TB infection model.  The resulting ED99 of 49 mg/Kg is within the range of commonly employed tuberculosis drugs, demonstrating the potential of this chem. series.  The in vitro and in vivo target validation evidence presented here adds further wt. to MmpL3 as a druggable target of interest for anti-tubercular drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyyLtc66FRAbVg90H21EOLACvtfcHk0lgne7LMo1ONsg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXjs12ntr0%253D&amp;md5=9dd29b729e6bdc9b94409bc1147e28e0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0056980&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0056980%26sid%3Dliteratum%253Aachs%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DBates%26aufirst%3DR.%2BH.%26aulast%3DAlfonso%26aufirst%3DS.%26aulast%3DCocozza%26aufirst%3DM.%26aulast%3DPorretta%26aufirst%3DG.%2BC.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DDe%2BLogu%26aufirst%3DA.%26aulast%3DAgus%26aufirst%3DE.%26aulast%3DLa%2BRosa%26aufirst%3DV.%26aulast%3DPasca%26aufirst%3DM.%2BR.%26aulast%3DDe%2BRossi%26aufirst%3DE.%26aulast%3DWae%26aufirst%3DB.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DManetti%26aufirst%3DF.%26aulast%3DBotta%26aufirst%3DM.%26aulast%3DBiava%26aufirst%3DM.%26atitle%3DImproved%2520BM212%2520MmpL3%2520inhibitor%2520analogue%2520shows%2520efficacy%2520in%2520acute%2520murine%2520model%2520of%2520tuberculosis%2520infection%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De56980%26doi%3D10.1371%2Fjournal.pone.0056980" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawate, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wivagg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazyanskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquadro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span> <span> </span><span class="NLM_article-title">Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1384</span>, <span class="refDoi">&nbsp;DOI: 10.1021/cb300151m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300151m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvV2guro%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=7&amp;publication_year=2012&amp;pages=1377-1384&amp;author=S.+A.+Stanleyauthor=S.+S.+Grantauthor=T.+Kawateauthor=N.+Iwaseauthor=M.+Shimizuauthor=C.+Wivaggauthor=M.+Silvisauthor=E.+Kazyanskayaauthor=J.+Aquadroauthor=A.+Golasauthor=M.+Fitzgeraldauthor=H.+Daiauthor=L.+Zhangauthor=D.+T.+Hung&amp;title=Identification+of+novel+inhibitors+of+M.+tuberculosis+growth+using+whole+cell+based+high-throughput+screening&amp;doi=10.1021%2Fcb300151m" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening</span></div><div class="casAuthors">Stanley, Sarah A.; Schmidt Grant, Sarah; Kawate, Tomohiko; Iwase, Noriaki; Shimizu, Motohisa; Wivagg, Carl; Silvis, Melanie; Kazyanskaya, Edward; Aquadro, John; Golas, Aaron; Fitzgerald, Michael; Dai, Huanqin; Zhang, Lixin; Hung, Deborah T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1377-1384</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the urgent need for new antitubercular drugs, few are on the horizon.  To combat the problem of emerging drug resistance, structurally unique chem. entities that inhibit new targets will be required.  Here, we describe our investigations using whole cell screening of a diverse collection of small mols. as a methodol. for identifying novel inhibitors that target new pathways for Mycobacterium tuberculosis drug discovery.  We find that conducting primary screens using model mycobacterial species may limit the potential for identifying new inhibitors with efficacy against M. tuberculosis.  In addn., we confirm the importance of developing in vitro assay conditions that are reflective of in vivo biol. for maximizing the proportion of hits from whole cell screening that are likely to have activity in vivo.  Finally, we describe the identification and characterization of two novel inhibitors that target steps in M. tuberculosis cell wall biosynthesis.  The first is a novel benzimidazole, I, that targets mycobacterial membrane protein large 3 (MmpL3), a proposed transporter for cell wall mycolic acids.  The second is a nitro-triazole, II, that inhibits decaprenylphosphoryl-β-d-ribose 2'-epimerase (DprE1), an epimerase required for cell wall biosynthesis.  These proteins are both among the small no. of new targets that have been identified by forward chem. genetics using resistance generation coupled with genome sequencing.  This suggests that methodologies currently employed for screening and target identification may lead to a bias in target discovery and that alternative methods should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPUQqAYK8L3LVg90H21EOLACvtfcHk0lgne7LMo1ONsg"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XmvV2guro%253D&amp;md5=7293e2cca5001af5bfcf5e1bb4fb1a70</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fcb300151m&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300151m%26sid%3Dliteratum%253Aachs%26aulast%3DStanley%26aufirst%3DS.%2BA.%26aulast%3DGrant%26aufirst%3DS.%2BS.%26aulast%3DKawate%26aufirst%3DT.%26aulast%3DIwase%26aufirst%3DN.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DWivagg%26aufirst%3DC.%26aulast%3DSilvis%26aufirst%3DM.%26aulast%3DKazyanskaya%26aufirst%3DE.%26aulast%3DAquadro%26aufirst%3DJ.%26aulast%3DGolas%26aufirst%3DA.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHung%26aufirst%3DD.%2BT.%26atitle%3DIdentification%2520of%2520novel%2520inhibitors%2520of%2520M.%2520tuberculosis%2520growth%2520using%2520whole%2520cell%2520based%2520high-throughput%2520screening%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1377%26epage%3D1384%26doi%3D10.1021%2Fcb300151m" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remuiñán, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Herrán, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullás, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemparte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Hoyos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Muro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile-Gabaldón, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spivey, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinidou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebollo-López, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza-Losana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammack, N.</span></span> <span> </span><span class="NLM_article-title">Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6’,7’-dihydrospiro[piperidine-4,4’-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e60933</span>, <span class="refDoi">&nbsp;DOI: 10.1371/journal.pone.0060933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1371%2Fjournal.pone.0060933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=23613759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFartro%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2013&amp;pages=e60933&amp;author=M.+J.+Remui%C3%B1%C3%A1nauthor=E.+P%C3%A9rez-Herr%C3%A1nauthor=J.+Rull%C3%A1sauthor=C.+Alemparteauthor=M.+Mart%C3%ADnez-Hoyosauthor=D.+J.+Dowauthor=J.+Afariauthor=N.+Mehtaauthor=J.+Esquiviasauthor=E.+Jim%C3%A9nezauthor=F.+Ortega-Muroauthor=M.+T.+Fraile-Gabald%C3%B3nauthor=V.+L.+Spiveyauthor=N.+J.+Lomanauthor=M.+J.+Pallenauthor=C.+Constantinidouauthor=D.+J.+Minickauthor=M.+Cachoauthor=M.+J.+Rebollo-L%C3%B3pezauthor=C.+Gonz%C3%A1lezauthor=V.+Sousaauthor=I.+Angulo-Barturenauthor=A.+Mendoza-Losanaauthor=D.+Barrosauthor=G.+S.+Besraauthor=L.+Ballellauthor=N.+Cammack&amp;title=Tetrahydropyrazolo%5B1%2C5-a%5Dpyrimidine-3-carboxamide+and+N-benzyl-6%E2%80%99%2C7%E2%80%99-dihydrospiro%5Bpiperidine-4%2C4%E2%80%99-thieno%5B3%2C2-c%5Dpyran%5D+analogues+with+bactericidal+efficacy+against+Mycobacterium+tuberculosis+targeting+MmpL3&amp;doi=10.1371%2Fjournal.pone.0060933" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3</span></div><div class="casAuthors">Remuinan, Modesto J.; Perez-Herran, Esther; Rullas, Joaquin; Alemparte, Carlos; Martinez-Hoyos, Maria; Dow, David J.; Afari, Johnson; Mehta, Nalini; Esquivias, Jorge; Jimenez, Elena; Ortega-Muro, Fatima; Fraile-Gabaldon, Maria Teresa; Spivey, Vickey L.; Loman, Nicholas J.; Pallen, Mark J.; Constantinidou, Chrystala; Minick, Douglas J.; Cacho, Monica; Rebollo-Lopez, Maria Jose; Gonzalez, Carolina; Sousa, Veronica; Angulo-Barturen, Inigo; Mendoza-Losana, Alfonso; Barros, David; Besra, Gurdyal S.; Ballell, Lluis; Cammack, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e60933</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB).  Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug resistant TB.  As part of the authors' efforts towards the discovery of new anti-tubercular leads, a no. of potent tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide (THPP) and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] (Spiro) analogs were recently identified against Mycobacterium tuberculosis and Mycobacterium bovis BCG through a high-throughput whole-cell screening campaign.  Herein, the authors describe the attractive in vitro and in vivo anti-tubercular profiles of both lead series.  The generation of M. tuberculosis spontaneous mutants and subsequent whole genome sequencing of several resistant mutants identified single mutations in the essential mmpL3 gene.  This genetic phenotype was further confirmed by a chem. phenotype, whereby M. bovis BCG treated with both the THPP and Spiro series resulted in the accumulation of trehalose monomycolate.  In vivo efficacy evaluation of two optimized THPP and Spiro leads showed how the compds. were able to reduce &gt;2 logs bacterial cfu counts in the lungs of infected mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCGBbs5TLQArVg90H21EOLACvtfcHk0ljPOFf0Eg4_tw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXmvFartro%253D&amp;md5=22123e5b0f762bcd2467bae122c372ca</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060933&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060933%26sid%3Dliteratum%253Aachs%26aulast%3DRemui%25C3%25B1%25C3%25A1n%26aufirst%3DM.%2BJ.%26aulast%3DP%25C3%25A9rez-Herr%25C3%25A1n%26aufirst%3DE.%26aulast%3DRull%25C3%25A1s%26aufirst%3DJ.%26aulast%3DAlemparte%26aufirst%3DC.%26aulast%3DMart%25C3%25ADnez-Hoyos%26aufirst%3DM.%26aulast%3DDow%26aufirst%3DD.%2BJ.%26aulast%3DAfari%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DN.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DE.%26aulast%3DOrtega-Muro%26aufirst%3DF.%26aulast%3DFraile-Gabald%25C3%25B3n%26aufirst%3DM.%2BT.%26aulast%3DSpivey%26aufirst%3DV.%2BL.%26aulast%3DLoman%26aufirst%3DN.%2BJ.%26aulast%3DPallen%26aufirst%3DM.%2BJ.%26aulast%3DConstantinidou%26aufirst%3DC.%26aulast%3DMinick%26aufirst%3DD.%2BJ.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DRebollo-L%25C3%25B3pez%26aufirst%3DM.%2BJ.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DC.%26aulast%3DSousa%26aufirst%3DV.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26aulast%3DMendoza-Losana%26aufirst%3DA.%26aulast%3DBarros%26aufirst%3DD.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DCammack%26aufirst%3DN.%26atitle%3DTetrahydropyrazolo%255B1%252C5-a%255Dpyrimidine-3-carboxamide%2520and%2520N-benzyl-6%25E2%2580%2599%252C7%25E2%2580%2599-dihydrospiro%255Bpiperidine-4%252C4%25E2%2580%2599-thieno%255B3%252C2-c%255Dpyran%255D%2520analogues%2520with%2520bactericidal%2520efficacy%2520against%2520Mycobacterium%2520tuberculosis%2520targeting%2520MmpL3%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De60933%26doi%3D10.1371%2Fjournal.pone.0060933" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondreddi, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshminarayana, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8849</span>– <span class="NLM_lpage">8859</span>, <span class="refDoi">&nbsp;DOI: 10.1021/jm4012774</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012774" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOisLjL" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=56&amp;publication_year=2013&amp;pages=8849-8859&amp;author=R.+R.+Kondreddiauthor=J.+Jiricekauthor=S.+P.+S.+Raoauthor=S.+B.+Lakshminarayanaauthor=L.+R.+Camachoauthor=R.+Raoauthor=M.+Herveauthor=P.+Bifaniauthor=N.+L.+Maauthor=K.+Kuhenauthor=A.+Gohauthor=A.+K.+Chatterjeeauthor=T.+Dickauthor=T.+T.+Diaganaauthor=U.+H.+Manjunathaauthor=P.+W.+Smith&amp;title=Design%2C+synthesis%2C+and+biological+evaluation+of+indole-2-carboxamides%3A+a+promising+class+of+antituberculosis+agents&amp;doi=10.1021%2Fjm4012774" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides: A Promising Class of Antituberculosis Agents</span></div><div class="casAuthors">Kondreddi, Ravinder Reddy; Jiricek, Jan; Rao, Srinivasa P. S.; Lakshminarayana, Suresh B.; Camacho, Luis R.; Rao, Ranga; Herve, Maxime; Bifani, Pablo; Ma, Ngai Ling; Kuhen, Kelli; Goh, Anne; Chatterjee, Arnab K.; Dick, Thomas; Diagana, Thierry T.; Manjunatha, Ujjini H.; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8849-8859</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indole-2-carboxamides have been identified as a promising class of antituberculosis agents from phenotypic screening against mycobacteria.  One of the hits, indole-2-carboxamide analog (I), had low micromolar potency against Mycobacterium tuberculosis (Mtb), high mouse liver microsomal clearance, and low aq. soly.  Structure-activity relationship studies revealed that attaching alkyl groups to the cyclohexyl ring significantly improved Mtb activity but reduced soly.  Furthermore, chloro, fluoro, or cyano substitutions on the 4- and 6-positions of the indole ring as well as Me substitution on the cyclohexyl ring significantly improved metabolic stability.  II and III, the lead candidates, displayed improved in vitro activity compared to most of the current std. TB drugs.  The low aq. soly. could not be mitigated because of the pos. correlation of lipophilicity with Mtb potency.  However, both compds. displayed favorable oral pharmacokinetic properties in rodents and demonstrated in vivo efficacy.  Thus, indole-2-carboxamides represent a promising new class of antituberculosis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4KW8om-6fZ7Vg90H21EOLACvtfcHk0lgerUD0DUts4Q"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOisLjL&amp;md5=ab732bc84632b1f9f364e45610bcbc1b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm4012774&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012774%26sid%3Dliteratum%253Aachs%26aulast%3DKondreddi%26aufirst%3DR.%2BR.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DLakshminarayana%26aufirst%3DS.%2BB.%26aulast%3DCamacho%26aufirst%3DL.%2BR.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DHerve%26aufirst%3DM.%26aulast%3DBifani%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DN.%2BL.%26aulast%3DKuhen%26aufirst%3DK.%26aulast%3DGoh%26aufirst%3DA.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520indole-2-carboxamides%253A%2520a%2520promising%2520class%2520of%2520antituberculosis%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8849%26epage%3D8859%26doi%3D10.1021%2Fjm4012774" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onajole, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipparaju, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammerman, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishai, W. R.</span></span> <span> </span><span class="NLM_article-title">Indoleamides are active against drug-resistant Mycobacterium tuberculosis</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2907</span>, <span class="refDoi">&nbsp;DOI: 10.1038/ncomms3907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fncomms3907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=24352433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A280%3ADC%252BC2c3oslKgtw%253D%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=4&amp;publication_year=2013&amp;pages=2907&amp;author=S.+Lunauthor=H.+Guoauthor=O.+K.+Onajoleauthor=M.+Pieroniauthor=H.+Gunosewoyoauthor=G.+Chenauthor=S.+K.+Tipparajuauthor=N.+C.+Ammermanauthor=A.+P.+Kozikowskiauthor=W.+R.+Bishai&amp;title=Indoleamides+are+active+against+drug-resistant+Mycobacterium+tuberculosis&amp;doi=10.1038%2Fncomms3907" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamides are active against drug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Lun Shichun; Guo Haidan; Onajole Oluseye K; Gunosewoyo Hendra; Chen Gang; Kozikowski Alan P; Pieroni Marco; Tipparaju Suresh K; Ammerman Nicole C; Bishai William R</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2907</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Responsible for nearly two million deaths each year, the infectious disease tuberculosis remains a serious global health challenge.  The emergence of multidrug- and extensively drug-resistant strains of Mycobacterium tuberculosis confounds control efforts, and new drugs with novel molecular targets are desperately needed.  Here we describe lead compounds, the indoleamides, with potent activity against both drug-susceptible and drug-resistant strains of M. tuberculosis by targeting the mycolic acid transporter MmpL3.  We identify a single mutation in mmpL3, which confers high resistance to the indoleamide class while remaining susceptible to currently used first- and second-line tuberculosis drugs, indicating a lack of cross-resistance.  Importantly, an indoleamide derivative exhibits dose-dependent antimycobacterial activity when orally administered to M. tuberculosis-infected mice.  The bioavailability of the indoleamides, combined with their ability to kill tubercle bacilli, indicates great potential for translational developments of this structure class for the treatment of drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4ame_FVdejL7NkxioyDXTfW6udTcc2eYO68UP_bMnELntkvexoksv"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A280%3ADC%252BC2c3oslKgtw%253D%253D&amp;md5=29323f5b10dff540b38973491545d1c5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fncomms3907&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms3907%26sid%3Dliteratum%253Aachs%26aulast%3DLun%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DPieroni%26aufirst%3DM.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DTipparaju%26aufirst%3DS.%2BK.%26aulast%3DAmmerman%26aufirst%3DN.%2BC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DBishai%26aufirst%3DW.%2BR.%26atitle%3DIndoleamides%2520are%2520active%2520against%2520drug-resistant%2520Mycobacterium%2520tuberculosis%26jtitle%3DNat.%2520Commun.%26date%3D2013%26volume%3D4%26spage%3D2907%26doi%3D10.1038%2Fncomms3907" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grzegorzewicz, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundi, V. A. K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruppo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Born, S. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korduláková, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavadi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">341</span>, <span class="refDoi">&nbsp;DOI: 10.1038/nchembio.794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fnchembio.794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=22344175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKktrg%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2012&amp;pages=334-341&amp;author=A.+E.+Grzegorzewiczauthor=H.+Phamauthor=V.+A.+K.+B.+Gundiauthor=M.+S.+Schermanauthor=E.+J.+Northauthor=T.+Hessauthor=V.+Jonesauthor=V.+Gruppoauthor=S.+E.+M.+Bornauthor=J.+Kordul%C3%A1kov%C3%A1author=S.+S.+Chavadiauthor=C.+Morisseauauthor=A.+J.+Lenaertsauthor=R.+E.+Leeauthor=M.+R.+McNeilauthor=M.+Jackson&amp;title=Inhibition+of+mycolic+acid+transport+across+the+Mycobacterium+tuberculosis+plasma+membrane&amp;doi=10.1038%2Fnchembio.794" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane</span></div><div class="casAuthors">Grzegorzewicz, Anna E.; Pham, Ha; Gundi, Vijay A. K. B.; Scherman, Michael S.; North, Elton J.; Hess, Tamara; Jones, Victoria; Gruppo, Veronica; Born, Sarah E. M.; Kordulakova, Jana; Chavadi, Sivagami Sundaram; Morisseau, Christophe; Lenaerts, Anne J.; Lee, Richard E.; McNeil, Michael R.; Jackson, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-341</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New chemotherapeutics active against multidrug-resistant Mycobacterium tuberculosis are urgently needed.  We report on the identification of an adamantyl urea compd. that shows potent bactericidal activity against M. tuberculosis and a unique mode of action, namely the abolition of the translocation of mycolic acids from the cytoplasm, where they are synthesized to the periplasmic side of the plasma membrane and are in turn transferred onto cell wall arabinogalactan or used in the formation of virulence-assocd., outer membrane, trehalose-contg. glycolipids.  Whole-genome sequencing of spontaneous-resistant mutants of M. tuberculosis selected in vitro followed by genetic validation expts. revealed that our prototype inhibitor targets the inner membrane transporter MmpL3.  Conditional gene expression of mmpL3 in mycobacteria and anal. of inhibitor-treated cells validate MmpL3 as essential for mycobacterial growth and support the involvement of this transporter in the translocation of trehalose monomycolate across the plasma membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow3tM24PWRw7Vg90H21EOLACvtfcHk0ljV-UGFTxRCUw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XisVKktrg%253D&amp;md5=0068aca13a9d9f342705035d0cb2c677</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.794&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.794%26sid%3Dliteratum%253Aachs%26aulast%3DGrzegorzewicz%26aufirst%3DA.%2BE.%26aulast%3DPham%26aufirst%3DH.%26aulast%3DGundi%26aufirst%3DV.%2BA.%2BK.%2BB.%26aulast%3DScherman%26aufirst%3DM.%2BS.%26aulast%3DNorth%26aufirst%3DE.%2BJ.%26aulast%3DHess%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DV.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DBorn%26aufirst%3DS.%2BE.%2BM.%26aulast%3DKordul%25C3%25A1kov%25C3%25A1%26aufirst%3DJ.%26aulast%3DChavadi%26aufirst%3DS.%2BS.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BE.%26aulast%3DMcNeil%26aufirst%3DM.%2BR.%26aulast%3DJackson%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520mycolic%2520acid%2520transport%2520across%2520the%2520Mycobacterium%2520tuberculosis%2520plasma%2520membrane%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D334%26epage%3D341%26doi%3D10.1038%2Fnchembio.794" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haiderer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramovitch, R. B.</span></span> <span> </span><span class="NLM_article-title">HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e02459</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.02459-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.02459-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=29661875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOlur3M" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=62&amp;publication_year=2018&amp;pages=e02459&amp;author=H.+Zhengauthor=J.+T.+Williamsauthor=G.+B.+Coulsonauthor=E.+R.+Haidererauthor=R.+B.+Abramovitch&amp;title=HC2091+Kills+Mycobacterium+tuberculosis+by+Targeting+the+MmpL3+Mycolic+Acid+Transporter&amp;doi=10.1128%2FAAC.02459-17" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter</span></div><div class="casAuthors">Zheng, Huiqing; Williams, John T.; Coulson, Garry B.; Haiderer, Elizabeth R.; Abramovitch, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e02459-17/1-e02459-17/12</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tuberculosis, caused by the intracellular pathogen Mycobacterium tuberculosis, is a deadly disease that requires a long course of treatment.  The emergence of drug-resistant strains has driven efforts to discover new small mols. that can kill the bacterium.  Here, we report characterizations of the compd. HC2091, which kills M. tuberculosis in a time- and dose-dependent manner in vitro and inhibits M. tuberculosis growth in macrophages.  Whole-genome sequencing of spontaneous HC2091-resistant mutants identified single-nucleotide variants in the mmpL3 mycolic acid transporter gene.  HC2091-resistant mutants do not exhibit cross-resistance with the well-characterized Mycobacterium membrane protein large 3 (MmpL3) inhibitor SQ109, suggesting a distinct mechanism of interaction with MmpL3.  Addnl., HC2091 does not modulate bacterial membrane potential or kill nonreplicating M. tuberculosis, thus acting differently from other known MmpL3 inhibitors.  RNA sequencing (RNA-seq) transcriptional profiling and lipid profiling of M. tuberculosis treated with HC2091 or SQ109 show that the two compds. target a similar pathway.  HC2091 has a chem. structure dissimilar to those of previously described MmpL3 inhibitors, supporting the notion that HC2091 is a new class of MmpL3 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiL0V3v68er7Vg90H21EOLACvtfcHk0ljV-UGFTxRCUw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOlur3M&amp;md5=19dd032282c9598fdd65f0d9039ce9ef</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1128%2FAAC.02459-17&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02459-17%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DCoulson%26aufirst%3DG.%2BB.%26aulast%3DHaiderer%26aufirst%3DE.%2BR.%26aulast%3DAbramovitch%26aufirst%3DR.%2BB.%26atitle%3DHC2091%2520Kills%2520Mycobacterium%2520tuberculosis%2520by%2520Targeting%2520the%2520MmpL3%2520Mycolic%2520Acid%2520Transporter%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De02459%26doi%3D10.1128%2FAAC.02459-17" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roquet-Banères, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onajole, O. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">337</span>, <span class="refDoi">&nbsp;DOI: 10.1021/acsinfecdis.9b00389</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.9b00389" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGhtbfN" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2020&amp;pages=324-337&amp;author=C.+Raynaudauthor=W.+Daherauthor=M.+D.+Johansenauthor=F.+Roquet-Ban%C3%A8resauthor=M.+Blaiseauthor=O.+K.+Onajoleauthor=A.+P.+Kozikowskiauthor=J.-L.+Herrmannauthor=J.+Dziadekauthor=K.+Gobisauthor=L.+Kremer&amp;title=Active+Benzimidazole+Derivatives+Targeting+the+MmpL3+Transporter+in+Mycobacterium+abscessus&amp;doi=10.1021%2Facsinfecdis.9b00389" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in Mycobacterium abscessus</span></div><div class="casAuthors">Raynaud, Clement; Daher, Wassim; Johansen, Matt D.; Roquet-Baneres, Francoise; Blaise, Mickael; Onajole, Oluseye K.; Kozikowski, Alan P.; Herrmann, Jean-Louis; Dziadek, Jaroslaw; Gobis, Katarzyna; Kremer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-337</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The prevalence of pulmonary infections due to nontuberculous mycobacteria such as Mycobacterium abscessus has been increasing and surpassing tuberculosis (TB) in some industrialized countries.  Because of intrinsic resistance to most antibiotics that drastically limits conventional chemotherapeutic treatment options, new anti-M. abscessus therapeutics are urgently needed against this emerging pathogen.  Extensive screening of a library of benzimidazole derivs. that were previously shown to be active against Mycobacterium tuberculosis led to the identification of a lead compd. exhibiting very potent in vitro activity against a wide panel of M. abscessus clin. strains.  Designated EJMCh-6, this compd., a 2-(2-cyclohexylethyl)-5,6-dimethyl-1H-benzo[d]imidazole, also exerted very strong activity against intramacrophage-residing M. abscessus.  Moreover, the treatment of infected zebrafish embryos with EJMCh-6 was correlated with significantly increased embryo survival and a decrease in the bacterial burden as compared to those for untreated fish.  Insights into the mechanism of action were inferred from the generation of spontaneous benzimidazole-resistant strains and the identification of a large set of missense mutations in MmpL3, the mycolic acid transporter in mycobacteria.  Overexpression of the mutated mmpL3 alleles in a susceptible M. abscessus strain was assocd. with high resistance levels to EJMCh-6 and to other known MmpL3 inhibitors.  Mapping the mutations conferring resistance on an MmpL3 three-dimensional homol. model defined a potential EJMCh-6-binding cavity.  These data emphasize a yet unexploited chem. structure class against M. abscessus with promising translational development for the treatment of M. abscessus lung diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWKP6HQM9btrVg90H21EOLACvtfcHk0ljQgszxa78xjA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXisVGhtbfN&amp;md5=3d5af8b3b2dab83f408912d04e666bb5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.9b00389&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.9b00389%26sid%3Dliteratum%253Aachs%26aulast%3DRaynaud%26aufirst%3DC.%26aulast%3DDaher%26aufirst%3DW.%26aulast%3DJohansen%26aufirst%3DM.%2BD.%26aulast%3DRoquet-Ban%25C3%25A8res%26aufirst%3DF.%26aulast%3DBlaise%26aufirst%3DM.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DHerrmann%26aufirst%3DJ.-L.%26aulast%3DDziadek%26aufirst%3DJ.%26aulast%3DGobis%26aufirst%3DK.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DActive%2520Benzimidazole%2520Derivatives%2520Targeting%2520the%2520MmpL3%2520Transporter%2520in%2520Mycobacterium%2520abscessus%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2020%26volume%3D6%26spage%3D324%26epage%3D337%26doi%3D10.1021%2Facsinfecdis.9b00389" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dal
Molin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selchow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschumi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laage-Witt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, P.</span></span> <span> </span><span class="NLM_article-title">Identification of novel scaffolds targeting Mycobacterium tuberculosis</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1601</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi">&nbsp;DOI: 10.1007/s00109-019-01840-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1007%2Fs00109-019-01840-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=31728550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12ks73M" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=97&amp;publication_year=2019&amp;pages=1601-1613&amp;author=M.+Dal%0AMolinauthor=P.+Selchowauthor=D.+Sch%C3%A4fleauthor=A.+Tschumiauthor=T.+Ryckmansauthor=S.+Laage-Wittauthor=P.+Sander&amp;title=Identification+of+novel+scaffolds+targeting+Mycobacterium+tuberculosis&amp;doi=10.1007%2Fs00109-019-01840-7" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel scaffolds targeting Mycobacterium tuberculosis</span></div><div class="casAuthors">Dal Molin, Michael; Selchow, Petra; Schafle, Daniel; Tschumi, Andreas; Ryckmans, Thomas; Laage-Witt, Stephan; Sander, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1601-1613</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Drug resistance in Mycobacterium tuberculosis is relentlessly progressing while only a handful of novel drug candidates are developed.  Here we describe a GFP-based high-throughput screening of 386,496 diverse compds. to identify putative tuberculosis drug candidates.  In an exploratory anal. of the model organism M. bovis BCG and M. smegmatis and the subsequent screening of the main library, we identified 6354 compds. with anti-mycobacterial activity.  These hit compds. were predominantly selective for mycobacteria while dozens had activity in the low μM range.  We tested toxicity against the human monocyte/macrophage cell line THP-1 and elaborated activity against M. tuberculosis growing in liq. broth, under unique conditions such as non-replicating persistence or inhibition of M. tuberculosis residing in macrophages.  Finally, spontaneous compd.-resistant M. tuberculosis mutants were selected and subsequently analyzed by whole genome sequencing.  In addn. to compds. targeting the well-described proteins Pks13 and MmpL3, we identified two novel scaffolds targeting the bifunctional guanosine pentaphosphate synthetase/ polyribonucleotide nucleotidyltransferase GpsI, or interacting with the aminopeptidase PepB, a probable pro-drug activator.  A newly identified scaffold targets the bifunctional enzyme GpsI.  The aminopeptidase PepB is interacting with a second novel scaffold.  Phenotypic screenings regularly identify novel compds. targeting Pks13 and MmpL3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpka14rxYjQgLVg90H21EOLACvtfcHk0ljQgszxa78xjA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXit12ks73M&amp;md5=91c786e6a7ea154583dc4943146b156b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs00109-019-01840-7&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-019-01840-7%26sid%3Dliteratum%253Aachs%26aulast%3DDal%2BMolin%26aufirst%3DM.%26aulast%3DSelchow%26aufirst%3DP.%26aulast%3DSch%25C3%25A4fle%26aufirst%3DD.%26aulast%3DTschumi%26aufirst%3DA.%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DLaage-Witt%26aufirst%3DS.%26aulast%3DSander%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520scaffolds%2520targeting%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2019%26volume%3D97%26spage%3D1601%26epage%3D1613%26doi%3D10.1007%2Fs00109-019-01840-7" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poce, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consalvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venditti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desideri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Menendez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barros Aguirre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Logu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioerger, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biava, M.</span></span> <span> </span><span class="NLM_article-title">Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1423</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi">&nbsp;DOI: 10.1021/acsmedchemlett.9b00204</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00204" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rM" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=10&amp;publication_year=2019&amp;pages=1423-1429&amp;author=G.+Poceauthor=S.+Consalviauthor=G.+Vendittiauthor=S.+Alfonsoauthor=N.+Desideriauthor=R.+Fernandez-Menendezauthor=R.+H.+Batesauthor=L.+Ballellauthor=D.+Barros+Aguirreauthor=J.+Rullasauthor=A.+De+Loguauthor=M.+Gardnerauthor=T.+R.+Ioergerauthor=E.+J.+Rubinauthor=M.+Biava&amp;title=Novel+Pyrazole-Containing+Compounds+Active+against+Mycobacterium+tuberculosis&amp;doi=10.1021%2Facsmedchemlett.9b00204" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis</span></div><div class="casAuthors">Poce, Giovanna; Consalvi, Sara; Venditti, Giulia; Alfonso, Salvatore; Desideri, Nicoletta; Fernandez-Menendez, Raquel; Bates, Robert H.; Ballell, Lluis; Barros Aguirre, David; Rullas, Joaquin; De Logu, Alessandro; Gardner, Michelle; Ioerger, Thomas R.; Rubin, Eric J.; Biava, Mariangela</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1423-1429</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 49 five-membered heterocyclic compds. contg. either a pyridine- or a pyrrole-type nitrogen were synthesized and tested against Mycobacterium tuberculosis.  Among them, only the 1,3,5-trisubstituted pyrazoles exhibited min. inhibitory concn. values in the low micromolar range, and some also exhibited an improved physicochem. profile without cytotoxic effects.  Three pyrazoles were subjected to an animal tuberculosis efficacy model, and 1-((1-(4-Fluorophenyl)-5-(4-isopropylphenyl)-1H-pyrazol-3-yl)methyl)-4-methoxypiperidine induced a statistically significant difference in lung bacterial counts compared with untreated mice.  Moreover, to det. the target of this series, resistors were generated, and whole genome sequencing revealed mutations in the mmpL3 gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQbGTdOFbohLVg90H21EOLACvtfcHk0ljQgszxa78xjA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rM&amp;md5=cd921aadaba2214fae338c358cea363b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00204&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00204%26sid%3Dliteratum%253Aachs%26aulast%3DPoce%26aufirst%3DG.%26aulast%3DConsalvi%26aufirst%3DS.%26aulast%3DVenditti%26aufirst%3DG.%26aulast%3DAlfonso%26aufirst%3DS.%26aulast%3DDesideri%26aufirst%3DN.%26aulast%3DFernandez-Menendez%26aufirst%3DR.%26aulast%3DBates%26aufirst%3DR.%2BH.%26aulast%3DBallell%26aufirst%3DL.%26aulast%3DBarros%2BAguirre%26aufirst%3DD.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DDe%2BLogu%26aufirst%3DA.%26aulast%3DGardner%26aufirst%3DM.%26aulast%3DIoerger%26aufirst%3DT.%2BR.%26aulast%3DRubin%26aufirst%3DE.%2BJ.%26aulast%3DBiava%26aufirst%3DM.%26atitle%3DNovel%2520Pyrazole-Containing%2520Compounds%2520Active%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1423%26epage%3D1429%26doi%3D10.1021%2Facsmedchemlett.9b00204" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roquet-Banères, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guérardel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">17512</span>– <span class="NLM_lpage">17523</span>, <span class="refDoi">&nbsp;DOI: 10.1074/jbc.RA119.010135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1074%2Fjbc.RA119.010135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=31562241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKlurfN" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=294&amp;publication_year=2019&amp;pages=17512-17523&amp;author=C.+Dupontauthor=Y.+Chenauthor=Z.+Xuauthor=F.+Roquet-Ban%C3%A8resauthor=M.+Blaiseauthor=A.-K.+Wittauthor=F.+Dubarauthor=C.+Biotauthor=Y.+Gu%C3%A9rardelauthor=F.+P.+Maurerauthor=S.-S.+Chngauthor=L.+Kremer&amp;title=A+piperidinol-containing+molecule+is+active+against+Mycobacterium+tuberculosis+by+inhibiting+the+mycolic+acid+flippase+activity+of+MmpL3&amp;doi=10.1074%2Fjbc.RA119.010135" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3</span></div><div class="casAuthors">Dupont, Christian; Chen, Yushu; Xu, Zhujun; Roquet-Baneres, Francoise; Blaise, Mickael; Witt, Anne-Kathrin; Dubar, Faustine; Biot, Christophe; Guerardel, Yann; Maurer, Florian P.; Chng, Shu-Sin; Kremer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">17512-17524</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, the causative agent of tuberculosis, remains a major human pathogen, and current treatment options to combat this disease are under threat because of the emergence of multidrug-resistant and extensively drug-resistant tuberculosis.  High-throughput whole-cell screening of an extensive compd. library has recently identified a piperidinol-contg. mol., PIPD1, as a potent lead compd. against M. tuberculosis.  Herein, we show that PIPD1 and related analogs exert in vitro bactericidal activity against the M. tuberculosis strain mc26230 and also against a panel of multidrug-resistant and extensively drug-resistant clin. isolates of M. tuberculosis, suggesting that PIPD1's mode of action differs from those of most first- and second-line anti-tubercular drugs.  Selection and DNA sequencing of PIPD1-resistant mycobacterial mutants revealed the presence of single-nucleotide polymorphisms in mmpL3, encoding an inner membrane-assocd. mycolic acid flippase in M. tuberculosis.  Results from functional assays with spheroplasts derived from a M. smegmatis strain lacking the endogenous mmpL3 gene but harboring the M. tuberculosis mmpL3 homolog indicated that PIPD1 inhibits the MmpL3-driven translocation of trehalose monomycolate across the inner membrane without altering the proton motive force.  Using a predictive structural model of MmpL3 from M. tuberculosis, docking studies revealed a PIPD1-binding cavity recently found to accommodate different inhibitors in M. smegmatis MmpL3.  In conclusion, our findings have uncovered bactericidal activity of a new chem. scaffold.  Its anti-tubercular activity is mediated by direct inhibition of the flippase activity of MmpL3 rather than by inhibition of the inner membrane proton motive force, significantly advancing our understanding of MmpL3-targeted inhibition in mycobacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcjxDOj6T9KbVg90H21EOLACvtfcHk0ljQgszxa78xjA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXitlKlurfN&amp;md5=3a099709e2505c05a6397742cfa9360d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.010135&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.010135%26sid%3Dliteratum%253Aachs%26aulast%3DDupont%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DRoquet-Ban%25C3%25A8res%26aufirst%3DF.%26aulast%3DBlaise%26aufirst%3DM.%26aulast%3DWitt%26aufirst%3DA.-K.%26aulast%3DDubar%26aufirst%3DF.%26aulast%3DBiot%26aufirst%3DC.%26aulast%3DGu%25C3%25A9rardel%26aufirst%3DY.%26aulast%3DMaurer%26aufirst%3DF.%2BP.%26aulast%3DChng%26aufirst%3DS.-S.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DA%2520piperidinol-containing%2520molecule%2520is%2520active%2520against%2520Mycobacterium%2520tuberculosis%2520by%2520inhibiting%2520the%2520mycolic%2520acid%2520flippase%2520activity%2520of%2520MmpL3%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D17512%26epage%3D17523%26doi%3D10.1074%2Fjbc.RA119.010135" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haiderer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulson, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Cabrera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramovitch, R. B.</span></span> <span> </span><span class="NLM_article-title">Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e00547</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.00547-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.00547-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=31405862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1eisbvE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=63&amp;publication_year=2019&amp;pages=e00547&amp;author=J.+T.+Williamsauthor=E.+R.+Haidererauthor=G.+B.+Coulsonauthor=K.+N.+Connerauthor=E.+Ellsworthauthor=C.+Chenauthor=N.+Alvarez-Cabreraauthor=W.+Liauthor=M.+Jacksonauthor=T.+Dickauthor=R.+B.+Abramovitch&amp;title=Identification+of+New+MmpL3+Inhibitors+by+Untargeted+and+Targeted+Mutant+Screens+Defines+MmpL3+Domains+with+Differential+Resistance&amp;doi=10.1128%2FAAC.00547-19" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new MmpL3 inhibitors by untargeted and targeted mutant screens defines MmpL3 domains with differential resistance</span></div><div class="casAuthors">Williams, John T.; Haiderer, Elizabeth R.; Coulson, Garry B.; Conner, Kayla N.; Ellsworth, Edmund; Chen, Chao; Alvarez-Cabrera, Nadine; Li, Wei; Jackson, Mary; Dick, Thomas; Abramovitch, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e00547-19</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Mycobacterium tuberculosis mycolate flippase MmpL3 has been the proposed target for multiple inhibitors with diverse chem. scaffolds.  This diversity in chem. scaffolds has made it difficult to predict compds. that inhibit MmpL3 without whole-genome sequencing of isolated resistant mutants.  Here, we describe the identification of four new inhibitors that select for resistance mutations in mmpL3.  Using these resistant mutants, we conducted a targeted whole-cell phenotypic screen of 163 novel M. tuberculosis growth inhibitors for differential growth inhibition of wild-type M. tuberculosis compared to the growth of a pool of 24 unique mmpL3 mutants.  The screen successfully identified six addnl. putative MmpL3 inhibitors.  The compds. were bactericidal both in vitro and against intracellular M. tuberculosis.  M. tuberculosis cells treated with these compds. were shown to accumulate trehalose monomycolates, have reduced levels of trehalose dimycolate, and displace an MmpL3-specific probe, supporting MmpL3 as the target.  The inhibitors were mycobacterium specific, with several also showing activity against the nontuberculous mycobacterial species M. abscessus.  Cluster anal. of cross-resistance profiles generated by dose-response expts. for each combination of 13 MmpL3 inhibitors against each of the 24 mmpL3 mutants defined two clades of inhibitors and two clades of mmpL3 mutants.  Pairwise combination studies of the inhibitors revealed interactions that were specific to the clades identified in the cross-resistance profiling.  Addnl., modeling of resistance-conferring substitutions to the MmpL3 crystal structure revealed clade-specific localization of the residues to specific domains of MmpL3, with the clades showing differential resistance.  Several compds. exhibited high soly. and stability in microsomes and low cytotoxicity in macrophages, supporting their further development.  The combined study of multiple mutants and novel compds. provides new insights into structure-function interactions of MmpL3 and small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVVOs0AmlkSrVg90H21EOLACvtfcHk0liWR5BphAuacA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXit1eisbvE&amp;md5=d8ff582f4e360ed404e7d9e49c5838fe</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1128%2FAAC.00547-19&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00547-19%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DHaiderer%26aufirst%3DE.%2BR.%26aulast%3DCoulson%26aufirst%3DG.%2BB.%26aulast%3DConner%26aufirst%3DK.%2BN.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DAlvarez-Cabrera%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DAbramovitch%26aufirst%3DR.%2BB.%26atitle%3DIdentification%2520of%2520New%2520MmpL3%2520Inhibitors%2520by%2520Untargeted%2520and%2520Targeted%2520Mutant%2520Screens%2520Defines%2520MmpL3%2520Domains%2520with%2520Differential%2520Resistance%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De00547%26doi%3D10.1128%2FAAC.00547-19" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Korycka-Machala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viljoen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawelczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzostek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strapagiel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadek, J.</span></span> <span> </span><span class="NLM_article-title">1H-Benzo[d]Imidazole Derivatives Affect MmpL3 in Mycobacterium tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e00441</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.00441-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.00441-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=31332069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1eisbvO" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=63&amp;publication_year=2019&amp;pages=e00441&amp;author=M.+Korycka-Machalaauthor=A.+Viljoenauthor=J.+Pawelczykauthor=P.+Borowkaauthor=B.+Dziadekauthor=K.+Gobisauthor=A.+Brzostekauthor=M.+Kawkaauthor=M.+Blaiseauthor=D.+Strapagielauthor=L.+Kremerauthor=J.+Dziadek&amp;title=1H-Benzo%5Bd%5DImidazole+Derivatives+Affect+MmpL3+in+Mycobacterium+tuberculosis&amp;doi=10.1128%2FAAC.00441-19" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">1H-Benzo[d]imidazole derivatives affect mmpL3 in Mycobacterium tuberculosis</span></div><div class="casAuthors">Korycka-Machala, Malgorzata; Viljoen, Albertus; Pawelczyk, Jakub; Borowka, Paulina; Dziadek, Bozena; Gobis, Katarzyna; Brzostek, Anna; Kawka, Malwina; Blaise, Mickael; Strapagiel, Dominik; Kremer, Laurent; Dziadek, Jaroslaw</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e00441-19</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">1H-benzo[d]imidazole derivs. exhibit antitubercular activity in vitro at a nanomolar range of concns. and are not toxic to human cells, but their mode of action remains unknown.  Here, we showed that these compds. are active against intracellular Mycobacterium tuberculosis.  To identify their target, we selected drug-resistant M. tuberculosis mutants and then used whole-genome sequencing to unravel mutations in the essential mmpL3 gene, which encodes the integral membrane protein that catalyzes the export of trehalose monomycolate, a precursor of the mycobacterial outer membrane component trehalose dimycolate (TDM), as well as mycolic acids bound to arabinogalactan.  The drug-resistant phenotype was also obsd. in the parental strain overexpressing the mmpL3 alleles carrying the mutations identified in the resistors.  However, no cross-resistance was obsd. between 1H-benzo[d]imidazole derivs. and SQ109, another MmpL3 inhibitor, or other first-line antitubercular drugs.  Metabolic labeling and quant. thin-layer chromatog. (TLC) anal. of radiolabeled lipids from M. tuberculosis cultures treated with the benzoimidazoles indicated an inhibition of trehalose dimycolate (TDM) synthesis, as well as reduced levels of mycolylated arabinogalactan, in agreement with the inhibition of MmpL3 activity.  Overall, this study emphasizes the pronounced activity of 1H-benzo[d]imidazole derivs. in interfering with mycolic acid metab. and their potential for therapeutic application in the fight against tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7u07oTQeSoLVg90H21EOLACvtfcHk0liWR5BphAuacA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1MXit1eisbvO&amp;md5=3c668ccbe1706f02f280dd6fb52e1275</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.00441-19&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00441-19%26sid%3Dliteratum%253Aachs%26aulast%3DKorycka-Machala%26aufirst%3DM.%26aulast%3DViljoen%26aufirst%3DA.%26aulast%3DPawelczyk%26aufirst%3DJ.%26aulast%3DBorowka%26aufirst%3DP.%26aulast%3DDziadek%26aufirst%3DB.%26aulast%3DGobis%26aufirst%3DK.%26aulast%3DBrzostek%26aufirst%3DA.%26aulast%3DKawka%26aufirst%3DM.%26aulast%3DBlaise%26aufirst%3DM.%26aulast%3DStrapagiel%26aufirst%3DD.%26aulast%3DKremer%26aufirst%3DL.%26aulast%3DDziadek%26aufirst%3DJ.%26atitle%3D1H-Benzo%255Bd%255DImidazole%2520Derivatives%2520Affect%2520MmpL3%2520in%2520Mycobacterium%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De00441%26doi%3D10.1128%2FAAC.00441-19" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiget, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Guerra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nxumalo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanye, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Herrán, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraile-Gabaldón, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esquivias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Encinas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Siles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osende, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiola, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remuiñán, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemparte, C.</span></span> <span> </span><span class="NLM_article-title">Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11327</span>– <span class="NLM_lpage">11340</span>, <span class="refDoi">&nbsp;DOI: 10.1021/acs.jmedchem.8b01533</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1OqsLjJ" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=61&amp;publication_year=2018&amp;pages=11327-11340&amp;author=A.+Guardiaauthor=J.+Baigetauthor=M.+Cachoauthor=A.+P%C3%A9rezauthor=M.+Ortega-Guerraauthor=W.+Nxumaloauthor=S.+D.+Khanyeauthor=J.+Rullasauthor=F.+Ortegaauthor=E.+Jim%C3%A9nezauthor=E.+P%C3%A9rez-Herr%C3%A1nauthor=M.+T.+Fraile-Gabald%C3%B3nauthor=J.+Esquiviasauthor=R.+Fernandezauthor=E.+Fern%C3%A1ndezauthor=L.+Encinasauthor=M.+Alonsoauthor=I.+Giordanoauthor=C.+Riveroauthor=J.+Miguel-Silesauthor=J.+G.+Osendeauthor=K.+A.+Badiolaauthor=P.+J.+Rutledgeauthor=M.+H.+Toddauthor=M.+Remui%C3%B1%C3%A1nauthor=C.+Alemparte&amp;title=Easy-To-Synthesize+Spirocyclic+Compounds+Possess+Remarkable+in+Vivo+Activity+against+Mycobacterium+tuberculosis&amp;doi=10.1021%2Facs.jmedchem.8b01533" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis</span></div><div class="casAuthors">Guardia, Ana; Baiget, Jessica; Cacho, Monica; Perez, Arancha; Ortega-Guerra, Montserrat; Nxumalo, Winston; Khanye, Setshaba D.; Rullas, Joaquin; Ortega, Fatima; Jimenez, Elena; Perez-Herran, Esther; Fraile-Gabaldon, Maria Teresa; Esquivias, Jorge; Fernandez, Raquel; Porras-De Francisco, Esther; Encinas, Lourdes; Alonso, Marta; Giordano, Ilaria; Rivero, Cristina; Miguel-Siles, Juan; Osende, Javier G.; Badiola, Katrina A.; Rutledge, Peter J.; Todd, Matthew H.; Remuinan, Modesto; Alemparte, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11327-11340</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Society urgently needs new, effective medicines for the treatment of tuberculosis.  To kick-start the required hit-to-lead campaigns, the libraries of pharmaceutical companies have recently been evaluated for starting points.  The GlaxoSmithKline (GSK) library yielded many high-quality hits, and the assocd. data were placed in the public domain to stimulate engagement by the wider community.  One such series, the spiro compds., are described here.  The compds. were explored by a combination of traditional inhouse research and open source methods.  The series benefits from a particularly simple structure and a short assocd. synthetic chem. route.  Many members of the series displayed striking potency and low toxicity, and highly promising in vivo activity in a mouse model was confirmed with one of the analogs.  Ultimately the series was discontinued due to concerns over safety, but the assocd. data remain public domain, empowering others to resume the series if the perceived deficiencies can be overcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmizcPsa-ok7Vg90H21EOLACvtfcHk0liWpD9d4RTJ0w"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC1cXit1OqsLjJ&amp;md5=ca3395ecd8dc725c5162f0965eee84db</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01533&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01533%26sid%3Dliteratum%253Aachs%26aulast%3DGuardia%26aufirst%3DA.%26aulast%3DBaiget%26aufirst%3DJ.%26aulast%3DCacho%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez%26aufirst%3DA.%26aulast%3DOrtega-Guerra%26aufirst%3DM.%26aulast%3DNxumalo%26aufirst%3DW.%26aulast%3DKhanye%26aufirst%3DS.%2BD.%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DOrtega%26aufirst%3DF.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DE.%26aulast%3DP%25C3%25A9rez-Herr%25C3%25A1n%26aufirst%3DE.%26aulast%3DFraile-Gabald%25C3%25B3n%26aufirst%3DM.%2BT.%26aulast%3DEsquivias%26aufirst%3DJ.%26aulast%3DFernandez%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DE.%26aulast%3DEncinas%26aufirst%3DL.%26aulast%3DAlonso%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DI.%26aulast%3DRivero%26aufirst%3DC.%26aulast%3DMiguel-Siles%26aufirst%3DJ.%26aulast%3DOsende%26aufirst%3DJ.%2BG.%26aulast%3DBadiola%26aufirst%3DK.%2BA.%26aulast%3DRutledge%26aufirst%3DP.%2BJ.%26aulast%3DTodd%26aufirst%3DM.%2BH.%26aulast%3DRemui%25C3%25B1%25C3%25A1n%26aufirst%3DM.%26aulast%3DAlemparte%26aufirst%3DC.%26atitle%3DEasy-To-Synthesize%2520Spirocyclic%2520Compounds%2520Possess%2520Remarkable%2520in%2520Vivo%2520Activity%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11327%26epage%3D11340%26doi%3D10.1021%2Facs.jmedchem.8b01533" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">655</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.drudis.2010.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.drudis.2010.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=20570751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=15&amp;publication_year=2010&amp;pages=648-655&amp;author=A.+P.+Hillauthor=R.+J.+Young&amp;title=Getting+physical+in+drug+discovery%3A+a+contemporary+perspective+on+solubility+and+hydrophobicity&amp;doi=10.1016%2Fj.drudis.2010.05.016" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span></div><div class="casAuthors">Hill, Alan P.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15/16</span>),
    <span class="NLM_cas:pages">648-655</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Suboptimal phys. properties have been identified as a particular shortcoming of compds. in contemporary drug discovery, contributing to high attrition levels.  An anal. of the relationship between hydrophobicity (calcd. and measured) and ∼100 k measured kinetic soly. values has been undertaken.  In line with the General Soly. Equation, ests. of hydrophobicity, particularly ACD c log D pH7.4, give a useful indication of the likely soly. classification of particular mols.  Taking ACD c log D pH7.4 values together with the no. of arom. rings in a given mol. provides enhanced prediction.  The Soly. Forecast Index' (SFI = c log D pH7.4 + #Ar) is proposed as a simple, yet effective, guide to predicting soly.  Moreover, anal. of measured distribution/partition coeff. values highlighted statistically significant shortcomings in the applicability of octanol/water as a model system for hydrophobicity detn. with poorly sol. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtQyfNjbFUrVg90H21EOLACvtfcHk0liWpD9d4RTJ0w"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P&amp;md5=7b201081c5586a6ea4b7af00d507d462</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.05.016&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%253A%2520a%2520contemporary%2520perspective%2520on%2520solubility%2520and%2520hydrophobicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D648%26epage%3D655%26doi%3D10.1016%2Fj.drudis.2010.05.016" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palovich, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. J.</span></span> <span> </span><span class="NLM_article-title">Quality guidelines for oral drug candidates: dose, solubility and lipophilicity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.drudis.2016.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.drudis.2016.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=27423371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aisb%252FK" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=21&amp;publication_year=2016&amp;pages=1719-1727&amp;author=M.+K.+Baylissauthor=J.+Butlerauthor=P.+L.+Feldmanauthor=D.+V.+S.+Greenauthor=P.+D.+Leesonauthor=M.+R.+Palovichauthor=A.+J.+Taylor&amp;title=Quality+guidelines+for+oral+drug+candidates%3A+dose%2C+solubility+and+lipophilicity&amp;doi=10.1016%2Fj.drudis.2016.07.007" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Quality guidelines for oral drug candidates: dose, solubility and lipophilicity</span></div><div class="casAuthors">Bayliss, Martin K.; Butler, James; Feldman, Paul L.; Green, Darren V. S.; Leeson, Paul D.; Palovich, Michael R.; Taylor, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1719-1727</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In an attempt to seek increased understanding of compd. attributes that influence successful drug pipeline progression, GlaxoSmithKline's portfolio of oral candidates was compared with ref. sets of marketed oral drugs.  The approach differs from other attrition studies by explicitly focusing on choosing 'the right compd.' by applying relevant, exptl. derived properties.  The anal. led to four proposed compd. quality categories, created by combining specific criteria for three measures: dose, soly. and the property forecast index, a composite measure of lipophilicity using chromatog. detd. Log D and aromaticity.  The 'three properties' provide benchmarked guidelines for project teams to use when seeking and selecting clin. candidates, because they reflect the property distribution of marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRMpjV3EZ_4rVg90H21EOLACvtfcHk0liWpD9d4RTJ0w"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC28Xht1aisb%252FK&amp;md5=d9d145b1ee399b6ad54cdc55fff43c48</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.07.007&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DBayliss%26aufirst%3DM.%2BK.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DFeldman%26aufirst%3DP.%2BL.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DPalovich%26aufirst%3DM.%2BR.%26aulast%3DTaylor%26aufirst%3DA.%2BJ.%26atitle%3DQuality%2520guidelines%2520for%2520oral%2520drug%2520candidates%253A%2520dose%252C%2520solubility%2520and%2520lipophilicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1719%26epage%3D1727%26doi%3D10.1016%2Fj.drudis.2016.07.007" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi">&nbsp;DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2007&amp;pages=881-890&amp;author=P.+D.+Leesonauthor=B.+Springthorpe&amp;title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&amp;doi=10.1038%2Fnrd2445" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0li4Pc5IVGmPXw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&amp;md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Molecular Property Design: Does Everyone Get It?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">725</span>, <span class="refDoi">&nbsp;DOI: 10.1021/acsmedchemlett.5b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=6&amp;publication_year=2015&amp;pages=722-725&amp;author=P.+D.+Leesonauthor=R.+J.+Young&amp;title=Molecular+Property+Design%3A+Does+Everyone+Get+It%3F&amp;doi=10.1021%2Facsmedchemlett.5b00157" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Property Design: Does Everyone Get It?</span></div><div class="casAuthors">Leeson, Paul D.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-725</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The principles of mol. property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space.  Lead optimization trajectories aimed at reducing physicochem. risk, assisted by ligand efficiency metrics, could help to reduce clin. attrition rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_t8gIn79arVg90H21EOLACvtfcHk0li4Pc5IVGmPXw"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D&amp;md5=5a807a8d049ce8cf4adc186891a9234d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00157&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00157%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520Property%2520Design%253A%2520Does%2520Everyone%2520Get%2520It%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D722%26epage%3D725%26doi%3D10.1021%2Facsmedchemlett.5b00157" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=16&amp;publication_year=2011&amp;pages=822-830&amp;author=R.+J.+Youngauthor=D.+V.+S.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&amp;title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity&amp;doi=10.1016%2Fj.drudis.2011.06.001" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0lhTJlreb7Am5Q"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&amp;md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirschl, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harikrishnan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seethala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael Lawrence, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, M. E.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6503</span>– <span class="NLM_lpage">6508</span>, <span class="refDoi">&nbsp;DOI: 10.1016/j.bmcl.2012.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1016%2Fj.bmcl.2012.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=22995620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlymtLbF" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=22&amp;publication_year=2012&amp;pages=6503-6508&amp;author=M.+M.+Millerauthor=Y.+Liuauthor=J.+Jiangauthor=J.+A.+Johnsonauthor=M.+Kamauauthor=D.+S.+Nirschlauthor=Y.+Wangauthor=L.+Harikrishnanauthor=D.+S.+Taylorauthor=A.+Y.+A.+Chenauthor=X.+Yinauthor=R.+Seethalaauthor=T.+L.+Petersonauthor=T.+Zvyagaauthor=J.+Zhangauthor=C.+S.+Huangauthor=R.+R.+Wexlerauthor=M.+A.+Possauthor=R.+Michael+Lawrenceauthor=L.+P.+Adamauthor=M.+E.+Salvati&amp;title=Identification+of+a+potent+and+metabolically+stable+series+of+fluorinated+diphenylpyridylethanamine-based+cholesteryl+ester+transfer+protein+inhibitors&amp;doi=10.1016%2Fj.bmcl.2012.08.011" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors</span></div><div class="casAuthors">Miller, Michael M.; Liu, Yalei; Jiang, Ji; Johnson, James A.; Kamau, Muthoni; Nirschl, David S.; Wang, Yufeng; Harikrishnan, Lalgudi; Taylor, David S.; Chen, Alice Ye A.; Yin, Xiaohong; Seethala, Ramakrishna; Peterson, Tara L.; Zvyaga, Tatyana; Zhang, Jun; Huang, Christine S.; Wexler, Ruth R.; Poss, Michael A.; Michael Lawrence, R.; Adam, Leonard P.; Salvati, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic &amp; Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6503-6508</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of diphenylpyridylethanamine-based inhibitors of cholesteryl ester transfer protein, e.g. I, is described.  Optimization of the urea moiety, particularly by incorporation of fluorine, is explored to balance in vitro metabolic stability with CETP potency in the whole plasma assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNLpqF9RExgLVg90H21EOLACvtfcHk0lgRTNMXKW5nTA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XhtlymtLbF&amp;md5=6473c4b4e6dbac03d5532e57932aa04c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.011&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DKamau%26aufirst%3DM.%26aulast%3DNirschl%26aufirst%3DD.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHarikrishnan%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DD.%2BS.%26aulast%3DChen%26aufirst%3DA.%2BY.%2BA.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSeethala%26aufirst%3DR.%26aulast%3DPeterson%26aufirst%3DT.%2BL.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DMichael%2BLawrence%26aufirst%3DR.%26aulast%3DAdam%26aufirst%3DL.%2BP.%26aulast%3DSalvati%26aufirst%3DM.%2BE.%26atitle%3DIdentification%2520of%2520a%2520potent%2520and%2520metabolically%2520stable%2520series%2520of%2520fluorinated%2520diphenylpyridylethanamine-based%2520cholesteryl%2520ester%2520transfer%2520protein%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6503%26epage%3D6508%26doi%3D10.1016%2Fj.bmcl.2012.08.011" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masimirembwa, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">199</span>, <span class="refDoi">&nbsp;DOI: 10.1124/dmd.109.028670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1124%2Fdmd.109.028670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=19797609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aqsr%252FE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=38&amp;publication_year=2010&amp;pages=187-199&amp;author=B.+Bonnauthor=C.+M.+Masimirembwaauthor=N.+Castagnoli&amp;title=Exploration+of+catalytic+properties+of+CYP2D6+and+CYP3A4+through+metabolic+studies+of+levorphanol+and+levallorphan&amp;doi=10.1124%2Fdmd.109.028670" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan</span></div><div class="casAuthors">Bonn, Britta; Masimirembwa, Collen M.; Castagnoli, Neal, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">187-199</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CYP2D6 and CYP3A4, two members of the cytochrome P 450 superfamily of monooxygenases, mediate the biotransformation of a variety of xenobiotics.  The two enzymes differ in substrate specificity and size and characteristics of the active site cavity.  The aim of this study was to det. whether the catalytic properties of these isoforms, reflected by the differences obsd. from crystal structures and homol. models, could be confirmed with exptl. data.  Detailed metabolite identification, reversible inhibition, and time-dependent inhibition were examd. for levorphanol and levallorphan with CYP2D6 and CYP3A4.  The studies were designed to provide a comparison of the orientations of substrates, the catalytic sites of the two enzymes, and the subsequent outcomes on metab. and inhibition.  The metabolite identification revealed that CYP3A4 catalyzed the formation of a variety of metabolites as a result of presenting different parts of the substrates to the heme.  CYP2D6 was a poorer catalyst that led to a more limited no. of metabolites that were interpreted in terms to two orientations of the substrates.  The inhibition studies showed evidence for strong reversible inhibition of CYP2D6 but not for CYP3A4.  Levallorphan acted as a time-dependent inhibitor on CYP3A4, indicating a productive binding mode with this enzyme not obsd. with CYP2D6 that presumably resulted from close interactions of the N-allyl moiety oriented toward the heme.  All the results are in agreement with the large and flexible active site of CYP3A4 and the more restricted active site of CYP2D6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGHPt2fpx8g7Vg90H21EOLACvtfcHk0lgRTNMXKW5nTA"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aqsr%252FE&amp;md5=cfe782b062b1bbac3c4e1f3c2d6a9618</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028670&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028670%26sid%3Dliteratum%253Aachs%26aulast%3DBonn%26aufirst%3DB.%26aulast%3DMasimirembwa%26aufirst%3DC.%2BM.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DExploration%2520of%2520catalytic%2520properties%2520of%2520CYP2D6%2520and%2520CYP3A4%2520through%2520metabolic%2520studies%2520of%2520levorphanol%2520and%2520levallorphan%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D187%26epage%3D199%26doi%3D10.1124%2Fdmd.109.028670" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi">&nbsp;DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=49&amp;publication_year=2006&amp;pages=5029-5046&amp;author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&amp;title=Medicinal+chemistry+of+hERG+optimizations%3A+Highlights+and+hang-ups&amp;doi=10.1021%2Fjm060379l" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lgbfJHyeY1Nag"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&amp;md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520Highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badiola, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triccas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. H.</span></span> <span> </span><span class="NLM_article-title">Efficient Synthesis and Anti-Tubercular Activity of a Series of Spirocycles: An Exercise in Open Science</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e111782</span>, <span class="refDoi">&nbsp;DOI: 10.1371/journal.pone.0111782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1371%2Fjournal.pone.0111782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=25493550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFyjs7nE" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=9&amp;publication_year=2014&amp;pages=e111782&amp;author=K.+A.+Badiolaauthor=D.+H.+Quanauthor=J.+A.+Triccasauthor=M.+H.+Todd&amp;title=Efficient+Synthesis+and+Anti-Tubercular+Activity+of+a+Series+of+Spirocycles%3A+An+Exercise+in+Open+Science&amp;doi=10.1371%2Fjournal.pone.0111782" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient synthesis and anti-tubercular activity of a series of spirocycles: an exercise in open science</span></div><div class="casAuthors">Badiola, Katrina A.; Quan, Diana H.; Triccas, James A.; Todd, Matthew H.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e111782/1-e111782/20, 20 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">An efficient synthesis of a series of spirocyclic pyrans I [R = benzodioxan-6-yl, benzodioxol-5-yl, 4-hydroxy-3-methoxyphenyl, etc.] and II [R1 = C6H5, 4-BrC6H4, 2-BrC6H4] via oxa-Pictet-Spengler reaction is developed.  The oxa-Pictet-Spengler reaction of 4-benzylpiperidone and 2-thiopheneethanol gives N-benzylated intermediate III, which on further debenzylation produces secondary amine IV.  Secondary amine IV upon reductive amination with aldehydes/ketones yielded spirocyclic pyrans I and upon acylation with acyl chlorides yielded spirocyclic pyrans II in moderate to good yields.  The synthesized spirocyclic pyrans I and II were tested against the virulent M. tuberculosis strain (H37Rv), of which compds. I [R = benzodioxan-6-yl, benzodioxol-5-yl, 4-chlorophenyl, 1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl] and III showd excellent anti-tubercular activity.  The toxicity of spirocyclic pyrans I displaying anti-H37Rv activity was assessed using the human monocytic cell line THP1, results showed that spirocyclic pyrans I [R = benzodioxan-6-yl, benzodioxol-5-yl, 4-chlorophenyl] and III displayed THP1 toxicty at relatively high concns.(&gt;50 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7oCV08HTMArVg90H21EOLACvtfcHk0lgbfJHyeY1Nag"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC2cXitFyjs7nE&amp;md5=ffff8fe33d16469205ea56402be70da2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0111782&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0111782%26sid%3Dliteratum%253Aachs%26aulast%3DBadiola%26aufirst%3DK.%2BA.%26aulast%3DQuan%26aufirst%3DD.%2BH.%26aulast%3DTriccas%26aufirst%3DJ.%2BA.%26aulast%3DTodd%26aufirst%3DM.%2BH.%26atitle%3DEfficient%2520Synthesis%2520and%2520Anti-Tubercular%2520Activity%2520of%2520a%2520Series%2520of%2520Spirocycles%253A%2520An%2520Exercise%2520in%2520Open%2520Science%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De111782%26doi%3D10.1371%2Fjournal.pone.0111782" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manabe, K.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5370</span>– <span class="NLM_lpage">5373</span>, <span class="refDoi">&nbsp;DOI: 10.1021/ol4026815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol4026815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text"></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKks77O" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=15&amp;publication_year=2013&amp;pages=5370-5373&amp;author=T.+Uedaauthor=H.+Konishiauthor=K.+Manabe&amp;title=Palladium-Catalyzed+Fluorocarbonylation+Using+N-Formylsaccharin+as+CO+Source%3A+General+Access+to+Carboxylic+Acid+Derivatives&amp;doi=10.1021%2Fol4026815" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives</span></div><div class="casAuthors">Ueda, Tsuyoshi; Konishi, Hideyuki; Manabe, Kei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5370-5373</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Formylsaccharin, an easily accessible cryst. compd., has been employed as an efficient CO source in Pd-catalyzed fluorocarbonylation of aryl halides to afford the corresponding acyl fluorides in high yields.  The reactions use a near-stoichiometric amt. of the CO source (1.2 equiv) and tolerate diverse functional groups.  The acyl fluorides obtained could be readily transformed into various carboxylic acid derivs. such as carboxylic acid, esters, thioesters, and amides in a one-pot procedure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqTUEhxhGH57Vg90H21EOLACvtfcHk0lgbfJHyeY1Nag"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKks77O&amp;md5=c3c3e96e8e986e2b8b496bb8846bea07</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fol4026815&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol4026815%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DH.%26aulast%3DManabe%26aufirst%3DK.%26atitle%3DPalladium-Catalyzed%2520Fluorocarbonylation%2520Using%2520N-Formylsaccharin%2520as%2520CO%2520Source%253A%2520General%2520Access%2520to%2520Carboxylic%2520Acid%2520Derivatives%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D5370%26epage%3D5373%26doi%3D10.1021%2Fol4026815" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ollinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraski, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alling, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, T.</span></span> <span> </span><span class="NLM_article-title">A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e60531</span>, <span class="refDoi">&nbsp;DOI: 10.1371/journal.pone.0060531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1371%2Fjournal.pone.0060531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=23593234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmt1Gls74%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2013&amp;pages=e60531&amp;author=J.+Ollingerauthor=M.+A.+Baileyauthor=G.+C.+Moraskiauthor=A.+Caseyauthor=S.+Florioauthor=T.+Allingauthor=M.+J.+Millerauthor=T.+Parish&amp;title=A+dual+read-out+assay+to+evaluate+the+potency+of+compounds+active+against+Mycobacterium+tuberculosis&amp;doi=10.1371%2Fjournal.pone.0060531" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis</span></div><div class="casAuthors">Ollinger, Juliane; Bailey, Mai Ann; Moraski, Garrett C.; Casey, Allen; Florio, Stephanie; Alling, Torey; Miller, Marvin J.; Parish, Tanya</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e60531</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tuberculosis is a serious global health problem caused by the bacterium Mycobacterium tuberculosis.  There is an urgent need for discovery and development of new treatments, but this can only be accomplished through rapid and reproducible M. tuberculosis assays designed to identify potent inhibitors.  We developed an automated 96-well assay utilizing a recombinant strain of M. tuberculosis expressing a far-red fluorescent reporter to det. the activity of novel compds.; this allowed us to measure growth by monitoring both optical d. and fluorescence.  We detd. that optical d. and fluorescence were correlated with cell no. during logarithmic phase growth.  Fluorescence was stably maintained without antibiotic selection over 5 days, during which time cells remained actively growing.  We optimized parameters for the assay, with the final format being 5 days' growth in 96-well plates in the presence of 2% w/v DMSO.  We confirmed reproducibility using rifampicin and other antibiotics.  The dual detection method allows for a reproducible calcn. of the min. inhibitory concn. (MIC), at the same time detecting artifacts such as fluorescence quenching or compd. pptn.  We used our assay to confirm anti-tubercular activity and establish the structure activity relationship (SAR) around the imidazo[1,2-a]pyridine-3-carboxamides, a promising series of M. tuberculosis inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzifhn6ZGfK7Vg90H21EOLACvtfcHk0lgbfJHyeY1Nag"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3sXmt1Gls74%253D&amp;md5=f8e7dcf8aa8dfe4b71c7a8885ad44bf1</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0060531&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0060531%26sid%3Dliteratum%253Aachs%26aulast%3DOllinger%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DM.%2BA.%26aulast%3DMoraski%26aufirst%3DG.%2BC.%26aulast%3DCasey%26aufirst%3DA.%26aulast%3DFlorio%26aufirst%3DS.%26aulast%3DAlling%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DM.%2BJ.%26aulast%3DParish%26aufirst%3DT.%26atitle%3DA%2520dual%2520read-out%2520assay%2520to%2520evaluate%2520the%2520potency%2520of%2520compounds%2520active%2520against%2520Mycobacterium%2520tuberculosis%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De60531%26doi%3D10.1371%2Fjournal.pone.0060531" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridal, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margulis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorota, S.</span></span> <span> </span><span class="NLM_article-title">Comparison of human Ether-a-go-go related gene screening assays based on IonWorks Quattro and thallium flux</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">765</span>, <span class="refDoi">&nbsp;DOI: 10.1089/adt.2010.0267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1089%2Fadt.2010.0267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=20658944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOjsLvL" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=8&amp;publication_year=2010&amp;pages=755-765&amp;author=T.+R.+Bridalauthor=M.+Margulisauthor=X.+Wangauthor=M.+Donioauthor=S.+Sorota&amp;title=Comparison+of+human+Ether-a-go-go+related+gene+screening+assays+based+on+IonWorks+Quattro+and+thallium+flux&amp;doi=10.1089%2Fadt.2010.0267" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of Human Ether-a-go-go Related Gene Screening Assays Based on IonWorks Quattro and Thallium Flux</span></div><div class="casAuthors">Bridal, Terry R.; Margulis, Michael; Wang, Xin; Donio, Michael; Sorota, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-765</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">In vitro screens using cellular prepns. expressing human Ether-a-go-go related gene (hERG) potassium channels have become an intrinsic tool for evaluating cardiac liability of compds. during early preclin. stage development.  Although hERG channel blocking effects are most reliably evaluated using the low-throughput, manual patch clamp technique, methods and technologies that yield hERG activity data in multiwell format are required to address increased throughput requirements.  In most cases, multiwell approaches to measuring hERG activity involve achieving a reasonable balance between throughput and data fidelity.  Here we compared two functional multiwell hERG assays: A fluorescence-based fluorometric imaging plate reader (FLIPR) screen measuring thallium (Tl+) influx through hERG channels and an automated patch clamp assay using an IonWorks Quattro.  Mean Z' values for FLIPR-Tl+ and IonWorks Quattro assays were similar, 0.57 ± 0.09 (±SD; n = 10) vs. 0.63 ± 0.11 (n = 12), resp.  IC50 detns. for a set of 17 ref. compds. were used to evaluate potency shifts relative to conventional voltage clamp data.  The ref. compd. set included members that are known to exert severe potency shifts in multiwell assays.  Mean potency shift values for FLIPR-Tl+ and IonWorks Quattro assays were 117- and 8-fold, resp.  On the basis of reduced potency shifts and low data variability, we conclude that the IonWorks Quattro screen was a better predictor of hERG activity in conventional whole-cell patch clamp than the Tl+ influx assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiyFqk1FTpqrVg90H21EOLACvtfcHk0liYr9SIiGT3PQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOjsLvL&amp;md5=50ffad1fc10ad4a7a944956b71a2fae1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1089%2Fadt.2010.0267&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2010.0267%26sid%3Dliteratum%253Aachs%26aulast%3DBridal%26aufirst%3DT.%2BR.%26aulast%3DMargulis%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDonio%26aufirst%3DM.%26aulast%3DSorota%26aufirst%3DS.%26atitle%3DComparison%2520of%2520human%2520Ether-a-go-go%2520related%2520gene%2520screening%2520assays%2520based%2520on%2520IonWorks%2520Quattro%2520and%2520thallium%2520flux%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2010%26volume%3D8%26spage%3D755%26epage%3D765%26doi%3D10.1089%2Fadt.2010.0267" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi">&nbsp;DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=11&amp;publication_year=2012&amp;pages=909-922&amp;author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&amp;title=Reducing+safety-related+drug+attrition%3A+the+use+of+in+vitro+pharmacological+profiling&amp;doi=10.1038%2Fnrd3845" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0liYr9SIiGT3PQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&amp;md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520safety-related%2520drug%2520attrition%253A%2520the%2520use%2520of%2520in%2520vitro%2520pharmacological%2520profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenaerts, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruppo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marietta, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, I. M.</span></span> <span> </span><span class="NLM_article-title">Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2294</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi">&nbsp;DOI: 10.1128/AAC.49.6.2294-2301.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facsomega.0c05589&amp;key=10.1128%2FAAC.49.6.2294-2301.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facsomega.0c05589&amp;key=15917524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facsomega.0c05589&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrw%253D" title="">CAS</a>],&nbsp;<a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&amp;volume=49&amp;publication_year=2005&amp;pages=2294-2301&amp;author=A.+J.+Lenaertsauthor=V.+Gruppoauthor=K.+S.+Mariettaauthor=C.+M.+Johnsonauthor=D.+K.+Driscollauthor=N.+M.+Tompkinsauthor=J.+D.+Roseauthor=R.+C.+Reynoldsauthor=I.+M.+Orme&amp;title=Preclinical+testing+of+the+nitroimidazopyran+PA-824+for+activity+against+Mycobacterium+tuberculosis+in+a+series+of+in+vitro+and+in+vivo+models&amp;doi=10.1128%2FAAC.49.6.2294-2301.2005" target="_blank">Google Scholar</a><div class="casRecord" id="
                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models</span></div><div class="casAuthors">Lenaerts, Anne J.; Gruppo, Veronica; Marietta, Karen S.; Johnson, Christine M.; Driscoll, Diane K.; Tompkins, Nicholas M.; Rose, Jerry D.; Reynolds, Robert C.; Orme, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2294-2301</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">This study extends earlier reports regarding the in vitro and in vivo efficacies of the nitroimidazopyran PA-824 against M. tuberculosis.  PA-824 was tested in vitro against a broad panel of multidrug-resistant clin. isolates and was found to be highly active against all isolates (MIC &lt;1 μg/mL).  The activity of PA-824 against M. tuberculosis was also assessed grown under conditions of O2 depletion.  PA-824 showed significant activity at 2, 10, and 50 μg/mL, similar to that of metronidazole, in a dose-dependent manner.  In a short-course mouse infection model, the efficacy of PA-824 at 50, 100, and 300 mg/kg of body wt. formulated in methylcellulose or cyclodextrin/lecithin after 9 oral treatments was compared with those of isoniazid, rifampin, and moxifloxacin.  PA-824 at 100 mg/kg in cyclodextrin/lecithin was as active as moxifloxacin at 100 mg/kg and isoniazid at 25 mg/kg and was slightly more active than rifampin at 20 mg/kg.  Long-term treatment with PA-824 at 100 mg/kg in cyclodextrin/lecithin reduced the bacterial load below 500 CFU in the lungs and spleen.  No significant differences in activity between PA-824 and the other single drug treatments tested (isoniazid at 25 mg/kg, rifampin at 10 mg/kg, gatifloxacin at 100 mg/kg, and moxifloxacin at 100 mg/kg) could be obsd.  In summary, its good activity in in vivo models, as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes PA-824 an attractive drug candidate for the therapy of tuberculosis.  These data indicate that there is significant potential for effective oral delivery of PA-824 for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder ®" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm0IFHIxA0KrVg90H21EOLACvtfcHk0liYr9SIiGT3PQ"> &gt;&gt; More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&amp;resolution=options&amp;coi=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrw%253D&amp;md5=69ac4231bc1270bee6203ee69e955e26</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.6.2294-2301.2005&amp;type=refOpenUrl&amp;url=https%3A%2F%2Flibkey.io%2Flibraries%2F163%2Fopenurl%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.6.2294-2301.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLenaerts%26aufirst%3DA.%2BJ.%26aulast%3DGruppo%26aufirst%3DV.%26aulast%3DMarietta%26aufirst%3DK.%2BS.%26aulast%3DJohnson%26aufirst%3DC.%2BM.%26aulast%3DDriscoll%26aufirst%3DD.%2BK.%26aulast%3DTompkins%26aufirst%3DN.%2BM.%26aulast%3DRose%26aufirst%3DJ.%2BD.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DOrme%26aufirst%3DI.%2BM.%26atitle%3DPreclinical%2520testing%2520of%2520the%2520nitroimidazopyran%2520PA-824%2520for%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520in%2520a%2520series%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520models%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D2294%26epage%3D2301%26doi%3D10.1128%2FAAC.49.6.2294-2301.2005" title="OpenURL INDIANA UNIV BLOOMINGTON" onclick="newWindow(this.href);return false" class="button_primary"><span>open URL</span></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i182">Supporting Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_08303"></div></div></div></div></div><hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsomega.0c05589?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsomega.0c05589</a>.</p><ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Metabolite identification methodologies, chromatograms, proposed metabolite structures, chemistry scheme, PAINS alert analysis and representative compound HPLC UV traces (<a class="ext-link" href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular strings (<a class="ext-link" href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_002.csv">CSV</a>)</p></li></ul><p></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_001.pdf">ao0c05589_si_001.pdf (1.45 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acsomega.0c05589/suppl_file/ao0c05589_si_002.csv">ao0c05589_si_002.csv (2.66 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms &amp; Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facsomega.0c05589&amp;pbContext=%3Bjournal%3Ajournal%3Aacsodf%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facsomega.0c05589%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Facsodf.2021.6.issue-3%3Bwebsite%3Awebsite%3Aacspubs%3BrequestedJournal%3Ajournal%3Aacsodf%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acsomega.0c05589" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2022<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS &amp; Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support &amp; Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"><input type="hidden" name="appID" value="literatum" class="appID"><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"><input type="hidden" name="clientID" value="atypon-lives" class="clientID"><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onclick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        <!-- <div id="gdpr-message-container">
			<a id="closebtn" href="#"><i class="icon-times-circle-o"></i></a> -->
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        <!-- </div> -->
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        <!-- AdRoll Pixel -->
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>

<!-- Twitter universal website tag code -->
<!-- Commented out for ACHS-6152
<script>
    !function(e,t,n,s,u,a){e.twq||(s=e.twq=function(){s.exe?s.exe.apply(s,arguments):s.queue.push(arguments);
    },s.version='1.1',s.queue=[],u=t.createElement(n),u.async=!0,u.src='//static.ads-twitter.com/uwt.js',
    a=t.getElementsByTagName(n)[0],a.parentNode.insertBefore(u,a))}(window,document,'script');
    // Insert Twitter Pixel ID and Standard Event data below
    twq('init','o3njp');
    twq('track','PageView');
</script>
-->
<!-- Facebook Pixel Code -->
<!-- Commented out for ACHS-6152
<script>
    !function(f,b,e,v,n,t,s)
    {if(f.fbq)return;n=f.fbq=function(){n.callMethod?
    n.callMethod.apply(n,arguments):n.queue.push(arguments)};
    if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';
    n.queue=[];t=b.createElement(e);t.async=!0;
    t.src=v;s=b.getElementsByTagName(e)[0];
    s.parentNode.insertBefore(t,s)}(window, document,'script',
    'https://connect.facebook.net/en_US/fbevents.js');
    fbq('init', '529840281033320');
    fbq('track', 'PageView');
</script>
<noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=529840281033320&amp;ev=PageView&amp;noscript=1"
/></noscript>
-->





        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
var currentJournal = "ACS Omega";
$(".citationLinks > a").click(function(e){
    if($(this).text() === "ACS Full Text ") {
        ga('send', 'event', 'Reference _Click', 'ACS Full Text', currentJournal);
    }
    else if($(this).text() === "Crossref") {
        ga('send', 'event', 'Reference _Click', 'Crossref', currentJournal);
    }
    else if($(this).text() === "CAS") {
        ga('send', 'event', 'Reference _Click', 'CAS', currentJournal);
    }
    else if($(this).text() === "PubMed") {
        ga('send', 'event', 'Reference _Click', 'PubMed', currentJournal);
    }
    else if($(this).text() === "Google Scholar") {
        ga('send', 'event', 'Reference _Click', 'Google Scholar', currentJournal);
    }
    else if($(this).hasClass("issue-item_open-url") === true) {
        ga('send', 'event', 'Reference _Click', 'OpenURL', currentJournal);
    }
});
</script>






        
        



        
    





        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        <div tabindex="0" class="showMenuAlertMsg-popup"><div class="pairing-affiliations-popup-content"><div class="pairing-affiliations-header"><button type="button" class="close paringAffClose"><i aria-hidden="true" class="icon-close_thin"></i></button></div><div class="responsrMsg"></div></div></div>




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	dartInstitutionType = 'education';
</script>
        </div>
    





        
        



        
    





        
        <script>
// LIT-455776 workaround
// Moving the popup before the header content for tab accessibility
document.addEventListener('DOMContentLoaded', () => {
    const headerNode = $('.header_content');
    const popupNode = $('.pairing-affiliations-popup');

    if (!headerNode.length || !popupNode.length)
        return;

    popupNode.insertBefore(headerNode);  
});
</script> 
        </div>
    </div>





	
    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-d93b9088814c7fcd2f1c.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-9dee82777d6af4ace557.js"></script>
<script type="text/javascript" src="/wro/l6j1~product.js"></script>

















<script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/v652eace1692a40cfa3763df669d7439c1639079717194" integrity="sha512-Gi7xpJR8tSkrpF7aordPZQlW2DLtzUlZcumS8dMQjwDHEnw9I7ZLyiOj/6tZStRBGtGgN6ceN6cMH8z7etPGlw==" data-cf-beacon="{&quot;rayId&quot;:&quot;70617fdbfd8220fd&quot;,&quot;token&quot;:&quot;0562ec7bcba14d1cae3543aa43d6e749&quot;,&quot;version&quot;:&quot;2021.12.0&quot;,&quot;si&quot;:100}" crossorigin="anonymous"></script>


<div style="visibility: hidden; height: 1px; width: 1px; position: absolute; top: -9999px; z-index: 100000;" id="_atssh"><iframe id="_atssh693" title="AddThis utility frame" style="height: 1px; width: 1px; position: absolute; top: 0px; z-index: 100000; border: 0px none; left: 0px;" src="https://s7.addthis.com/static/sh.f48a1a04fe8dbf021b4cda1d.html#rand=0.6280376422017017&amp;iit=1651670068588&amp;tmr=load%3D1651670068311%26core%3D1651670068360%26main%3D1651670068577%26ifr%3D1651670068594&amp;cb=0&amp;cdn=0&amp;md=0&amp;kw=&amp;ab=-&amp;dh=pubs.acs.org&amp;dr=&amp;du=https%3A%2F%2Fpubs.acs.org%2Fdoi%2F10.1021%2Facsomega.0c05589&amp;href=https%3A%2F%2Fpubs.acs.org%2Fdoi%2F10.1021%2Facsomega.0c05589&amp;dt=Spirocycle%20MmpL3%20Inhibitors%20with%20Improved%20hERG%20and%20Cytotoxicity%20Profiles%20as%20Inhibitors%20of%20Mycobacterium%20tuberculosis%20Growth&amp;dbg=0&amp;cap=tc%3D0%26ab%3D0&amp;inst=1&amp;jsl=1&amp;prod=undefined&amp;lng=en&amp;ogt=site_name%2Ctype%3DArticle%2Cdescription%2Cimage%2Ctitle%2Curl&amp;pc=men&amp;pub=xa-4faab26f2cff13a7&amp;ssl=1&amp;sid=62727c34ed079f2d&amp;srf=0.01&amp;ver=300&amp;xck=0&amp;xtr=0&amp;og=url%3Dhttps%253A%252F%252Fpubs.acs.org%252Fdoi%252Ffull%252F10.1021%252Facsomega.0c05589%26title%3DSpirocycle%2520MmpL3%2520Inhibitors%2520with%2520Improved%2520hERG%2520and%2520Cytotoxicity%2520Profiles%2520as%2520Inhibitors%2520of%2520Mycobacterium%2520tuberculosis%2520Growth%26image%3Dhttps%253A%252F%252Fpubs.acs.org%252Fcms%252F10.1021%252Facsomega.0c05589%252Fasset%252Fimages%252Facsomega.0c05589.social.jpeg_v03%26description%3DWith%2520the%2520emergence%2520of%2520multi-drug-resistant%2520strains%2520of%2520Mycobacterium%2520tuberculosis%252C%2520there%2520is%2520a%2520pressing%2520need%2520for%2520new%2520oral%2520drugs%2520with%2520novel%2520mechanisms%2520of%2520action.%2520A%2520number%2520of%2520scaffolds%2520with%2520potent%2520anti-tubercular%2520in%2520vitro%2520activity%2520have%2520been%2520identified%2520from%2520phenotypic%2520screening%2520that%2520appear%2520to%2520target%2520MmpL3.%2520However%252C%2520the%2520scaffolds%2520are%2520typically%2520lipophilic%252C%2520which%2520facilitates%2520partitioning%2520into%2520hydrophobic%2520membranes%252C%2520and%2520several%2520contain%2520basic%2520amine%2520groups.%2520Highly%2520lipophilic%2520basic%2520amines%2520are%2520typically%2520cytotoxic%2520against%2520mammalian%2520cell%2520lines%2520and%2520have%2520associated%2520off-target%2520risks%252C%2520such%2520as%2520inhibition%2520of%2520human%2520ether-%25C3%25A0-go-go%2520related%2520gene%2520(hERG)%2520and%2520IKr%2520potassium%2520current%2520modulation.%2520The%2520spirocycle%2520compound%25203%2520was%2520reported%2520to%2520target%2520MmpL3%2520and%2520displayed%2520promising%2520efficacy%2520in%2520a%2520murine%2520model%2520of%2520acute%2520tuberculosis%2520(TB)%2520infection.%2520However%252C%2520this%2520highly%2520lipophilic%2520monobasic%2520amine%2520was%2520cytotoxic%2520and%2520inhibited%2520the%2520hERG%2520ion%2520channel.%2520Herein%252C%2520the%2520related%2520spirocycles%2520(1%25E2%2580%25932)%2520are%2520described%252C%2520which%2520were%2520identified%2520following%2520phenotypic%2520screening%2520of%2520the%2520Eli%2520Lilly%2520corporate%2520library%2520against%2520M.%2520tuberculosis.%2520The%2520novel%2520N-alkylated%2520pyrazole%2520portion%2520offered%2520improved%2520physicochemical%2520properties%252C%2520and%2520optimization%2520led%2520to%2520identification%2520of%2520a%2520zwitterion%2520series%252C%2520exemplified%2520by%2520lead%252029%252C%2520with%2520decreased%2520HepG2%2520cytotoxicity%2520as%2520well%2520as%2520limited%2520hERG%2520ion%2520channel%2520inhibition.%2520Strains%2520with%2520mutations%2520in%2520MmpL3%2520were%2520resistant%2520to%252029%252C%2520and%2520under%2520replicating%2520conditions%252C%252029%2520demonstrated%2520bactericidal%2520activity%2520against%2520M.%2520tuberculosis.%2520Unfortunately%252C%2520compound%252029%2520had%2520no%2520efficacy%2520in%2520an%2520acute%2520model%2520of%2520TB%2520infection%253B%2520this%2520was%2520most%2520likely%2520due%2520to%2520the%2520in%2520vivo%2520exposure%2520remaining%2520above%2520the%2520minimal%2520inhibitory%2520concentration%2520for%2520only%2520a%2520limited%2520time.%26type%3DArticle%26site_name%3DACS%2520Publications&amp;csi=undefined&amp;rev=v8.28.8-wp&amp;ct=1&amp;xld=1&amp;xd=1"></iframe></div><style id="service-icons-0"></style></body></html>